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 Nanoscience and nanotechnology refer to a recent scientific approach 
situated at the convergence of physics, chemistry, biology and engineering. 
They deal with the production and manipulation of materials that have at least 
one dimension between 1 and 100 nm. Although nanoscience and 
nanotechnology broke into scientific literature in the 1980s, nanomaterials were 
actually used since ancient times. Two of the most famous examples are the 
Damascus steel, which was produced by Persians from the twelfth to the 
seventeenth century and resulted of material changes at the nanometric scale, 
and the red ruby stain glass of cathedrals built in the Middle Age. However, 
these old techniques remained empirical and were only based on people’s 
know-how. It was not until 1959 that the nanotechnology concept was first 
described during Richard Feynman’s lecture, “there’s plenty of room at the 
bottom”. He claimed that new properties should be reached by modifying the 
materials directly at the atomic level. Indeed, the properties of materials may 
change at this tiny scale. Therefore, mechanical properties, electric or thermal 
conductivity, magnetism, etc. might be enhanced while comparing a nanometric 
material with its homologous macroscopic material.[1] 
                                                          
[1] R. Feynman, There's plenty of room at the bottom, American Physical Society meeting, 
Caltech, 1959, December 29th. 
Chapter 1 
4 
 A large variety of nanomaterials exists (figure C1-1). They can be organic, 
inorganic or hybrids and adopt different morphologies. They are found as 
spheres, helixes, rods, fibers, etc. Some of them are natural whereas others are 
synthetic. Undoubtedly, numerous nanomaterials can be found in biological 
systems. For example, the protein membrane of viruses, the capsid, is a highly 
functionalized nanomaterial, the size of which ranges between 10 and 400 nm. 
Keratin is a natural biopolymer that can self-assemble into helix-forming fibers 
of micrometer length and with nanometric width. It can be found in hair, nails 
or other horny materials. 
 Synthetic nanomaterials can be based on metals or oxides, such as gold 
or silica, or organic compounds. As examples, fullerene and graphene are well-
known nanomaterials that are usually added to improve the properties of other 
materials.  Besides, giant polymeric molecules can rapidly reach the nanometric 
size and small organic molecules, such as surfactants, can spontaneously self-
assemble into nanosized structures. A large number of procedures have been 
engineered for the synthesis of nanomaterials with a homogenous size and 
morphology. In parallel, other procedures have been developed to modify the 
nanomaterials in order to improve their properties.[2] 
  
Figure C1-1: Examples of nano- or nanostructured materials. 
 In the last centuries, medicine, jointly to science, has evolved and some 
acute or fatal diseases, such as small pox, have been eradicated. France, Japan, 
                                                          
[2] J.J. Ramsden, Nanotechnology: an introduction, 2nd edition, 2016, Elsevier, Oxford, UK. 
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Canada and Australia are the countries in which the life expectancy is the 
highest: it rises to more than 83 years for women and more than 78 years for 
men. However, as population became older, degenerative and cardiovascular 
diseases, such as cancers or Alzheimer’s disease, started to spread. For instance, 
the OMS predicted that cancer death would increase by 45 % in the world 
between 2007 and 2030. At the same time, new severe diseases have appeared 
like the acquired immune deficiency syndrome (AIDS), Ebola virus disease, 
Creutzfeldt–Jakob disease, etc. while other older ones, like influenza or malaria, 
still provoke numerous deaths worldwide. 
 New treatments have been developed to cure patients that have 
contracted these severe diseases although they usually cause painful side 
effects. For example, chemotherapeutic cancer treatments are usually based on 
cytotoxic agents that interfere with the cell division. Thus, they naturally target 
cancer cells that have an abnormal replication. Unfortunately, they also damage 
healthy cells that divide rapidly such as cells located in the bone narrow, in the 
digestive system and in the hair or the skin, generating side effects that are 
hardly endured by patients. Triple therapies, used as treatments against AIDS or 
hepatitis C viral infection, are also known to produce harsh side effects. As these 
diseases present a slow evolution with generally few symptoms, patients might 
be tempted to stop the treatment, provoking its failure. Brain diseases, such as 
Alzheimer’s or Parkinson’s diseases, are particularly difficult to cure in part due 
to the difficulty for the drugs to reach the brain tissues. Therefore, the 
development of novel innovative therapies that can reduce the side effects of 
these treatments or improve their efficacy is a current need.  
 It is in this context of development of new nanomaterials and social 
expectancies for new therapies easier to handle that nanomedicine rose in the 
2000’s. Thanks to their nanometric size that facilitates their mobility in 
physiological media, inside and outside the cells, combined with the evolution 
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of the procedures for nanomaterial preparation, nanomaterials specially 
designed to improve various biomedical applications are nowadays available. 
Thus, nanomedicine actually investigates medical diagnostic and imaging, smart 
drug delivery, drugs resistance, tissue reparation as well as new therapies like 
gene delivery or new antibacterial therapies against multi-resistant bacteria 
(Figure C1-2).[3] 
 
Figure C1-2: Nanomedicine applications. 
 
 Even if nanomedicine is a young and interdisciplinary field,  
hundreds of nanomedical products have been approved or are under 
clinical investigation. Probably, it is for drug delivery purposes that the  
benefits of nanomedicine have gone the farthest.[4] For example, paclitaxel is an 
anticancer drug, commercialized under the name Taxol®, that is generally 
administrated using a formulation based on  ethanol associated with a 
heterogeneous mixture of surfactantcs (Cremophor EL®). This formulation 
allows increasing the water solubility of the drug but may cause allergic 
                                                          
[3] T.L. Doane, C. Burda, The unique role of nanoparticles in nanomedicine: imaging, drug 
delivery and therapy, Chem. Soc. Rev., 2012, 41, 2885-2911. 
[4] Y. Min, J.M. Caster, M.J. Eblan, A.Z. Wang, Clinical translation of nanomedicine, Chem. Rev., 
2015, 115, 11147-11190. 
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reactions and precipitation during its administration to the patients.[5] Two new 
formulations based on nanomaterials have been developed, approved and 
commercialized to overcome these drawbacks. Genexol-PM® formulation 
associates the drug with nanosized amphiphilic polymers[6] while Abraxane® 
associates the drug with protein-based nanoparticles.[7] Another example is 
Vivagel®; this condom lubricant contains a nanometric dendrimer that is able to 
stack on the surface of the human immunodeficiency virus (HIV) limiting its 
transmission. The active ingredient is the dendritic nanomaterial and any other 
antiviral drug has to be include in this formulation.[8] 
 Among all the new possibilities offered by nanomedicine, this thesis will 
focus on drug delivery and gene therapy. New dendritic systems, based on 
previously existing polyester structures or novel poly(esteramide) architectures, 
are proposed to afford new solutions to these nanomedical applications. The 
synthesis and the properties of these new materials are described and their 
possible applications are discussed in comparison with other well-known 
standard systems. 
 
                                                          
[5] A.K. Singla, A. Garg, D. Aggarwal, Paclitaxel and its formulations, Int. J. Pharm., 2002, 235, 
179-192. 
[6] S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S. Wan Kim, M.H. Seo, In vivo evaluation of 
polymeric micellar paclitaxel formulation: toxicity and efficacy, J. Control. Release, 2001, 72, 
191-202. 
[7] F. Dosio, P. Brusa, P. Crosasso, S. Arpicco, L. Catte, Preparation, characterization and 
properties in vitro and in vivo of a paclitaxel–albumin conjugate, J. Control. Release, 1997, 47, 
293-304. 
[8] J. O’Loughlin, I.Y. Millwood, H.M. McDonald, C.F. Price, J.M. Kaldor, J.R. Paull, Safety, 
tolerability, and pharmacokinetics of SPL7013 Gel (Vivagel): a dose ranging, phase I study, Sex. 
Transm. Dis., 2010, 37, 100-104. 
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2.1- Drug and gene delivery, two 
attractive nanomedicine applications
 
 
 Important concepts related with the application of nanomedicine to drug 
and gene delivery, as well as relevant previous works are discussed in this 
section. 
 
2.1.1 - Smart nanocarriers for drug delivery 
2.1.1.1 - General aspects of advanced drug delivery systems 
 Drug delivery carriers are defined as vehicles employed for the delivery 
of drugs in order to target the sites of their pharmacological actions. They can 
be nanometrically sized or bigger. Their goal is to provide a more effective way 
to deliver the drugs, modifying their physicochemical properties and/or allowing 
them to overcome some biological barriers. Drug delivery systems started to be 
used in the 1960’s when the first sustained drug release devices based on 
silicone rubber was employed to control the diffusion of ocular (pilocarpine) or 
contraceptive (progesterone) drugs in the body.[9] Sustained release was then 
extended to other drugs by controlling their diffusion or dissolution into the 
physiological medium employing oral or topical administration routes.[10] 
                                                          
[9] J. Folkman, D.M. Long, The use of silicone rubber as a carrier for prolonged drug therapy, 
Surg. Res., 1964, 4, 139-142. 
[10] A.S. Hoffman, The origins and evolution of "controlled" drug delivery systems, J. Control. 
Release, 2008, 132, 153-163. 
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 Later, in 1980’s, a new class of drug delivery carriers emerged and was 
defined as “smart carriers”. They were designed to extend the available drug 
library and improve their selectivity, effectiveness and/or safety. To do so, 
aspects other than sustained drug release were taken into account, i.e. drug 
aqueous media solubility and stability, drug pharmacokinetics, targeted drug 
release, etc.[10] 
 Solubility in aqueous media and stability are important factors to 
consider in drug design. Low water solubility and/or stability can impede the 
use of new drugs as effective therapeutic agents. Camptothecin drug is a good 
example to illustrate these two limitations. This drug shows a remarkable 
anticancer activity but it has failed to pass clinical trials. Indeed, it presents 
really low water solubility associated to low water stability (figure C2-1). To 
overcome these drawbacks, camptothecin has been chemically modified in 
order to increase both its water solubility and its stability. Currently, topotecan® 
and irinotecan® are two camptothecin analogues approved by the Food and 
Drug Administration (FDA) for chemotherapy. Another way is to associate 
camptothecin with drug delivery nanocarriers that would increase its water 
 
 
Figure C2-1: Camptothecin drug and its two FDA (Food and Drug Administration) 
approved chemotherapeutic analogues and two drug delivery carriers based on 
organic and inorganic nanoparticles. 1 Adapted from refs.  [11b], 2 adapted from ref. 
[11c]. 
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solubility and activity. Hence, good in vitro and in vivo anticancer activity have 
been observed after administration of covalent or non-covalent camptothecin 
loaded carriers.[11] 
 Drug pharmacokinetics refers to the study of a drug and its metabolites 
in the body over time and gathers other parameters that can be tuned by drug 
delivery. These parameters correspond to seven properties: liberation, 
absorption, distribution, metabolism, excretion, toxicity and activity/response, 
also called LADMET-R properties. Liberation and absorption are responsible of 
the bioavailability of the drug and are the first two steps. They correspond to 
the liberation of the active form of the drug form the formulated medication 
and its entry into the bloodstream. The third property is distribution, which 
corresponds to the repartition of the drug into the different tissues. Metabolism 
and excretion processes modify the presence of the active form of the drug 
within the body. Two other parameters must be taken in account: the toxicity of 
the drug and of its metabolites and how the diseased tissues would response to 
the drug activity (figure C2-2).[12] 
 Drug delivery nanocarriers can easily modify some of these parameters 
in order to improve the pharmacokinetics of a drug.[13] Thus: 
 - They can increase the drug penetration into the bloodstream, affording a
 better and less factors dependent drug bioavailability.[14] 
                                                          
[11] a) P. Botella, E. Rivero-Buceta, Safe approaches for camptothecin delivery: structural 
analogues and nanomedicines, J. Control. Release, 2017, 247, 28-54; b) J. Lu, Z. Li, J.I. Zink, F. 
Tamanoi F, In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-
delivery system: enhanced efficacy by folate modification, Nanomedicine, 2012, 8, 212-220; d) 
K.T. Householder, D.M. Di Perna, P.E. Chung, G.M. Wohlleb, H.D. Dhruv, M.E. Berens, R.W. 
Sirianni, Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of 
intracranial glioma, Int. J. Pharm., 2015, 479, 374-380. 
[12] A. Ruiz-Garcia, M. Bermejo, A. Moss, V.G. Casabo, Pharmacokinetics in drug discovery, J. 
Pharm. Sci., 2008, 97, 654-690. 
[13] M. Hamidi, A, Azadi, P. Rafiei, H. Ashrafi, A pharmacokinetic overview of nanotechnology-
based drug delivery systems: an ADME-oriented approach, Crit. Rev. Ther. Drug Carrier Syst., 
2013, 30, 435-467. 
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Figure C2-2: schematic representation of the LADMET-R properties. 
 - They can improve the circulation time of the drug in the bloodstream, 
 avoiding rapid clearance by the kidneys or the reticulo-endothelial system 
 (RES). Low molecular drugs, with size inferior to 10 nm, are particularly  
 affected by renal clearance whereas high molecular drugs with size of 
 hundreds of nanometers, such as proteins, may be quickly detected by RES 
 and eliminated from the bloodstream.[15] 
 - They can ameliorate the drug concentration within the desired tissues, by 
 especially targeting the diseased ones.[16] 
 - They can limit the drug side effects, such as cytotoxicity, as a consequence 
 of a better bioavailability and a higher drug concentration within the 
 diseased tissues,[17] 
 - etc. 
                                                                                                                                                                          
[14] C. Feng, J. Li, Y. Mu, M. Kong, Y. Li, M.A. Raja, X.J. Cheng, Y. Liu, X. Guang Chen, Multilayer 
micro-dispersing system as oral carriers for co-delivery of doxorubicin hydrochloride and P-gp 
inhibitor, Int. J. Biol. Macromolec., 2017, 97A, 170-180. 
[15] L.X. Long, J. Zhao, K. Li, L.G. He, X.M. Qian, C.Y. Liu, L.M. Wang, X.Q. Yang, J. Sun, Y. Ren, 
C.S. Kang, X.B. Yuan, Synthesis of star-branched PLA-b-PMPC copolymer micelles as long blood 
circulation vectors to enhance tumor-targeted delivery of hydrophobic drugs in vivo, Mater. 
Chem. Phys., 2016, 180, 184-194. 
[16] L. B-Peppas, J.O. Blanchette, Nanoparticle and targeted systems for cancer therapy, Adv. 
Drug Deliv. Rev., 2004, 56, 1649-1659. 
[17] I. Ojima, E.S. Zuniga, W.T: Berger, J.D. Seitz, Tumor-targeting drug delivery of new-
generation taxoids, Future Med. Chem., 2012, 4, 33-50. 
State of the art 
15 
 Many efforts have been made in order to develop targeted drug delivery 
nanocarriers. Indeed, these carriers can carry drugs into the diseased tissues 
improving specific drug distribution and therefore reducing both the quantity of 
drug that has to be administrated to patients and the drug side effects. 
Targeting can be either active or passive. 
 Passive targeting is based on the enhanced permeability and retention 
(EPR) effect, which has shown a good selectivity for solid tumors. Indeed, solid 
tumors need high supply of nutrients and oxygen to sustain their quick growth. 
This results in the formation of blood vessels with a defective architecture, more 
permeable than normal ones, and favors the absorption and retention of 
nanocarrier/drug conjugates within the interstitial space between the blood 
vessels and the tumors (figure C2-3).[18] 
 
Figure C2-3: Blood vessels of normal tissues and solid tumor (T points the tumor 
whereas N points normal tissues), adapted from ref. [18]. Schematic representations of 
the normal and tumor tissues. Drug carrier size schematic scale and its relation with 
penetration into tumors. 
                                                          
[18] J.W. Nichols, Y.H. Bae, EPR: Evidence and fallacy, J. Control. Release, 2014, 190, 451-464. 
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 The circulation time in the bloodstream of the drug delivery system and 
its size are the two key parameters that favor the EPR effect. To reach and be 
able to accumulate in the tumor tissues, drug delivery systems must have a long 
circulation time, avoiding renal and RES rapid clearance. Moreover, small 
carriers (light green in figure C2-3), with sizes lower than 50 nm, would 
penetrate deeper into the interstitial spaces between blood vessels and solid 
tumors cells and their therapeutic effect would therefore affect a higher 
proportion of cancerous cells. In contrast, bigger carriers (dark green in figure 
C2-3) would stay on the surfaces of the tumors, affecting less cancerous cells and 
being eventually dragged by the bloodstream flow. Besides, the EPR effect can 
be promoted by increasing the blood flow to the tumor tissues by inducing 
hypertension or employing vasodilators, such as nitric oxide.[19] 
 Active targeting is much more versatile than passive one and many 
different tissues and cells can be reached. Two distinct strategies are commonly 
followed to achieve it (figure C2-4): 
 -  the nanocarrier can specifically target a receptor that is currently 
 overexpressed by the diseased cell, or 
 - the release of the drug from the nanocarrier can be triggered only after 
 exposure to one or various stimulus. 
Many different moieties have been employed to achieve active targeted drug 
delivery. As examples, antibodies, peptides or folic acid, receptor of which is 
highly overexpressed in various tumor cells, have enabled effective drug 
targeting during in vivo assays.[20] Stimulus mediated drug targeting can be 
1 
                                                          
[19] a) Lammers T, Smart drug delivery systems: back to the future vs. clinical reality, Int. J. 
Pharm., 2013, 454, 527-529; b) J. Fang, H. Nakamura, H. Maeda, The EPR effect: unique 
features of tumor blood vessels for drug delivery, factors involved, and limitations and 
augmentation of the effect, Adv. Drug Deliv. Rev., 2011, 63, 136-151. 
[20] a) S.C. Alley , N.M. Oakley, P.D. Senter, Antibody–drug conjugates: targeted drug delivery 
for cancer, Curr. Op. Chem. Biol., 2010, 14, 529-537; b) S. Majumdar, T.J. Siahaan, Peptide-
mediated targeted drug delivery, Med. Res. Rev., 2012, 32, 637-658; c) J. Sudimack, R.J. Lee, 
Targeted drug delivery via the folate receptor, Adv. Drug Deliv. Rev., 2000, 41, 147-162. 
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Figure C2-4: Representation of receptor-targeted and stimuli-responsive carriers. 
attained by playing with the specific physiological conditions of the target 
diseased tissues. For example, tumor cells have lower pH than healthy cells and 
may present a hypoxic reductive disorder; several drug carriers have been 
designed to respond to these stimuli and successfully release their cargo in such 
tissues.[21] The stimulus may also be external; therefore drug nanocarriers that 
respond to light,[22] temperature,[23] magnetic field[24] and ultrasounds[25] have 
been designed as well as drug carriers that are able to respond to various 
stimuli.[26] 
                                                          
[21] a) Y. Liu, W. Wang, J. Yang, C. Zhou, J. Sun, pH-sensitive polymeric micelles triggered drug 
release for extracellular and intracellular drug targeting delivery, Asian J. Pharm. Sci., 2013,8, 
159-167; b) H. Alimoradi, S.S. Matikonda, A.B. Gamble, G.I. Giles, K. Greish, Hypoxia responsive 
drug delivery systems in tumor therapy, Curr. Pharm. Des., 2016, 22, 2808-2820. 
[22] G. Yang, J. Liu, Y. Wu, L. Feng, Z. Liu, Near-infrared-light responsive nanoscale drug 
delivery systems for cancer treatment, Coord. Chem. Rev., 2016, 320-321, 100-117. 
[23] M. Karimi, P.S. Zangabad, A. Ghasemi, M. Amiri, M. Bahrami, H. Malekzad, H.G. Asl, Z. 
Mahdieh, M. Bozorgomid, A. Ghasemi, M.R.R.T. Boyuk, M.R. Hamblin, Temperature-responsive 
smart nanocarriers for delivery of therapeutic agents: applications and recent advances, ACS 
Appl. Mater. interfaces, 2016, 8, 21107-21133. 
[24] M. Bonini, D. Berti, P. Baglioni, Nanostructures for magnetically triggered release of drugs 
and biomolecules, Curr. Opin. Colloid Interface Sci., 2013, 18, 459-467 
[25] Boissenot, A. Bordat, E. Fattal, N. Tsapis, Ultrasound-triggered drug delivery for cancer 
treatment using drug delivery systems: from theoretical considerations to practical 
applications, J. Control. Release, 2016, 144-163. 
[26] R. Cheng, F. Meng, C. Deng, H.A. Klok, Z. Zhonga, Dual and multi-stimuli responsive 
polymeric nanoparticles for programmed site-specific drug delivery, Biomaterials, 2013, 34, 
3647-3657. 
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2.1.1.2- Designing new smart nanocarriers and nanocarrier/drug conjugation 
 Important features have been defined to be considered in order to design 
drug nanocarriers that, in a smart way, would deliver the drug they carry into 
the diseased tissues (figure C2-5).  
 
Figure C2-5: “Smart nanocarriers” properties. 
 Firstly, drug nanocarriers must be water soluble and stable in aqueous 
physiological media and in the bloodstream to afford a good drug bioavailability 
and capacity to reach the desired tissues. Self-aggregation of nanocarriers, 
which may reduce their water solubility and mobility, must be avoided. Thus, 
polyethylene glycol (PEG) moieties are usually added at the nanocarriers’ 
periphery as PEG repulsion between chains impedes the aggregation between 
various nanocarriers and also limits the RES clearance, increasing the 
bloodstream stability.[27] The insertion of chemical groups that can be ionized at 
physiological pH, such as carboxylic acids or primary amino groups, is another 
possibility. These groups increase the water solubility of the nanomaterials and 
limit their aggregation by electrostatic repulsion.[28] 
                                                          
[27] P. Mishra, B. Nayak, R.K. Dey, PEGylation in anti-cancer therapy: An overview, Asian J. 
Pharmacol., 2016, 11, 337-348. 
[28] P. Charoongchit, J. Suksiriworapong, K. Sripha, S. Mao, A. Sapin-Minet, P. Maincent, V.B. 
Junyaprasert, Self-aggregation of cationically modified poly(ε-caprolactone)2-co-poly(ethylene 
glycol) copolymers: Effect of cationic grafting ligand and poly(ε-caprolactone) chain length, 
Mat. Sci. Eng. C, 2017, 72, 444-455. 
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 Secondly, drug nanocarriers must be fully biocompatible. 
Biocompatibility is defined as the property of not producing a toxic, injurious, or 
immunologic response in living tissues. A large variety of materials are per se 
biocompatible and can be used without further modification like natural or 
synthetic polyethers, polyesters, etc. For example, natural polysaccharides, like 
chitosan, or natural poly(amino acids) like proteins and synthetic polyethers, 
like Pluronic®, or synthetic polyesters like, polylactic  
acid, have been successfully used as biocompatible drug carriers.[ 29 ] The 
biocompatibility of some slightly cytotoxic materials can generally be improved 
by chemical modifications that affect the surface of the nanocarrier. The most 
common ones are the addition of polyethylene chains, but fatty acid, amino acid 
or sugars derivatives have also been employed.[30] 
 Thirdly, they must be biodegradable to avoid nanocarrier accumulation in 
the tissues. Besides, the degradation processes must limit the formation of 
cytotoxic fragments. Organic materials and in particular those based on 
polyesters, polyamides and polyethers that can be easily degraded in small 
biocompatible fragments by either enzymatic activity or water hydrolysis appear 
as attractive materials. Furthermore, the degradation reactions of the materials 
can be used to improve the drug release. Indeed, chemical groups sensitive to 
acidic pH or reductive environment such as carbonate groups or disulfide bonds 
                                                          
[29] a) J. Nicolas, S. Mura, D. Brambilla, N. Mackiewicz, P. Couvreur, Design, functionalization 
strategies and biomedical applications of targeted biodegradable/biocompatible polymer-
based nanocarriers for drug delivery, Chem. Soc. Rev., 2013, 42, 1147-1235; b) Y. Cheng, L. 
Zhao, Y. Li, T. Xu, Design of biocompatible dendrimers for cancer diagnosis and therapy: 
current status and future perspectives, Chem. Soc. Rev., 2011, 40, 2673-2703. 
[30] M. Ciolkowski, J.F. Petersen, m. Ficker, A. Janaszewska, J.B. Christensen, B. Klajnert, M. 
Bryszewska, Surface modification of PAMAM dendrimer improves its biocompatibility, 
Nanomedicine, 2012, 8, 815-817. 
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may be inserted into the nanocarriers structure to favor an optimal and 
controlled release of drugs.[31] 
 Fourthly, good cellular uptake is another important requirement. Various 
pathways can occur during cellular uptake; they are principally regulated by the 
size, morphology and surface functionalization of the nanocarriers (figure C2-6). 
 
Figure C2-6: Different pathways of cellular uptake, adapted from ref. [32]. 
 Small nanoparticles with size under 10 nm usually enter into the cells by 
simple diffusion across the cell membrane. Particles with size comprised 
between 10 and 150 nm usually enter into the cell according to endocytic 
pathways. The cell membrane deforms itself into an alveolus that contains the 
nanocarriers. This hole closes up forming an endosome. Later, the nanocarriers 
must leave this endosome to enter into the cytoplasm. Endocytic pathways can 
be receptor mediated, with clathrin or caveolin, or receptor independent. 
                                                          
[31] N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad, Degradable controlled-release polymers and 
polymeric nanoparticles: mechanisms of controlling drug release, Chem. Rev., 2016, 116, 2602-
2663. 
[32] Z. Mao, X. Zhou, C. Gao, Influence of structure and properties of colloidal biomaterials on 
cellular uptake and cell functions, Biomater. Sci., 2013, 1, 896-911. 
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Finally, bigger particles can enter the cells mediating macropinocytosis and 
phagocytosis. 
 It is commonly assumed that a spherical morphology with a diameter 
bellow 100 nm favors the cellular uptake. Cellular uptake can also be promoted 
by the functionalization of the nanocarriers with peripheral cationic groups. 
Indeed, electrostatic interactions between cationic nanocarriers and negatively 
charged membrane may occur resulting in a better cellular internalization.[33] 
 Finally and prior to its delivery, the drug must be loaded inside the 
nanocarriers. Drugs can be inserted into the nanocarriers by non-covalent and 
covalent strategies (figure C2-7).[34] 
 
Figure C2-7: Covalent and non-covalent strategies for loading drugs into nanocarriers. 
                                                          
[33] a) X. Hu, J. Hu, J. Tian, Z. Ge, G. Zhang, K. Luo, S. Liu, Polyprodrug amphiphiles: hierarchical 
assemblies for shape-regulated cellular internalization, trafficking, and drug delivery, J. Am. 
Chem. Soc., 2013, 135, 17617-17629; b) M. Elsabahy, K.L. Wooley, Design of polymeric 
nanoparticles for biomedical delivery applications, Chem. Soc. Rev., 2012,41, 2545-2561; c) M. 
Adabi, M. Naghibzadeh, M. Adabi, M.A. Zarrinfard, S.S. Esnaashari, A.M. Seifalian, R. Faridi-
Majidi, H.T. Aiyelabegan, H. Ghanbari, Biocompatibility and nanostructured materials: 
applications in nanomedicine, artificial cells, nanomedicine, and biotechnology, in press, DOI: 
10.1080/21691401.2016.1178134. 
[34] K. Ulbrich, K. Holá, V. Šubr, A. Bakandritsos, J. Tučekand, R. Zbořil, Targeted drug delivery 
with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release 
control, and clinical studies, Chem. Rev., 2016, 116, 5338-5431. 
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 Non-covalent strategies are based on various equilibria, which must be 
shifted to a better affinity of the drug for the nanocarrier than for the external 
medium. In the case of lipophilic drugs, loading is mainly based on favorable 
lipophilic interactions between the drug molecules and the lipophilic parts of 
the nanocarriers. The low water solubility of lipophilic drugs usually shifts the 
equilibrium towards the formation of stable drug/nanocarrier conjugates. 
Hydrophilic and amphiphilic drugs may also be encapsulated within the 
nanocarriers; they are respectively located in the hydrophilic parts or at the 
frontiers between the two parts. The conjugate formation can be reinforced by 
other favorable interactions, such as hydrogen or halogen bounds. 
 Drug encapsulation based on non-covalent interactions has the 
advantages to be easy to carry out and versatile. Therefore, many encapsulation 
techniques are currently described in the literature. However, the release of 
drugs might be too fast (“burst release”), especially during in vivo experiments 
in which the drug/nanocarrier conjugates are highly diluted and constantly 
washed by human plasma (“sink-conditions”). Such “burst release” can be 
avoided by closing up the nanocarriers after drug encapsulation by covalent 
cross-linking. The encapsulated drug molecules remain therefore entrapped 
within the nanocarriers and can only be expelled after reopening or destruction 
of the nanocarriers. This effect can be stimuli dependent in order to favor a 
targeted release.[35]  
 Drugs can also be covalently linked to the nanocarrier structures. 
Covalent bonds between nanocarriers and drugs are advantageously highly 
stable. A more controlled drug release can be induced, allowing a perfect 
                                                          
[35] a) E.V. Skorb, H. Möhwald, “Smart” surface capsules for delivery devices, Adv. Mater. 
Interfaces, 2014, 1, 1400237; b) C. Pinto Reis, R.J. Neufeld, A.J. Ribeiro, F. Veiga, 
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles, 
Nanomedicine, 2006, 2, 8-21. 
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control of the drug pharmacokinetics, favoring good drug bioavailability and 
constant drug concentration into the bloodstream. 
 Furthermore, stimuli-sensitive covalent bonds, such as hydrazone 
linkages, can be employed to attach the drugs on the nanocarriers and induce 
targeted drug release after exposure to mild acidic pH. Nevertheless, 
drug/nanocarrier covalent linkages are almost always based on costly chemical 
synthesis with usually expensive and unstable drugs and are tedious to be 
scaled-up.[36] 
 A wide variety of nanocarriers fulfill the above mentioned criteria of 
water solubility and stability, biocompatibility, biodegradability and favored 
cellular uptake, in which various drugs have been loaded by covalent and non-
covalent strategies. Thus, many organic, inorganic and hybrid materials have 
been used for the design of drug delivery nanocarriers such as polymers and 
dendrimers, liposomes, inorganic nanoparticles (based on silica, gold, iron, etc.), 
quantum dots, fullerene, graphene, carbon nanotubes and nanodiamonds, 
metal organic frameworks, etc.[34] 
 
 
 
 
  
                                                          
[36] a) Y. Chen, T. Xu, The effect of dendrimers on the pharmacodynamic and pharmacokinetic 
behaviors of non-covalently or covalently attached drugs, Eur. J. Med. Chem., 2008, 43, 2291-
2297; b) K.R. Est, S. Otto, Reversible covalent chemistry in drug delivery, Curr. Drug Discov. 
Technol., 2005, 2, 123-160. 
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2.1.2- Gene therapy 
 
2.1.2.1- An innovative, precise and versatile new therapy 
 Gene therapy is defined as the therapeutic delivery of exogenous 
genome into specific cells in order to treat diseases. It can be used to treat 
genetic diseases, such as muscular dystrophy, but also other diseases such as 
cardiovascular, neurological, or infectious diseases and cancer. The exogenous 
genetic material would modify the natural production of proteins in the target 
cells, altering the expression of specific genes or triggering the production of 
cytotoxic proteins in order to kill cancerous cells, for example.[37] 
 Various forms of genetic material can be administered to the patient; the 
most common ones are plasmid deoxyribonucleic acid (pDNA) and small 
interfering ribonucleic acid (siRNA) (figure C2-8). pDNAs are circular DNA 
molecules that contain a gene that would induce, after recombination with the 
original host cell DNA in its nucleus, the production of a desired protein. siRNA 
can specifically knock down the expression of a deleterious gene in the cell 
cytoplasm. To express a gene, the cell produces a messenger RNA (mRNA) that 
transcripts and transports the genetic information from the nucleus, where the 
DNA is located, to the ribosomes. The ribosomes are located in the cell 
cytoplasm and, after receiving the mRNA information, start the production of 
the corresponding protein. siRNA is complementary to  a given messenger RNA 
and forms a stable complex with it. The mRNA can no longer be translated by 
the ribosomes and the production of the corresponding protein stops.[38] 
 
                                                          
[37] H.M. Blau, M.L. Springer, Gene therapy - a novel form of drug delivery, N. Engl. J. Med., 
1995, 333, 1204-1207. 
[38] L. Naldini, Gene therapy returns to centre stage, Nature, 2015, 526, 351-360. 
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Figure C2-8: pDNA transfection (up) and siRNA silencing (down) mechanisms. 
 The concept of gene therapy appeared in the 1970’s and the first 
approved and successful gene therapy investigations in humans occurred in the 
beginning of the 1990’s.[39] In 2016, 2409 clinical trials had been conducted with 
94 trials in phase III or IV.[40] Only two gene therapies are currently approved in 
Europe. The first one treats a rare genetic condition called “lipoprotein lipase 
                                                          
[39] a) T. Friedmann, R. Roblin, Gene therapy for human genetic disease?, Science, 1972, 175, 
949-955; b) S.A. Rosenberg, P. Aebersold, K. Cornetta, A. Kasid, R.A. Morgan, R. Moen, E.M. 
Karson, M.T. Lotze, J.C. Yang, S.L. Topalian, M.J. Merino, K. Culver, A.D. Miller, R.M. Blaese, 
W.F. Anderson, Gene transfer into humans — immunotherapy of patients with advanced 
melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction, N. 
Engl. J. Med., 1990, 323, 570-578 
[40] Gene therapy clinical trials worldwide database, http://www.abedia.com/wiley/phases.ph 
p, Wiley, 2016. 
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deficiency” that affects digestion and impedes the degradation of fatty acids.[41] 
The second one treats children with severe combined immunodeficiency 
syndrome, known as “bubble babies”.[42] A third therapy was approved in China 
and treats squamous cell malignant cancer.[43] 
 Three principal barriers need to be overcome to convert gene therapy 
into a safe and efficient therapy:[44] 
 - As a drug, genetic material must reach and be internalized by the target 
 cells while being protected from the physiological medium and immune 
 system aggressions. Ex vivo procedures have been developed to 
 administrate genetic material in addition to classical in vivo procedures. 
 During ex vivo administration, selected cells are collected from the patient, 
 then treated in vitro with genetic materials and, finally, after having being 
 successfully modified genetically, reintroduced to the patient. 
 - The expression of exogenous genome must be time sustained and must 
 not be lost during cell division or after natural epigenetic modifications. 
 Otherwise, gene therapy would be limited to quiescent tissues like brain 
 that have a low cell turnover or to treat episodic diseases, such as cancers 
 or infections. 
 - The host immune response is the final major concern. The immune 
 system tends to eliminate all foreign genome and this bothers the gene 
 therapy administration procedures. Furthermore, it can also be activated 
 during the transcription of the genome by classifying the new proteins as 
 foreign and invasive, triggering their destruction. 
                                                          
[41] A. Pollack, European agency backs approval of a gene therapy, New York Times, July, 21th, 
2012, B1. 
[42] A. Coghlan, Gene therapy gets approval for ‘bubble kids’ in world first, New Scientist, 
April, 9th, 2016, issue 3068. 
[43] S. Pearson, H. Jia, K. Kandachi, China approves first gene therapy, Nat. Biotechnol., 2004, 
22, 3-4. 
[44] M.A. Kay, State-of-the-art gene-based therapies: the road ahead, Nat. Rev., 2011, 12, 316-
328. 
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2.1.2.2- Vectorisation of gene therapy for a better efficiency 
 Gene therapy may be carried out by directly injecting naked pDNA into 
the tissues. However, this technique presents a really low efficiency since 
foreign genetic material is usually rejected and rapidly destroyed.[45]  
 In order to favor the delivery of exogenous genome to target cells, gene 
vectors have been introduced. They can be viral or synthetic. Viral vectors were 
the first ones to be developed and are still the most commonly exploited. 
Indeed, viruses are infectious agents that transport their own RNA or DNA into 
cells where they replicate. They effectively protect the genetic material they 
carry from physiological medium and are rather stable in the bloodstream. They 
naturally target specific cells and easily release their genetic cargo inside them. 
A large variety of viruses have been employed to successfully deliver foreign 
genetic material into cells such as retroviruses, lentiviruses, adenoviruses, 
adeno-associated viruses, simplex herpes virus and vaccinia virus. The three 
currently approved gene therapies are based on three distinct types of viruses: 
the retroviruses, the adenoviruses and the adeno-associated viruses.[46] 
 However, viral vectors are associated to issues that cannot be ignored. 
First of all, viral vectors are expensive and their manufacturing production is 
harsh to be handled. Secondly, the size of the genetic material is limited by the 
size of the virus cavity and restrains gene delivery to small plasmid DNA and 
RNA. Thirdly, the virus may induce an immunogenic response after being 
administrated to the patient, limiting the efficiency of further administration. 
Besides, this immunogenic response might have even been acquired by the 
                                                          
[45] H. Herweijer, J.A. Wolff, Progress and prospects: naked DNA gene transfer and therapy, 
Gene Therapy, 2003, 10, 453-458. 
[46] a) M.A. Kay, J.C. Glorioso, L. Naldini, Viral vectors for gene therapy: the art of turning 
infectious agents into vehicles of therapeutics, Nat. Med., 2001, 7, 33-40; b) O.W. Mertena, B. 
Gaillet, Viral vectors for gene therapy and gene modification approaches, Biochem. Eng. J., 
2016, 108, 98-115. 
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patient before any gene treatment (after a normal exposure to unmodified 
viruses). Finally, long term safety and patient tolerability is still unknown.[46] 
 Therefore, biocompatible and biodegradable synthetic vectors are being 
investigated and developed to compete with viruses and outstrip the viruses’ 
inherent drawbacks. They form complexes with genetic material that would 
enable the administration and uptake of the exogenous genome into target 
cells. The complexes are principally based on physical electrostatic interactions 
between anionic phosphate groups belonging to the DNA with cationic groups 
belonging to the non-viral vector. An excess of cationic vectors would form 
stable, dense and positively charged complexes wherein the genetic material is 
located in the center of the complexes, protected from external aggressions 
(figure C2-9).[47,28b] 
 After being formed, the vector-genome complex must act like a virus and 
pass through the natural barriers that impede the delivery of foreign genetic 
material into the cell. The cell internalization of the complexes usually follows 
endocytic pathways. Once in the cell, the complexes must escape from the 
endosome to enter into the cytoplasm. While siRNA can be released anywhere 
in the cytoplasm to be active, pDNA must be released close to the cell nucleus 
to be able to penetrate inside it and modify the endogenous DNA (figure C2-
10).[47] 
  
Figure C2-9: pDNA complexation by cationic non-viral vector. 
                                                          
[47] D.W. Pack, A.S. Hoffman, S. Pun, P.S. Stayton, Design and development of polymers for 
gene delivery, Nat. Rev., 2005, 4, 581-593. 
[28b] M. Ramamoorth et al., J. Clin. Diagn. Res., 2015, 9, GE01-GE06. 
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Figure C2-10: pDNA and siRNA complexes routes to efficient gene transfection. 
 As described for drug delivery vectors, synthetic vectors for gene therapy 
can be intelligently designed to reach efficient gene therapy in a safety way. 
Biocompatible and biodegradable cationic vectors that can interact with 
polyanionic pDNA o siRNA usually contain numerous tertiary amino groups that 
are protonated at physiological pH or other quaternary amino groups. The 
complex they form with genetic material must be stable in the bloodstream to 
be able to reach the target cells for in vivo gene therapy procedures. The 
cellular internalization by means of endocytosis is favored for particles with size 
up to 100 nm that are positively charged to interact with the negatively charged 
cell membrane.[48] 
 Endosomal escape can be favored by the addition of moieties that 
naturally destabilize the endosome. Indeed, various proteins and peptides or 
chemical agents, such as chloroquine, can induce pore formation in the 
endosome membrane or can fusion with it, destabilizing the membrane and 
breaking it down. Interestingly, some polymers that possess secondary and 
tertiary amino groups are able to catch protons and may promote the 
breakdown of the endosome membrane. This property is known as the “proton 
sponge effect”. After endosome formation, the pH of the endosome naturally 
                                                          
[48] A.E. Nel, L. Madler, D. Velegol, T. Xia, E.M.V. Hoek, P. Somasundaran, F. Klaessig, V. 
Castranova, M. Thompson, Understanding biophysicochemical interactions at the nano-bio 
interface, Nat. Mater., 2009, 8, 543-557. 
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decreases, starting from physiological pH, at 7.4, to more acidic pH, near 5.0. 
Secondary and principally tertiary amino groups are being gradually protonated 
while the pH decreases and disturb this natural process. Thus, to counteract the 
“proton sponge effect” of these polymers, more and more protons are injected 
inside the endosome by the cell. As a water molecule and a chlorine ion are 
injected jointly to a proton, the endosome starts to swell until it blows up, 
liberating its contents into the cytoplasm (Figure C2-11).[48,49] 
 
Figure C2-11: Schematic representation of the “proton sponge effect”. a) The 
pDNA/vector complex is located within the endosome. b) H+ ions sent by the cell to 
decrease the pH of the endosome are catch by the gene vector and the endosome 
starts to swell. c) The endosome blows up before reaching ph 5.0.  
 After entering the cytoplasm, the complexes that bear pDNA must 
approach the nearest possible to the nucleus to avoid the destruction of pDNA. 
It has been observed that complexes can naturally move into the cytoplasm and 
reach the cell nucleus. The addition of some peptide sequences that naturally 
go to the nucleus might assist this approach. The internalization of the 
complexes into the cell nucleus is highly challenging and the exogenous DNA is 
usually recombined with the DNA host cell during the cell division when the 
nucleus membrane is open.[50] 
                                                          
[49] a) A.K. Varkouhi, M. Scholte, G. Storm, H.J. Haisma, Endosomal escape pathways for 
delivery of biological, J. Control. Release, 2011, 151, 220-228; b) J. Behr, The proton sponge: a 
trick to enter cells the viruses did not exploit, Chimia, 1997, 51, 34-36. 
[50] C.M. Roth, S. Sundaram, Engineering synthetic vectors for improved DNA delivery: insights 
from intracellular pathways, Annu. Rev. Biomed. Eng., 2004, 6, 397-426. 
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 Finally, both siRNA and pDNA must be released from the complexes to 
be expressed. A good balance between efficient packing for extracellular 
protection and intracellular release must be reached to obtain good 
transfection efficiency. Thus, some synthetic vectors have shown enhanced 
gene transfection efficiency after being partially degraded. The non-viral vector 
degradation can proceed before the complex formation with pDNA[51] or during 
the gene transfection by the cytoplasm reductive environment or by the lower 
pH in the endosomes.[52] 
 As with drug delivery, many synthetic gene vectors based on a variety of 
organic, inorganic and hybrid materials have been successfully used for in vitro 
and in vivo assays. Among them, cationic lipids, lipid nanoemulsions, solid lipidic 
nanoparticles, peptides, polymers and dendrimers, inorganic nanoparticles 
(based on gold, silica or calcium phosphate, etc.) have received enormous 
attention from research groups.[28b]  
 Additionally, some organic synthetic non-viral vectors are commercially 
available:[53]  
 - lipofectamine® 2000 or 3000 are the most effective commercial agents. 
 They are based on cationic lipids that naturally self-assemble in water 
 forming stable liposomes in which DNA can intercalate, 
 - FuGENE® 6 or HD are another lipid formulations,  
 - jetPEI® is based on linear polyethylenimine polymer,  
 - ExpressFectTM is a cationic polymer, 
                                                          
[51] M.X. Tang, C.T. Redemann, F.C. Szoka, In vitro gene delivery by degraded polyamidoamine 
dendrimers, Bioconjugate Chem., 1996, 7, 703-714. 
[52] a) D. Ouyang, N. Shah, H. Zhang, S.C. Smith, H.S. Parekh, Reducible disulfide-based non-
viral gene delivery systems, Mini Rev. Med. Chem., 2009, 9, 1242-1250; b) P. Venugopalan, S. 
Jain, S. Sankar, P. Singh, A. Rawat, S.P. Vyas, pH-sensitive liposomes: mechanism of triggered 
release to drug and gene delivery prospects, Pharmazie, 2002, 57, 659-671. 
[28b] M. Ramamoorth et al., J. Clin. Diagn. Res., 2015, 9, GE01-GE06. 
[53] S. Yamano, J. Dai, A.M. Moursi, Comparison of transfection efficiency of nonviral gene 
transfer reagents, Mol. Biotechnol., 2010, 46, 287-300. 
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 - Superfect® reagents are based on poly(amido amine) dendrimers, 
 - Arrest-InTM is a formulation that combines lipids and polymers, 
 -etc. 
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2.2 - Dendritic derivatives alluring 
materials for nanomedicine applications 
 
 Dendrimers show interesting features that have prompted their 
investigation and the development of new dendritic derivatives for drug 
delivery and non-viral gene therapy. Indeed, dendrimers are macromolecules 
that can be easily designed by convenient and precise modifications to afford 
relevant vectors with engaging properties, and have been therefore extensively 
studied as drug and gene nanocarriers. During the last decade, a big number of 
reviews and books dealing with dendrimers and their nanomedicine 
applications have been published.[54] Among them, a specially relevant review 
deals with some clinical applications of dendrimers as biomedical materials.[55]  
                                                          
[54] a) H.J. Hsu, J. Bugno, S. Lee, S. Hong, Dendrimer-based nanocarriers: a versatile platform 
for drug delivery, WIREs Nanomed. Nanobiotechnol., 2017, 9, e1409; b) M. Selin, L. Peltonen, 
L.M. Bimbo, Dendrimers and their supramolecular nanostructures for biomedical applications, 
J. Drug Deliv. Sci. Tech., 2016, 10; c) A. Mascaraque , A. Sousa-Herves , J. Rojo, Medicinal 
applications of dendrimers, Reference Module in Chemistry, Molecular Sciences and Chemical 
Engineering, 2016, DOI: 10.1016/B978-0-12-409547-2.12571-5; d) H. Yang, Targeted 
nanosystems: advances in targeted dendrimers for cancer therapy, Nanomedicine, 2016, 12, 
309; e) A.K. Sharma, A. Gothwal, P. Kesharwani, H. Alsaab, A.K. Iyer, U. Gupta, Dendrimer 
nanoarchitectures for cancer diagnosis and anticancer drug delivery, Drug Discov. Today, 2016, 
In press, DOI: 0.1016/j.drudis.2016.09.013; f) L.P. Wu, M. Ficker, J.B. Christensen, P.N. 
Trohopoulos, S.M. Moghimi, Dendrimers in medicine: therapeutic concepts and 
pharmaceutical challenges, 2015, 26, 1198-1211; g) A. J. Perisé-Barrios, D. Sepúlveda-Crespo, 
D. Shcharbin, B. Rasines, R. Gómez, B. Klajnert-Maculewicz, M. Bryszewska, F. J. de la Mata and 
M. A. Muñoz-Fernández, Dendrimers, Chapter 7 In J. Callejas-Fernández, J. Estelrich, M. 
Quesada-Pérez, J. Forcada, Soft nanoparticles for biomedical applications, 2014, RSC, London; 
h) A.M. Caminade, C.O. Turrin, Dendrimers for drug delivery, J. Mater. Chem. B, 2014, 2, 4055-
4066; i) P. Kesharwani, K. Jain, N.K.Jain, Dendrimer as nanocarrier for drug delivery, Progress 
Polym. Sci., 2014, 39, 268-307. 
[55] R.M. Kannan, E. Nance, S. Kannan, D.A Tomalia,  Emerging concepts in dendrimer-based 
nanomedicine: from design principles to clinical applications, J. Intern. Med., 2014,276, 576-
617. 
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2.2.1- Dendrimers, an overview 
 
2.2.1.1- General properties of dendrimers 
 Dendrimers are ramified polymers with a repetitive tree-like structure. 
They present a perfectly defined skeleton, resulting in almost uniform and 
monodisperse polymers with a large number of functional groups at the 
periphery. Their name describes their original structure; the Greek words 
“dendron” and “meros” respectively mean tree and part. Each wedge moiety of 
a dendrimer is called dendron (figure C2-12). 
 
Figure C2-12: Schematic representations of a dendrimer and a dendron. 
 Dendrimers are composed of three parts: the core, the internal branches 
and the peripheral groups. The core of the dendrimers is multifunctional and 
determines both the shape of the dendrimers and their directionality. Starting 
from its central core, the dendrimer grows up in a repetitive manner forming 
the internal branches. The number of repetitive units conditions the generation 
of the dendrimer and its size.[56] 
                                                          
[56] a) F. Vögtle, G. Richardt, N. Werner, Dendrimer chemistry, 2009, WILEY-VCH, Weinheim; 
b) E. Abbasi, S.F. Aval, A. Aknarzahed, M. Milani, H.T. Nasrabadi, S.W. Joo, Y. Hanifeh, K. Nejati-
Koshki, R. Pashaei-Asl, Dendrimers: synthesis, applications, and properties, Nanoscale Res. 
Lett., 2014, 9, 247; c) S. Hernández-Ainsa, M. Marcos, J.L: Serrano, Chapter 3: Dendrimeric and 
hyperbranched liquid crystal structures In: Handbook of liquid crystals, 7 volume ses, 2nd 
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 One of the most interesting features of the dendrimer structure is the 
presence of numerous and accessible peripheral groups. The number of these 
groups increases exponentially with the generation of the dendrimer and allows 
an easy functionalization with many different moieties. Moreover, the stimuli-
response and activity of the moieties located at the periphery of the dendrimers 
may be increased when compared to one of the free moieties diluted in 
solution. This property is known as the “dendritic effect”.[57] 
 In addition, dendrimers adopt preferentially a spherical shape with few 
interactions between molecules. In contrast with linear polymeric chains, which 
usually form random coils that are entangled like “cooked spaghettis”, 
dendrimers generally appear as spherical and dispersed molecules, like “green 
peas”. This property is related with the generation of the dendrimer: 
dendrimers of low generations are generally flexible and open molecules 
whereas dendrimers of high generations usually adopt a spherical and dense 
shape showing a closed surface. Hence, dendrimers are more soluble than their 
corresponding linear polymers and their solutions have a lower viscosity.[58] 
 Finally, the density of the dendrimeric molecules varies from their core to 
their periphery. Dendrimers present holes in their architecture that are situated 
between internal branches making them appropriate macromolecules for “host-
guest” systems. Indeed, these internal void spaces can be filled with small 
molecules like solvent molecules or other molecules of interest, like drugs. In 
1994, Meijer et al. introduced the term of “dendrimer box” to describe this 
                                                                                                                                                                          
edition by J.W. Goodby, P.J. Collings T.Kato, C. Tschierske, H. Gleeson, P. Raynes, 2013, Wiley-
VCH, Weinheim, Germany. 
[57] a) A.M. Caminade, A. Ouali, R. Laurent, C.O. Turrin, J.P. Majoral, The dendritic effect 
illustrated with phosphorus dendrimers, Chem. Soc. Rev., 2015, 44, 3890-3899; b) E.M Munoz, 
J. Correa, R. Riguera, E. Fernandez-Megia, Real-time evaluation of binding mechanisms in 
multivalent interactions: a surface plasmon resonance kinetic approach, J. Am. Chem. Soc., 
2013, 135, 5966-5969. 
[58] J.M.J. Fréchet, Functional polymers and dendrimers: reactivity, molecular architecture, 
and interfacial energy, Science, 1994, 263, 1710-1715. 
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phenomenon. A solid shell made of ter-butoxyphenylalanine amino acid were 
synthesized at the periphery of a flexible poly(propyleneimine) dendrimer in the 
presence of guest molecules. The guest molecules that were inside the internal 
dendrimer void spaces remained entrapped and could only get out of the 
dendrimer after being exposed to an external stimulus (figure C2-13).[59] 
 
Figure C2-13: Meijer’s “dendritic box”. a) The guest molecules are entrapped in the 
dendrimer. b) After exposition to a stimulus, the shell of the dendrimer is removed and 
the guest molecules are released outside the dendrimer. 
 
 
 
 
 
 
 
 
 
                                                          
[59] J.F. Jansen, E.M. de Brabander-van den Berg, E.W. Meijer EW, Encapsulation of guest 
molecules into a dendritic box, Science, 1994, 266, 1226-1229: b) J.F. Jansen, E.W. Meijer, E.M. 
de Brabander-van den Berg , The dendritic box: shape-selective liberation of encapsulated 
guests, J. Am. Chem. Soc., 1995, 117, 4417-4418. 
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2.2.1.2- Synthesis of dendrimers 
 Dendrimers constitute a relatively recent research line in the field of 
polymers. The first dendritic structure was published by Vötgle et al. in 1978 
when this group synthesized a series of new macromolecules named “cascade 
polymers”.[ 60] Later, in 1981, Denkewalter et al. patented a new type of 
dendrimer based on poly-(L)-lysine (PLL).[ 61] Due to the limitations of the 
synthetic and analytic methods available at this time, the synthesis of new 
dendrimers remained undeveloped until 1985. During this year, Tomalia et al. 
and Newkome et al. described independently the synthesis of two new 
dendrimers. On the one hand, Tomalia’s group synthesized poly(amidoamine) 
dendrimers (PAMAMs) that were described as “starburst-dendritic 
macromolecules”, using the term dendrimer for the first time.[62] On the other 
hand, Newkome’s group prepared polyethers “arborol”.[63] Five years later, in 
1990, Hawker, Fréchet et al. described a new synthetic process to synthesize 
the dendrimers. These years marked a turning point for dendrimeric 
macromolecules, and they started to spread among the scientific community 
(figure C2-14).[64] 
 Two principal synthetic methods are employed to synthesize the 
dendrimers: the divergent one and the convergent one. The divergent way was 
first employed by Tomalia’s and Newkome’s groups. The dendrimer starts 
  
 
                                                          
[60] E. Buhleier, W. Wehner, F. Vögtle, Cascade”- and “nonskid-chain-like” synthesis of 
molecular cavity topologies, Synthesis, 1978, 9, 155-158. 
[61] R.G. Denkewalter, J.F. Kolc, W.J. Lukasavage, in US Pat. 4.360.646, 1979.  
[62] D.A. Tomalia, H. Baker, J. R. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, P. 
Smith, A new class of polymers: starburst-dendritic macromolecules, Polym. J., 1985, 17, 117-
132. 
[63] G.R. Newkome, Z.Q. Yao, G.R. Baker, V.K. Gupta, Micelles part 1. Cascade molecules: a 
new approach to micelles. A [27]-arborol, J. Org. Chem., 1985, 50, 2003-2004. 
[64] C. Hawker, J.M.J. Fréchet, A new convergent approach to monodisperse molecules, J. 
Chem. Soc., Chem. Commun., 1990, 15, 1010-1013. 
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Figure C2-14: Vötgle’s cascade molecule, Denkenwalter’s poly-(L)-lysine, Fréchet’s 
dendrimer, Tomalia’s dendrimer and 2,2’-bis(hydroxymethyl)propionic acid based (bis-
MPA) polyester dendrimer. 
growing from its core to its periphery by iterative synthetic steps: in each step a 
new generation of the dendrimer is formed by the addition of an appropriate 
amount of monomer. Briefly, a multifunctional core bearing nB active groups 
reacts with n ABn* monomers, in which A is a chemical group that can react with 
the B group. To avoid side reactions that would decrease the yield, B chemical 
groups must be protected (B* corresponds to B protected group). Hence, each 
step of generation growth has to be followed by the deprotection of the B* 
chemical groups to continue building the dendrimer. This two-step process 
“addition of monomer/deprotection of peripheral reactive groups” has to be 
repeated until the desired dendrimer generation is reached (figure C2-15).[62,63] 
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Figure C2-15: Synthesis of dendrimers following the divergent pathway. 
  The ABn* monomers are generally cheap and easily available allowing 
the addition of a large excess of monomer during the growing step and assuring 
a complete addition of the monomer to each of the peripheral reactive groups 
of the dendrimer. Nevertheless, and even using an excess of monomer, the 
principal limitation of this synthetic pathway is the difficulty to obtain pure 
monodisperse high generation dendrimers for which the risk of uncompleted 
growing reactions is big and leads to imperfect macromolecules. For instance, 
during many years, it was though that dendrimers had a maximum size that 
could not be exceeded, according to De Genes’ theory,[65] until Simanek’s group 
reached the synthesis of a 13th generation dendrimer with a size similar to that 
of small viruses.[66] 
 The convergent method was first employed by Hawker and Fréchet’s 
group. A dendron, made of *ABn monomers, is synthesized following the same 
two steps procedure employed by the divergent method. In this case, the 
chemical group A, located at the focal point of the dendron, must be protected 
to avoid side reactions (*A). When the desired generation is reached, the *A 
                                                          
[65] P.G. de Gennes, H. Hervet, Statistics of « starburst » polymers,  J. Phys. Lett. Fr., 1983, 44, 
351-360. 
[66] J. Lim, M. Kostiainen, J. Maly, V.C.P. da Costa, O. Annunziata, G.M. Pavan, E.E. Simanek, 
Synthesis of large dendrimers with the dimensions of small viruses, J. Am. Chem Soc., 2013, 
135, 4660-4663. 
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group is deprotected and reacts with the corresponding dendrimer core (figure 
C2-16). The final reaction must proceed with an elevated yield as the synthesis 
of dendrons is costly and this avoids the addition of a large excess of dendron. 
Besides, the steric hindrance may limit the addition of various large dendrons to 
a small core.[45] 
 
Figure C2-16: Synthesis of dendrimers following the convergent pathway. 
 More recently, new synthetic pathways have been described to 
synthesize dendrimers. The double growth methods are surely the most 
common ones. They consist on the synthesis of low generation dendrons and/or 
dendrimers, which can be easily obtained and combined to afford high 
generation dendrimers and dendrons without requiring excessively complicated 
reactions (figure C2-17).[ 67 ] In the “double-exponential method”, two low 
generation dendrons are allowed to react to form a new high generation 
dendron. For example, this strategy allows the easy synthesis of a 4th generation 
dendron starting from two 2nd generation dendrons. This strategy presents the 
advantage of simplifying the synthesis and purification of high generation 
intermediate dendrons. In another synthetic pathway, the “double-stage 
convergent method”, low generation dendrons are allowed to react with a low 
generation dendrimer that would act as the new dendrimer core. For example, 
                                                          
[67] M.V. Walter, M. Malkoch, Accelerated approaches to dendrimers. Materials science and 
technology, 2006, Wiley-VCH, London, UK. 
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when 2nd generation dendrons react with a 2nd generation dendrimer, a 4th 
generation dendrimer is obtained. In this modified convergent synthetic 
pathway, the steric hindrance is less important as the core is bigger and the 
dendrons are smaller. 
 
Figure C2-17: Double stage convergent and double exponential synthetic pathway. 
 Another new strategy is the orthogonal growth that can be employed in 
either a divergent or a convergent pathway. Dendrimers are composed of two 
monomers ABn and CDn. A groups only react with D groups, whereas C groups 
only react with B groups. This strategy allows bypassing the deprotection 
reaction steps of the peripheral group. Therefore, the synthesis of dendrimers is 
much faster and, for instance, a 6th generation dendrimer could be synthesized 
in one single day (figure C2-18).[68] 
 
Figure C2-18: Divergent orthogonal growth synthetic pathway. 
                                                          
[68] P. Antoni, M.J. Robb, L. Campos, M. Montanez, A. Hult, E. Malmström, M. Malkoch, C.J. 
Hawker, Pushing the limits for thiol-ene and CuAAC reactions: synthesis of a 6th generation 
dendrimer in a single day, Macromolecules, 2010, 43, 6625-6631. 
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 Recent advances in organic synthesis have been applied to dendrimer 
synthesis in order to obtain dendrimers in a faster way and/or of higher 
generations. The “click chemistry” concept was first described by Sharpless et 
al. in 2001. The dendritic community was interested in the high yields and the 
good orthogonality of the click chemistry reactions. Nowadays, they are 
commonly employed to synthesize a large variety of dendrimers. The most used 
click chemistry reactions are the copper(I) azide-alkyne cycloaddition (CuAAC), 
the thiol-ene and thiol-yne reactions and the Diels-Alder reaction.[ 69 ] In 
particular, these reactions have been used to obtain new and more complex 
dendrimers with heterofunctional groups, like Janus dendrimers,[ 70] onion-
peel[71] and 3-faces dendrimers[72] (figure C2-19).  
 
Figure C2-19: Janus, onion-peel and 3-face dendrimers. 
 
 Dendrimers heterofunctionality has also been introduced by employing 
innovative monomers with more than one reactive groups, eg. A-(BC) 
monomers, or by employing AB2* monomers with different protective groups 
  
                                                          
[69] a) M. Sowinska, Z. Urbanczyk-Lipkowska, Advances in the chemistry of dendrimers, New J. 
Chem., 2014, 38, 2168-2203; b) M. Arseneault, C. Wafer, J.F. Morin, Recent advances in click 
chemistry applied to dendrimer synthesis, Molecules, 2015, 20, 9263-9294. 
[70] A.M Caminade, R. Laurent, B. Delavaux-Nicot, J.P. Majoral, "Janus" dendrimers: syntheses 
and properties, New J. Chem., 2012, 36, 217-226. 
[71] R. Sharma, K. Naresh,  Y.M. Chabre, R. Rej,  N.K. Saadeh, R. Roy, “Onion peel” dendrimers: 
a straightforward synthetic approach towards highly diversified architectures, Polym. Chem., 
2014, 5, 4321-4331 
[72] M. Arseneault, P. Dufour, I. Levesque, J.F. Morin, Synthesis of a controlled three-faced 
PAMAM particle, Polym. Chem., 2011, 2, 2293-2298. 
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that can be selectively deprotected.[73] 
 Other synthetic approaches, like supramolecular chemistry, have been 
studied in order to facilitate the synthesis of dendrimers. Supramolecular 
chemistry is based on non-covalent bonds between atoms. It allows the 
formation of large structures by self-assembly of small molecules.[ 74 ] In 
convergent synthesis, supramolecular chemistry is generally used to bind the 
dendrons to the core. Among others, metal coordination[75] and H bonds[76] 
have been used as non-covalent interactions. Supramolecular chemistry has 
also been used in the double stage convergent synthetic pathway. Small 
dendrons were linked via supramolecular chemistry to small dendrimers in 
order to obtain a new assembly named megamer.[77] 
 
 
 
 
  
                                                          
[73] a) R.S. Navath, A.R. Menjoge, B. Wang, R. Romero, S. Kannan, R.M. Kannan, Amino acid-
functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug 
delivery applications, Biomacromolecules, 2010, 11, 1544-1563; b) A.P. Goodwin, S.S. Lam, 
J.M.J. Fréchet, Rapid, efficient synthesis of heterobifunctional biodegradable dendrimers J. Am. 
Chem. Soc., 2007, 129, 6994-6995. 
[74] J.M.J. Fréchet, Dendrimers and supramolecular chemistry, PNAS, 99,  4782-4787. 
[75] G.R. Newkome, R. Güther, C.N. Moorefield, F. Cardullo, L. Echegoyen, E. Pérez-Cordero, H. 
Luftmann, Routes to dendritic networks: bis-dendrimers by coupling of cascade 
macromolecules through metal centers, Angew. Chem. Int. Ed., 1995, 34, 2023-2026 
[76] S.C. Zimmerman, F. Zeng, D.E.C. Reichert, S.V. Kolotuchin, Self-assembling dendrimers, 
Science, 1996, 271, 1095-1098. 
[77] S. Uppuluri, D.R. Swanson, L.T. Piehler, J. Li, G.L. Hagnauer, D.A. Tomalia, Core–shell 
tecto(dendrimers): I. synthesis and characterization of saturated shell models, Adv. Mat., 2000, 
12, 796-800. 
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2.2.2- Dendritic-polymer hybrids, derivatives at the 
intersection of classical polymers and dendrimers 
 
2.2.2.1- Hyperbranched polymers 
 Despite the significant progress in dendrimer synthesis, high generation 
dendrimers are still obtained after a long, multi-step and challenging process. A 
new class of macromolecules has emerged at the intersection of linear polymers 
and dendrimers: the hyperbranched polymers. They combine both, some 
advantages of linear polymers and some advantages of dendrimers. As the 
linear polymers, they can be synthesized in one-pot reaction and, as 
dendrimers, they have numerous and available chemical groups at their 
periphery and present a globular shape (figure C2-20).[78] 
 
Figure C2-20: Schematic representation of a dendrimer (left), a linear polymer (right) 
and a hyperbranched polymer (middle). 
 Hyperbranched polymers are, as their name suggests, highly ramified 
macromolecules, and like the dendrimers, they are characterized by a 
generation number that defines their average size and their average number of 
peripheral groups.  
 The first hyperbranched polymer was synthesized in 1982 by Kricheldorf 
et al., who reported the synthesis of a new poly(3-hydroxybenzoate), a highly 
                                                          
[78] M. Jikei, M.A. Kakimoto, Hyperbranched polymers: a promising new class of materials, 
Prog. Polym. Sci., 2001, 26, 1233-1285. 
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ramified polyester synthesized in bulk.[79] Like in the case of dendrimers, some 
years were necessary after this first report for hyperbranched polymers to catch 
the interest of the scientific community. Nowadays, a large variety of 
hyperbranched polymers exists including polyesters, polyethers, polyamines, 
polyamides, polystyrene derivatives, etc.[80] Due to their easy synthesis in one-
pot reaction, some of them have been commercialized at very competitive 
prices. Thus, for example, in Sigma-Aldrich©, 1 g of polyester hyperbranched 
polymer of 3rd generation costs 18.50 € whereas 1 g of polyester dendrimer of 
3rd generation costs 1302.00 €. 
 Hyperbranched polymers are mainly synthesized using the 
polycondensation of ABx monomers. In general, the self-polycondensation of 
AB groups needs the addition of a catalyst to activate either A or B chemical 
groups (figure C2-21).[81]  Two other ones are currently used for the synthesis of 
hyperbranched polymers: the self-condensing vinyl polymerization[82] and the 
multibranching ring-opening polymerization.[83]  
                                                          
[79] H.R. Kricheldorf, Q.Z. Zang, G. Schwarz, New polymer syntheses: 6. Linear and branched 
poly(3-hydroxy-benzoates), Polymer, 1982, 23, 1821-1829. 
[80] a) Y.H. Kim, O.W. Webster, Water soluble hyperbranched polyphenylene: "a unimolecular 
micelle?", J. Am. Chem. Soc., 1990, 112, 4592-4593; b) Y. Zheng, S. Li,   Z. Weng C. Gao,  
Hyperbranched polymers: advances from synthesis to applications, Chem. Soc. Rev., 2015, 44, 
4091-4130. 
[81] a) E. Malmström, A. Hult, Kinetics of formation of hyperbranched polyesters based on 2,2-
bis(methylol)propionic acid, Macromolecules, 1996, 29, 1222-1228; b) C. J. Hawker, R. Lee, 
J.M.J. Fréchet, One-step synthesis of hyperbranched dendritic polyesters, J. Am. Chem. Soc., 
1991, 113, 4583-4588; c) A. Blencowe, L. Davidson, W. Hayes, Synthesis and characterization of 
hyperbranched polyesters incorporating the AB2 monomer 3,5-bis(3-hydroxylprop-1-
ynyl)benzoic acid, Eur. Polym. J., 2003, 39, 1955-1563. 
[82] J.A. Alfurhood, P.R. Bachlera, B.S. Sumerlin, Hyperbranched polymers via RAFT self-
condensing vinyl polymerization, Polym. Chem., 2016, 7, 3361-3369. 
[83] A. Sunder , R. Hanselmann , H. Frey ,R. Mülhaupt, Controlled synthesis of hyperbranched 
polyglycerols by ring-opening multibranching polymerization, Macromolecules, 1999, 32, 
4240–4246. 
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Figure C2-21: Schematic synthesis of hyperbranched polymers by polycondensation. 
 The one-step synthesis of hyperbranched polymers is much easier and 
faster than the multi-step synthesis of the dendrimers but it has the 
disadvantage to give macromolecules with higher polydispersity. This is 
principally due to the coupling of growing molecules between themselves 
forming bigger and larger molecules that would have more terminal groups and 
therefore would have even more probability to couple with other molecules. 
The polydispersity index is calculated according to the equation (1).[78]  
(1) Ð = Mw/Mn 
where Ð is the polydispersity index, Mw, the mass average molecular weight and 
Mn the number average molecular weight. 
 Additionally, hyperbranched polymers have a more irregular structure 
than dendrimers and all the terminal groups are not only located at the 
periphery but also in the internal branches (figure C2-22). Indeed, 
hyperbranched polymers are not fully branched macromolecules and present 
pending terminal groups in their inner branches. 
 
Figure C2-22: Schematic architectures of a hyperbranched polymer (left) and a 
dendrimer (right). 
                                                          
[78] M. Jikei et al., Progr. Polym. Sci., 2001, 26, 1233. 
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The degree of branching, DB, is calculated according to the equation (2).[78]  
(2) 𝐷𝐵 =  𝑈𝑏 + 𝑈𝑝
𝑈𝑏 + 𝑈𝑝 + 𝑈𝑡  
where Ub is the number of fully branched internal groups, Ut the number of 
internal terminal groups and Up the number of peripheral terminal groups. 
 For dendrimers, both the polydispersity index and the degree of 
branching are equal to 1. However, for hyperbranched polymers, the 
polydispersity index is always higher than 1 and, at the contrary, the degree of 
branching is always lower than 1. Both tendencies rise when the proportion of 
pending internal terminal groups increases. In fact, the closer these values are 
to 1, the closer to a dendrimer is the hyperbranched polymer. 
 Several synthetic processes have been employed to reduce the 
polydispersity and the number of internal terminal groups of hyperbranched 
polymers. The most common one is the addition of a small multifunctional core 
upon which the monomers would condensate. This technique is usually 
combined with a slow addition of the monomer that would favor a regular 
growing of the macromolecule.[84] Playing with the kinetics of competitive 
polycondensation reactions may also reduce the macromolecule defects.[85] 
Recently, click chemistry reactions have been used as coupling reactions 
between monomers in order to obtain macromolecules closer to dendrimers. 
Thus, hyperbranched polymers with Ð ≤ 1.3 and DB ≥ 0.7 were synthesized by 
CuAAC.[86] 
                                                          
[84] R. Hanselmann , D. Hölter , H. Frey, Hyperbranched polymers prepared via the core-
dilution/slow addition technique:  computer simulation of molecular weight distribution and 
degree of branching, Macromolecules, 1998, 31, 3790-3801. 
[85] Y. Ohta, S. Fujii, A. Yokoyama, T. Furuyama, M. Uchiyama, T. Yokozawa, Synthesis of well-
defined hyperbranched polyamides by condensation polymerization of AB2 monomer through 
changed substituent effects, Angew. Chem. Int. Ed., 2009, 48, 5942-5945. 
[86] a) Y. Shi, R.W. Graff, X. Cao, X. Wang, H. Gao, Chain-growth click polymerization of AB2 
monomers for the formation of hyperbranched polymers with low polydispersities in a one-pot 
process, Angew. Chem. Int. Ed., 2015, 54, 7631-7635. 
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 Another strategy is the combination of hyperbranched polymers of small 
generations with dendrons. Indeed, hyperbranched polymers can be used as a 
core in the double stage convergent synthesis instead of a low generation 
dendrimer and this allows the preparation of dendronized hyperbranched 
polymers (DHPs) also named pseudo-dendrimers (figure C2-23).[87] 
 
Figure C2-23: Schematic synthesis of a dendronized hyperbranched polymer (DHP). 
 In 1998, Frey et al. reported for the first time the synthesis of 
hyperbranched polymer-dendron hybrids by post-functionalizing a 
hyperbranched polymer with a 1st generation dendron.[88] The coupling of 
higher generation dendrons with hyperbranched polymers was carried out in 
2012 by Lederer et al. that reported new DHPs with properties really similar 
than the ones observed for classical dendrimers.[89] In general, the preparation 
of the dendrons requires a multi-step synthesis, whereas the hyperbranched 
polymer is prepared in a one-step reaction. It is important to remark that the 
reactivity of the terminal internal groups of the hyperbranched polymer is 
                                                          
[87] A. Lederer, W. Burchard, T. Hartmann, J.S. Haataja, N. Houbenov, A. Janke, P. Firedel, R. 
Schweinds, P. Linder, Dendronized hyperbranched macromolecules: soft matter with a novel 
type of segmental distribution, Angew. Chem. Int. Ed., 2015, 54, 12578-12583. 
[88] C. Lach, H. Frey, Enhancing the degree of branching of hyperbranched polymers by 
postsynthetic modification, Macromolecules, 1998, 31, 2381-2383 
[89] A. Lederer, T. Hartmann, H. Komber, Sphere-like fourth generation pseudo-dendrimers 
with a hyperbranched core, Macromol. Rapid Commun., 2012, 33, 1440-1444. 
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different from this of the peripheral groups. However, for these high generation 
derivatives, the final properties of the dendronized hyperbranched polymer are 
closer to the dendrimer of comparable size as the internal terminal groups are 
hidden in the deep inner part of the macromolecule.  
 The recent synthesis of these new hybrid macromolecules, between 
hyperbranched polymers and dendrimers, represent a good opportunity to 
synthesize globular polymers with properties similar to high generation 
dendrimers without requiring a too complicated synthetic procedure.[87-89] 
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2.2.2.2- Hybrid linear-dendritic block copolymers (HDLBCs) 
 Another class of hybrid dendritic polymers consists on a linear polymeric 
chain grafted with one or two dendrons at the ending positions. In the first case, 
hybrid linear-dendritic block copolymers (HLDBCs) are obtained (figure C2-24-
A), and in the second case, hybrid dendritic-linear-dendritic block copolymers 
(HDLDBCs) are made (figure C2-24-B). A third type of structure named as 
dendronized polymers is formed when dendrons are located along the polymer 
chain, but they won’t be discussed herein.[90] 
 
Figure C2-24: Schematic representations of one hybrid linear-dendritic block copolymer 
(HDLBC) (A) and one hybrid dendritic-linear-dendritic block copolymer (HDLDBC) (B). 
 The first synthesis of a hybrid dendritic-linear-dendritic block copolymer 
(HDLDBC) was described by Fréchet et al. in 1992. This compound was obtained 
following a convergent approach: the authors coupled a previously synthesized 
poly(benzylether) dendron with a linear polyethylene oxide (PEO) chain, i.e. 
“coupling strategy” (figure C2-25-A).[91] Two years later, in 1994, Chapman et al. 
published the synthesis of a HLDBC using a divergent approach. In this case, a 
poly-(L)-lysine dendron was grown up in the terminal position of a PEO linear 
chain, the author named this method as the “chain first strategy” (figure  
                                                          
[90] D.A. Tomalia, J.M.J Fréchet, Dendrimers and other dendritic polymers, 2002, John Wiley & 
Sons, Ltd, Chischester, UK. 
[91] I. Gitsov, K.L. Wooley, J.M.J. Fréchet, Novel polyether copolymers consisting of linear and 
dendritic blocks, Angew. Chem. Int. Ed., 1992, 31, 1200-1202. 
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C2-25-B).[92] During the same year, Fréchet et al. described a different approach 
that consists in growing up the polymer chain at the focal point of the dendron. 
This strategy was called the “dendron first strategy” (figure C2-25-C).[93] 
 
Figure C2-25: Synthesis of one HLDBC employing the “coupling strategy” (A), the “chain 
first strategy” (B) and the “dendron first strategy” (C). 
 The “coupling strategy” shows some limits as the reactivity of the 
chemical groups at the extremities of the polymer and at the focal point of the 
dendron may be low. As a consequence, the coupling reaction is generally 
uncompleted and the purification of the blends containing the reactive linear 
polymer and dendron, as well as the final HLDBC, is challenging. Indeed, the 
new hybrid enhances the compatibility of the two reactants with the final 
product and hinders their effective separation. Nevertheless, using click 
chemistry reactions, Oriol et al. successfully published the “coupling” synthesis 
of an HLDBC based on linear polyethylene glycol (PEG) chain and bis-MPA 
                                                          
[92] T.M. Chapman, G.L. Hillyer, E.J. Mahan, K.A. Shaffer, Hydraamphiphiles: novel linear 
dendritic block copolymer surfactants, J. Am. Chem. Soc., 1994, 116, 11195-11196. 
[93] I. Gitsov, P.T. Ivanova, J.M.J. Fréchet, Dendrimers as macroiniciator for anionic ring-
opening polymerization. Polymerization of ε-caprolactone, Macromol. Rapid Commun., 1994, 
15, 387-393. 
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polyester dendrons.[ 94] In parallel, Serrano et al. described the successful 
synthesis of an HDLDBC based on a triblock polyethylene oxide - polypropylene 
oxide - polyethylene oxide (PEO-PPO-PEO) linear chain, commercialized under 
the name Pluronic® F-127, with two bis-MPA dendrons using the same click 
chemistry approach.[95] 
 The “chain first strategy” procedure is the most common method used 
to synthesize HLDBCs as it allows the synthesis of a variety of different high 
generation dendrons upon the linear chain. Among other examples, Meijer et al. 
grew up to the 5th generation a poly(propylene imine) dendron from a 
polystyrene linear chain,[96] and Fréchet et al. synthesized a 6th generation 
polyester dendron at the terminal position of a PEO linear chain.[97] 
 The “dendron first strategy” is the less spread method used to synthesize 
HLDBCs. Only few examples are described dealing with the synthesis of linear 
chains of polystyrene and poly(N-isopropylacrylamide) at the focal point of 
poly(benzylether) dendrons.[98]  
                                                          
[94] E. Blasco, J.L. Serrano, M. Piñol, L. Oriol, Light responsive vesicles based on linear–
dendritic block copolymers using azobenzene–aliphatic codendrons, Macromolecules, 2013, 
46, 5951-5960. 
[95] J. Movellan, P. Urbán, E. Moles, J.M. de la Fuente, T. Sierra, J.L. Serrano, X. Fernàndez-
Busquets, Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of 
antimalarial drugs, Biomaterials, 2014, 35, 7940-7950. 
[96] J.C.M. van Hest, D.A.P. Delnoye, M.W.P.L. Baars, C. Elissen-Román, M. H. P. van Genderen, 
E.W. Meijer, Polystyrene–poly(propylene imine) dendrimers: synthesis, characterization, and 
association behavior of a new class of amphiphiles, J. Eur. Chem., 1996, 2, 1616-1626. 
[97] H. Ihre, O.L. Padilla de Jesús, J.M.J. Fréchet, Fast and convenient divergent synthesis of 
aliphatic ester dendrimers by anhydride coupling, J. Am. Chem. Soc., 2001, 123, 5908-5917. 
[98] a) K. Matyjaszewski, T. Shigemoto, J.M.J. Fréchet , M. Leduc, Controlled/“living” radical 
polymerization with dendrimers containing stable radicals, Macromolecules, 1996, 29, 4167-
4179; b) Z. Ge, S. Luo, S. Liu, Syntheses and self-assembly of poly(benzyl ether)-b-poly(N-
isopropylacrylamide) dendritic–linear diblock copolymers, J. Polym. Sci. Part A. Polym. Chem., 
2006, 44, 1357-1371. 
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2.2.3 - Self-assembly in water of amphiphilic 
dendrimers and hybrid linear-dendritic block 
copolymers 
 
2.2.3.1 - Amphiphilic derivatives in water 
 When an amphiphilic derivative is dissolved in a solvent, such as an 
aqueous media, it can self assemble into supramolecular aggregates. On the 
one hand, the lipophilic parts of the amphiphilic molecule self-interact and 
situate themselves in the inner part of the new supramolecular aggregate to 
avoid unfavorable interactions with external water. On the other hand, the 
hydrophilic parts are located at the periphery of the supramolecular aggregates 
and interact with the external water stabilizing the aggregates. A large variety of 
aggregates with different morphologies can be obtained like micelles, vesicles, 
sponge phases, etc. (figure C2-26).[99] 
 The different morphologies of the aggregates formed by the amphiphiles 
are related with the architecture of their components. The packing parameter, 
p, was introduced to classify the aggregates and associate their morphology 
with their components. It is calculated according to the equation (3). 
(3) 𝑝 = 𝑉
𝑎0 × 𝑙 
where V is the volume of the lipophilic part, a0 is the surface area of the 
hydrophilic part and l is the length of the lipophilic part.[100] 
                                                          
[ 99 ] M. Ramanathan, L.K. Shrestha, T. Mori, Q. Ji, J.P. Hill, K. Ariga, Amphiphile 
nanoarchitectonics: from basic physical chemistry to advanced applications, Phys. Chem. 
Chem. Phys., 2013, 15, 10580-10611. 
[100] J.N. Israelachvili, D.J. Mitchell, B.W. Ninham, Theory of self-assembly of hydrocarbon 
amphiphiles into micelles and bilayers, J. Chem. Soc., Faraday Trans. 2, 1976, 72, 1525-1568. 
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Figure C2-26: Forms of the amphiphile according to its p valor and related to the 
morphology of the corresponding self-assembled aggregate. 
 When p is inferior to 1/3, the amphiphile adopts a conical shape and 
forms spherical micelles in water. When p is comprised between 1/3 and 1, the 
amphiphile presents a truncated conical shape, and it adopts a cylindrical shape 
when p becomes equal to 1. When p is comprised between 1/3 and 1/2, 
cylindrical micelles are formed and when p is comprised between 1/2 and 1, the 
amphiphiles self-assemble into flexible and curved bilayers (Lα phase) and can 
form more complex structures like vesicles or sponge phases. In contrast to 
micelles, vesicles are not dense spheres and present a vacuole in their center. 
Sponge phases (L3 phases) are bicontinuous cubic phases. When p is equal to 1, 
the amphiphiles form planar bilayers that usually stack one on top of each other 
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(Lβ phase). Finally, when p is superior to 1, the amphiphiles form inverted 
structures. 
 The formation of supramolecular aggregates by dissolution of an 
amphiphile in water can only occur when the amphiphile is above a given 
concentration. This concentration, which depends on the amphiphile nature, 
the solvent, the temperature, the pressure and the ionic force, is called “critical 
aggregation concentration” (CAC). At concentrations below the CAC, the 
amphiphile is fully dissolved in the solvent and no interactions between the 
amphiphilic molecules occur. Some amphiphiles situate themselves at the 
surface of the solvent where they contribute to reduce the interfacial tension 
between the air and the solvent. The increase of the amphiphile concentration 
leads to a saturation of the solvent surface. Above this concentration, the 
amphiphiles can self-assemble into aggregates (figure C2-27).[101] 
 
Figure C2-27: Localization of the amphiphiles in a solution while increasing their 
concentration and formation of aggregates above the CAC. 
  
                                                          
[101] M.J. Rosen, J.T. Kunjappu, Surfactants and interfacial phenomena, 4th edition, 2012, John 
Wiley & Sons, Inc, Hoboken, USA. 
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2.2.3.2- Amphiphilic dendritic derivatives, interesting supramolecular 
aggregates 
 The most common dendritic amphiphiles are dendrimers and 
hyperbranched polymers with a lipophilic internal core surrounded with by a 
hydrophilic shell. These compounds are usually soluble in water and can act as 
micelles even though they are composed of only one and unique molecule. They 
were described as “unimolecular micelles” (figure C2-28).[102] These micelle-like 
molecules are small, usually between 5 and 20 nm. Therefore, they are not very 
sensitive to reticuloendothelial system (RES) clearance and can be easily 
internalized by cells. Moreover, they can encapsulate small lipophilic molecules, 
such as drugs or dyes, in their inner structure, thus increasing their solubility in 
water.[103] 
 Some high generation dendrimers naturally possess the property of 
forming “unimolecular micelles” in water even though aggregation between 
 
 
Figure C2-28: Schematic representation of a “unimolecular micelle” and TEM image 
after dissolution in water, adapted from ref. [108]. 
                                                          
[102] G.R. Newkome, C.N. Moorefield, G.R. Baker, M.J. Saunders, S.H. Grossman, Unimolecular 
micelles, Angew. Chem. Int. Ed., 1991, 30, 1178-1180. 
[103] a) F. Xiaoshan,  L. Zibiao, X.J. Loh, Recent development of unimolecular micelles as 
functional materials and applications, Polym. Chem., 2016, 7, 5898-5919; b) M. Liu, K. Kono, 
J.M.J Fréchet, Water-soluble dendritic unimolecular micelles: their potential as drug delivery 
agents, J. Control. Release, 2000, 65, 121-131. 
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various macromolecules are generally observed.[104] In order to increase the 
stability of the “unimolecular micelles”, dendrimer post-functionalization  
with hydrophilic chains[105], lipophilic chains[106] or both[107] were performed. 
Additionally, targeting moieties have been added at the periphery of these 
structures to reach specific diseased tissues.[108] 
 In contrast to core-shell amphihilic dendrimers that give unimolecular 
micelles, numerous amphiphiles based on dendrimers have been synthesized 
that form aggregates in water. Particularly, because of their controlled and 
versatile architecture, amphiphilic Janus dendrimers, and hybrid linear-
dendritic block copolymers (HLDBCs) afford interesting possibilities to form 
nanoaggregates while encapsulating lipophilic, amphiphilic and hydrophilic 
drugs within their diverse structures modifying their bioavailability and in 
particular water solubility, release profile and activity.[109] 
 Amphiphilic Janus dendrimers are composed of two antagonistic parts: 
one is hydrophilic whereas the second one is lipophilic. They can consist of  
two dendrons based on the same monomer forming therefore homodendritic  
                                                          
[104] C. Yu , L. Ma, K. Li, S. Li, Y. Liu, Y. Zhou, D. Yan, Molecular dynamics simulation studies of 
hyperbranched polyglycerols and their encapsulation behaviors of small drug molecules, Phys. 
Chem. Chem. Phys., 2016, 18, 22446-22457 
[105] K. Sharma, O.Y. Zolotarskaya, K.J. Wynne, H. Yang, Poly (ethylene glycol)-armed 
hyperbranched polyoxetanes for anticancer drug delivery, J. Bioact. Compat. Polym., 2012, 27, 
525-539. 
[106] L. Ye, K. Letchford, M. Heller, R. Liggins, D. Guan, J.N. Kizhakkedathu, D.E. Brooks, J.K. 
Jackson, H.M. Burt, Synthesis and characterization of carboxylic acid conjugated, 
hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for 
Cisplatin 
[107] Y. Xiao, H. Hong, A. Javadi, J.W. Engle, W. Xu, Y. Yang, Y. Zhang, T.E. Barnhart, W. Cai, S 
Gong, Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron 
emission tomography imaging, Biomaterials, 2012, 33, 3071-3082. 
[108] W. Cao, J. Zhou, A. Mann, Y. Wang, L. Zhu, Folate-functionalized unimolecular micelles 
based on a degradable amphiphilic dendrimer-like star polymer for cancer cell-targeted drug 
delivery, Biomacromolecules, 2011, 12, 2697-2707. 
[109] B.N.S. Thota, L.H. Urner, R. Haag, Supramolecular architectures of dendritic amphiphiles 
in water, Chem. Rev., 2016, 116, 2079-2102. 
Chapter 2 
58 
 
Figure C2-29: Chemical structures of a homodendritic (A) and a heterodendritic (B) 
amphiphilic Janus dendrimer and cryoTEM images of various aggregates formed by 
some amphiphilic Janus dendrimers (C), adapted from ref. [111]. Chemical structure of 
an amphiphilic dendron (D) (adapted from ref. [112]). The red block represents the 
lipophilic block and the blue block represents the hydrophilic block.  
structures (figure C2-29-A) or, alternatively, they can be formed by two 
dendrons based on different monomers forming heterodendritic structures 
(figure C2-29-B).[110]  
 The difference of hydrophilicity of the two dendrons is usually reached by 
the addition of hydrophilic or lipophilic moieties at the terminal groups of one 
of the dendrons constituting the final Janus dendrimer (figure C2-29-B) or by the 
addition of hydrophilic moieties at the terminal groups of one of the dendrons 
and the addition of lipophilic moieties at the terminal groups of the other 
                                                          
[110] D.R. Sikwal, R.S. Kalhapure, T. Govender, An emerging class of amphiphilic dendrimers 
for pharmaceutical and biomedical applications: Janus amphiphilic dendrimers, Eur. J. Pharm. 
Sci., 2017, 97, 113-134. 
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dendron (figure C2-29-A). Playing with the different generations of the 
hydrophilic and lipophilic dendrons, a large variety of different aggregates with 
tunable, highly controlled and predictable morphologies and sizes can be 
obtained (figureC2-30-C).[111] 
 In parallel, amphiphilic dendrons have also been developed (figure C2-
29-D). They are more simple structures, based on a hydrophilic dendron and a 
lipophilic chain.[112] As a result of self-aggregation, the resulting nanostructures 
can act as high generation dendrimers bearing numerous peripheral groups 
while they are only based on dendrimers or dendrons of small generation. 
These non-covalent structures usually afford a lower synthetic cost and a higher 
biocompatibility and biodegradability than their related high generation 
dendrimers. 
 Hybrid linear-dendritic block copolymers (HLDBCs and HDLDBCs) are 
another dendritic family that can exhibit amphiphilic properties. Three main 
procedures allow obtaining these amphiphilic hybrids (figure C2-30): 
 - by coupling hydrophilic dendron(s) with a lipophilic linear polymer, 
 - by coupling lipophilic dendron(s) with a hydrophilic linear polymer, 
 - by coupling hydrophilic or lipophilic dendron(s) with an amphiphilic linear 
 polymer. 
                                                          
[111] V. Percec, D.A. Wilson, P. Leowanawat, C.J. Wilson, A.D. Hughes, M.S. Kaucher, D.A. 
Hammer, D.H. Levine, A.J. Kim, F.S. Bates, K.P. Davis, T.P. Lodge, M.L. Klein, R.H. DeVane, E. 
Aqad, B.M. Rosen, A.O. Argintaru, M.J. Sienkowska, K. Rissanen, S. Nummelin, J. Ropponen, 
Self-assembly of Janus dendrimers into uniform dendrimersomes and other complex 
architectures, Science, 2010, 328, 1009-1014; c) M. Peterca, V. Percec, P. Leowanawat, A. 
Bertin, Predicting the size and properties of dendrimersomes from the lamellar structure of 
their amphiphilic Janus dendrimers, J. Am. Chem. Soc., 2011, 133, 20507-20520. 
[112] a) M. Calderón, M.I. Velasco, M.C. Strumia, A.T. Lorenzo, A.J. Müller, M.R. Rojas, A.E. 
Sáez, Synthesis of amphiphilic dendrons and their interactions in aqueous solutions with 
cetyltrimethylammonium p-toluenesulfonate (CTAT), J. Colloid Inter. Sci., 2009, 336, 462-469; 
b) S.M. Bromfield, P. Posocco, C.W. Chan, M. Calderon, S.E. Guimond, J.E. Turnbull, S. Pricl, 
D.K. Smith, Nanoscale self-assembled multivalent (SAMul) heparin binders in highly 
competitive, biologically relevant, aqueous media, Chem. Sci., 2014; 5, 1484-1492. 
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 As occurs with Janus dendrimers, a large variety or different aggregates 
with tunable and highly controlled morphologies has been described using 
amphiphilic hybrid linear-dendritic block copolymers (HLDBCs).[113] 
 Moreover, stimuli-responsive amphiphilic HLDBCs have been described. 
The morphologies of the aggregates formed by such compounds can be 
modified after exposure to an external input. For example, spherical aggregates 
based on thermoresponsive poly(N-isopropylacrylamide) polymer and polyether 
dendron have been transformed into bigger entangled nanotubes after being 
heated[114] and spherical aggregates, worm-like micelles, spherical and tubular 
vesicles have been obtained with a unique polyampholyte HLDBC based on a 
pH-sensitive poly-(L)-lysine linear polymer and a poly(L-glutamic acid)-
poly(amidoamine) dendritic construct.[115] 
 
Figure C2-30: Schematic representation of an amphiphilic HLDBC based on polyether 
dendron and thermoresponsive poly(N-isoproprylacrylamide); after being heated the 
spherical aggregates were transformed into entangled nanotubes, adapted from ref. 
[114]. 
                                                          
[113] a) X. Fan, Y. Zhao, W. Xu, L. Li, Linear–dendritic block copolymer for drug and gene 
delivery, Mat. Sci. Eng. C, 2016, 62, 943-959, b) Q. Yu, J. Liu, D. Chen, R. Wang, Self-assembly of 
linear-dendritic triblock copolymer dependent on variant generations, Polymer, 2015, 79, 179-
186. 
[114] L. Zhu, G. Zhu, M. Li, E. Wang, R. Zhu, X. Qi, Thermosensitive aggregates self-assembled 
by an asymmetric block copolymer of dendritic polyether and poly(N-isopropylacrylamide), 
Eur. Polym. J., 2002, 38, 2503-2506. 
[115] L. Chen, T. Chen, W. Fang, Y. Wen, S. Lin, J. Lin, C. Cai, Synthesis and pH-responsive 
“schizophrenic” aggregation of a linear-dendron-like polyampholyte based on oppositely 
charged polypeptides, Biomacromolecules, 2013, 14, 4320-4330. 
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 An interesting characteristic of the amphiphilic dendritic aggregates 
based on either Janus dendrimer or hybrid linear-dendritic block copolymers 
(HLDBCs and HDLDBCs) when compared with the ones based on small molecule 
surfactants is their resistance to dilution. In fact, when administered as a 
nanomedicine treatment, the aggregates are generally highly diluted and 
sometimes below their CAC, which should induce their break down. Fortunately, 
the disassembly of aggregates based on high molecular weight amphiphiles, 
such as the dendritic amphiphiles, is not kinetically favored and may be delayed 
from days to weeks making these aggregates highly suitable for drug 
delivery.[116] 
  
                                                          
[116] a) H. Gheybi, M. Adeli, Supramolecular anticancer drug delivery systems based on linear-
dendritic copolymers, Polym. Chem., 2015, 6, 2580-2615; b) P. Opanasopit, M. Yokoyama, M. 
Watanabe, K. Kawano, Y. Maitani, T. Okano, Block copolymer design for camptothecin 
incorporation into polymeric micelles for passive tumor targeting., Pharm. Res., 2004, 21, 
2001-2008.   
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2.3- An extended library of dendritic 
materials for drug and gene delivery 
 A large variety of dendrimers are currently investigated as vectors for 
gene and drug delivery purposes. Herein, some relevant examples of the most 
used dendritic architectures, including dendrimers, hyperbranched polymers, 
self-assembling amphiphilic dendrimers and hybrid linear-dendritic block 
copolymers will be commented.  
2.3.1- Most common dendrimers and dendritic 
derivatives based on nitrogen functions 
 
2.3.1.1- Poly(amidoamine) dendrimers 
 Poly(amidoamine) dendrimers, abbreviated as PAMAMs, are one of the 
most commonly used dendrimers in nanomedicine as evidenced by the more 
than 400 articles containing PAMAM in their title and reviews dealing 
exclusively with it published since 2010,[117] as well as numerous patents.[118] 
                                                          
[117] a) D. Luong, P. Kesharwani, R. Deshmukh, M.C.I.M. Amin, U. Gupta, K. Greish, A.K. Iyer, 
PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective 
anticancer drug and gene delivery, Acta Biomaterialia, 2016, 43, 14-29; b) E.B. Bahadıra, M.K. 
Sezgintürk, Poly(amidoamine) (PAMAM): an emerging material for electrochemical 
bio(sensing) applications, Talanta, 2016, 148, 427-438; c) P. Kesharwani, S. Banerjee, U. Gupta, 
M.C.I.M. Amin, S. Padhye, F.H. Sarkar, A.K. Iyer, PAMAM dendrimers as promising nanocarriers 
for RNAi therapeutics, Materials Today, 2015, 18, 565-572; d) M. Labieniec-Watala, C. Watala, 
PAMAM dendrimers: destined for success or doomed to fail? plain and modified PAMAM 
dendrimers in the context of biomedical applications,  J. Pharm. Sci., 2015, 104, 2-14; 
e) S. Sadekar, H. Ghandehari, Transepithelial transport and toxicity of PAMAM dendrimers: 
Implications for oral drug delivery, Adv. Drug Deliv. Rev., 2012, 64, 571-588. 
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PAMAM dendrimers were first synthesized by Tomalia’s group in 1985[62] and 
are nowadays commercially available up to the 10th generation with size ranging 
from 0.1 to 13 nm (figure C2-31).[119] 
  
Figure C2-31: PAMAM dendrimer of 2nd generation. 
 
 PAMAM dendrimers have demonstrated their high potential for 
applications in biomedicine,[116-117] catalysis,[120] material science including liquid 
crystals[121] and material engineering.[122]  
 Particularly, in the biomedical field, PAMAM dendrimers were the first 
dendrimers to show effective in vitro plasmid gene transfection in liver, kidney 
                                                                                                                                                                          
[118] D. Rajasekhar, P.C Liao, Patents and the development on polymer based nanomaterial 
(PAMAM dendrimer) for biomedical applications, Recent Patent Biomed. Eng., 2012, 5, 159-
174. 
[62] D.A. Tomalia et al., Polym. J., 1985, 17, 117; cf p.35 
[119] www.dendritech.com 
[120] D. Wang, D. Astruc, Dendritic catalysis - basic concepts and recent trends, Coord. Chem. 
Rev., 2013, 257, 2317-2334 
[ 121 ] M. Marcos, R. Giménez, J.L. Serrano, B. Donnio, B. Heinrich, D. Guillon,  
Dendromesogens: liquid crystal organizations of poly(amidoamine) dendrimers versus 
starburst structures, Chem. Eur. J., 2001, 7, 1006-1013 
[122] L.M. Bronstein, Z.B. Shifrina, Dendrimers as encapsulating, stabilizing, or directing agents 
for inorganic nanoparticles, Chem. Rev., 2011, 111, 5301-5344. 
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and cancerous cells, results reported in 1993.[123] These promising results in 
pDNA transfection with PAMAMs could be extended to other cells and with 
other genetic material, like siRNA for example.[124] 
 PAMAM dendrimers have also been deeply studied for drug delivery. 
They can form dendrimer-drug conjugates by means of drug encapsulation or 
drug-dendrimer covalent bonds, which have been explored to improve the 
activity of various anticancer or antiviral drugs while reducing their side effects. 
Thus, anticancer,[125] antiviral,[126] and antiobiotic[127] properties and/or efficacy 
of various drugs have been successively improved in vitro and in vivo after 
conjugation with PAMAMs. 
 Nevertheless, PAMAM dendrimers are neither fully biocompatible nor 
biodegradable, their cytotoxicity increasing with the dendrimer generation, and 
this limits their applications in nanomedicine.[128] Several strategies have been 
pursued to overcome this drawback. The biocompatibility of high generation 
                                                          
[123] J. Haensler, F.C. Szoka, Polyamidoamine cascade polymers mediate efficient transfection 
of cells in culture, Bioconj. Chem., 1993, 4, 372-379. 
[124] a) J.D. Eichman, A.U. Bielinska, J.F. Kukowska-Latallo, J.R. Baker, The use of PAMAM 
dendrimers in the efficient transfer of genetic material into cells, PSTT, 2000, 3, 232-245; b) 
Liu, X. Liu, P. Rocchi, F. Qu, J.L. Iovanna, L. Peng, Arginine-terminated generation 4 PAMAM 
dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo, 
Bioconjugate Chem., 2014, 25, 521-532. 
[125] Q. Zhong, E.R. Bielski, L.S. Rodrigues, M.R. Brown, J.J. Reineke, S.R.P. Da Rocha, 
Conjugation to poly(amidoamine) dendrimers and pulmonary delivery reduce cardiac 
accumulation and enhance antitumor activity of doxorubicin in lung metastasis, Mol. 
Pharmaceutics, 2016, 13, 2363-2375 
[126] J.J. Landers, Z. Cao, I. Lee, L.T. Piehler, P.P. Myc, A. Myc, T. Hamouda, A.T. Galecki, J.R. 
Baker Jr. Prevention of influenza pneumonitis by sialic acid–conjugated dendritic polymers, J. 
Infect. Dis., 2002, 186, 1222-1230 
[127] R.S. Navath, A.R. Menjoge, H. Da, R. Romero, S. Kannan, R.M. Kannan, Injectable PAMAM 
dendrimer–PEG hydrogels for the treatment of genital infections: formulation and in vitro and 
in vivo evaluation, Mol. Pharmaceutics, 2011, 8, 1209-1223. 
[128] S.P. Mukherjee, H.J. Byrne, Basic Science, Polyamidoamine dendrimer nanoparticle 
cytotoxicity, oxidative stress, caspase activation and inflammatory response: experimental 
observation and numerical simulation, Nanomedicine, 2013, 9, 202-211. 
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PAMAMs has been principally enhanced by PEGylation.[129] Additionally, the 
self-assembly of low generation amphiphilic PAMAM derivatives, such  
as Janus dendrimers[130] or amphiphilic dendrons,[131] allows the formation of 
macromolecular aggregates in water that show the same potential in gene 
transfection than high generation PAMAMs while showing higher 
biocompatibility and biodegradability.  
  
                                                          
[129] D. Luong, P. Kesharwania, R. Deshmukha, Mo. Cairul I.l. Amin, U. Gupta, K. Greish, A.K. 
Iyer, PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective 
anticancer drug and gene delivery, Acta Biomater., 2016, 43, 14-29. 
[130] T. Wei, C. Chen, J. Liu, C. Liu, P. Posocco, X. Liu, Q. Cheng, S. Huo, Z. Liang, M. Fermeglia, 
S. Pricl, X.J. Liang, P. Rocchi, L. Peng, Anticancer drug nanomicelles formed by self-assembling 
amphiphilic dendrimer to combat cancer drug resistance, Proc. Natl. Acad. Sci. USA., 2015, 
112, 2978-2983. 
[131] T. Yu, X. Liu, A.L. Bolcato-Bellemin, Y. Wang, C. Liu, P. Erbacher, F. Qu, P. Rocchi, J.P. Behr, 
L. Peng, An amphiphilic dendrimer for effective delivery of small interfering RNA and gene 
silencing in vitro and in vivo, Angew. Chem. Int. Ed., 2012, 51, 8478-8484. 
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2.3.1.2- Poly(imine) dendrimers 
  Commercial poly(propylene imine) (PPI) and poly(ethylene imine) (PEI) 
dendrimers were first synthesized by Vögtle’s group in 1978 [60,132] and by 
Imae’s group in 2008,[133] respectively (figure C2-32).  
 
Figure C2-32: Examples of poly(ethylene imine) (left) and poly(propylene imine) (right) 
dendrimers. 
 PPI and PEI dendrimers are widely used in gene delivery. They have 
shown effective gene transfection of pDNA and siRNA in vitro and in vivo. 
However, the gene transfection efficacy of these dendrimers is  limited by their 
low biocompatibility.[134] As PAMAM dendrimers, the biocompatibility of PPI 
dendrimers has been enhanced by either PEGylation or formation of 
macromolecular aggregates in water based on amphiphilic HLDBC.[135] 
  
                                                          
[60] E. Buhleier, Synthesis, 1978, 9, 155; cf p.35. 
[132] www.signaaldrich.com 
[133] a) O. Yemul, T. Imae, Synthesis and characterization of poly(ethyleneimine) dendrimers, 
Colloid Polym. Sci., 2008, 286, 747-752; b) www.nanopartica.com. 
[134] a) B.H. Zinselmeyer, S.P. Mackay, A.G. Schatzlein, I.F. Uchegbu, The lower-generation 
polypropylenimine dendrimers are effective gene-transfer agents, Pharm. Res., 2002, 19, 960-
967; b) K. Nam, S. Jung, J.P. Nam, S. Wan Kim, Poly(ethylenimine) conjugated bioreducible 
dendrimer for efficient gene delivery, J. Control. Release, 2015, 220, 447-455. 
[135] a) V. Russ, M. Günther, A. Halama, M.Ogris, E. Wagner, Oligoethylenimine-grafted 
polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene 
delivery, J. Control. Release, 2008, 132, 131-140. b) J. Gu, J. Hao, X. Fang, X. Sha, Factors 
influencing the transfection efficiency and cellular uptake mechanisms of Pluronic P123-
modified polypropyleneimine/pDNA polyplexes in multidrug resistant breast cancer cells, 
Colloids Surf. B; 2016, 140, 83-93. 
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 PPI dendrimers have also been used in drug delivery after surface 
modifications. As examples, PEGylated PPI functionalized with folic acid could 
improve its tumor targeting,[136] and sugar modified PPI could enhance the 
activity of cytarabine, an anticancer drug.[137] 
 Additionally, non-commercial 1,3,5-triazine based dendrimers have 
been developed by Simanek’s group complementary to PPIs and PEIs (figure  
C2-33).[138] They have been used in nanomedicine and could transfer siRNA in 
vitro,[139] and deliver the low water soluble paclitaxel, an antitumor drug, with 
higher or similar efficacy in vivo than formulations of the commercial agent.[140]  
 
Figure C2-33: Example of 1,3,5-triazine dendrimer.   
                                                          
[136] S. Thakur, R.K. Tekade, P. Kesharwani, N.K. Jain, The effect of polyethylene glycol spacer 
chain length on the tumor-targeting potential of folate-modified PPI dendrimers, J. Nanopart. 
Res., 2013, 15, 1625. 
[137] A. Szulc, L. Pulaski, D. Appelhans, B. Voit, B. Klajnert-Maculewicz, Sugar-modified 
poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug 
resistance, Int. J. Pharm., 2016, 513, 572-583. 
[138] J. Lim, E.E. Simanek, Triazine dendrimers as drug delivery systems: from synthesis to 
therapy, Adv. Drug Deliv. Rev., 2012, 64, 826-835. 
[139] O.M. Merkel, M.A. Mintzer, D. Librizzi, O. Samsonova, T. Dicke, B. Sproat, H. Garn, P.J. 
Barth, E.E. Simanek, T.Kissel, Triazine dendrimers as nonviral vectors for in vitro and in vivo 
RNAi: the effects of peripheral groups and core structure on biological activity, Mol. Pharm., 
2010, 7, 969-983. 
[140] S.T. Lo, S. Stern, J.D. Clogston, J. Zheng, P.P. Adiseshaiah, M. Dobrovolskaia, J. Lim, A.K. 
Patri, X. Sun, E.E. Simanek, Biological assessment of triazine dendrimer: toxicological profiles, 
solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel 
construct, Mol. Pharm., 2010, 7, 993-1006. 
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2.3.1.3 - Polyamide dendrimers 
  Commercial poly-(L)-lysine (PLL) dendrimers were first synthesized by 
Denkewalter’s group in 1979,[61] and are the most common polyamide 
dendrimers used in nanomedicine (figure C2-34). In contrast to poly(imine) 
dendrimers mentioned above, PLLs are in general biocompatible at the 
concentrations used for nanomedicine assays although they still present some 
biodegradation issues. Nevertheless, successful in vitro gene transfection[141] 
and in vivo anticancer doxorubicin drug delivery[ 142 ] with PLL dendritic 
derivatives have been reported. 
 
Figure C2-34: Example of poly-(L)-lysine (PLL) dendrimer.  
 Other non-commercial polyamide dendrimers are currently used in 
nanomedicine such as gallic acid-triethylene glycol (GATG) dendrons that 
showed effective in vitro pDNA transfection.[143] 
 
                                                          
[141] M. Ohsaki, T. Okuda, A. Wada, T. Hirayama, T. Niidome,H. Aoyag, In vitro gene 
transfection using dendritic poly(l-lysine), Bioconjugate Chem., 2002, 13, 510-517. 
[142] K.T. Al-Jamal, W.T. Al-Jamal, J.T.W. Wang, N. Rubio, J. Buddle, D. Gathercole, M. Zloh,K. 
Kostarelos, Cationic poly-l-lysine dendrimer complexes doxorubicin and delays tumor growth 
in vitro and in vivo, ACS Nano, 2013, 7, 1905-1917. 
[143] M. De la Fuente, M. Raviña, A. Sousa-Herves, J. Correa, R. Riguera, E. Fernandez-Megia, 
A. Sanchez, M.A. Alonso, Exploring the efficiency of gallic acid-based dendrimers and their 
block copolymers with PEG as gene carriers, Nanomedicine, 2012, 7, 1667-1681.  
[61] R.G. Denkewalter, et al. in US Pat. 4.360.646, 1979. 
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 Polycarbamate dendrimers (figure C2-35) have also been developed. As 
the carbamate group can be quickly degraded when exposed to acidic pH or 
enzymes. Few examples of these dendrimers have been used in drug delivery. 
Among them, a self-immolative polycarbamate dendrimer could specifically 
release anticancer melphalan, doxorubicin and camptothecin drugs after being 
exposed to enzymes thus enhancing their drug activity.[144] 
 
Figure C2-35: Example of polycarbamate dendrimer. 
  
                                                          
[144] a) M. Grinda, J. Clarhaut, B. Renoux, I. Tranoy-Opalinski, S. Papo, A self-immolative 
dendritic glucuronide prodrug of doxorubicin, Med. Chem. Commun., 2012, 3, 68-70; b) A. Sagi, 
E. Segal, R. Satchi-Fainaro, D. Shabata, Remarkable drug-release enhancement with an 
elimination-based AB3 self-immolative dendritic amplifier, Bioorg. Med. Chem., 2007, 15, 3720-
3727. 
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2.3.2 - Most common dendrimers and dendritic 
derivatives based on oxygen functions 
 
2.3.2.1 - Bis-MPA and other polyester dendrimers 
 Among polyester dendrimers, commercial 2,2-bis(hydroxymethyl) 
propionic acid (bis-MPA) dendrimers, based on aliphatic ester groups with 
hydroxyl groups at the periphery, are the most widespread one (figure  
C2-36).[145]  
 
Figure C2-36: 2,2-bis(hydroxymethyl)propionic acid (bis-MPA) dendrimers. 
 Since their first synthesis described by Hult’s group in 1996,[146] the 
synthesis of bis-MPA dendrimers has progressed considerably. Indeed, 
nowadays three protected monomers are currently used to grow the  
dendrimer up to the 6th generation, carrying out versatile procedures that  
may be divergent, convergent or double exponential.[96,144-147] Moreover, new 
                                                          
[96] H. Ihre et al.,  J. Am. Chem. Soc., 2001, 123, 5908. 
[145] A. Carlmark, E. Malmström, M. Malkoch, Dendritic architectures based on bis-MPA: 
functional polymeric scaffolds for application-driven research, Chem. Soc. Rev., 2013, 42, 5858-
5879. 
[146] H. Ihre, A. Hult, E. Söderlind, Synthesis, characterization and 1H NMR self-diffusion 
studies of dendritic aliphatic polyesters based on 2,2-bis(hydroxymethyl)propionic acid and 
1,1,1-tris(hydroxyphenyl)ethane, J. Am. Chem. Soc., 1996, 118, 6388-6395. 
[147] A.P. Goodwin, S.S. Lam, J.M.J. Fréchet, Rapid, efficient synthesis of heterobifunctional 
biodegradable dendrimers, J. Am. Chem. Soc., 2007, 129, 6994-6995. 
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esterification conditions that differ from the classical Steglich’s esterification 
and anhydride coupling have also been described to grow the dendrimer up. For 
instance 1,1’-carbonyldiimidazole/cesium fluoride coupling has been employed 
to synthesize bis-MPA dendrimer up to the 6th generation. In this recent 
procedure, the imidazole moiety activates the carboxylic group of the bis-MPA 
monomer while the fluoride group activates the terminal OH groups of the 
dendrimer allowing high reaction yields (close to 90 %) and easier purifications 
processes.[148] 
 Bis-MPA dendrimers consist of a moderated lipophilic inner part 
surrounded by a hydrophilic shell that allows the water solubility of the whole 
structure. Moreover, they are highly biocompatible and can be easily degraded, 
by simple hydrolysis or by enzymatic activity, into small fragments that do not 
precipitate in water and are not cytotoxic. These properties make them really 
interesting for nanomedicine studies when compared to poly(imine) and 
poly(amidoamine) dendrimers.[149] 
 Therefore, a large variety of bis-MPA dendritic derivatives have been 
synthesized over the years. For instance, 3-arms and 4-arms bis-MPA 
hyperbranched polyesters, respectively based on bis-MPA or pentaerythritol 
ethoxylate, Mn 270,[150, 151] HLDBCs and HDLDBCs with PEG and Janus type 
dendrimers are commercially available.[149]  
 This type of dendritic structure has been widely studied in nanomedicine. 
Bis-MPA dendrimers and hyperbranched polymers have a lipophilic core - 
                                                          
[148] S. García-Gallego, D. Hult, J.V. Olsson, M. Malkoch, Fluoride-promoted esterification with 
imidazolide-activated compounds: a modular and sustainable approach to dendrimers, Angew. 
Chem. Int. Ed., 2015, 127, 2446-2449. 
[149] N. Feliu, M.V. Walter, M.I. Montañez, A. Kunzmann, A. Hult, A. Nyström, M. Malkoch, B. 
Fadeel, Stability and biocompatibility of a library of polyester dendrimers in comparison to 
polyamidoamine dendrimers, Biomaterials, 2012, 33, 1970-1981. 
[150] www.polymerfactory.com 
[151] www.sigmaaldrich.com 
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hydrophilic shell structure that may lead to "unimolecular micelles”, and this 
makes them suitable derivatives for drug delivery purposes. Lipophilic drugs can 
be encapsulated within the internal voids of the dendritic macromolecules or 
can be covalently linked to them.[152]  
 The stability of these “unimolecular micelles” has been enhanced by 
PEGylation resulting in HLDBC and HDLDBC derivatives. For example, lipophilic 
paclitaxel,[153] as well as hydrophilic doxorubicin,[154] two anticancer drugs have 
been successfully encapsulated within these structures improving their physical 
properties. Moreover, pH sensitive HDLBCs have been synthesized to release 
doxorubicin after exposure to mildly acidic pH,[155] as well as light and thermo 
sensitive HLDBCs.[156] 
 Bis-MPA based Janus dendrimers have also been used as drug 
nanocarriers. For example, a series of Janus dendrimers functionalized in one of 
its two sides by aliphatic lipophilic chains have been studied. These dendrimers 
can self-assemble in water forming a large variety of nanostructures; the 
morphology of them depends on the balance between the size of  
                                                          
[152] O.L. Padilla de Jesús, H.R. Ihre, L. Gagne, J.M.J Fréchet, F.C. Szoka, Polyester dendritic 
systems for drug delivery applications: in vitro and in vivo evaluation, Bioconjugate Chem. 
2002, 13, 453-461. 
[153] C. Kontoyianni, Z. Sideratou, T. Theodossiou, L.A. Tziveleka, D. Tsiourvas, C.M. Paleos, A 
novel micellar PEGylated hyperbranched polyester as a prospective drug delivery system for 
paclitaxel, Macromol Biosci., 2008, 8, 871-881. 
[154] Z. Wu, X. Zeng, Y. Zhang, N. Feliu, P. Lundberg, B. Fadeel, M. Malkoch, A.M. Nyström, 
Linear-dendritic polymeric amphiphiles as carriers of doxorubicin - In vitro evaluation of 
biocompatibility and drug delivery, J. Polym. Sci. Part A: Polym. Chem., 2012, 50,217-226 
[155] E.R. Gillies, J.M.J. Fréchet, pH-responsive copolymer assemblies for controlled release of 
doxorubicin, Bioconjugate Chem., 2005, 16, 361-368. 
[156] a) J. del Barrio, L. Oriol, C. Sánchez, JL. Serrano, A. Di Cicco, P. Keller, M.H. Li, Self-
assembly of linear-dendritic diblock copolymers: from nanofibers to polymersomes, J. Am. 
Chem. Soc., 2010, 132, 3762-3769; b) H. García-Juan, A. Nogales, E. Blasco, J.C. Martínez, I. Šics, 
T.A. Ezquerra, M. Piñol, L. Oriol, Self-assembly of thermo and light responsive amphiphilic 
linear dendritic block copolymers, Eur. Polym. J., 2016, 81, 621-633. 
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hydrophilic and the lipophilic dendrons (figure C2-37).[157] Furthermore, they 
could encapsulate lipophilic plitidepsin anticancer drug, increasing its water 
solubility without altering its activity into various cancer cell lines. Other bis-
MPA Janus dendrimers bearing doxorubicin in one side and polyethylene glycol 
chains in the other side has been synthesized. The bloodstream circulation of 
the drug was increased when compared to the free drug and a complete tumor 
regression was observed in vivo.[158] 
 
Figure C2-37: Different morphologies formed by the amphiphilic Janus bis-MPA 
dendrimers observed in TEM, adapted from [157]. 
 In gene therapy, bis-MPA dendritic derivatives have shown promising 
results but more investigation efforts are still required to achieve efficient gene 
transfection. Thus, biocompatible amino functionalized bis-MPA dendrimers 
with tetra ethylene glycol moieties showed good pDNA complexation ability but 
                                                          
[157] E. Fedeli, A. Lancelot, J.L. Serrano, P. Calvo, T. Sierra T, Self-assembling amphiphilic Janus 
dendrimers: mesomorphic properties and aggregation in water, New J. Chem., 2015, 39, 1960-
1967. 
[158] C.C. Lee, E.R. Gillies, M.E. Fox, S.J. Guillaudeu, J.M.J. Fréchet, E.E. Dy, F.C. Szoka, A single 
dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon 
carcinomas, Proc. Natl. Acad. Sci. USA, 2006, 103, 16649–16654. 
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failed to transfect pDNA.[159] Self-assembling Janus bis-MPA dendrimers bearing 
spermine at the periphery were also synthesized for this purpose and were fully 
biocompatible and biodegradable. However, and as the previous materials, even 
showing good pDNA complexation efficiency, they failed to transfect it into the 
cells.[160] The main reason evoked by the authors was the difficulty of these 
materials to release the pDNA within the cells. The more promising derivatives 
are amine modified hyperbranched polymers. They were totally biocompatible 
and biodegradable and could transfect pDNA in vitro. However, the transfection 
efficiency remained low when compared to commercial agents.[161] 
 Other polyester dendrimers have been synthesized in order to be used 
as drug delivery systems for lipophilic and hydrophobic drugs. For example, 
polyglycerolsuccinic acid (PGLSA) dendrimers could encapsulate small lipophilic 
molecules like anticancer camptothecin while maintaining its activity.[ 162 ] 
Hydrophilic doxorubicin drug was encapsulated within polyester dendrimers 
based on 2,2-bis(acryloyloxymethyl)propionic acid and 1-thioglycerol 
monomers.[163] 
  
                                                          
[159] J. Movellan, R. González-Pastor, P. Martín-Duque, T. Sierra, J.M. de la Fuente, J.L. 
Serrano, New ionic bis-MPA and PAMAM dendrimers: a study of their biocompatibility and 
DNA-complexation, Macromol. Biosci., 2015, 15, 657-667. 
[160] a) A. Barnard, P. Posocco, S. Pricl, M. Calderon, R. Haag, M.E. Hwang, V.W.T. Shum, D.W. 
Pack, D.K. Smith, Degradable self-assembling dendrons for gene delivery: experimental and 
theoretical insights into the barriers to cellular uptake, J. Am. Chem. Soc., 2011, 133, 20288-
20300; b) G.M. Pavan, A. Danani, S. Pricl, D.K. Smith, Modeling the multivalent recognition 
between dendritic molecules and DNA: understanding how ligand “sacrifice” and screening can 
enhance binding, J. Am. Chem. Soc., 2009, 131, 9686-9694 
[161] R. Reul, J. Nguyen, T. Kissel, Amine-modified hyperbranched polyesters as non-toxic, 
biodegradable gene delivery systems, Biomaterials, 2009, 30, 5815-5824. 
[162] M. T. Morgan, M.A. Carnahan, C.E. Immoos, A.A. Ribeiro , S. Finkelstein , S.J. Lee,M.W. 
Grinstaff, Dendritic molecular capsules for hydrophobic compounds, J. Am. Chem. Soc., 2003, 
125, 15485-15489 
[163] X. Ma, Z. Zhou,E. Jin, Q. Sun,B. Zhang, J. Tang, Y. Shen, Facile synthesis of polyester 
dendrimers as drug delivery  carriers, Macromolecules, 2013, 46, 37-42. 
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2.3.2.2- Polyether dendrimers 
 Commercial polyglycerol (PG) dendrimers and hyperbranched polymers 
are the most common polyether dendrimers used for nanomedicine 
applications.[164] They were first synthesized by Fréchet’s group in 1998 (figure 
C2-38).[165]  
 
Figure C2-38: Polyether (PG) dendrimers. 
 As they are highly biocompatible, PG dendrimers and hyperbranched 
polymers have been used in drug delivery. PG dendrimers that are composed of 
a lipophilic core surrounded by a hydrophilic shell are more suitable to 
encapsulate lipophilic drugs, such as paclitaxel,[166] whereas hyperbranched 
polymers, that present pending hydroxyl groups in their inner structure, are 
more adapted for hydrophilic drug encapsulation.[167] 
 This type of dendrimer has also been used in gene therapy. For example, 
amino-functionalized hyperbranched PG could complex pDNA and transfect it in 
                                                          
[164]M. Calderón, M.A. Quadir, S.K. Sharma, R. Haag, Dendritic polyglycerols for biomedical 
applications, Adv. Mater., 2010, 22, 190-218; b) www.nanopartica.com. 
[ 165 ]M. Jayaraman, J.M.J. Fréchet, A convergent route to novel aliphatic polyether 
dendrimers, J. Am. Chem. Soc., 1998, 120, 12996-12997. 
[166] T. Ooya, J. Lee, K. Park, Hydrotropic dendrimers of generation 4 and 5: synthesis, 
characterization and hydrotropic solubilization of paclitaxedl, Biconjugate Chem., 2004, 15, 
1221-1229. 
[167]  A. Sunder, M. Krämer, R. Hanselmann, R. Mülhaupt, H. Frey, Molecular nanocapsules 
based on amphiphilic hyperbranched polycglycerols, Angew. Chem. Int. Ed., 1999, 38, 3552-
3555. 
Chapter 2 
76 
vitro without showing any cytotoxicity,[ 168 ] and amphiphiles based on 
hydrophilic PG dendrons functionalized with amino moieties could self-
assemble in water and deliver siRNA at a level similar to commercial agents.[169]  
  
                                                          
[168] Leto-Aikaterini Tziveleka, A.M.G. Psarra, D. Tsiourvas, C.M. Paleos, Synthesis and 
evaluation of functional hyperbranched polyether polyols as prospected gene carriers, Int. J. 
Pharm., 2008, 356, 314-324 
[169] A. Tschiche, A.M. Staedtler, S. Malhotra, H. Bauer, C. Böttcher, S. Sharbati,M. Calderón, 
M. Koch,T.M. Zollner, A. Barnard, D.K. Smith, R. Einspanier, N. Schmidt, R. Haag, Polyglycerol-
based amphiphilic dendrons as potential siRNA carriers for in vivo applications, J. Mater. Chem. 
B, 2014, 2, 2153-2167. 
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2.3.2.3 - Other dendrimers used for nanomedicine 
 Phosphorus has been incorporated to various dendritic structures 
providing phosphorus containing dendrimers that are water soluble and 
biocompatible.[170] They have been used in drug delivery, for example 
enhancing the in vivo biodistribution of carteolol, a drug used to treat 
glaucoma.171 Additionally, after functionalization with pyrrolidinium cationic 
group, they showed effective pDNA transfection in vitro although it showed less 
efficiency than lipofectamine®, a commercial agent.[172]  
 Organosilicon dendrimers, based on carbosilane (Si-C) and carbosiloxane 
(Si-O) have also been synthesized and studied for nanomedicine purposes as 
they are generally biocompatible and biodegradable.[173] For instance, anionic 
and cationic carbosilane dendrimers have been used in drug delivery associated 
with antiviral drugs or with ibuprofen.[ 174 ] For gene delivery purposes, 
carbosilane dendrimers have been able to deliver anti-HIV siRNA in vivo with 
high efficiency and low cytotoxicity.[175]  
                                                          
[ 170 ] A.M. Caminade, C.O. Turrin, J.P. Majoral, Biological properties of phosphorus 
dendrimers, New. J. Chem., 2010, 34, 1512-1524. 
[171] G. Spataro, F. Malecaze, C.O. Turrin, V. Soler, C. Duhayon, P.P. Elena, J.P. Majoral, A.M. 
Caminade, Designing dendrimers for ocular drug delivery, Eur. J. Med. Chem., 2010, 45, 326-
334. 
[172] C. Padié, M. Maszewsk, K. Majchrzak, B. Nawrot, A.M. Caminade J.P. Majoral, 
Polycationic phosphorus dendrimers: synthesis, characterization, study of cytotoxicity, 
complexation of DNA, and transfection experiments, New. J. Chem., 2009, 33, 318-326. 
[173] C. Kim, J.H. Hong, Carbosilane and carbosiloxane dendrimers, Molecules, 2009, 14, 3719-
3730. 
[174] a) D. Sepúlveda-Crespo, J.L. Jiménez, R. Gómez, F.J. de la Mata, P.L. Majano, M.Á. 
Muñoz-Fernández, P. Gastaminza, Polyanionic carbosilane dendrimers prevent hepatitis C virus 
infection in cell culture, Nanomedicine, 2017, 49-58; b) A.J. Perisé-Barrios, E. Fuentes-
Paniagua, J. Sánchez-Nieves, M.J. Serramía, E. Alonso, R.M. Reguera, R. Gómez, F.J. de la Mata, 
M.Á. Muñoz-Fernandez, Improved efficiency of ibuprofen by cationic carbosilane dendritic 
conjugates, Mol. Pharmaceutics, 2016, 13, 3427-3438. 
[175] M.J. Serramía, S. Álvarez, E. Fuentes-Paniagua, M.I. Clemente, J. Sánchez-Nieves, R. 
Gómez, J.F. de la Mata, M.Á. Muñoz-Fernández, In vivo delivery of siRNA to the brain by 
carbosilane dendrimer, J. Controll. Release, 2015, 200, 60-70. 
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 The main objective of this PhD fits within the main research lines of the 
Liquid Crystals and Polymers group of the University of Zaragoza: 
Design, preparation and study of new dendritic systems for both, gene and 
drug delivery.  
 Among the numerous dendritic derivatives used for these nanomedical 
applications, the poly(amidoamine) dendrimers stands out as the most 
investigated and alluring materials; however, its biocompatibility and 
biodegradability issues are hampering its transfer to clinical therapeutic 
assays.[172] On the other hand, polyester dendritic systems based on 2,2’-
bis(hydroxymethyl)propionic acid (bis-MPA) are fully biocompatible and 
biodegradable; nevertheless their use has not as widespread as this 
poly(amidoamines), principally because of their lowest efficiency, especially in 
gene transfection.[173] Poly(ester amide) dendritic derivatives might appeared as 
interesting materials combining the efficiency of poly(amidoamine) dendrimers 
with the biocompatibility of polyester dendrimers but their investigation 
remained essentially limited to linear polymers.[174] 
                                                          
[172] M. Labieniec-Watala, C. Watala, PAMAM dendrimers: destined for success or doomed to 
fail? Plain and modified PAMAM dendrimers in the context of biomedical applications, J. 
Pharm. Sci., 2015, 104,2-14 
[173] S. García-Gallego, A.M. Nyström, M. Malkoch, Chemistry of multifunctional polymers 
based on bis-MPA and their cutting-edge applications, Progr. Polym. Sci., 2015, 48, 85-110. 
[174] a) A. C. Fonseca, M. H. Girl, O. N. Simões, Biodegradable poly(ester amide)s – A 
remarkable opportunity for the biomedical area: Review on the synthesis, characterization and 
applications, Prog. Polym. Sci., 2014, 39, 1291-1311; b) D. Pahovnik, A. Čusak, S. Reven, E. 
Žagar, Synthesis of poly(ester-amide) dendrimers based on 2,2-bis(hydroxymethyl) propanoic 
acid and glycine, J. Polym. Sci. Part A: Polym. Chem., 2014, 52, 3292-3301; c) X. Li,X.Lu, Y. Lin, J. 
Zhan, Y. Li, Z. liu, X. Chen, S. Liu, Syntheis and charachterization of hyperbrnached poly(ester-
amide)s from commercially available dicarboxylicacids and multihydroxyl primary amines, 
Macromolecules, 2006, 39, 7889-7899. 
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 Taking in account the previous works developed in our group, we decided 
to use two dendron architectures based on 2,2’-bis(hydroxymethyl)propionic 
acid (bis-MPA) modified with glycine moieties (figure C3-1): 
 - In the first case, the glycine moieties were added at the periphery of the 
 dendron in order to obtain amino-terminated bis-MPA polyester 
 dendrons. This dendron structure has been previously studied in our group. 
 - In the second case, the glycine moieties were added at both, the 
 periphery and the internal branches of the dendrons in order to obtain 
 a new type of poly(ester amide) dendrons based on  
 2,2’-bis(glyciloxymethyl)propionic acid (bis-GMPA).  
 
Figure C3-1: amino-terminated bis-MPA polyester dendron of 3rd generation (left) and 
amino-terminated bis-GMPA poly(ester amide) dendron of 2nd generation (right) with 
an azide group at the focal point.  
  The insertion of internal amide groups in the bis-GMPA architecture 
would increase its hydrophilic character and might induce the formation of 
favorable hydrogen bonds among dendrons and/or with small guest molecules, 
such as drugs. 
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  Using these two dendron structures, we have designed four types of 
dendritic derivative. In all cases, the possibility of playing with the amphiphilic 
nature of the compounds has been considered (figure C3-2). 
 (A) Janus dendrimers: 
 which are composed in one of the two hydrophilic dendrons mentioned 
 and a lipophilic dendron derived from bis-MPA functionalized with 
 terminal stearic acids. 
 (B) Hybrid dendritic-linear-dendritic block copolymers (HDLDBCs): 
 which are formed by a commercial amphiphilic linear triblock copolymer 
 based  on polyethylene oxide - polypropylene oxide - polyethylene oxide 
 (PEO-PPO-PEO), commercialized under the name, Pluronic® F-127, 
 modified in its terminal positions by the two hydrophilic dendron
 moieties. 
 (C) Dendronized hyperbranched polymers (DHPs): 
 which are composed by a central core derived from commercial bis-MPA 
 hyperbranched polyesters grafted with peripheral amino-terminated bis-
 MPA dendrons. 
 (D) bis-GMPA dendrimers: 
 Due to the novelty of the bis-GMPA dendrons, two dendrimers based on 
 these structures have been synthesized by a convergent method using 
 tripropargyl amine as a central core. 
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Figure C3-2: Chemical structures of the dendritic systems designed. 
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 Using these four dendritic systems, we have planned the following 
specific objectives for this work: 
 (I) Study of the abilities of the amphiphilic Janus dendrimers and the 
 HDLDBCs to transport and deliver camptothecin for anti-Hepatitis C 
 therapy.  
 This work was carried out in collaboration with Dr. Olga Abián of the 
 Biocomputation and Physics of Complex Systems (BIFI). 
 (II) Study of the potential of the globular bis-MPA DHPs and the bis-GMPA 
 dendrimers to transfect siRNA and pDNA.  
 This work was carried out in collaboration with Dr. María Pilar Martín-
 Duque of the Center for Biomedical research of Aragon (CIBA). 
 (III) Study of the potential of the bis-MPA and bis-GMPA HDLDBCs and bis-
 MPA DHPs to promote drug targeting of antimalarial drugs.  
 This work was carried out in collaboration with Dr. Xavier Fernàndez-
 Busquets of the Barcelona Institute for Global Health (ISGlobal) and the 
 Institute for Bioengineering of Catalonia (IBEC). 
 In order to reach these objectives, some secondary objectives have been 
necessary and are herein detailed. 
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Objective (I): 
 (i) Synthesis and chemical characterization of the amphiphilic derivatives 
 based on the Janus dendrimers and the HDLDBCs. 
 (ii) Study of the self-assembly in water of these amphiphilic dendritic 
 derivatives and of the size and morphology of the aggregates. Moreover, as 
 Pluronic® F-127 has a lower critical solution temperature (LCST) in water, 
 the size of its aggregates will be studied at different temperatures. 
 (iii) Encapsulation of camptothecin, CPT, used as anti-hepatitis C drug,  into 
 the aggregates formed by the amphiphilic Janus dendrimers and the 
 HDLDBCs and its influence on the size and  morphology of the aggregates.  
 (iv) Evaluation of the activity against the hepatitis-C virus replication and the 
 cytotoxicity of the dendritic derivatives and dendritic nanocarrier/CPT 
 conjugates with respect to the free drug. 
 (v) Synthesis of a low-water soluble dendritic fluorophore based on the 
 commercial rhodamine B in order to label the aggregates formed by the 
 amphiphilic dendritic derivatives and study their cellular uptake. 
 (vi) Encapsulation of this low-water soluble fluorophore, together with
 camptothecin, within the Janus dendrimers and the study of its influence on 
 the morphology, size and drug activity. 
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Objective (II): 
 (i) Synthesis and chemical characterization of the bis-GMPA dendrimers and 
 the bis-MPA dendronized hyperbranched polymers (DHPs).  
 (ii) Study of their acid-base properties and their aggregation in water. 
 (iii) Formation of dendriplexes by electrostatic interactions with pDNA 
 and siRNA by the bis-GMPA dendrimers and the bis-MPA DHPs, as well as 
 study of their morphology, size and net charge.  
 (xiv) In vitro pDNA and siRNA transfection experiments with these 
 derivatives into cancerous and healthy cells. 
Objective (III): 
 (i) Synthesis of the lipophilic base forms of chloroquine, primaquine and 
 quinacrine, three antimalarial drugs from their commercial hydrophilic salt 
 forms. 
 (ii) Encapsulation of these drugs in their hydrophilic and lipophilic forms 
 within the DHPs and the HDLDBCs.  
 (iii) Formation of complexes by electrostatic interactions with the  
 bis-MPA DHPs and heparin, a polysaccharide that favors the targeting of 
 drug nanocarriers to the parasite infected red blood cells. The formation of 
 the complexes will be study with the DHPs and with the DHP/antimalarial 
 drug conjugates. Their morphology and size of will be studied.  
 (iv) Labeling of the DHP and HDLDBC with fluorofores based on the 
 commercial rhodamine B in order to study their targeting abilities to the 
 parasite infected red blood cells.  
 (v) Study of the antimalarial activity of the dendritic nanocarrier/drug 
 conjugates and the dendritic nanocarrier/heparin/drug conjugates with 
 respect with the free drugs.  
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 In this chapter, new amphiphilic Janus dendrimers and hybrid dendritic-
linear-dendritic block copolymers (HDLDBCs) based on 2,2-bis(hydroxymethyl) 
propionic acid (bis-MPA) and 2,2-bis(glyciloxymethyl)propionic acid (bis-GMPA) 
are described as nanocarriers to deliver camptothecin as an anti-hepatitis C 
virus drug.  
 First, the synthesis and characterization of the dendrons of bis-MPA and 
bis-GMPA used to build the dendritic systems as well as their biocompatibility 
and degradability are described. Second, the synthesis, characterization and 
self-assembly in water of the amphiphilic Janus dendrimers and the HDLDBCs 
are studied. Finally, their ability to deliver camptothecin and increase its 
biological properties so as to decrease the replication of the hepatitis C virus in 
infected hepatic cells is discussed. 
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4.1- Bis-MPA and bis-GMPA dendrons 
 
 This first part describes the synthesis, chemical characterization and the 
properties of dendrons based on 2,2’-bis(hydroxymethyl)propionic acid (bis-
MPA) and 2,2’-bis(glyciloxymethyl)propionic acid (bis-GMPA) that will be further 
used to build dendritic derivatives.  
 On the one hand, polyester bis-MPA dendrons are functionalized at their 
periphery with terminal glycine moieties in order to enhance their cellular 
internalization[160a] and their abilities to transport both, drugs[179] and genetic 
material.[180] On the other hand, these dendrons are functionalized at their 
periphery with lipophilic alkyl chains in order to trigger the self-assembly in 
aqueous media of amphiphilic dendritic derivatives. The former has an azide 
group at their focal point while the letter has an alkyne group to allow their 
coupling by means of a copper(I) azide-alkyne cycloaddition (CuAAC) reaction. 
As the synthesis and the biological properties of these dendrons have been 
extensively described in two previous thesis reports of the group[181,182] and 
three papers[95,157,159], they will be herein briefly commented. 
                                                          
[95] J. Movellan, P. Urbán et al., Biomacromolecules, 2014, 35, 7940. 
[157] E. Fedeli et al., New. J. Chem., 2015, 39, 1960. 
[159] J. Movellan et al., Macromol. Biosci., 2015, 15, 657. 
[160a] A. Barnard et al., J. Am. Chem. Soc., 2011, 133, 20288-20300. 
[179] S. Tarvirdipour, E. Vasheghani-Farahani, M. Soleimani, H. Bardaniac, Functionalized 
magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer 
cells, Int. J. Pharm., 2016, 501, 331-341.  
[180] S. Malhotra, H. Bauer, A. Tschiche, A.M. Staedtler, A. Mohr, M. Calderón, V.S. Parmar, L. 
Hoeke, S. Sharbati, R. Einspanier, R. Haag, Glycine-Terminated Dendritic Amphiphiles for 
Nonviral Gene Delivery., Biomacromolecules, 2012, 13, 3087-98. 
[181] J. Movellan, Dendritic derivatives as building blocks for biomedical applications, 2013, 
Universidad de Zaragoza. 
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 As part of the objectives of the work of this thesis, a new type 
poly(esteramide) dendrons has been prepared. They are based on  
2,2’-bis(glyciloxymethyl)propionic acid and contain internal and peripheral 
glycine moieties. Additionally, these dendrons have an azide group at their focal 
point so that they can be coupled with complementary moieties by CuAAC 
reactions. The synthesis, chemical characterization, biocompatibility and 
degradability of the new bis-GMPA dendrons are fully described.  
 The CuAAC “click chemistry” was performed with the bis-MPA and bis-
GMPA dendrons bearing terminal t-Boc protected amino groups in order to 
avoid the unfavorable complexation of the copper catalyst by the amino-
terminated dendrons, since this might reduce the reaction conversion. Hence, 
each “click chemistry” coupling was always followed by the deprotection of the 
terminal amino groups in acidic conditions in order to obtain the final dendritic 
derivatives.  
  
                                                                                                                                                                          
[182] E. Fedeli, Self-assembly of dendrimeric derivatives: possible vectors for drug delivery, 
2013, Universidad de Zaragoza. 
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4.1.1- Bis-MPA dendrons 
 
4.1.1.1- t-Boc protected amino terminated bis-MPA dendrons 
 2,2’-bis(hydroxymethyl)propionic acid (bis-MPA) dendron derivatives 
bearing peripheral t-Boc protected amino groups and an azide group at the focal 
point were synthesized up to the 3rd generation following a divergent pathway 
first described by our group in 2014.[95] 
 First of all, the ketal-protected bis-MPA monomer was synthesized in 
one step during which the two terminal hydroxyl groups were protected with a 
ketal group (figure C4-1). For this purpose, commercial bis-MPA reacted with 
2,2-dimethoxypropane, in the presence of p-toluenesulfonic acid as catalyst, in 
dry acetone. The final product was purified by several washings with aqueous 
solutions yielding 69 % of the pure protected bis-MPA monomer.  
 
Figure C4-1: Synthesis of ketal-protected bis-MPA monomer*. 
 In order to perform the subsequent copper(I) catalyzed azide-alkyne 
cycloaddition with the dendron derivatives, the focal point of the pre-
hydrophilic dendrons derivatives was functionalized with a hexan-1-azide chain 
(figure CIV-2-A). For that purpose, 6-chloro-hexan-1-ol reacted with sodium 
azide in dimethylformamide at 100ºC. The azide group, according to a 
nucleophile substitution of type II, replaced the chlorine atom of the alkyl chain 
and 6-azidehexan-1-ol chain was obtained. 
                                                          
[95] J. Movellan, P. Urbán et al., Biomacromolecules, 2014, 35, 7940. 
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 Then, 6-azidehexan-1-ol chain reacted with the ketal-protected bis-MPA 
monomer in dry dichloromethane according to a Steglich’s esterification 
procedure (figure C4-2-A, general procedure I). 
 
Figure C4-2 : A) general procedure I): esterification reaction for growing up the bis-
MPA dendron derivatives and B) general procedure II): deprotection of the terminal 
hydroxyl groups. See chapter 7 for the description of the general procedures. 
 DCC (dicyclohexylcarbodiimide) acts as a coupling agent and is consumed 
during the reaction forming dicyclohexylcarbodiurea (DCU) while DPTS (4-
(dimethylamino)pyridium 4-toluenesulfonate) acts as a catalyst and is 
regenerated after the esterification. After completion of the reaction, DCU was 
removed by filtration and by precipitation in hexanes. Then, the crude product 
was purified by flash chromatography on silica gel to obtain the pure dendron, 
named as N3-[bisMPA,G1]-(ketal)1.  
 The deprotection of the terminal hydroxyl groups was carried out by 
hydrolysis of the ketal using a Dowex® proton exchange resin in methanol 
(figure C4-2-B, general procedure II). This resin allowed the hydrolysis of the 
terminal ketal protective groups of the dendron without reacting with their 
internal ester groups. After completion of the reaction, the resin was easily 
removed by filtration and any other purification was required to obtain pure N3-
[bisMPA,G1]-(OH)2.  
 Following an iterative procedure that used the reaction sequence 
explained above, bis-MPA dendron derivatives bearing an azide group at the 
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focal point were synthesized up to the 3rd generation. Both, esterification 
couplings and the ketal deprotections gave high conversion yields even for the 
highest generation (up to 75 %). Finally, the dendrons of 2nd and 3rd generation 
reacted with N-(tert-butoxycarbonyl)glycine (t-Boc-glycine) using the Steglich’s 
esterification protocol to obtain t-Boc amino protected bis-MPA dendrons of 2nd 
and 3rd generation bearing 4 and 8 t-Boc-glycine moieties at their periphery, 
respectively (figure C4-3, general procedure III). These dendrons were named as 
N3-[bisMPA,G2]-(NHBoc)4 and N3-[bisMPA,G3]-(NHBoc)8, and were obtained 
with 19 % and 20 % global yields for the 2nd and 3rd generation, respectively. 
 
 
Figure C4-3: Synthesis of t-Boc amino protected bis-MPA dendrons of 2nd and 3rd 
generation bearing the 6-azidehexyloxy chain at their focal point. See chapter 7 for 
the description of the general procedures. 
 All the final dendrons and intermediates were characterized by 1H and 13C 
nuclear magnetic resonance (NMR), mass spectrometry (MS), Fourier 
transformed infrared spectroscopy (FTIR) and elemental analysis (EA). Size 
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exclusion chromatography (SEC) was carried out only for the final t-Boc 
protected amino dendrons (figure C4-4). The complete characterization data are 
gathered in the chapter 7. 
 The correct insertion of the terminal t-Boc glycine moieties at the 
periphery of the dendrons was asserted by the presence of two peaks in the 1H 
NMR spectrum at 1.43 and 3.88 ppm corresponding to the methyl protons of 
the t-Boc protective group (H-23) and the methylene protons of the glycine 
moiety (H-20), respectively. Additionally, a broad signal is observed at 5.29 ppm, 
which corresponds to the protons attached to the nitrogen atom. In the 13C 
NMR spectrum, the presence of peaks at 28.3, 42.2, 79.8, 155.8 and 170.0 ppm 
also confirms the correct functionalization of the dendron. Besides, a triplet at 
3.27 ppm and a peak at 51.1 ppm corresponding to the methylene protons in 
the α-position of the azide group (H-1 and C-1) are observed in the 1H and 13C 
NMR spectra. 
 Moreover, the presence of the glycine moieties is observed in the FTIR 
spectra in which a band at 3383 cm-1 corresponding to the N-H stretching and 
another band at 1717 cm-1 corresponding to the N-C=O stretching can be seen.  
Also, a band at 2102 cm-1 that corresponded to the azide group is also observed. 
 In MS and SEC, only one peak is observed for each dendron confirming 
the monodispersity and the perfect functionalization of the terminal groups of 
the bis-MPA dendrons. 
  
 
Figure C4-4: Chemical characterization of N3-[bisMPA,G3](NHBoc)8: 1H NMR (A) and 13C (B) recorded in CDCl3 at 400 MHz and 75 MHz respectively,  
FTIR (C), SEC (D) and MS (E). The signals corresponding to the t-Boc glycine are colored in orange and the ones characteristics of the  
azidomethylene group are colored in green.
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4.1.1.2- Lipophilic bis-MPA dendrons 
 Lipophilic bis-MPA dendrons with terminal aliphatic linear chains of 
seventeen carbons (C17) and a propargyl group at the focal point were 
synthesized up to the 2nd generation. As the previous bis-MPA dendrons, the 
synthesis followed a divergent pathway that had been first described by our 
group in 2015 (figure C4-5).[157] 
 
Figure C4-5: Synthesis of the lipophilic dendron of bis-MPA of 1st and 2nd generation 
with C17 aliphatic linear chains at the periphery and a propargyl group at the focal 
point. See chapter 7 for the description of the general procedures. 
 The propargyl group was inserted at the focal point of the ketal-
protected bis-MPA monomer by means of a Steglich’s esterification. The 
protecting group was removed using the method described before yielding the 
bis-MPA dendron of 1st generation bearing an alkyne group at its focal point,  
                                                          
[157] E. Fedeli et al., New. J. Chem., 2015, 39, 1960. 
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≡-[bisMPA,G1]-(OH)2. This dendron was grown up in order to obtain the 
dendron of 2nd generation, ≡-[bisMPA,G2]-(OH)4. Finally, the peripheral 
hydroxyl groups of the dendrons of the 1st and 2nd generation reacted with 
stearic acid using the Steglich’s esterification conditions (figure C4-5, general 
procedure IV). Thus, two lipophilic bis-MPA dendrons of 1st and 2nd generation 
were obtained with an alkyne group at their focal point and 2 and 4 terminal 
aliphatic chains with global yields of 39 % and 37 %, respectively. These 
dendrons were named as ≡-[bisMPA,G1]-(C17)2 and ≡-[bisMPA,G2]-(C17)4. 
 All the final dendrons and intermediates were characterized by 1H and 13C 
nuclear magnetic resonance (NMR), mass spectrometry (MS), Fourier transform 
infrared spectroscopy (FTIR) and elemental analysis (EA). Size exclusion 
chromatography (SEC) was carried out only for the final dendrons (figure C4-6, 
see chapter 7 for the complete chemical characterization of the derivatives). 
 The correct insertion of the alkyl chains at the periphery of the dendrons 
was asserted by the apparition of four peaks in the 1H NMR spectrum at 0.88, 
1.25, 1.58 and 2.29 ppm corresponding to the methyl proton (H-16) and the 
methylene protons (H-15, H-14 and H-13) respectively. In the 13C NMR 
spectrum, the presence of the chains was confirmed by the apparition of 
various peaks at 14.1, between 17.8 and 34.0 and at 173.1 ppm.  
 In MS, the molecular peak more sodium can be observed for the two 
dendrons. Some low intense peaks are observed in the spectra although they do 
not correspond to dendrons with uncomplete functionalization. In SEC, only a 
monomodal peak is observed attesting the perfect functionalization of the 
dendrons. 
  
  
 
Figure C4-6: Chemical characterization of ≡-[bisMPA,G2]-(C17)4: 1H NMR (A) and 13C (B) recorded in CDCl3 at 400 MHz and 75 MHz respectively,  
FTIR (C), SEC (D) and MS (E). The signals corresponding to the alkyl chains are colored in blue and the ones of the proprargyl moiety are colored in brown.
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 Additionally, a triplet at 2.50 and a doublet at 4.72 ppm corresponding to 
the protons of the propargyl moiety (H-1 and H-3 respectively) are observed in 
the 1H NMR spectrum. Likewise, the peaks corresponding to their relative 
carbons are observed at 75.4 and 52.8 ppm respectively in the 13C NRM spectra.  
 Due to their low intensity, the bands corresponding to the stretching of 
the alkyne groups (H-C≡ and C≡C) are not visible in the dendron spectra after 
the functionalization with the terminal alkyl chains.  
  
Chaper 4 
104 
4.1.2- bis-GMPA dendrons 
 New hydrophilic bis-(glyciloxymethyl)propionic acid (bis-GMPA) dendrons 
with the 6-azidehexyloxy group at the focal point were synthesized up to the 4th 
generation. They were synthesized according to an original divergent synthesis. 
 t-Boc amino-protected bis-GMPA monomer was synthesized in three 
steps starting from commercial bis-MPA (figure C4-7). First of all, the acid moiety 
of the bis-MPA was protected with a benzyl group. Then, its terminal hydroxyl 
groups reacted with t-Boc protected glycine according to the Steglich’s 
esterification conditions. Finally, the benzyl protecting group was removed by 
hydrogenation in the presence of Pd/C as catalyst obtaining the t-Boc protected 
bis-GMPA monomer with a global yield of 59 %. The terminal amines of the bis-
GMPA monomer were protected with t-Boc groups to avoid side reactions 
during the dendron growing up reactions. This protecting group can be easily 
removed in acidic conditions. 
 
Figure C4-7: synthesis of the t-Boc protected bis-GMPA monomer. 
 The synthesis of the bis-GMPA dendrons with an azide group at the focal 
point started from the bis-MPA dendron of 1st generation, N3-[bisMPA,G1]-
(OH)2 (figure C4-2) that reacted with t-Boc glycine in order to obtain the new bis-
GMPA dendron with t-Boc terminal amino groups. The protecting groups were 
removed in acidic conditions in ethyl acetate giving rise to the bis-GMPA 
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dendron of 1st generation with terminal ammonium groups, N3-
[bisGMPA](NH3+Cl-)2 with 30% overall yield (figure C4-8). 
 
Figure C4-8: Synthesis of the1st generation bis-GMPA dendron. 
 Bis-GMPA dendrons of 2nd to 4th generation were prepared by 
subsequent amide couplings (figure C4-9-A, general procedure V). 
 
Figure CIV-9: A) general procedure V): generation growing up by amide coupling 
reaction with the t-boc protected bis-GMPA monomer and B) general procedure VI): 
deprotection of the terminal amino groups. See chapter 7 for the description of the 
general procedures. 
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 The reaction conditions were similar to the Steglich’s esterification 
previously described. The t-boc-protected bis-GMPA  monomer was allowed to 
react with the terminal ammonium groups of dendron N3-[bisGMPA,G1] 
(NH3+Cl-)2 in the presence of dicyclohexylcarbodiimide (DCC),  
1-hydroxybenzotriazole hydrate (HOBt) and 4-(dimethylamino)pyridine (DMAP), 
according to a protocol adapted from Fernández-Megía et al.[183] DCC and HOBt 
act as coupling agents whereas DMAP plays a double role: first, it neutralizes 
the acidic ammonium salts of the dendrons and second, it activates the bis-
GMPA monomer. The reaction was performed in a mixture of dry 
dichloromethane and dry dimethylformamide to allow the dissolution of all the 
reagents. After completion of the reaction, DCU and HOBt precipitates were 
removed by a primary filtration and by a subsequent precipitation in a mixture 
of hexanes and ethyl acetate. The crude product was finally purified by flash 
chromatography on silica gel. The growing up amide couplings showed  
yields between 43 and 61 %. N,N'-carbonyldiimidazole (CDI) and N-
hydroxysuccinimide (NHS) were tested as coupling agents instead of DCC but 
showed lower reaction yields. 
 The deprotection of the terminal amino groups was carried out in acidic 
conditions. The protected dendrimer was dissolved in ethyl acetate in the 
presence of hydrochloric acid (3 M) (figure C4-9-B, general procedure VI). After 
the removal of the t-Boc protecting groups, the terminal amino groups reacted 
with hydrochloride acid to form the ammonium salt that precipitated in ethyl 
acetate. The precipitation not only favors the purification of the compounds, 
but also protects the internal amide and ester groups of the dendron from 
acidic hydrolysis. The deprotection of the terminal amines gave yields between 
89 and 98 %. 
                                                          
[183] E. Fernández-Megía, J. Correa, I. Rodríguez-Meizoso, R. Riguera, A click approach to 
unprotected glycodendrimers, Macromolecules, 2006, 39, 2113-2120. 
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 Following this synthetic protocol, and according to a divergent strategy, 
three new hydrophilic poly(esteramide) dendrons derived from bis-GMPA were 
synthesized, i.e.  N3-[bisGMPA,G2](NH3+Cl-)4, with a 7 % global yield,  
N3-[bisGMPA,G3](NH3+Cl-)8 with a 4 % global yield and N3-[bisGMPA,G4] 
(NH3+Cl-)16 with a 2 % global yield (figure C4-10). 
 
Figure C4-10: Dendrons of bis-GMPA of the 2nd, 3rd and 4th generation. 
 All the dendrons were characterized by 1H and 13C nuclear magnetic 
resonance (NMR), Fourier transform infrared spectroscopy (FTIR) and elemental 
analysis (EA). Additionally, the dendrons bearing the t-Boc protecting groups 
were characterized by mass spectrometry (MS) and size exclusion 
chromatography (SEC). The complete characterization data are gathered in the 
chapter 7. 
 The analyses of the 1H and 13C NMR spectra of the bis-GMPA dendrons 
and their comparison with the spectra of an analogous bis-MPA dendron helped 
the signal assignation to the corresponding protons and carbons and assess 
their correct synthesis (figure C4-11). Moreover, 1H-1H correlation spectroscopy 
(COSY) was performed to corroborate the proton assignation (annexes 1).  
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Figure C4-11: 1H-NMR spectrum of N3-[bisGMPA,G2](NH3+Cl-)4 (up) and  
N3-[bisMPA,G2](OH)4 (down) recorded in CD3OD at 400 MHz. 
 The signals corresponding to the protons that belong to the 6-
azidohexyloxy chain of both dendrons (H-1 to H-6) appear almost identical. In 
the spectrum of the bis-GMPA dendrons, the triplet corresponding to the 
methylene protons in the α-position of the azide group (H-1) is overlapped with 
the signal of the solvent. Nevertheless, the correlation of this triplet with the 
signal corresponding to its vicinal methylene protons (H-2) is observed in 1H-1H 
COSY (see annexes 1). The singlets corresponding to the methyl protons (H-9 
and H-15) appear between 1.1 and 1.4 ppm in both dendrons even if their 
respective signals appear inverted.  
 The signals corresponding to the other protons appear at different 
chemical shifts in both spectra. In the spectrum of the bis-GMPA dendron, new 
singlets are observed near 3.9 ppm that correspond to the methylene protons 
of the glycine groups (H-12 and H-18). Additionally, the signals corresponding to 
the oxymethylene protons are clearly different. First, the ABq systems 
Amphiphilic bis-MPA and bis-GMPA dendritic derivatives for camptothecin delivery 
109 
corresponding to the terminal hydroxymethylene protons -CH2-OH (H-16), 
which appear between 3.6 and 3.7 ppm in the bis-MPA derivative, are not 
observed in the bis-GMPA dendron, pointing out its complete functionalization 
with terminal glycine groups. Second, an additional peak is observed between 
4.2 and 4.6 ppm in the bis-GMPA spectrum, which corresponds to the 
oxymethylene protons of the terminal ester groups, -CH2-OOC- (H-16). Also, the 
signal corresponding to the oxymethylene protons of the internal ester group 
(H-10) is clearly distinct. In the bis-MPA spectrum, it appears as a clear ABq 
system whereas in the bis-GMPA spectrum, the ABq system is much less 
defined. 
 Figure C4-12 gathers the regions of the 1H-NMR spectra corresponding to 
the methylene protons -CH2-N- and -CH2-O- of the bis-GMPA dendrons from the 
1st to the 4th generation. It is possible to distinguish between the peripheral 
protons and those that belong to the internal branches. The methylene protons 
of the external glycine moieties, CH2-N-, appear at higher fields (3.94 ppm) than 
the protons belonging to the internal glycine moieties (3.96 - 4.00 ppm). With 
respect to oxymethylene groups, -CH2-O-, the ABq signals that correspond to 
the peripheral bis-MPA moieties appear at lower fields (4.40 - 4.60 ppm) than 
the protons belonging to the internal bis-MPA moieties (4.33 ppm). Logically, 
the triplet that corresponds to the oxymethylene protons of the 6-azidohexyloxy 
chain appears at the same positions regardless the dendron generation. 
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Figure C4-12: Expansions of the 1H-NMR spectra of bis-GMPA dendrons from the 1st to 
the 4th generation from 3.90 ppm to 4.55 ppm. 
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 The 13C-NMR spectrum of the 2nd generation poly(esteramide) dendron 
of bis-GMPA, N3-[bisGMPA,G2]-(NH3+Cl-)4, is represented and described as an 
example in figure C4-13, together with it homologous bis-MPA dendron. Their 
comparison helped to interpret the spectrum of the new dendron. Additionally, 
1H-13C hetero nuclear single-quantum correlation spectroscopy (HSQC) was 
performed to corroborate the carbon assignation (see annexes 1). 
 
Figure C4-13: 13C-NMR spectrum of N3-[bisGMPA,G2](NH3+Cl-)4 (up) and  
N3-[bisMPA,G2](OH)4 (down) recorded in CD3OD at 100 MHz. 
 New peaks corresponding to the internal and peripheral glycine moieties 
are observed in the bis-GMPA spectrum. Thus, two peaks are observed at 41.1 
and 42.1 ppm, which correspond to the methylene carbon of the glycine groups 
(C-18 and C-12 respectively). As for carbonyl carbon atoms, two representative 
peaks that appear at 168.2 and 174.9 ppm confirm the presence of glycine 
groups within the dendron structure. The first one corresponds to the external 
ester groups (C-17) while the second one corresponds to the amide groups  
(C-13). 
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 The difference between the bis-MPA and bis-GMPA dendrons is also 
clearly observed in FTIR spectroscopy (figure C4-14). 
 
Figure C4-14: FTIR spectra of the dendron of bis-GMPA of 2nd generation (up) and of 
the dendron of bis-MPA of 3rd generation (down). 
 The spectrum of the bis-GMPA dendron shows a broad band with various 
maxima between 3400 and 2600 cm-1 that correspond to the ammonium 
groups. This is in contrast to the spectrum of the bis-MPA dendron that shows 
an only band at 3283 cm-1 belonging to the hydroxyl groups. Whereas the 
presence of the ester groups was confirmed by an intense band around 1737 
cm-1 in both dendrons, the bis-GMPA dendron exhibits an additional band at 
1665 cm-1 corresponding to the amide groups, together with a band at 1541 cm-
1 corresponding to the vibration deformations of the N-H bonds. Finally, the 
presence of the azide group in both dendrons was confirmed by a sharp band at 
2100 cm-1. 
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 The monodispersity of the dendrons was controlled by MS and SEC 
(figure C4-15). 
 
Figure C4-15: MS spectra (A) and SEC chromatograms (B) of the bis-GMPA dendrons 
with terminal t-Boc amino groups from the 1st to the 4th generation. 
 ESI+ spectrum was recorded for the smallest bis-GMPA dendron. A peak 
that corresponds to [M + Na]+ is observed together with fragmentation peaks. 
MALDI+-TOF spectra were recorded for the bis-GMPA dendrons of higher 
generations. Only one peak is observed for the 2nd and 3th generation that 
correspond to [M + Na]+ in each spectrum. In the case of the 3rd generation 
dendron, other peaks resulting from the fragmentation of the dendron are 
visible in addition to the [M + Na]+ peak.  
 SEC chromatograms show only one monomodal and symmetrical peak 
for each dendron. The polydispersity of the dendrons was determined using 
poly(methyl methacrylate) (PMMA) as a reference and had values between 1.01 
and 1.04 as expected for monodisperse dendrons. 
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4.1.3- Biocompatibility and degradability 
 The biocompatibility, as well as the degradability, of new materials is an 
important requirement for their further use in nanomedicine. The 
biocompatibility and biodegradability of bis-MPA dendrons has already been 
intensively studied. In general, they show high biocompatibility and they can be 
degraded in the body by either enzymatic ester cleavage or by hydrolysis in 
water.[149] 
 In a previous work, our group studied the biocompatibility and 
degradability of a 3rd generation hydrophilic bis-MPA dendron with terminal 
glycine moieties  in cancerous human brain cells line (U251 MG) and in mouse 
origin mesenchymal cells line (mMSCs).[95,159] In both cases, the cell viability was 
higher to 80 % after 72 hours at concentration 1 mM. The dendron degradability 
at 37ºC in water was also studied. The dendron was effectively degraded by 
hydrolysis. In these compounds, the ester linkages of the glycine moieties with 
the bis-MPA dendrons were the first ester groups to be hydrolyzed. 
 The biocompatibility of the bis-GMPA dendrons of 2nd, 3rd and 4th 
generation that will be further used during in vitro assays was studied in human 
cancerous cells line (HeLa) and in mouse mesenchymal cells line (mMSCs). These 
studies were carried by Rebeca González and belong to her thesis research work 
(figure C4-16).[184 In both cases, cell viability was higher than 70 % at 1 mg·mL-1 
after 72 hours. The weaker biocompatibility of the 2nd generation dendron can 
be explained by the higher relative abundance of the toxic azide groups. 
 
 
                                                          
[149] N. Feliu et al., Biomaterials, 2012, 33, 1970. 
[95 ] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
[159] J. Movellan et al., Macromol. Biosci., 2015, 15 657. 
[184] R. González, Estudio de dendrímeros y nanopartículas de oro para su uso en 
tratamientos antitumorales, 2017, Universidad de Zaragoza. 
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Figure C4-16: Cell viability of the three bis-GMPA dendrons of the 2nd, 3rd and 4th 
generation at 1 mg/mL after 72 hours. 
 The degradability of the bis-GMPA dendrons of 2nd, 3rd and 4th generation 
was studied in deuterated water and in deuterated water with H2SO4 (pH near 
1). 1H NMR experiments were carried out at different times to observe the 
degradation of the dendrons. The regions of the spectra that give more 
information about de degradation process are gathered in figure C4-17. The 
signal of the methylene protons in the α-position of the azide group (3.2 ppm), 
which should not be modified by hydrolysis, was used as a reference to measure 
the intensity of the other signals. 
 In deuterated water, the degradation of all the dendrons was observed. 
After 5 days, a signal near 3.8 ppm started to be observable and its intensity 
increases with time. It corresponds to hydroxymethylene protons, -CH2-OH, that 
appear in the periphery of the dendron meaning that the ester groups of the 
dendrons were slowly hydrolyzed, inducing the destruction of the 
macromolecular dendrons into small fragments. 
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Figure C4-17: Degradation of N3-[bisGMPA,G2](NH3+Cl-)4 in D2O and in D2O+H2SO4 
observed in 1H NMR. 
 In deuterated water with sulfuric acid, pH near 1, the rate of the 
degradation of dendrons is accelerated. After only 1 day, the signals 
corresponding to the hydroxymethylene protons, -CH2-OH, could be observed. 
And, after two days, the general aspect of the signals corresponding to the 
oxymethylene protons attached to the ester groups, -CH2-OC(O)-, and in the  
α-position of the nitrogen atoms, -CH2-N-, were modified indicating that the 
degradation process was affecting the full dendron structure.  
 After 7 days, the ABq signal near 4.35 ppm that corresponded to the  
-CH2-OC(O)- of the peripheral generation was replaced by a new ABq signal with 
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a bigger ΔνAB. Moreover, in the hydroxymethylene zone, -CH2-OH zone, the ABx 
system, characteristic of the hydroxyl terminated bis-MPA dendrons, started to 
be clearly observable leading to think that the dendron had lost these four 
terminal external glycine moieties. The modifications observed in the -CH2-N- 
zone corroborated this supposition. The integration of the peak corresponding 
to the external methylene protons decreased and a new signal, which relative 
integration increased with time, appeared at 3.8 ppm and should correspond to 
the -CH2-N of the free glycine.  
 Additional signals that did not correspond to the undegraded dendron 
and to the dendron without peripheral glycine moieties were also observed in 
the spectra. They can correspond to intermediates that have lost only a part of 
their four peripheral glycine moieties or to other degradation products resulting 
from the cleavage of internal ester or amide bonds. 
 The same behavior was observed for the dendrons of the 3rd and 4th 
generation (table C4-1). 
Tables C4-1: Degradation of the bis-GMPA dendrons of 2nd, 3rd and 4th generation in 
D2O and in D2O+H2SO4 . 
dendron 
generation 
relative integration 
of -CH2OC(O)- 
relative 
integration of -
CH2O-OH- 
% 
degradation 
 in D2O 
G2 11.12 1.76 14 
G3 20.54 2.02 14 
G4 40.00 7.24 20 
 in D2O + H2SO4 
G2 6.28 6.73 52 
G3 9.46 13.04 58 
G4 14.67 22.21 60 
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4.2- Amphiphilic bis-MPA and bis-GMPA 
dendritic derivatives 
 
 Two types of amphiphilic dendritic derivative based on bis-MPA and bis-
GMPA were synthesized: amphiphilic Janus dendrimers and hybrid dendritic-
linear-dendritic block copolymers (HDLDBCs).  
 The amphiphilic Janus dendrimers are divided in two series. Series A 
gathers dendrimers in which the hydrophilic block consists on 2nd or 3rd 
generation bis-MPA dendrons with terminal amino groups (bis-MPA/bis-MPA 
series), whereas series B corresponds to dendrimers in which the hydrophilic 
block consists on 2nd  or 3rd generation bis-GMPA dendrons (bis-GMPA/bis-MPA 
series). For the two series, 1st and 2nd generation bis-MPA dendrons with 
terminal C17 alkyl chains constitute the lipophilic block (figure C4-18). 
 Series A includes four amphiphilic Janus bisMPA/bisMPA dendrimers:  
 - (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1]-(C17)2 that consists of a hydrophilic 
 dendron of 2nd generation and a lipophilic one of 1st generation, 
 - (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G2]-(C17)4* that consist of a  hydrophilic 
 dendron of 2nd generation and a lipophilic one of 2nd generation, 
 - (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G1]-(C17)2 that consists of a  hydrophilic 
 dendron of 3rd generation and a lipophilic one of 1st generation, 
 -(NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2]-(C17)4* that consists of a  hydrophilic 
 dendron of 3rd generation and a lipophilic one of 2nd generation. 
The two Janus dendrimers marked with a star have been previously described 
by our group.[95]  
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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The series B contained the following three amphiphilic bis-GMPA/bis-MPA 
Janus dendrimers: 
 -(NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1]-(C17)2 that consists of a 
 hydrophilic dendron of 2nd generation of bis-GMPA and a lipophilic 
 dendron of bis-MPA of 1st generation, 
 -(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1]-(C17)2 that consists of a 
 hydrophilic dendron of 3rd generation of bis-GMPA and a lipophilic 
 dendron of bis-MPA of 1st generation, 
 -(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2]-(C17)4 that consists of a 
 hydrophilic dendron of bis-GMPA of 3rd generation and a lipophilic 
 dendron of bis-MPA of 2nd generation. 
 The Janus dendrimer (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G2]-(C17)4 was 
not synthesized given the low water solubility and encapsulation abilities shown 
by its homologous dendrimer in series A ((NH3+Cl-)4[bisMPA,G2]-[bisMPA,G2]-
(C17)4). 
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Figure C4-18: Chemical structures of the four amphiphilic bis-MPA/bis-MPA Janus 
dendrimers and the three amphiphilic bis-GMPA/bis-MPA Janus dendrimers. 
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 The variation in the chemical composition of the hydrophilic dendron, 
bis-MPA or bis-GMPA, associated to different combinations between the 
hydrophilic and lipophilic dendrons enabled to obtain amphiphilic Janus 
dendrimers with different molecular weight and variable hydrophilic/lipophilic 
ratios (H/L) (table C4-2). H/L ratio was calculated by dividing the number of 
hydrophilic groups by the number of lipophilic ones. Terminal ammonium salts 
and internal amide groups were considered as hydrophilic groups whereas the 
terminal aliphatic chains were considered as lipophilic groups. The other groups, 
including the aliphatic esters and triazole rings, were not considered for this 
calculation. 
Table C4-2: Molecular weights (MW) and hydrophilic/lipophilic ratios (H/L) calculated 
for the two series of amphiphilic Janus dendrimers. 
 MW (g.mol-1) relative H/L 
hydrophilic bis-MPA 
/ 
lipophilic bis-MPA 
(NH3+Cl-)4[G2]-[G1]-(C17)2 1571 4/2 =2 
(NH3+Cl-)4[G2]-[G2]-(C17)4 2336 4/4 = 1 
(NH3+Cl-)8[G3]-[G1]-(C17)2 2409 8/2 = 4 
(NH3+Cl-)8[G3]-[G2]-(C17)4 3174 8/4 = 2 
hydrophilic b-GMPA 
/ 
lipophilic bis-MPA 
(NH3+Cl-)4[G1]-[G1]-(C17)2 1685 (4+2)/2 = 3 
(NH3+Cl-)8[G2]-[G1]-(C17)2 2752 (8+6)/2 = 7 
(NH3+Cl-)8[G2]-[G2]-(C17)4 3517 (8+6)/4 = 3.5 
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 The 3rd series (C) brings together two amphiphilic hybrid dendritic-linear-
dendritic block copolymers (HDLDBCs), which are represented in figure C4-19. 
Both derivatives were based on commercial amphiphilic linear triblock 
copolymer Pluronic® F-127, which was functionalized at its two terminal 
positions by 3rd generation amino-terminated bis-MPA dendrons or by 3rd 
generation bis-GMPA dendrons, named as bisMPA-PLU-bisMPA and bisGMPA-
PLU-bisGMPA, respectively. The first HDLDBC was previously published by our 
group.[95] 
 
Figure C4-19: Chemical structures of Pluronic® F-127 and the two HDLDBC derivatives. 
  
  
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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 The derivatives of this series have a much higher molecular weight than 
the Janus dendrimers (approximately 16 300 and 17 000 g.mol-1, respectively). 
Their corresponding hydrophilic/lipophilic ratio is mainly conditioned by the 
amphiphilic linear triblock Pluronic® F-127 that consists in two peripheral blocks 
of poly(ethylene oxide) (PEO) of 99 units each and one central block of 
poly(propylene oxide) (PPO) of 67 units, resulting in compounds of higher 
hydrophilicity than that the previous Janus dendrimers. 
 Moreover, Pluronic® F127 shows a lower critical solution temperature 
(LCST) in water, which means a decrease in solubility attributed to changes in 
the overall hydrophilicity of the polymer chain upon temperature increase. The 
effect induces the formation of micelles in water at room temperature whose 
lipophilic core, based on the PPO blocks, is surrounded by a hydrophilic shell, 
based on PEO blocks.[185] 
 
 
 
 
 
 
 
                                                          
[185] a) A.V. Kabanov, E.V. Batrakova, V.Y. Alakhov, Pluronic® block copolymers as novel 
polymer therapeutics for drug and gene delivery, J. Control. Release, 2002, 82, 189-212; b) W. 
Zhang, K. Gilstrap, L. Wu, R.K.C. Bahadur, M.A. Moss, Q. Wang, X-n Lu, X. He, Synthesis and 
characterization of thermally responsive pluronic F127−chitosan nanocapsules for controlled 
release and intracellular delivery of small molecules, ACS Nano, 2010, 4, 6747-6759; c)T.T.C 
Nguyen, C.K. Nguyen, T.H. Nguyen, N.Q. Tran, Highly lipophilic pluronics-conjugated 
polyamidoamine dendrimer nanocarriers as potential delivery system for hydrophobic drugs, 
Mat. Sci. Eng. C, 2017, 70, 992-999. 
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4.2.1- Synthesis and chemical characterization 
4.2.1.1- Synthesis of the amphiphilic Janus dendrimers 
 The hydrophilic and lipophilic dendrons were linked via copper(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. The Huisgen 
reaction, known from decades, consists on the formation of a triazole ring by 
heating an azide and alkyne groups together.[186] This reaction used to show low 
transformation rates and a mixture of different products were generally 
obtained. However, the introduction of copper(I) as catalyst, as proposed by the 
Sharpless’s group,  increased dramatically the reaction rates even at room 
temperature.[187] This modification widely extended the library of the starting 
products that could tolerate the reaction conditions and, furthermore, it favors 
the formation of the 1,4-isomer.[188] 
 For our syntheses, the copper(I) catalytic species was formed in situ by 
the reduction of copper(II) salt by (L)-ascorbate. Tris(benzyltriazolylmethyl) 
amine (TBTA) was added to increase the stability of the Cu(I) species.[189] This 
catalytic system was chosen as it is easier to handle, more stable and cheaper 
than halogen copper derivatives (CuI and CuBr) and had already proved its 
advantages to synthesize dendrimers and dendritic systems.[190] 
                                                          
[186] R. Huisgen, 1,3-Dipolar cycloadditions. Past and future, Angew. Chem. Int. Ed. Engl., 
1963, 2, 565-598. 
[187] H.C. Kolb, M.G. Finn, K.B. Sharpless, Click chemistry: diverse chemical function from a 
few good reactions, Angew. Chem. Int. Ed., 2001, 40, 2004-2021. 
[188] J.E. Hein, V.V. Fokin, Copper-catalyzed azide–alkyne cycloaddition (CuAAC) and beyond: 
new reactivity of copper(I) acetylides, Chem. Soc. Rev., 2010, 39,1302-1315. 
[189] T.R. Chan, R. Hilgraf, K.B. Sharpless, V.V. Fokin Copper(I)-catalyzed synthesis of azoles. 
DFT study predicts unprecedented reactivity and intermediates, Org. Lett., 2004, 17, 2853-
2855. 
[190] G. Franc, A.K. Kakkar, "Click" methodologies: efficient, simple and greener routes to 
design dendrimers, Chem. Soc. Rev., 2010, 39, 1536-1544. 
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Figure C4-20: Synthesis of the amphiphilic Janus dendrimers of the two series (see 
chapter 7 for the detailed description of the synthesis and the general procedures VII) 
and VI)). 
 As the terminal primary amines could have complexed the copper 
species, lowering the conversion of the reaction, the CuAAC coupling reactions 
were achieved with the t-Boc protected dendrons. Besides, the products 
obtained after the CuAAC were lipophilic allowing their purification by flash 
chromatography on silica gel.  
 The t-Boc protected and lipophilic dendrons were mixed together in the 
presence of CuSO4.5H2O, (L)-ascorbate and TBTA into dry dimethylformamide at 
45ºC during 1 day (figure C4-20, general procedure VII). The Janus dendrimers 
were first purified by several washings with brine and an aqueous KCN solution 
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before performing flash chromatography on silica gel. An excess of the lipophilic 
dendron (1.2 or 1.5 mole of lipophilic dendron per mole of t-Boc protected 
dendron) was added to consume all the t-Boc protected dendrons during the 
CuAAC. Therefore, the crude products only contained the Janus dendrimer and 
the excess of lipophilic dendron that could be easily separated. 
 Finally, the t-Boc protecting groups were removed in acidic conditions in 
ethyl acetate, forming the ammonium salts which precipitated in the reaction 
medium (figure C4-20, general procedure VI). After removing the hydrochloric 
acid under vacuum, the final products were recovered by centrifugation and 
washed with pure ethyl acetate to remove the remaining acid traces. At this 
point, the Janus dendrimers became amphiphilic: they were composed of a 
hydrophilic part that had ammonium salts at its periphery and a lipophilic part 
that had aliphatic chains at its periphery. 
 The CuAAC reaction yields obtained were in the range of 69 and 92 % for 
the bis-MPA/bis-MPA series and between 68 and 84 % for the bis-GMPA/bis-
MPA series. The t-Boc deprotection reactions showed quantitative yields in all 
cases. 
 The intermediate Janus dendrimers with the terminal t-Boc protecting 
groups were characterized by means of 1H and 13C nuclear magnetic resonance 
(NMR), mass spectrometry (MS), Fourier transform infrared spectrometry 
(FTIR), elemental analysis (EA) and size exclusion chromatography (SEC). The 
final amphiphilic Janus dendrimers were characterized by 1H and 13C nuclear 
magnetic resonance (NMR), mass spectrometry (MS) and Fourier transform 
infrared spectrometry (FTIR). The complete characterization data are gathered 
in chapter 7. 
 As an example, the 1H-NMR spectra of (NH3+Cl-)4[bisMPA,G2]-
[bisMPA,G1](C17)2 and (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 are depicted 
in figure C4-21. 
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Figure C4-21: 1H-NMR spectra of (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1](C17)2 (A) and 
(NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 (B) in CD3OD recorded at 400 MHz. The 
overlapping of the peaks corresponding to the protons H-3 with H-16 (bis-MPA) or  
H-18 (bis-GMPA) was resolved by 1H-1H COSY experiments (see annexes 2 & 3). 
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 For both amphiphilic Janus dendrimers, the formation of the triazole ring 
was confirmed by the appearance of a peak at 8.06 ppm corresponding to the 
proton H-17 (bis-MPA) or H-19 (bis-GMPA). Comparing the spectra of these final 
dendrimers with their corresponding starting dendrons, three signals are shifted 
downfield. The methylene protons in the α- and β-positions of the triazole ring 
belonging to the hydrophilic block (H-16/18 and H-15/17) are respectively 
shifted from 3.25 to 4.43 ppm and from 1.63 to 1.95 ppm, while the signals 
corresponding to the oxymethylene protons in the α-position of the triazole ring 
belonging to the lipophilic block (H-19/21) are shifted from 4.70 to 5.25 ppm. 
The other signals remain unchanged and a perfect correlation was observed for 
the signals integration belonging to the two different blocks.  
  The 13C NMR spectra of both Janus dendrimers (NH3+Cl-)4[bisGMPA,G2]-
[bisMPA,G1](C17)2 and  (NHBoc)4[bisGMPA,G2]-[bisMPA,G1](C17)2 with 
terminal t-Boc protected amino groups and free ammonium groups together 
with these of their respective starting dendrons, (NH3+Cl-)4[bisGMPA,G2]-N3 and 
(C17)2[bisMPA,G1]-(≡) are depicted in figure C4-22. 
 
Figure C4-22: 13C-NMR spectra of (NHBoc)4[bisGMPA,G2]-[bisMPA,G1](C17)2 and the 
two starting dendrons (NH3+Cl-)4[bisGMPA,G2]-N3 and (C17)2[bisMPA,G1]-(≡) in CDCl3 
and (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 in CD3OD, at 75 or 100 MHz. 
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 With respect to the spectra of its corresponding starting dendrons, two 
new peaks are visible for the Janus dendrimers at 124 and 142 ppm (in blue); 
they correspond to the carbons of the triazole ring, (C-19 and C-20, 
respectively). This observation is also valid for the bis-MPA/bis-MPA 
dendrimers (annexes 4). 
 After the CuAAC, the correct deprotection of the terminal amino groups 
was confirmed by the disappearance of the signals at 28.3, 80.0 and 155.8 ppm 
corresponding to the t-Boc protecting groups (in orange). 
 The monodispersity of the Janus dendrimers and the absence of free 
dendrons that had not reacted during the CuAAC process were confirmed by 
SEC and MS (figure C4-23). SEC could only be performed with the Janus 
dendrimers whose amines were protected by the t-Boc groups as the final 
amphiphilic Janus dendrimers showed low solubility in the SEC elution solvent 
(tetrahydrofuran (THF)).  
 In all cases, a unique and symmetrical monomodal peak is observed in 
the SEC chromatogram. The polydispersity was calculated equal to 1.02 using 
PMMA as standard internal reference as expected for dendrimers.  
 MS was performed with the Janus dendrimers after the deprotection of 
the terminal amino groups. A peak that corresponds to the amphiliphilic Janus 
dendrimers whose amines are unprotected and unprotonated (-NH2 form) plus 
sodium is observed for all the Janus dendrimers. Unlike linear polydisperse 
polymers, the dendrimers don’t appear as a distribution of mass peaks, 
confirming therefore their monodispersity. 
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Figure C4-23: A) SEC chromatograms of the bis-MPA/bis-MPA (I) and bis-GMPA/bis-
MPA (II) Janus dendrimers series with the t-Boc protecting groups (-NHBoc form) and 
B) MS spectra of the bis-MPA/bis-MPA (I) and bis-GMPA/bis-MPA (II) Janus dendrimers 
after removing the t-Boc protecting groups (-NH2 form). 
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4.2.1.2- Hybrid dendritic-linear-dendritic block copolymers (HDLDBCs) 
 Amphiphilic linear tri-block Pluronic® F-127 was decorated at its terminal 
positions with two hydrophilic dendrons of bis-MPA and bis-GMPA of 3rd 
generation bearing 8 terminal amino groups. To perform the CuAAC coupling 
between the dendrons and the linear polymer, alkyne moieties were 
incorporated at the terminal position of the Pluronic® F-127 by means of a bis 
(4-propargyloxybenzoate) derivative. 
 Commercial methyl 4-hydroxybenzoate reacted with propargyl  
bromide using Williamson etherification conditions to obtain  
4-propargyloxybenzoate. Then, the methyl ester was hydrolyzed with lithium 
hydroxide in a mixture of water and methanol to give 4-propargylbenzoic acid 
(figure C4-24-A). 
 4-propargyloxybenzoic acid reacted then with Pluronic® F-127 (HO-PLU-
OH) according to the Steglich’s esterification conditions (in presence of DCC 
and DMAP) in a mixture of dry THF and dry DCM at 45ºC (figure C4-24-B). The 
final product was purified by precipitation into cold diethyl ether and the 
dicyclohexylurea (DCU) that was formed during the reaction was removed by 
precipitation in toluene. Pluronic® F-127 is soluble in toluene whereas the DCU 
is totally insoluble and can be easily removed by filtration. 
 The two 3rd generation dendrons of bis-MPA or bis-GMPA bearing 8 
terminal t-Boc amino groups were grafted on the Pluronic® via CuAAC in 
dimethylformamide at 45ºC under argon atmosphere during 2 days (figure  
C4-24-B, general procedure VIII)). The Cu(I) catalytic species was formed “in situ” 
by reduction of Cu(II) salt with (L)-ascorbate and TBTA was added to increase its 
stability. An excess of dendron (1.3 mole of dendron per 1.0 mole of alkyne 
group) was used to obtain a complete functionalization of the linear polymer. 
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Figure C4-24: Synthesis of 4-propargylbenzoic acid (A) and synthesis of the two 
HDLDBCs starting from the commercial Pluronic® F-127 (B) (see chapter 7 for the 
detailed description of the synthesis and the general procedures VIII) and IX)). 
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 After completion of the reaction, the reaction mixtures were diluted in 
dichloromethane and washed several times with hot brine. The final products 
were precipitated several times into cold diethyl ether and remaining impurities 
of low molecular weight were removed by dialysis against methanol.  
 Following this protocol, the complete functionalization of Pluronic® F-127 
at its extremities was achieved. Unfortunately, the reaction yields were low-
moderate, 38 % for the HDLDBC with the bis-MPA dendrons and 61 % for the 
HDLDBC with the bis-GMPA dendrons. The main reason was the numerous but 
necessary precipitations of the products into cold diethyl in order to obtain the 
final products with the appropriate degree of purity. 
 Finally, the t-Boc protecting groups were removed in acidic conditions 
into ethyl acetate (figure C4-24-B, general procedure IX)). After completion of 
the reaction, the HDLDBCs bearing the dendrons with terminal ammonium salt 
formed a gel in the reaction medium. The hydrochloric acid was removed under 
vacuum and the gel was washed two times with pure ethyl acetate in order to 
remove the acid traces. After evaporation of the organic solvent, the pure 
products were obtained with quantitative yields. 
 The correct functionalization of the HDLDBC derivatives combining 
commercial Pluronic® F-127 and bis-GMPA or bis-MPA dendrons was controlled 
by 1H and 13C nuclear magnetic resonance (NMR), Fourier transform infrared 
spectrometry (FTIR) and size exclusion chromatography (SEC). The complete 
characterization data are gathered in chapter 7. 
  
  
Chaper 4 
134 
 As an example, the 1H and an expansion of the 13C NMR spectra of 
(NH3+Cl-)8bisGMPA-PLU-bisGMPA(NH3+Cl-)8 are depicted in figure C4-25. 
 
Figure C4-25: 1H-NMR (A) and 13C-NMR (110 to 185 nm) (B) spectra in CD3OD recorded 
at 400 and 125 MHz, respectively, for (NH3+Cl-)8bisGMPA-PLU- bisGMPA(NH3+Cl-)8. 1H 
NMR spectra of ≡-PLU-≡ and (NH3+Cl-)8[bisGMPA,G3]-N3 are included to help the peak 
assignation. 
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  The correct assignation of the peaks observed in the 1H NMR spectrum 
was asserted by 1H-1H COSY experiments (see annexes 5) and corroborated by 
their relative integration.  
 The formation of the triazole rings was confirmed by the appearance of a 
peak at 8.19 ppm (H-15) in the 1H NMR spectrum and by the appearance of two 
peaks at 125.8 (C-15) and 140.4 ppm (C-14) in the 13C NMR spectrum.  
 Additionally, three signals are shifted downfield in the 1H NMR spectra of 
the final HDLDBC when compared with the spectra of its two precursors. Thus, 
the signal corresponding to the protons in the α-position of the triazole rings 
belonging to the linear polymeric part (H-13) is shifted from 4.72 to 5.30 ppm. 
With respect to the dendritic part, the signals corresponding to the protons in 
the α- and β-positions of the triazole rings (H-16 and H-17) are shifted from 3.20 
and 1.65 to 4.45 and 1.95 ppm, respectively. The other signals are not modified 
after the click chemistry reaction. 
   The characteristic bands of the two bis-GMPA dendrons and of the 
central linear Pluronic® F-127 can be observed in the FTIR spectrum of (NH3+Cl-)8 
bisGMPA-PLU-bisGMPA (NH3+Cl-)8  (figure C4-26).  
 
Figure C4-26: FTIR spectra of the 2nd generation bis-GMPA dendron (up), the HDLDBC 
(middle) and the F-127 Pluronic® (down). 
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 The presence of the central Pluronic® F-127 polyether was asserted by 
the intense band at 1101 cm-1 that corresponds to the C-O bonds, and the two 
intense bands at 2881 and 1344 cm-1 corresponding to the C-H bonds. The 
presence of the poly(esteramide) bis-GMPA dendrons was confirmed by the 
appearance of two bands at 1755 and 1664 cm-1 which correspond to the 
carbonyl groups. The band corresponding to the stretching of the N-H+ bond is 
difficult to observe in this polymer because it appears as a broad band. 
Additionally, the band corresponding to the azide group near 2100 cm-1 is no 
longer observed in the HDLDBC spectrum proving the formation of the triazole 
moiety between the Pluronic® and the two bis-GMPA dendrons. 
  SEC was performed for (NHBoc)8bisGMPA-PLU-bisGMPA(NHBoc)8 and its 
corresponding precursors in THF (figure C4-27).  
 
Figure C4-27: SEC spectra of the starting dendron of 3rd generation of bis-GMPA, the 
commercial Pluronic® F-127 and of the intermediate HDLDBC. 
 Two peaks, the first one being really more intense than the second one, 
are observed in the chromatogram of both, the commercial Pluronic® F-127 and 
the HDLDBC, showing the polydispersity of these compounds. Nevertheless, the 
correct functionalization of the Pluronic® by the dendrons could be asserted as 
the two peaks corresponding to the HDLDBC show both lower retention time in 
comparison with the two peaks of the starting Pluronic® F-127. Additionally, no 
peak corresponding to residual free bis-GMPA dendron can be observed. 
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4.2.2- Self-assembly in water 
 Both, the Janus dendrimers and HDLDBCs have been designed to exhibit 
amphiphilic character. Indeed, the Janus dendrimers consist of a lipophilic  
bis-MPA dendron and a hydrophilic bis-MPA or bis-GMPA dendrons; and the 
HDLDBCs consist of a central lipophilic block of polypropylene oxide (PPO) and 
two blocks of polyethylene oxide (PEO) that were linked to bis-MPA or  
bis-GMPA hydrophilic dendrons at their terminal position. 
 The different nature of the blocks can trigger spontaneous self-assembly 
in water. The poor affinity of the lipophilic block for the external aqueous 
medium favors intermolecular lipophilic interactions leading to the formation of 
lipophilic domains surrounded and stabilized by hydrophilic ones. A large variety 
of different structures can be obtained such as micelles, vesicles, lamellar and 
sponge phases, etc.[109] 
 
 
 
 
 
 
  
                                                          
[109] B.N.S. Thota et al., Chem. Rev., 2016, 116, 2079-2102. 
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4.2.2.1- Amphiphilic Janus dendrimers 
Self-assembly processes 
 The self-assembly in water of all the Janus dendrimers was carried out 
using the oil-in-water technique (figure C4-28).[95] According to this method, the 
Janus dendrimers were first dissolved into dichloromethane, and then an 
appropriate amount of distilled water was added. The aqueous and organic 
phases were mixed by vigorous stirring forming an emulsion from which the 
dichloromethane was slowly evaporated using a ventilation system. When all 
the dichloromethane was evaporated, a clearly and transparent aqueous 
solution containing the dendritic nanoaggregates was obtained. 
 
Figure C4-28: Schematic representation of the formation of the nanoaggregates by self-
assembling of the Janus dendrimers using the oil-in-water technique. 
  
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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Critical aggregation concentration (CAC) 
 The critical aggregation concentration (CAC) in distilled water was 
determined using nile red as a solvatochromic fluorophore.[ 191 ] The 
fluorescence intensity of nile red is low in a hydrophilic environment and high in 
a lipophilic environment. 
 Below the CAC, the nile red is located in water and presents weak 
fluorescence intensity (λmax = 653 nm). In contrast, above the CAC, nile red 
migrates to the lipophilic inner part of the aggregates and presents an intense 
fluorescence emission (λmax ≈ 630 nm). Hence, the CAC can be determined by 
drawing the fluorescence intensity of nile red as a function of the amphiphile 
concentration. The change of the curve slope corresponds to the beginning of 
lipophilic domains formation, i.e. the CAC.  
 Figure C4-29 gathers the plots corresponding to all the dendrimers. An 
abrupt change of the curve slope is observed in each case allowing the 
determination of the CAC for all the dendrimers (table C4-3). 
 
                                                          
[191] M.C.A. Stuart, J.C. van de Pas, J.B.F.N. Engberts, The use of Nile Red to monitor the 
aggregation behavior in ternary surfactant–water–organic solvent systems, J. Phys. Org. 
Chem., 2005, 18, 929-934. 
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Figure C4-29: Determination of the CAC employing the nile red technique for the Janus 
dendrimers. 
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Table C4-3: Critical aggregation concentration (CAC) of the Janus dendrimer in distilled 
water given in mg/mL and in mol/L. 
   Janus dendrimer CAC 
(mg/mL) (mol/L) 
bis-MPA 
/ 
bis-MPA 
(NH3+Cl-)4[G2]-[G1](C17)2 5.2·10-2 3.3·10–5 
(NH3+Cl-)8[G3]-[G1](C17)2 2.6·10-2 1.1·10–5 
(NH3+Cl-)4[G2]-[G2](C17)4 4.4·10-2 1.9·10–5 
(NH3+Cl-)8[G3]-[G2](C17)4 9.8·10-2 3.1·10–5 
bis-GMPA 
/ 
bis-MPA 
(NH3+Cl-)4[G2]-[G1](C17)2 2.8·10-2 1.7·10-5 
(NH3+Cl-)8[G3]-[G1](C17)2 2.8·10-2 1.0·10-5 
(NH3+Cl-)8[G3]-[G2](C17)4 4.3·10-2 1.3·10-5 
All the Janus dendrimers present a CAC near 2 x 10-5 mol/L regardless the 
nature of the hydrophilic dendron and the different dendron generations. 
Interestingly, in the case of the bis-GMPA/bis-MPA Janus dendrimers bearing 
the hydrophilic dendron of the 3rd generation a previous smooth change of the 
curve slope is observed at lower concentrations, 8.7 x 10-7 mol/L for (NH3+Cl-)8 
[bisGMPA,G3]-[bisMPA,G1](C17)2 and 3.0 x 10-6 mol/L for (NH3+Cl-)8 
[bisGMPA,G3]-[bisMPA,G2](C17)2 (figure C4-29). They indicate that two 
different aggregation processes must exist for these derivatives. Nevertheless, if 
the abrupt curve slope changes correspond to the formation of aggregates with 
a sufficiently extended lipophilic domain to encapsulate big amount of nile red, 
defined as the CAC, further investigation is needed to determine what type of 
lipophilic interactions between nile red and the dendrimers, or some dendritic 
aggregates, can take place at these lower concentrations. 
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Transmission electron microscopy (TEM) 
 The morphology and the size of the aggregates were investigated using 
transmission electron microscopy (TEM) at the concentration of 1 mg/mL 
(above the CAC) (figure C4-30 and table C4-4). Regarding the bis-MPA/bis-MPA 
series, the morphology of the aggregates depends on the generation of the 
lipophilic dendron. The 1st generation dendron promotes spherical micelles with 
an average size about 14.5 ± 3.9 nm for (NH3+Cl-)4[bisMPA,G2]-
[bisMPA,G1](C17)2 and about 15.5 ± 4.0 nm for (NH3+Cl-)8[bisMPA,G3]-
[bisMPA,G1](C17)2. The lipophilic dendron of 2nd generation gives rise to 
aggregates with a bilayer morphology. When it is combined with the hydrophilic 
dendron of 2nd generation, (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G2](C17)4, stacked 
rigid bilayers with an average width of 5 nm are observed. When it is linked to 
the hydrophilic dendron of 3rd generation, (NH3+Cl-)8[bisMPA,G3]-
[bisMPA,G2](C17)4, vesicles and flexible bilayers are observed. The vesicles 
have an average diameter of 52.3 ± 11.9 nm and the bilayers have an average 
width of 7 nm. 
 With respect to the bis-GMPA/bis-MPA series, micelles were observed in 
all cases. The Janus dendrimers bearing the small lipophilic dendron form 
spherical micelles with an average size of 13.1 ± 3.6 nm for (NH3+Cl)4 
[bisGMPA,G2]-[bisMPA,G1](C17)2 and 14.6 ± 3.1 nm for (NH3+Cl-)8 
[bisGMPA,G3]-[bisMPA,G1](C17)2. The Janus dendrimer bearing the biggest 
lipophilic dendron, (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4, forms a mixture 
of spherical and ovoidal micelles with a bigger size, around 18.8 ± 5.6 nm. 
  
 
Figure C4-30: TEM images of the two series of Janus dendrimers at 1.00 mg/mL. 
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 In general the size of the lipophilic dendron appeared as the main factor 
that determined the morphology of the final aggregates. For Janus dendrimers 
based on a 1st generation lipophilic dendron, spherical micelles with relatively 
similar sizes (between 13.1 and 15.5 nm) are observed, whereas for Janus 
dendrimers based on a 2nd generation lipophilic dendron, aggregates with 
variable morphologies are visible. Using this last dendron, a mixture of spherical 
and ovoidal micelles are observed when it is linked to the 2nd generation bis-
GMPA dendron (H/L =3.5), a mixture of flexible bilayers and vesicles are 
observed when it is linked to the 3rd generation bis-MPA dendron (H/L =2) and 
rigid bilayers that tend to stack are formed when it is linked to the 2nd 
generation bis-MPA dendron (H/L =1). The less hydrophilic is the final Janus 
dendrimer, the larger the lipophilic domains inside the aggregates are.[157]  
  
                                                          
[157]  E. Fedeli et al., New. J. Chem., 2015, 39, 1960. 
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Cryogenic transmission electron microscopy (cryoTEM) 
 The morphology and the size of the aggregates formed by the Janus 
dendrimers were also investigated using cryogenic transmission electron 
microscopy (cryoTEM) at the same concentration of 1 mg/mL (figure C4-31 and 
table C4-4). CryoTEM permits to observe the aggregates as they are in aqueous 
solution, since the liquid sample is not dried but directly and quickly cryogenized 
employing liquid ethane before observation.  
 In almost all the cases, two size-population distributions are observed in 
cryoTEM images: small aggregates with sizes ranged from 20 to 60 nm that 
should correspond to the micelles, bilayers and/or vesicles observed in TEM 
together with bigger spherical aggregates with sizes around 200 nm that must 
be due to self-aggregation. (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1](C17)2 and 
(NH3+Cl-)8[bisMPA,G3]-[bisMPA,G1](C17)2 show aggregates with sizes near 20 
nm which correspond to micelles. (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2](C17)4 
shows spherical aggregates with diameters close to 60 nm and smaller 
aggregates with sizes near 20. Finally, in the case of (NH3+Cl-)4 
[bisMPA,G2]-[bisMPA,G2](C17)4, only the biggest aggregates are observed; 
they present either a spherical shape or a more distorted shape which is 
coherent with the TEM image where the rigid bilayers appear stacked between 
themselves into bigger structures. 
  
  
 
Figure C4-31: CryoTEM images of the two series of Janus dendrimers at 1.00 mg/mL. The smallest aggregates (micelles, bilayers or vesicles) can 
be marked with black arrows. 
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 In the case of the bis-GMPA/bis-MPA series, two size-population 
distributions are also observed. (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 
shows small spherical aggregates with sizes near 30 nm and bigger ones with 
sizes around 150 nm. (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2 forms 
spherical aggregates with sizes between 20 and 50 nm and bigger ones with 
sizes between 150 and 500 nm.  (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4 
forms small spherical aggregates with size between 20 and 50 nm and bigger 
ones with sizes around 200 nm.  
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Dynamic light scattering (DLS) 
 The size of the hydrodynamic volume of the aggregates was measured by 
dynamic light scattering (DLS), technique that is only valid for spherical 
aggregates. When possible, the results were treated employing two 
mathematical approaches: the number average data and the intensity average 
data. The intensity average data are more sensitive to the largest particles 
whereas the number average data are more sensitive to the smallest particles. 
The results are gathered in the table C4-4 together with the sizes previously 
measured in TEM and cryoTEM images. 
 As observed before in cryoTEM, two size-population distributions were 
measured in the samples: small particles and bigger ones. 
 With regard to the number average data treatment, sizes comprised 
between 1.0 and 3.2 nm were determined for the dendrimers bearing the 1st 
generation bis-MPA lipophilic dendron, (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1] 
(C17)2, (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G1](C17)2,  (NH3+Cl-)4[bisGMPA,G2]-
[bisMPA,G1](C17)2 and (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2. These 
small particles should correspond to the spherical micelles observed in TEM and 
cryoTEM. In the case of the dendrimers bearing the 2nd generation bis-MPA 
lipophilic dendron, some major difference were observed between the 3 
different dendrimers as previously observed in TEM and cryoTEM. The size 
calculated for the (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4 aggregates is 
about 7.8 nm with a higher polydispersity. This difference can be related to the 
less spherical shape of the micelles, as observed by TEM. The size calculated for 
(NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2](C17)4 is bigger, near 62.9 nm, which is 
relatively close to the size of the vesicles measured in TEM and cryoTEM.  
 
     
Table C4-4: Morphology and size of the aggregates formed by the amphiphilic Janus dendrimers determined by TEM, cryoTEM and 
DLS (with number and data average treatments). 
 Janus dendrimer 
TEM DLS 
number 
DH 
cryoTEM DLS 
intensity 
DH shape 
diameter 
/width shape size 
bis-
MPA 
/ 
bis-
MPA 
(NH3+Cl-)4[G2]-[G1](C17)2 
spherical 
micelles 14.5 ± 3.9 nm 
3.2  
± 0.0 nm spherical 
ca.20 nm  
& 200 nm 
95.6  
± 25.6 nm 
(NH3+Cl-)8[G3]-[G1](C17)2 
spherical 
micelles 15.5 ± 4.0 nm 
1.1  
± 0.1 nm  spherical 
ca.20 nm 
& 200 nm 
87.8  
± 26.9 nm 
(NH3+Cl-)4[G2]-[G2](C17)4 rigid bilayers 5 nm 
no spherical 
aggregates 
spherical &  
ill-defined ca.200 nm 
579.5 
± 77.8 nm 
(NH3+Cl-)8[G3]-[G2](C17)4 
vesicles & 
flexible bilayers 
52.3 ± 11.9  
& 7 nm 
62.9  
± 0.6 nm spherical 
ca.20-60 nm  
& 200 nm 
340.4  
± 149.9 nm 
bis-
GMPA 
/ 
bis-
MPA 
(NH3+Cl-)4[G2]-[G1](C17)2 
spherical 
micelles 13.1 ± 3.6 nm 
2.6  
± 0.4 nm spherical 
ca.30 nm  
& 150 nm 
208.2  
± 120.0 nm 
(NH3+Cl-)8[G3]-[G1](C17)2 
spherical 
micelles 14.6 ± 3.1 nm 
1.0  
± 0.1 nm spherical 
ca.20-50 nm  
& 100-500 nm 
159.4  
± 63.1 nm  
(NH3+Cl-)8[G3]-[G2] (C17)4 
spherical & 
ovoidal micelles 18.8 ± 5.6 nm 
7.8  
± 1.4 nm spherical 
ca.20-50 nm 
& 200 nm 
260.1  
± 163.0 nm 
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 With respect to the intensity data treatment, bigger aggregates with high 
polydispersity were detected. These bigger aggregates should correspond to the 
micellar and bilayered aggregates observed in cryoTEM formed by self-
aggregation of various micelles, vesicles and/or bilayers.[192]  
 As a general trend, it can be noticed that the size and the polydispersity is 
lower for the bis-MPA/bis-MPA series than for the bis-GMPA/bis-MPA series.  
 
 
 
  
 
 
 
                                                          
[192] Y. Hed, Y. Zhang, O.C.J. Andrén, X. Zeng, A.M. Nyström, M. Malkoch, Side-by-side 
comparison of dendritic-linear hybrids and their hyperbranched analogs as micellar carriers of 
chemotherapeutics, J. Polym. Sci. Pol. Chem., 2013, 51, 3992-3996. 
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Overview 
 Amphiphilic bis-MPA/bis-MPA and bis-GMPA/bis-MPA Janus dendrimers 
can self-assemble in water forming aggregates with different morphologies. 
According to the generation of the lipophilic bis-MPA dendron, it is possible to 
design the final morphology of the nanostructures. Employing the lipophilic 
dendron of 1st generation, spherical micelles are always obtained. In contrast, 
employing the lipophilic dendron of 2nd generation, micelles, vesicles and 
flexible or rigid bilayers can be obtained depending on the hydrophilic dendron 
nature and generation (figure C4-32). Additionally, in all cases, bigger aggregates 
are observed. They are ascribed to the self-aggregation of various particles. 
 
Figure C4-32: Schematic representation of the amphiphilic Janus dendrimer self-
assembly in water. 
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4.2.2.2- Hybrid sendritic-linear-dendritic block copolymers 
Self-assembly process 
 The two HDLDBCs are formed by Pluronic® F-127, a thermoresponsive 
amphiphilic tri-block copolymer and hydrophilic bis-MPA and bis-GMPA 
dendrons. In this case, micelles can be spontaneously formed by solubilizing the 
solid HDLDBCs in water at 4ºC and slowly heating their solution to room 
temperature (figure C4-33).[193] 
 
Figure C4-33: Formation of the micelles by the HDLDBCs by slow heating to room 
temperature. 
Critical aggregation concentration (CAC) 
 The critical aggregation concentrations were determined for the two 
HDLDBCs using the nile red fluorophore as it was carried out before for the 
amphiphilic Janus dendrimers (figure C4-34). 
                                                          
[193] I. Jiménez-Pardo, Hidrogeles termosensibles y fotopolimerizables derivados de Pluronic® 
para aplicaciones biomédicas, 2014, Univerisdad de Zaragoza. 
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Figure C4-34: Determination of the CAC employing the nile red technique for the 
HDLDCs and the commercial Pluronic® F-127. 
 Pluronic® F127 and the HDLDBC derivatives, show an abrupt change of 
the curve slope that corresponds to the CAC (table C4-5). The CACs are lower for 
the two HDLDBCs in comparison with the commercial F-127 Pluronic®. As 
observed for some Janus dendrimers, the bis-GMPA based HDLDBC shows a 
previous smooth change in the curve slope at 7.1 x 10-6 mol/L that must 
correspond to lipophilic interactions between nile red and the HDLDC previous 
to the micelle formation although further investigation is required to fully study 
this phenomenon.  
Table C4-5: CAC of the Janus dendrimer in distilled water in mg/mL and in mol/L. 
Pluronic® derivatives CAC (mg/mL) (mol/L) 
F-127 1.4  1.1 x 10-4 
bisMPA-[PLU]-bisMPA 0.5 2.9 x 10-5 
bisGMPA-[PLU]-bisGMPA 1.0 6.1 x 10-5 
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Transmission electronic microscopy (TEM) and cryogenic transmission electron 
microscopy (cryoTEM) 
 The morphology and the size of the aggregates formed by the HDLDBCs 
in water at room temperature were studied by TEM and cryoTEM at a 
concentration of 1.0 mg/mL, which is superior to the CAC (figure C4-35). 
 
Figure C4-35: TEM and cryoTEM images of the two HDLDBCs at 1.0 mg/mL in water at 
room temperature. 
 Spherical micelles were observed in TEM and cryoTEM images for both 
HDLDBCs. TEM images show polydisperse micelles for the bisMPA-[PLU]-
bisMPA with an average size around 18.7 ± 5.9 nm, whereas monodisperse 
micelles appear for the bisGMPA-[PLU]-bisGMPA, with an average size around 
13.4 ± 2.5 nm. CryoTEM images reveal micelles with two size-population 
distributions in the case of bisMPA-[PLU]-bisMPA, small micelles with sizes 
around 60 nm and bigger aggregates with sizes near 150 nm. In the case of 
bisGMPA-[PLU]-bisGMPA, only one size-population distribution of micelles is 
observed with sizes in the range of 40 and 70 nm. 
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Dynamic light scattering (DLS) 
 The hydrodynamic diameter of the aggregates was also measured 
employing the dynamic light scattering technique. As Pluronic® F-127 is a 
thermosensitive polymer,[185a]  DLS measurements were carried out at different 
temperatures, i.e. 25, 37 and 45ºC to observe the effect of temperature changes 
on the size of the aggregates. The results were treated employing two 
mathematical approaches: intensity average data and number average data 
(table C4-6). 
Table C4-6: Hydrodynamic diameter of the aggregates measured with DLS according to 
two different mathematical data approaches (in number and in intensity). 
 Pluronic® F-127  
 25ºC 37ºC  
number 4.89 ± 1.3 (100%) 18.4 ± 4.4 (100%)  
intensity 7.8 ± 2.6 (70%) 159.6 ± 96.2 (16%) 25.7 ± 6.7 (100%)  
 bisMPA-[PLU]-bisMPA 
 25ºC 37ºC 45ºC 
number 20.8 ± 5.6 (67%) 124.8 ± 54.2 (33%) 23.1 ± 4.5 (100%) 16.2 ± 5.1 (100%) 
intensity 27.2 ± 3.6 (7%) 222.8 ± 79.5 (90%) 
27.5 ± 5.0 (33%) 
141.6 ± 25.5 (67%) 
21.4 ± 7.3 (29%) 
90.3 ± 38.1 (71%) 
 bisGMPA-[PLU]-bisGMPA 
 25ºC 37ºC 45ºC 
number 143.8 ± 56.2 (100%) 24.4 ± 5.6 (100%) 21.6 ± 4.9 (100%) 
intensity 224.8 ± 88.9 (96%) 31.7 ± 8.2 (13%) 208.6 ± 65.0 (87%) 
25.8 ± 5.6 (18%) 
169.7± 42.3 (82%) 
 At 25 and 37ºC, the aggregates formed by the two HDLDBCs are bigger 
(more than 100 nm) than the aggregates formed by Pluronic® F-127. Thus, the 
                                                          
[185a] A.V. Kabanov et al., J. Control. Release, 2002, 82, 189-212. 
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addition of the dendrons must favor the formation of micellar aggregates. 
Moreover, and as observed before in cryoTEM, two size distributions were 
measured at 25ºC in the case of bisMPA-[PLU]-bisMPA whereas only one size-
population was measured in the case of bisGMPA-[PLU]-bisGMPA. 
Nevertheless, the diameters measured for the aggregates were always bigger 
when employing the DLS than when deduced from cryoTEM images. 
 When increasing the temperature, the average size of the aggregates 
decreases and the percentage of the smallest aggregates population increases. 
At higher temperature, polyethylene oxide (PEO) blocks are less hydrophilic and 
water starts to be expelled out of the hydrophilic shell. Consequently, the 
average particle-size decreases (figure C4-36). This effect is more significant for 
the bisMPA-[PLU]-bisMPA than for bisGMPA-[PLU]-bisGMPA derivatives. 
 
Figure C4-36: Average particle size decrease of the HDLDBC aggregates when they are 
heated. The average size represented here was measured applying the intensity 
average data approach. 
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4.3- Amphiphilic Janus dendrimers and 
HDLDBCs as camptothecin nanocarriers 
 
 Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV), 
an RNA virus. It may trigger chronic disorders that particularly affect the liver. 
HCV causes cirrhosis that might induce hepatocellular carcinoma, a malignant 
liver cancer. This disease affects between 150 and 200 million people (~3% of 
the world population) spread all over the globe. In Spain, it is estimated that 
around 480000 and 760000 people are infected by the virus (~1% of 
population). HCV is transferred via blood-to-blood contact, and the use of 
deficiently sterilized intravenous injection material is the main reason of HCV 
spreading.[194] 
 The hepatitis C viral infection can be effectively treated. A bi-therapeutic 
treatment based on Ribavirin, a large spectral antiviral drug, and interferons, 
proteins that defend the organism against pathogens were previously used. 
Nevertheless, this treatment is responsible for serious and numerous side 
effects. Patients usually suffer fevers, headaches, dry skin, hair lost, anemia, 
conjunctivitis, depressions, teratogenic complications, etc. 
 Recently, a variety of new antiviral treatments specific to hepatitis C virus 
has been developed: ledipasvir, sofosbuvir, paritaprevir, ombitasvir, dasabuvir. 
They inhibit the action of some HCV enzymes and can be used alone or in 
association with ribavirin and interferons. As they block specifically the 
activity of HCV enzymes, they are globally well tolerated by the patients. 
Moreover, they have shown a spectacular efficiency: near 90 % of the patients 
could be cured in some cases. However, their complex structure and HCV 
                                                          
[194] M. Bruguera, X. Forns, Hepatitis C in Spain, Medicina Clínica, 2006, 127, 113-117. 
Chapter 4 
158 
specificity makes them challenging to investigate and produce and are highly 
sensitive to virus mutations. They are, therefore, highly expensive and their 
availability for the treatment of HCV infected people is restrained.[195]  
 Thus, in order to extend the library of anti-HCV drugs, in the Institute for 
Biocomputation and Physics of Complex Systems (BIFI) of the University of 
Zaragoza, Dr. Olga Abián, Dr. Adrián Velazquez-Campoy and collaborators 
started to investigate new alleosteric inhibitors of the NS3 protease, an enzyme 
that belongs to the HCV virus.[196] Whereas competitive inhibitors block the 
active site of enzymes, allosteric inhibitors interfere with the binding properties 
of enzymes. They bind the enzymes in a region different of their active site and 
induce conformational modifications that consequently block their activity. 
Allosteric inhibitors are generally less specific than competitive inhibitors, easier 
to synthesize and less sensitive to drug resistance. In this particular case, NS3 
protease needs to be coordinated with Zn2+ ions and NS4A peptide to pass from 
an inactive form to the active one. The BIFI group looked for allosteric inhibitors 
that would increase the stability of the inactive form and would impede its 
transformation into the active form (figure C4-37). 
                                                          
[195] a) G. Fanjul, E. Villanueva, Hepatitis C: el nuevo campo de batalla por el acceso a 
medicamentos esenciales, 2016, ISGlobal, creative commons; b) J. Zhang, J.C. Garrison, L.Y. 
Poluektova, T.K. Bronich, N.A. Osna, Liver-targeted antiviral peptide nanocomplexes as 
potential anti-HCV therapeutics, Biomaterials, 2015, 70, 37-47. 
[196] a) O. Abián, S. Vega, J. Sancho, A. Velazquez-Campoy, Allosteric inhibitors of the NS3 
protease from the hepatitis C virus, PLoS ONE, 2013, 8, e69773; b) R. Clavería-Gimeno, S. Vega, 
V. Grazu, J.M. de la Fuente, A. Lanas, A. Velázquez-Campoy, O. Abián, Rescuing compound 
bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier, 
Int. J. Nanomedicine, 2015, 10, 2249-2259. 
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Figure C4-37: Schematic representation of the allosteric inhibition of NS3 protease by 
camptothecin (CPT) drug. 
 Camptothecin (CPT) (figure C4-37), a well-known versatile drug 
investigated in cancer and antiviral therapy,[197] showed a remarkable potential 
when used as an NS3 protease allosteric inhibitor.[196] This might convert it into 
an interesting alternative as anti-HCV drug with respect to the harmful and 
unspecific old HCV-treatments and to the specific and expensive new 
treatments. However, CPT presents some drawbacks that may hinder its future 
as an alternative anti-HCV drug: 
 - it is a low water-soluble drug; indeed, camptothecin is usually 
 delivered during in vitro or in vivo experiments after dissolution into organic 
 solvents such as ethanol or dimethyl sulfoxide, 
 - it is a cytotoxic drug that damages the DNA, 
 - it is unstable in the physiological serum, camptothecin contains a lactone 
 ring that is spontaneously hydrolyzed at physiological pH turning down its 
 activity. 
                                                          
[197] a) Y.Q. Liu, W.Q. Li, S.L. Morris-Natschke, K. Qian, L. Yang, G.X. Zhu, X.B. Wu, A.L. Chen, 
S.Y. Zhang, Z.L. Song, K.H. Lee, Perspectives on biologically active camptothecin derivatives, 
Med. Res. Rev., 2015, 35, 735-789; b) P. Pantazis, Z. Han, D. Chatterjee, J. Wyche, Water-
insoluble camptothecin analogues as potential antiviral drugs, J. Biomed. Sci., 1999, 6, 1-7; c) 
A.L. Bodley AL, T.A. Shapiro, Molecular and cytotoxic effects of camptothecin, a topoisomerase 
I inhibitor, on trypanosomes and Leishmania, Proc. Natl. Acad. Sci. U S A, 1995, 92, 3726-3730. 
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 As a strategy to overcome these issues and improve its natural 
therapeutic abilities, camptothecin has already been encapsulated within 
various nanocarrier systems, among which dendritic systems represent a good 
alternative. For instance, the anticancer activity of CPT has been enhanced after 
its encapsulation within carbonated poly(glycerol succinic acid) dendrimers[198] 
and PAMAM dendrimers.[199] CPT was also covalently attached to dendritic 
structures based on poly-(L)-lysine[ 200] or polycarbamate.[ 201] Moreover, an 
interesting Janus dendrimer bearing folic acid moieties at one face and 
camptothecin drug at the other face was synthesized.[202] This dendrimer was 
still water soluble even after the covalent incorporation of 16 molecules of 
camptothecin. 
 The Liquid Crystals and Polymers Group (CLIP) of the University of 
Zaragoza had previously encapsulated camptothecin within different types of 
amphiphilic block copolymers. Linear amphiphilic Pluronic® F-127 triblock 
copolymer was functionalized at its extremities with two bis-MPA dendrons 
functionalized with acrylate groups, and the stability of the micelles across time 
was increased by photo-induced reticulation. Camptothecin water solubility was 
enhanced as well as its biocompatibility while its antiviral activity remained 
                                                          
[198] M.T. Morgan, Y. Nakanishi, D.J. Kroll, A.P. Griset, M.A. Carnahan, M. Wathier, N.H. 
Oberlies, G. Manikumar, M.C. Wani, M.W. Grinstaff, Dendrimer-encapsulated camptothecins: 
increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity 
in vitro, Cancer Res., 2006, 66, 11913-11921. 
[199] S. Sadekar, G. Thiagarajan, K. Bartlett D. Hubbard, A. Ray L.D. McGill, H. Ghandehari, 
Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin, Int. 
J. Pharm., 2013, 456, 175-185 
[200] M.E. Fox, S. Guillaudeu, J.M.J. Fréchet, K. Jerger, N. Macaraeg, F.C. Szoka, Synthesis and 
in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer−camptothecin conjugates, 
Mol. Pharmaceutics, 2009, 6, 1562-1572. 
[201] A. Gopin, S. Ebner, B. Attali, S. Doron, Enzymatic activation of second-generation 
dendritic Prodrugs:  conjugation of self-immolative dendrimers with poly(ethylene glycol) via 
click chemistry, Bioconj. Chem., 2006, 17, 1432-1440 
[202] X. Feng, J. Pinaud, E.L. Chaikof, D. Taton, Y. Gnanou, Sequential  functionalization of 
janus-type dendrimer-like poly(ethylene oxide)s with camptothecin and folic acid,  J. Polym. 
Sci. A Polym. Chem., 2011, 49, 2839-2849. 
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unaltered (figure C4-38).[203] Also, a lipophilic polymethacrylate block bearing 
2,6-diacylaminopyridine pendant units and a hydrophilic poly(ethylene glycol) 
block of two different molar masses, 2000 and 10000 provided block-
copolymers that self-assembled in water forming spherical micelles with a 
lipophilic core and a hydrophilic shell. These micelles could encapsulate 
camptothecin and enhance its water solubility (figure  C4-38).[204] 
 Following this research line, camptothecin was chosen to be 
encapsulated within the different nanostructures formed by the amphiphilic 
Janus dendrimers and by the hybrid dendritic-linear-dendritic block copolymers 
(HDLDBCs), in order to investigated their potential as anti-HCV drug carriers. The 
lipophilic drug encapsulation abilities as well as the biocompatibility and 
antiviral activity of the encapsulated drug is discussed and related to the 
different nature and morphologies of the dendritic nanocarriers. 
 
Figure C4-38: Representation of the chemical structure of the amphiphiles and 
respective TEM images of the spherical micelles they formed in water, adapted from 
ref. [203] and [204].  
                                                          
[203] I. Jiménez-Pardo, R. González-Pastor, A. Lancelot, R. Clavería-Gimeno, A. Velázquez-
Campoy, O. Abián, M.B. Ros, T. Sierra, Shell Cross-Linked Polymeric Micelles as Camptothecin 
Nanocarriers for Anti-HCV Therapy, Macromol. Biosci., 2015, 15, 1381-1391. 
[204] Concellon, R. Clavería-Gimeno, A. Velázquez-Campoy, O. Abian, M. Pinol, L. Oriol, 
Polymeric micelles from block copolymers containing 2,6-diacylaminopyridine units for 
encapsulation of hydrophobic drugs, RSC Adv., 2016, 6, 24066-24075. 
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4.3.1- Nanocarrier/camptothecin conjugates 
4.3.1.1- Camptothecin encapsulation 
 Camptothecin (CPT) was encapsulated within the nanostructures formed 
by the two types of dendritic derivatives, the Janus dendrimers and the hybrid 
dendritic-linear-dendritic block copolymers (HDLDBCs), employing the solvent 
diffusion technique (figure C4-39). 
 
Figure C4-39: Schematic drawing of the camptothecin (CPT) encapsulation process 
within the dendritic nanocarriers by the solvent diffusion technique. 
 The empty nanocarriers were prepared in distilled water using the 
solvent evaporation technique for the Janus dendrimers (see p. 138) and the 
slow heating procedure for the HDLDBCs derivatives (see p 152). Interestingly, 
the pH of the corresponding final aqueous solutions was acid, between 3.08 and 
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3.82.a At acidic pH, the equilibrium between the insoluble and active lactone 
form of camptothecin and its water soluble inactive sodium salt form is shifted 
to the lactone form, favoring the stability of the active form of the drug (figure  
C4-40).[205] 
 
Figure C4-40: equilibrium of the two forms of camptothecin in water. 
 A solution of camptothecin in dimethyl sulfoxide (DMSO) was added into 
the nanocarrier aqueous solutions. They were stirred overnight to let enter the 
drug inside the lipophilic core of the nanocarriers. Then, DMSO was removed by 
dialysis against distilled water. The drug that couldn’t be encapsulated within 
the nanocarrier, insoluble in water, precipitated and it was removed by 
filtration. The amount of encapsulated drug was directly measured by 
fluorescence (see chapter 7 for detailed protocol).  
 Camptothecin was encapsulated within the dendritic nanocarriers at a 
feeding ratio of 0.1/1 (wCPT/wdend.). The final ratio of camptothecin encapsulated 
within the dendritic nanocarriers is given in weight and in mole in table C4-7 
together with the corresponding encapsulation efficiencies. 
  
                                                          
a cf. chapter 7 to see the pH of each dendritic derivatives dissolution at 1 mg/mL in distilled 
water. 
[205] Fassberg, V.J. Stella, A kinetic and mechanistic study of the hydrolysis of camptothecin 
and some analogues, J. Pharm. Sci., 1992, 81  676-684. 
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Table C4-7: Amount of camptothecin encapsulated within the dendritic nanocarriers. 
adnc means dendritic nanocarrier and bEE means encapsulation efficiency; it was 
calculated by dividing the mass of camptothecin encapsulated within the dendritic 
nanocarriers by the mass of camptothecin added at the beginning of the encapsulation 
process. The aggregates morphology corresponds to TEM observations. 
  
  
 
Janus dendrimers 
  
 H/L MW (g/mol) 
aggregates 
morphology 
mg CPT 
/ 
mg dnca 
mol CPT 
/ 
mol dnca 
EEb 
(%) 
hydrophilic 
bisMPA 
/ 
lipophilic 
bisMPA 
[G2]-[G1] 2 1571 spherical micelles 0.014 0.0631 14 
[G3]-[G1] 4 2409 spherical micelles 0.013 0.0899 13 
[G2]-[G2] 1 2336 X < 0.001 < 0.001 < 1 
[G3]-[G2] 2 3174 flexible bilayers 0.006 0.0547 6 
hydrophilic 
bisGMPA 
/ 
lipophilic 
bisMPA 
[G2]-[G1] 3 1685 spherical micelles 0.061 0.295 60 
[G3]-[G1] 7 2752 spherical micelles 0.059 0.466 61 
[G3]-[G2] 3.5 3517 cylindrical micelles 0.054 0.546 54 
  HDLDBCs 
  H/L MW (g/mol) 
aggregates 
morphology 
mg CPT 
/ 
mg dnca 
mol CPT 
/ 
mol dnca 
EEb 
(%) 
bisMPA-[PLU]-bisMPA ≈ 
Plu. 
F-127 
16 320 sph. & ovoidal micelles 0.029 1.361 29 
bisGMPA-[PLU]-bisGMPA 17 000 sph. & ovoidal micelles 0.046 2.24 46 
 
 Encapsulation efficiencies (EE) depends significantly on the nature of the 
hydrophilic dendron. The highest EE values, in the range of 54 and 61 %, 
correspond to bis-GMPA/bis-MPA Janus dendrimers series. The HDLDBC series 
also shows high encapsulation efficiency with values of 29 and 46 %. Finally, the 
bis-MPA/bis-MPA Janus dendrimers series show the lowest efficiency, < 15 %. 
In fact, the insertion of hydrophilic dendrons derived from bis-GMPA instead of 
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bis-MPA clearly increased the amount of camptothecin encapsulated inside the 
dendritic nanocarriers. This effect is very significant when comparing the two 
Janus dendrimer series, in which the amount of encapsulated camptothecin is 
more than 6 times higher when the bis-GMPA hydrophilic dendrons are used. It 
is also different for the two HDLDBCs, the HDLDBC bearing the two bis-GMPA 
dendrons encapsulates 1.5 times more CPT than the one bearing the two bis-
MPA dendrons.  
 All the bis-GMPA/bis-MPA dendrimers can encapsulate similar amounts 
of CPT with negligible influence of their hydrophilic/lipophilic ratio (H/L) and 
size. In contrast, for the bis-MPA/bis-MPA dendrimers, the two dendrimers 
bearing the smallest lipophilic dendron could encapsulate higher amount of 
CPT, than the other two. Thus, the most lipophilic (NH3+Cl-)4 
[bisMPA,G2]-[bisMPA,G2](C17)4 (H/L =1) showed an EE below 1 % 
demonstrating its inability to form stable dendrimer/CPT conjugates in water.  
 The higher drug contents observed for the amphiphilic derivatives 
bearing the bis-GMPA hydrophilic dendron may be explained by the possible 
formation of favorable H-bonding interactions between the lactone, hydroxyl 
and ketone groups of the drug with the internal amide groups of the dendron. 
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3.3.1.2- Morphological studies 
 The size and the different morphologies of all the nanocarrier/CPT 
conjugates were investigated by TEM and cryoTEM together with DLS 
measurements.  
Amphiphilic Janus dendrimer/CPT conjugates 
 Within the bis-MPA/bis-MPA series, TEM images (figure C4-41 and table 
C4-8) show spherical micelles for (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1](C17)2/CPT 
and (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G1](C17)2/CPT, with diameters significantly 
bigger than those of the empty nanocarriers. (NH3+Cl-)4[bisMPA,G2]-
[bisMPA,G1](C17)2/CPT shows aggregates with sizes of around 35.5 ± 7.8 nm, 
2.5 times bigger than the aggregates without CPT, whereas (NH3+Cl-)8 
[bisMPA,G3]-[bisMPA,G1](C17)2/CPT forms aggregates with sizes around 19.9 ± 
4.1 nm, 1.5 times bigger than the aggregates without CPT. In both cases and as 
before, two size-population distributions are visible in cryoTEM images (figure 
C4-41 and table C4-8): small rounded micelles (ca. 20-40 nm) appear together 
with big aggregates (ca. 100-400 nm). In contrast, (NH3+Cl-)8[bisMPA,G3]-
[bisMPA,G2](C17)4/CPT conjugates appear as interconnected flexible bilayers in 
TEM images. CryoTEM images show ill-defined shapes, although small micelles 
can also be detected. It seems that the incorporation of camptothecin within 
these aggregates destabilized them and promoted the formation of less 
spherical nanostructures.  
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Figure C4-41: TEM and cryoTEM images of the nanocarriers/CPT conjugates formed by 
the two series of amphiphilic Janus dendrimers, bis-MPA/bis-MPA series (up) and  
bis-GMPA/bis-MPA (down). Smaller aggregates are marked with black arrows.  
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 Within the bis-GMPA/bis-MPA series, (NH3+Cl-)4[bisGMPA,G2]-
[bisMPA,G1](C17)2/CPT and (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2/CPT 
conjugates appear as spherical micelles in TEM images (figure C4-41). (NH3+Cl-)4 
[bisGMPA,G2]-[bisMPA,G1](C17)2/CPT formed micelles with sizes of around 
29.6 ± 6.2 nm, 2.3 times bigger than the aggregates without CPT, while  
(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2/CPT formed micelles with 
diameters around 18.0 ± 4.2 nm, 1.2 times bigger than the aggregates without 
CPT. In both cases, these micelles appear slightly bigger in cryoTEM images, 30 -
50 nm and 20 - 30 nm, respectively. Some bigger aggregates (ca. 100 - 400 nm) 
are also observed but in a lower proportion than the ones observed for the bis-
MPA/bis-MPA series. In contrast, the spherical and ovoidal micelles formed by 
(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4 in water (figure C4-30, p. 143) were 
deformed after the formation of the nanocarrier/CPT conjugates. In TEM, they 
appear as cylindrical micelles with a width ca. 5 nm while in cryoTEM, ovoidal 
and ill-defined aggregates with diameters in the range of 20 and 40 nm are 
observed alongside with bigger aggregates with sizes higher than 100 nm. 
 The hydrodynamic diameters of the nanocarrier/CPT conjugates were 
measured by DLS although these measurements showed little reliability since 
CPT is a photosensitive drug and interacts with light, disturbing DLS 
measurements. For this reason, the results are not included in the discussion 
but are gathered in annexes 6. Qualitatively, it can be said that, as observed in 
microscopy images, the size of the aggregates increases after camptothecin 
encapsulation.  
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Table C4-8: Morphology and size of the amphiphilic Janus dendrimer/CPT conjugates 
determined by TEM and cryoTEM. 
 amphiphilic Janus dendrimers/CPT conjugates 
 TEM cryoTEM 
 morphology diameter/width morphology diameter 
[G2]-[G1] spherical micelles 35.5 ± 7.8 nm 
spherical 
aggregates 
ca.20-40 nm  
& ≥ 100 nm 
[G3]-[G1] spherical micelles 19.9 ± 4.1 nm 
spherical 
aggregates 
ca.20-40 nm  
& ≥ 100 nm 
[G3]-[G2] flexible  bilayers 9 nm 
ill-defined shape 
& sph. aggregates 
ca.20-40 nm  
& ≥ 100 nm 
[G2]-[G1] spherical micelles 29.6 ± 6.2 nm 
spherical 
aggregates 
ca.30-50 nm  
& ≥ 100 nm 
[G3]-[G1] spherical micelles 18.0 ± 4.2 nm 
spherical 
aggregates 
ca.20-30 nm  
& ≥ 100 nm 
[G3]-[G2] cylindrical micelles  5 nm ill-defined shape 
ca.20-40 nm  
& ≥ 100 nm 
 It can be summarized that camptothecin encapsulation certainly affects 
the aggregates formed by the amphiphilic Janus dendrimers. On the one hand, 
the amphiphilic dendrimers bearing the smallest lipophilic dendron, 1st 
generation, that preferentially form spherical micelles, maintain their spherical 
morphology although, their size increases. On the other hand, the amphiphilic 
dendrimers bearing the biggest lipophilic dendron, 2nd generation, undergo 
morphological changes through the formation of nanostructures containing 
more extended lipophilic domains. Indeed, (NH3+Cl-)8[bisGMPA,G3]-
[bisMPA,G2](C17)4 changes from a mixture of spherical and ovoidal micelles to 
cylindrical ones, while (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2](C17)4 changes from 
a mixture of flexible bilayers and vesicles to interconnected flexible bilayers. 
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Amphiphilic HDLDBC/CPT conjugates 
 As it can be observed in TEM images (figure C4-42), the morphology of 
the aggregates formed by both HDLDBCs results modified after the 
encapsulation of camptothecin. They change from regular spherical aggregates 
(figure C4-35, p. 154) to a mixture of ovoidal and spherical aggregates with 
bigger size. bisMPA-[PLU]-bisMPA/CPT conjugates formed aggregates with an 
average size of 21.0 ± 4.9  (1.1 times bigger than the empty aggregates) while 
bisGMPA-[PLU]-bisGMPA/CPT conjugates formed aggregates with an average 
size of 30.9 ± 9.4 nm (2.3 times bigger than the empty aggregates). The more 
elevated standard deviation observed for the bis-GMPA based HDLDBC must be 
due to the formation of less spherical HDLDBC/CPT conjugates.  
 
Figure C4-42: TEM and cryoTEM images of the HDLDBCs/CPT conjugates. 
 These small aggregates are also visible in cryoTEM images in which 
bisMPA-[PLU]-bisMPA/CPT conjugates appear as spherical aggregates with an 
average size of ca. 25 - 30 nm while bisGMPA-[PLU]-bisGMPA/CPT conjugates 
appear as a mixture of spherical and ovoidal aggregates with an average size of 
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ca. 25 - 35 nm. In both cases, no bigger aggregates with size superior to 100 nm, 
corresponding to self-aggregation of various micelles, can be observed.  
 The hydrodynamic diameters of the aggregates were measured by DLS 
(see annexes 6). Again and although these data are not fully reliable, it can be 
notice that the portion of the size-population composed of small hydrodynamic 
diameters increases after camptothecin encapsulation, limiting the micelles self-
aggregation.  
 The encapsulation of camptothecin within the HDLDBCs aggregates had a 
comparable effect than temperature on the size and dispersion of the 
aggregates formed by the HDLDBCs in water. Both limit the self-aggregation of 
micelles (figure C4-43).  
 
Figure C4-43: Schematic representation of the effect of the temperature (right) or the 
encapsulation of camptothecin (left) on the aggregates formed by the HDLDBCs in 
water. 
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4.3.2- In vitro evaluation of the nanocarrier/CPT 
conjugates 
 All the nanocarrier/CPT conjugates described in this chapter were studied 
in vitro in order to determine their potential as inhibitors of HCV replication. The 
experiments were carried out in the laboratories of the Institute for 
Biocomputation and Physics of Complex Systems (BIFI), in collaboration with Dr. 
Olga Abián, Dr. Adrián Velázquez-Campoy and Rafael Clavería-Gimeno. In this 
section, the most relevant results that allow the discussion about the potential 
of these systems are presented. Detailed studies of the bioactivity are gathered 
in the thesis report of Rafael Clavería-Gimeno. 
4.3.2.1- Antiviral activity against HCV and cytotoxicity 
 Prior to the activity studies of the different nanocarrier/CPT conjugates, 
the cytotoxicity and antiviral activity of the empty nanostructures formed by the 
dendritic derivatives were evaluated with HCV infected human heptoma cell 
lines (Huh). The concentrations tested were related to their CPT load (figure  
C4-44). 
 The cell viability of all the amphiphilic Janus dendrimers was found to be 
higher than 70 % at all the concentrations tested. This value corresponds to the 
accepted limit to distinguish biocompatible materials from toxic ones.[200] These 
results allowed to assert the interest of these dendrimers to form biocompatible 
nanocarrier drugs vectors for hepatic diseases. In particular, (NH3+Cl-)4 
[bisMPA,G2]-[bisMPA,G1](C17)2, (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2](C17)4, 
(NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 and (NH3+Cl-)8[bisGMPA,G3]-
[bisMPA,G2](C17)4 show remarkable biocompatibility with hepatic cell viability  
                                                          
[200] Norm UNE-EN ISO-10993-5, 2009. Biological evaluation of medical devices- part 5: tests 
in vitro for cytotoxicity. 
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Figure C4-44: Cell viability (lines) and antiviral activity (bars) of the bisMPA/bisMPA (up 
& left) and bisGMPA/bisMPA (up & right) amphiphilic Janus dendrimers series and of 
the HDLDBCs series (down). 
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superior to 90 %. The two most hydrophilic Janus dendrimers of each series,  
 (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G1](C17)2 and (NH3+Cl-)8[bisGMPA,G3]-
[bisMPA,G1](C17)2 are slightly more cytotoxic than the other dendrimers. 
 As for antiviral activity, the aggregates formed by the Janus dendrimers 
(NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1](C17)2, (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2] 
(C17)4, (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 and (NH3+Cl-)8[bisGMPA,G3]-
[bisMPA,G2](C17)4 do not affect the viral replication that is over 90 % in all the 
cases. The most hydrophilic dendrimers of each series, (NH3+Cl-)8[bisMPA,G3]-
[bisMPA,G1](C17)2 and (NH3+Cl-)8[bisGMPA,G2]-[bisMPA,G1](C17)2 are again 
slightly different from the other Janus dendrimers. A decrease of the viral 
replication to 70 % and 80 % is observed, respectively, but it must be associated 
to a cytotoxic effect.  
 The amphiphilic HDLDBCs are less biocompatible than the Janus 
dendrimers in human heptoma cell cultures (figure C4-44). bisGMPA-[PLU]-
bisGMPA  shows high viability at the lowest concentrations that decreases 
below the 70 % threshold  at the highest concentration tested (0.45 µM). 
bisMPA-[PLU]-bisMPA is the less biocompatible system with this cell line, cell 
viability decreases below 70 % for concentrations higher than 0.14 µM.  
 bisGMPA-[PLU]-bisGMPA does not present any antiviral activity. The viral 
replication is close to 100 % at all the tested concentrations with the exception 
of the highest concentration, at which the cytotoxic effect is present. In a similar 
way, bisMPA-[PLU]-bisMPA does not present any antiviral activity. In this case, 
the viral replication was close to 100 %, even when the HDLDBC biocompatibility 
decreased.  
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 The biocompatibility and the antiviral activity of all the nanocarrier/CPT 
conjugates were then evaluated with HCV infected cells with increasing 
concentrations of camptothecin (from 0 to 1 or 2 µM). As the cells might 
respond differently after their exposure to camptothecin, each nanocarrier/CPT 
conjugate was compared to its own control, consisting on a solution of free 
camptothecin in DMSO. The concentration-effect curves for each 
nanocarrier/CPT conjugate and its free camptothecin control are represented in 
figure C4-45. 
 For each conjugate, three parameters that permit to assess their 
potential as anti-HCV systems are given in table C4-9: the half-maximal cytotoxic 
concentration (CC50), which represents the concentration of drug at which cell 
viability is reduced to 50 %, the half-maximal inhibition concentration (IC50), 
which represents the concentration at which the viral replication is reduced to 
50%, and the therapeutic index (TI), which compares the efficacy of a drug with 
its cytotoxicity. CC50 and IC50 were determined from the concentration-effect 
curves (figure C4-47) and the TI was calculated according to the following 
equation (4): 
 (4) TI = CC50
EC50
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Figure C4-45: Cell viability (lines) and antiviral activity (bars) of the nanocarrier/drug 
conjugates of the bisMPA/bisMPA series (up & left), bisGMPA/bisMPA series (up & 
right) and the HDLDBCs series (down). Free camptothecin is represented in blue and 
nanocarrier/CPT conjugates are represented in green or violet. 
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Table C4-9: IC50, CC50 and TI values determined for the nanocarrier/CPT conjugates and 
their internal free CPT control. CC50 and IC50 values are given in µM. The different CC50 
and IC50 obtained for each free CPT control are due to the variation of the cell response 
overtime. a dnc means dendritic nanocarrier. * inferior TI values for the dnc/CPT 
conjugates than the free drug. 
 Amphiphilic Janus dendrimers 
  CC50 IC50 TI 
bis-MPA 
/ 
bis-MPA 
[G2]-[G1] 
dnca/CPT 0.5 0.1 5.0 
free CPT 0.5 0.2 2.5 
[G3]-[G1] 
dnc/CPT 0.2 0.03 6.7 
free CPT 0.6 0.3 3.0 
[G3]-[G2] 
dnc/CPT 0.9 0.3 3.0 
free CPT 0.6 0.4 1.5 
bis-GMPA 
/ 
bis-MPA 
[G2]-[G1] 
dnc/CPT 0.4 < 0.03 * 
free CPT 0.5 < 0.03 * 
[G3]-[G1] 
dnc/CPT 0.5 0.06 * 
free CPT 1.0 0.08 * 
[G3]-[G2] 
dnc/CPT 0.5 < 0.03 * 
free CPT 0.7 < 0.03 * 
 HDLDBCs 
   CC50 IC50 TI 
bisMPA-[PLU]-bisMPA 
dnc/CPT 0.1 0.03 3.3 
free CPT 0.5 0.2 2.5 
bisGMPA-[PLU]-bisGMPA 
dnc/CPT 0.7 0.06 11.7 
free CPT 0.4 0.4 4.0 
 As a general and first observation, camptothecin maintained its activity 
against the hepatitis C viral replication after being encapsulated within all the 
nanocarriers hereby tested. All of them were therefore able to enhance the 
water solubility of the camptothecin, protect the drug from hydrolysis in 
physiological media and deliver it to infected human heptoma cells without 
requiring the addition of any organic solvent. Interestingly, the different 
nanocarrier/CPT conjugates do not trigger the same cell response when 
compared to their corresponding free CPT control. 
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 With respect to the bis-MPA/bis-MPA amphiphilic Janus dendrimers 
series, all the three nanocarrier/CPT conjugates tested show better therapeutic 
index (TI) values than the free camptothecin. In particular (NH3+Cl)8 
[bisMPA,G3]-[bisMPA,G1](C17)2/CPT, the amphiphilic Janus dendrimer with the 
highest hydrophilic/lipophilic ratio (H/L), shows the highest therapeutic index. 
Indeed, even if the CC50 of this nanocarrier/CPT conjugate is lower than that 
measured for its free camptothecin control (0.2 and 0.6 µM, respectively), its 
antiviral activity is 10 times higher (0.03 and 0.3 µM, respectively). Impressively, 
at low drug concentrations, this nanocarrier/CPT conjugate can certainly inhibit 
the virus replication while remaining highly biocompatible. For example at a 
concentration of drug equal to 0.03 µM, the virus replication is reduced down to 
33 % and the cell viability is still high, 79 %. 
 (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1](C17)2/CPT and (NH3+Cl-)8 
[bisMPA,G3]-[bisMPA,G2](C17)4/CPT conjugates also show better therapeutic 
indexes than free camptothecin, 5.0 and 3.0, respectively. The (NH3+Cl-)4 
[bisMPA,G2]-[bisMPA,G1](C17)2/CPT conjugate is more effective than its free 
drug control while presenting similar biocompatibility. The (NH3+Cl-)8 
[bisMPA,G3]-[bisMPA,G2](C17)4/CPT conjugate shows similar antiviral activity 
than its free drug control but exhibits higher biocompatibility. 
 Unfortunately, all the three nanocarrier/CPT conjugates derived from 
dendrimers of the bis-GMPA/bis-MPA series show cell viabilities and antiviral 
activities slightly lower than their corresponding free drug control making 
pointless the calculation of the therapeutic index.  
 Finally, the HDLDBC/CPT conjugates showed different results depending 
on the nature of the dendritic blocks. bisGMPA-[PLU]-bisGMPA/CPT conjugate 
has a remarkable therapeutic index of 11.7, 3 times higher than that of its free 
camptothecin control (4.0). The antiviral activity of the encapsulated 
camptothecin was enhanced at low concentrations while its biocompatibility 
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remained highly elevated. For instance, at a concentration of encapsulated drug 
of 0.03 µM, the viral replication went down to 50 % while the biocompatibility 
was equal to 89 %. In contrast, bisMPA-[PLU]-bisMPA/CPT conjugate showed 
poorer biological abilities. As for the other HDLDBC, the activity of the drug 
results enhanced at low concentrations. For instance, at a concentration of 
encapsulated drug of 0.03 µM, the viral replication goes down to 41 % while the 
biocompatibility is equal to 82 %. However, the rapid decrease of the cell 
viability of the nanocarrier/CPT conjugate restrains its use to only really low 
concentrations. Its lower biocompatibility must certainly be a consequence of 
the lower biocompatibility of the empty nanocarriers formed by this HDLDBC 
(figure C4-44, p. 173). 
 Summarizing, eight of the nine nanocarriers described in this chapter 
result interesting candidates to promote the use of camptothecin as an anti-
HCV drug. All of them are able to enhance the solubilization of its active lactone 
form in water, avoiding the use of an organic co-solvent during drug 
administration. Moreover, five of them improve the camptothecin activity 
against the hepatitis C virus at low drug concentrations, resulting into better 
therapeutic indexes when compared with free camptothecin. 
 The bis-GMPA/bis-MPA amphiphilic Janus dendrimer series that shows 
the most interesting capacity to encapsulate camptothecin, shows the poorest 
biological activities related to CPT therapeutic action. In contrast, the bis-
MPA/bis-MPA amphiphilic Janus dendrimer series that shows the poorest 
abilities to encapsulate the drug, shows more interesting biological activities in 
this respect. 
  The bisGMPA-[PLU]-bisGMPA HDLDBC appears as the most promising 
material to deliver camptothecin. It combines good abilities to encapsulate the 
drug providing a nanocarrier/CPT conjugate that improves the drug activity 
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against the hepatitis C virus replication, while reducing its cytotoxicity for 
hepatic cells. 
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4.3.2.2- Cell internalization 
 Because of the novelty of the bis-GMPA/bis-MPA amphiphilic Janus 
dendrimers and their good encapsulation abilities, they were chosen to perform 
a study of cell internalization that involves double encapsulation using a drug 
(CPT) and a fluorescent probe. The objective was to study by imaging flow 
cytometry, technique that combines flow cytometry with fluorescence, the 
cellular uptake of these nanocarriers while evaluating the bioactivity of the 
systems.  
 In order to label the nanocarriers with a fluorescent probe, we 
synthesized a fluorophore derived from rhodamine B (figure C4-48), specially 
designed to integrate within the structure of the micelles formed by amphiphilic 
dendrimers. The new fluorophore consists on rhodamine B linked to a 1st 
generation lipophilic dendron of bis-MPA, RhB-[bisMPA,G1](C17)2 (abbreviated 
as RhB(C17)2), by means of click chemistry. The aim was to prepare a fluorescent 
probe versatile enough to be used within many micellar carriers, while 
minimizing the possibilities of fast release of water soluble fluorescent probes, 
such as rhodamine B.  
Synthesis of RhB(C17)2 
 Red rhodamine B fluorophore is commonly used to efficiently mark 
materials in order to carry out biological experiments. This affordable water 
soluble fluorophore has an elevated absorption coefficient and broad 
fluorescence in the visible region. Moreover, it is highly stable and its acid 
moiety allows easy and versatile modifications.[206] 
                                                          
[206] M. Beija, C.A.M. Afonso, J.M.G. Martinho, Synthesis and applications of rhodamine 
derivatives as fluorescent probes, Chem. Soc. Rev., 2009, 38, 2410-2433; b) X. Chen, Q. Wu, L. 
Henschke, G. Weber, T. Weil, An efficient and versatile approach for the preparation of a 
rhodamine B ester bioprobe library, Dyes Pigm., 2012, 94, 296-303. 
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 Commercial rhodamine B fluorophore was linked to a 1st generation 
lipophilic dendron of bis-MPA by means of CuAAC in order to obtain a modified 
red fluorophore with a low water solubility which interestingly presents a 
lipophilic block similar to that of the Janus dendrimers (figure C4-46). Thus, the 
acid moiety of the commercial rhodamine B was first modified with 6-
azidohexan-1-ol to incorporate an azide group on the fluorophore. The CuAAC 
was carried out with the 1st generation lipophilic dendron of bis-MPA in 
conditions similar to those employed during the synthesis of the Janus 
dendrimers (see chapter 7 for detailed procedure).[203] 
 
Figure C4-46: Synthesis of the low-water soluble modified rhodamine (RhB(C17)2) 
starting from the commercial rhodamine B fluorophore (see chapter 7 for the detailed 
procedure employed for the synthesis).  
 The modified rhodamine B derivative (RhB(C17)2) was readily synthesized 
in a scale of hundred of milligrams, with a global yield of 34 %. This fluorophore 
is insoluble in water, and was characterized by 1H and 13C nuclear magnetic 
resonance (NMR), mass spectrometry (MS), Fourier transform infrared 
spectroscopy (FTIR) and elemental analysis (EA). The complete chemical 
characterization data are gathered in chapter 7. 
                                                          
[203] I. Jiménez-Pardo et al., Macromol. Biosci., 2015, 15, 1381. 
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 The completion of the CuAAC reaction was first asserted by 1H NMR. A 
singlet corresponding to the proton of the triazole ring, H-17, appears at 7.97 
ppm in the RhB(C17)2 spectra. Additionally, two peaks corresponding to the 
protons in the α-positions of the triazole ring, H-16 and H-19, are shifted 
downfield when compared to the spectra of the corresponding starting 
compounds, from 3.23 to 4.40 ppm and from 4.71 to 5.24 ppm, respectively 
(figure C4-47). Unfortunately, the peaks corresponding to the carbon atoms of 
the triazole ring cannot be observed in the 13C NMR spectrum; however, the 
coupling between proton H-17 and the carbon C-17 of the triazole ring can be 
observed in 1H-13C HSQC experiments (see annexes 7).  
 
Figure C4-47: 1H NMR spectrum of low-water soluble modified rhodamine B, 
RhB(C17)2. 
 The FTIR spectrum doesn’t show the characteristic bands corresponding 
to the azide and alkyne groups (figure C4-48-A), and an only peak is observed in 
the MS spectrum that corresponds to the correctly functionalized cationic 
fluorophore without chlorine (figure C4-48-B).  
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Figure C4-48: FTIR (A) and MALDI+-Tof (B) spectra of the low-water soluble modified 
rhodamine B (RhB(C17)2). 
Encapsulation of RhB(C17)2 
 The lipophilic modified rhodamine was encapsulated within the three  
bis-GMPA/bis-MPA amphiphilic Janus dendrimers employing the oil-in-water 
emulsion method (figure C4-49). 
 
Figure C4-49: Solubilization and encapsulation of low-water soluble rhodamine B, 
RhB(C17)2, using the oil-in-water emulsion method. 
 The amphiphilic Janus dendrimers and RhB(C17)2 were dissolved into 
dichloromethane and an appropriate amount of distilled water was added to 
the solution. The biphasic system was vigorously stirred to form an emulsion 
from which the volatile organic solvent was slowly removed by evaporation 
using a ventilation system. When all the organic solvent was evaporated, a clear 
Amphiphilic bis-MPA and bis-GMPA dendritic derivatives for camptothecin delivery 
185 
violet solution of the nanocarriers/RhB(C17)2 conjugates was obtained (see 
chapter 7 for detailed protocol).  
 At a feeding ratio of 0.15/1 (wRhB(C17)/wdend.), any precipitate could be 
observed after the formation of the nanocarrier/RhB(C17)2 conjugates in water. 
Therefore, it was assumed that all the new red fluorophore RhB(C17)2 was 
encapsulated within the nanocarriers.  
 As the nanocarrier/RhB(C17)2 conjugates were based on non-covalent 
interactions between the amphiphilic Janus dendrimers and the non-water 
soluble rhodamine B fluorophore, release studies were carried out to assert the 
time-persistence and effectiveness of the fluorescent labeling of the 
nanocarriers. Release experiments were carried out by dialysis of a solution of 
nanocarrier/RhB(C17)2 conjugates against a volume 100 times higher of distilled 
water (“sink conditions”) (figure C4-50). 
 
Figure C4-50: RhB(C17)2 release curves from the three nanocarriers/RhB(C17)2 
conjugates and RhB release curve from (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2/ 
RhB conjugate. 
 While the unmodified commercial rhodamine B (RhB) was released in a 
continuous way from the nanocarrier/RhB conjugates, the low-water soluble 
modified rhodamine B (RhB(C17)2) was efficiently retained within the three 
nanocarriers/fluorophore conjugates. After 72 hours, between 99.8 and 99.9 % 
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of the encapsulated modified rhodamine remained in the 
nanocarriers/RhB(C17)2 conjugates whereas only 3 % of commercial rhodamine 
remained within the nanocarrier/RhB conjugate. 
 Hence, by a simple chemical modification achieved in two steps, the 
commercial rhodamine B fluorophore was modified into a less water soluble 
fluorophore (RhB(C17)2) that can effectively and easily label the nanocarriers by 
non-covalent interactions during at least 72 hours. 
RhB(C17)2 and CPT co-encapsulation 
 Co-encapsulation of the low-water soluble modified rhodamine B and 
camptothecin was carried out in two steps. First, the nanocarrier/RhB(C17)2 
conjugates were prepared according to the oil-in-water emulsion method (see 
section 4.2.2.1, p. 138). Second, and as before, camptothecin was encapsulated 
within the nanocarrier/RhB(C17)2  conjugates employing the solvent diffusion 
technique (see section 4.3.1.1, p. 162) in order to obtain the final 
nanocarrier/RhB(C17)2/CPT conjugates (figure C4-51, see chapter 7 for detailed 
protocol). 
 
Figure C4-51: Preparation of the bis-GMPA/bis-MPA based amphiphilic Janus 
dendrimers/RhB(C17)2/CPT co-conjugates. 
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 RhB(C17)2 was encapsulated within the bis-GMPA/bis-MPA amphiphilic 
Janus dendrimers at a feeding ratio of 0.15/1 (wRhB(C17)/wdend.) while 
camptothecin was encapsulated within the nanocarriers at a feeding ratio of 
0.10/1 (wCPT/wdend.). The amounts of RhB(C17)2 and CPT encapsulated within the 
dendritic nanocarriers were calculated in weight and in mole and their 
encapsulation efficiencies (EE) were determined (table C4-10). 
Table C4-10: Amount of RhB(C17)2 and CPT encapsulated within the dendritic 
nanocarriers. adnc means dendritic nanocarrier and bEE means encapsulation efficiency 
and was calculated dividing the amount of substance at the end of the encapsulation 
process by the amount added at the beginning. 
 
Amphiphilic bis-GMPA/bis-MPA dendrimers 
 
loaded 
substance 
aggregates 
morphology 
mg sub. 
/ 
mg dnca 
mol sub. 
/ 
mol dnca 
EEb 
(%) 
[G2]-[G1] 
CPT spherical micelles 0.061 0.295 60 
RhB(C17)2 spherical micelles 0.15 0.193 100 
RhB(C17)2 
/CPT elongated micelles 
0.15 
/0.018 
0.193 
/0.087 
100 
/19 
[G3]-[G1] 
CPT spherical micelles 0.059 0.466 61 
RhB(C17)2 
spherical & ovoidal 
micelles 0.15 0.315 100 
RhB(C17)2 
/CPT spherical micelles 
0.15 
/0.024 
0.315 
/0.186 
100 
/24 
[G3]-[G2] 
CPT cylindrical micelles 0.054 0.549 54 
RhB(C17)2 spherical micelles 0.15 0.403 100 
RhB(C17)2 
/CPT 
ovoidal micelles 
& vesicles 
0.15 
/0.039 
0.403 
/0.394 
100 
/39 
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 As no colored precipitate was observed during the co-encapsulation 
process, it was assumed that all the modified rhodamine B remained 
encapsulated within the conjugates. However, a white precipitate appeared 
during the co-encapsulation process that corresponded to camptothecin. The 
precipitate was removed by filtration and the amount of camptothecin 
encapsulated within the nanocarrier/RhB(C17)2/CPT conjugates was determined 
by fluorescence. The presence of the modified rhodamine B within the 
nanocarriers affected negatively the camptothecin encapsulation efficiency. 
However and fortunately, the amount of camptothecin encapsulated within the 
nanocarriers remained relatively high and the camptothecin encapsulation 
efficiency ranged from 19 to 39 %. 
 (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4, the biggest amphiphilic 
Janus dendrimer, was the less affected. The encapsulation efficiency of 
camptothecin goes down from 54 to 39 % with the presence of the modified 
rhodamine B. In the cases of (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 and 
(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2, the camptothecin encapsulation 
efficiency decreases significantly from 60 to 19 % and from 61 to 24 %, 
respectively. Clearly, the size of the amphiphilic Janus dendrimer appears as a 
key factor for the co-encapsulation efficiency. 
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Size and morphology of the nanocarrier/RhB(C17)2/CPT conjugates  
 The size and morphology of the Janus dendrimers/RhB(C17)2/CPT 
conjugates was studied by TEM and cryoTEM (figure C4-52 and table C4-11). 
 
Figure C4-52: TEM (up) and cryoTEM (down) images of the Janus 
dendrimer/RhB(C17)2/CPT conjugates. 
 
Table C4-11: Size and morphology of the Janus dendrimers/RhB(C17)2/CPT conjugates 
determined by TEM and cryoTEM. 
 amphiphilic bis-GMPA/bis-MPA Janus dendrimers 
 TEM cryoTEM 
 morphology size morphology size 
[G2]-[G1] elongated micelles 21.7 ± 4.9 nm 
spherical 
aggregates 
ca.30-50 nm  
& ≥ 200 nm 
[G3]-[G1] spherical micelles 19.0 ± 4.1 nm 
spherical 
aggregates 
ca.20-30 nm  
& ≥ 200 nm 
[G3]-[G2] micelles & vesicles 
22.3 ± 8.3 nm 
40.4 ± 7.9 nm 
spherical 
aggregates 
ca.20-60 nm  
& ≥ 200 nm 
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 The (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2/RhB(C17)2/CPT and 
(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2/RhB(C17)2/CPT conjugates give rise 
to micelles whose sizes are close to those formed by the Janus dendrimer/CPT 
conjugates (see table C4-8, p. 169) . In cryoTEM images, these spherical 
aggregates are also observed together with some bigger aggregates that should 
correspond to micelle self-aggregation.  
 In contrast, the (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4/RhB(C17)2/ 
CPT conjugate underwent some morphological changes when compared to its 
respective nanocarrier/CPT conjugate (see table C4-8, p. 169),  forming now a 
mixture of ovoidal micelles and small vesicles. In cryoTEM images, two size-
population distributions are observed: spherical aggregates with sizes ranged 
from 20 to 60 nm together with some bigger aggregates with sizes bigger than 
200 nm.  
 As a summary, the labeling of the nanocarrier/drug conjugates by the 
modified rhodamine B fluorophore did not induce morphological changes in two 
of the three nanocarrier/RhB(C17)2/CPT conjugates.  
In vitro antiviral activity and cytotoxicity 
 The biocompatibility and the antiviral activity of the nanocarrier/ 
RhB(C17)2/CPT  conjugates were evaluated in human hepatoma cells in order to 
determine if the presence of the fluorophore has an influence on the biological 
properties of the encapsulated camptothecin. Two systems were studied: 
(NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2/RhB(C17)2/CPT as a model for the 
micelles whose morphology are nor modified by the incorporation of RhB(C17)2 
and (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2](C17)4/RhB(C17)2/CPT that underwent 
morphological changes after the addition of RhB(C17)2 
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 The incorporation of modified rhodamine B, RhB(C17)2, within the two 
dendritic nanocarriers affected only slightly their biocompatibility and antiviral 
activity (figure C4-53-A). They appear almost identical as the one previously 
measured for the nanocarriers without RhB(C17)2. Likewise, the two 
nanocarrier/RhB(C17)2/CPT conjugates show similar biocompatibility with this 
cell line and antiviral replication than their respective nanocarriers/CPT 
conjugates (figure C4-53-B). 
 
Figure C4-53: Cell viability (lines) and antiviral activity (bars) of the empty nanocarriers  
in violet and of the nanocarrier/RhB(C17)2 conjugates in burgundy (A) and of the 
nanocarriers/CPT and nanocarriers/RhB(C17)2/CPT conjugates (B). Free CPT is 
represented in blue. 
  Therefore, the labeling of these nanocarrier/CPT conjugates by the 
modified rhodamine B (RhB(C17)2) does not alter their biological properties in 
HCV-infected  human hepatoma cells.  
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Cellular internalization 
 Flow-cytometry assays were carried out with the two bis-GMPA/ 
bis-MPA dendritic nanocarriers to determine if they were effectively capable of 
delivering camptothecin into the hepatic cells in spite of showing different 
morphologies. Two parameters were measured: the presence of modified 
rhodamine B in the cells and the correct organization of the cellular cycle. 
Camptothecin forms stable complexes with DNA and this hampers the regular 
cell division, disorganizing the cellular cycle. Propidium iodide stoichiometrically 
stains the DNA cell and allows classifying the cells that can replicate (which 
show n and 2n DNA population) from those that cannot replicate (which only 
show n DNA population). 
 The empty nanocarriers, nanocarrier/RhB(C17)2 conjugates, 
nanocarrier/CPT conjugates and nanocarrier/RhB(C17)2/CPT conjugates were 
studied. Two cell controls were carried out, one without adding anything to the 
cells and the other one adding camptothecin to the cells to quantify its activity. 
An organized cellular cycle (n and 2n DNA population) would testify the absence 
of active camptothecin, whereas a disorganized cellular cycle (only n DNA 
population) would confirm the presence of active camptothecin (table C4-18). 
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Table C4-18: Lipophilic modified rhodamine (RhB(C17)2) internalization level and 
organization of the cellular cycle measured by flow-cytometry assays. aDL means 
detection limit. 
 bis-GMPA/bis-MPA Janus dendrimers 
 channel [G2]-[G1] [G3]-[G2] 
free CPT 
RhB(C17)2 (%) < DLa < DL 
cellular cycle disorganized disorganized 
nanocarriers 
RhB(C17)2  (%) < DL < DL 
cellular cycle organized organized 
nanocarriers/ 
RhB(C17)2 
RhB(C17)2  (%) 34.7 67.3 
cellular cycle organized organized 
nanocarriers/CPT 
RhB(C17)2  (%) < DL < DL 
cellular cycle disorganized disorganized 
nanocarriers/ 
RhB(C17)2/CPT 
RhB(C17)2  (%) 46.1 51.6 
cellular cycle disorganized disorganized 
 (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1](C17)2 and (NH3+Cl-)8[bisGMPA,G3]-
[bisMPA,G2](C17)4 show the same results. As expected, the empty nanocarriers 
does not give any positive signal for RhB(C17)2 and CPT, while the 
nanocarrier/RhB(C17)2 conjugates only give a positive signal for the rhodamine 
channel, which is coherent with the results obtained during the biocompatibility 
assays. Neither the empty nanocarriers, nor the nanocarrier/RhB(C17)2 
conjugates were cytotoxic; they did not perturb the normal cellular cycle of 
hepatic cells.  
 All the nanocarrier conjugates with camptothecin disturbed the cellular 
cycle, confirming that the encapsulation of the drug within the diverse 
conjugates does not affect its activity. Besides, the nanocarrier/RhB(C17)2/CPT 
conjugates additionally give a positive signal for RhB(C17)2 that proves the 
correct internalization of the whole nanocarrier/RhB(C17)2/CPT conjugates in 
the cells. 
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 The low-water soluble modified rhodamine B appears as an efficient 
fluorophore that allows the labeling of various amphiphilic nanocarriers while 
inducing few morphological changes in the nanocarrier/drug conjugates, and 
showing similar anti-HCV activity than the unlabeled nanocarrier/drug 
conjugates. 
 As the labeling is based on non-covalent interactions, various dendritic 
nanocarriers could be effectively labeled by the same modified fluorophore 
without requiring additional covalent synthesis. 
  
Amphiphilic bis-MPA and bis-GMPA dendritic derivatives for camptothecin delivery 
195 
4.4- General remarks 
Summary of results 
 Three series of amphiphilic dendritic derivatives were synthesized in 
order to transport and deliver camptothecin, an alleosteric inhibitor of the 
hepatitis C virus, into human hepatic cells. 
 The nature of the amphiphilic dendritic derivatives, either Janus 
dendrimers or hybrid dendritic-lineal-dendritic block copolymers, as well as the 
variety of hydrophilic and lipophilic dendrons employed for their synthesis 
allowed the formation of diverse nanocarriers to transport camptothecin. 
 One of the series of the amphiphilic Janus dendrimers was fluorescently 
labeled with a commercial fluorophore modified with a lipophilic dendron, and 
this permitted to confirm their cellular internalization into hepatic cells. 
Conclusions 
 Eight of the nine dendritic systems presented hereby could effectively 
encapsulate and deliver camptothecin into HCV-infected hepatic cells.  
 Among them, the amphiphilic hybrid dendritic-lineal-dendritic block 
copolymers based on bis-GMPA dendrons and Pluronic® F-127 appeared to be 
the best candidate as it presented good level of camptothecin encapsulation (46 
µg of camptothecin per mg of derivative) and a better therapeutic index than 
the free drug (almost 3 times higher). 
 The addition of a lipophilic dendron to the rhodamine B allows a simple, 
versatile and time-persistent labeling by non-covalent interactions of the 
amphiphilic Janus dendrimer/drug conjugates without altering their biological 
properties.  
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Future investigation 
 In order to perform further in vivo tests, the release of camptothecin 
from the nanocarriers/CPT conjugates must be studied. The reticulation of the 
nanocarriers might be studied to perform a sustained drug release, as well as 
the design of “on/off systems” to favor targeting abilities. 
 The targeting abilities of the nanocarriers might be promoted following a 
protocol similar than the one employed with rhodamine B. The addition of a 
lipophilic dendron on small targeting molecules might favor stable and time-
persistent non-covalent interactions between these modified targeting 
molecules with the nanocarriers avoiding covalent synthesis.  
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 In this chapter, new globular dendrimers based 2,2-
bis(glyciloxymethyl)propionic acid (bis-GMPA) and dendronized hyperbranched 
polymers (DHPs) based on 2,2-bis(hydroxylmethyl)propionic acid (bis-MPA) are 
described as  vectors for gene transfection. 
 Firstly, the synthesis and the characterization of the materials are 
commented. Secondly, their potential as gene transfection vector for pDNA and 
siRNA is reported.  
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5.1- bis-GMPA and bis-MPA globular 
dendritic derivatives 
 
 In order to perform non-viral gene transfection, a high number of amino 
groups is required to efficiently complex the genetic material. Therefore, two 
dendrimers based on bis-GMPA of 3rd and 4th generation were synthesized with 
respectively 28 and 48 terminal ammonium groups and 18 and 46 internal 
amide groups. In addition, three commercial bis-MPA hyperbranched polyesters 
decorated with hydrophilic dendrons of bis-MPA bearing terminal amino groups 
were synthesized. It resulted into three new dendronized hyperbranched 
polymers (DHPs) with theoretically 128, 256 and 512 terminal ammonium 
groups. (figure C5-1).  
 
Figure C5-1: Gneral chemical structure of the two bis-GMPA dendrimers and the three 
bis-MPA dendronized hyperbranched polymers. 
  
Chapter 5 
202 
5.1.1- Synthesis and chemical characterization 
 
5.1.1.1- Bis-GMPA dendrimers 
 2,2’-bis(glyciloxymethyl)propionic acid (bis-GMPA) dendrimers were 
synthesized following an  original convergent pathway (figure C5-2). Bis-GMPA 
dendrons of the 3rd and 4th generation were linked to a core of tripropargyl 
amine by means of CuAAC. Because of its high conversion yields and the few by 
product generated, CuAAC “click chemistry” has been widely used for the 
convergent synthesis of dendrimers.[69,207] For example, a tripropargyl amino 
core permits the construction of globular dendrimers consisting of three 
dendrons in a convergent way using this methodology.[208] In our case, a 
hexamethylenic chain was used as spacer between the core and the bis-GMPA 
dendrons in order to favor the complete functionalization of the core and afford 
flexibility of the final dendritic structure which might help their abilities to form 
dendriplexes with pDNA and siRNA.[209] 
                                                          
[69] a) M. Sowinska et al., New J. Chem., 2014, 38, 2168; b) M. Arseneault et al., Molecules, 
2015, 20, 9263. 
[207] W. Lee,  J. H. Kim, B.K. Kim, J.H. Kim, W.S. Shin, S.H Jin, Convergent synthesis of PAMAM 
dendrimers using click chemistry of azide-functionalized PAMAM dendrons, Tetrahedon Lett., 
2006, 62, 9193-9200. 
[208] J.W. Lee,  B.K. Kim, A facile route to triazole dendrimers via click chemistry linking 
tripodal acetylene and dendrons, Bull.Korean Chem. Soc., 2005, 6, 658-600. 
[209] J.A. Kretzmann, D. Ho, C.W. Evans, J.H. C. Plani-Lam, B. Garcia-Bloj, E. Mohamed, M.L. 
O'Mara, E. Ford, D.E. K. Tan, R. Lister, P. Blancafort, M. Norret, K.S. Iyer, Synthetically 
controlling dendrimer flexibility improves delivery of large plasmid DNA, Chem. Sci., 2017, in 
pres press press press, DOI: 10.1039/c7sc00097a.  
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Figure C5-2: Synthesis of the bis-GMPA dendrimer of 3rd generation (see chapter 7 for 
detailled general procedure X) and VI)). 
 The synthesis of the bis-GMPA dendrons of the 3rd and 4th generation 
with t-Boc protected amino groups with an azide group in the focal point is 
described in section 4.1.2 (see p. 104). These dendrons were made to react with 
tripropargyl amine by means of Copper(I) azide-alkyne cycloaddition (CuAAC) in 
dimethylformamide (figure C5-2, general procedure X). An excess of dendron 
(1.2 mole of dendron per mole of alkyne groups) was added to ensure a 
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complete functionalization of the dendrimer core. The Cu(I) catalytic species 
was formed “in situ” by reduction of Cu(II) salts of CuSO4·5H2O using (L)-
ascorbate in the presence of TBTA to increase its stability.[189] 
 After completion of the reaction, the reaction mixture was washed 
several times with different aqueous solutions, including a KCN solution, in 
order to eliminate the dimethylformamide solvent and the catalytic system. The 
crude products were precipiated in a mixture of ethyl acetate and hexanes to 
remove the dendron that had not reacted. Then, dialysis against methanol was 
carried out to remove all the small impurities.  
 Finally, the t-Boc protecting groups were quantitatively removed in acidic 
conditions in ethyl acetate, forming the ammonium salts that precipitated from 
the reaction mixture. Hydrochloric acid was, then, removed under vacuum. The 
final products were recovered by centrifugation and washed with pure ethyl 
acetate to remove the remaining acid traces. 
 The total yield of both reactions was quite high, i.e. 85 % and 78 % for the 
3rd and 4th generation dendrimer, respectively. 
 The final dendrimers were characterized with 1H and 13C nuclear 
magnetic resonance (NMR), Fourier transform infrared spectroscopy (FTIR). 
Elemental analysis (EA) and size exclusion chromatography (SEC) were 
performed with the t-Boc protected precursors. The complete chemical 
characterization data are gathered in chapter 7. The correct formation of the 
triazole ring was first confirmed by 1H NMR and 13C NMR spectrometry (figure 
C5-3).  
                                                          
[189] T. R. Chan et al., Org. Lett., 2004, 6, 2853. 
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Figure C5-3: 1H NMR spectrum of N3-[bisGMPA,G3](NH3+Cl-)8 (up) and 1H NMR (middle) 
and 13C NMR (down) spectra of D[bisGMPA,G3](NH3+Cl-)24  recorded in CD3OD at 400 
and 100 MHz, respectively. 
  
 The 1H NMR spectrum of the dendrimer shows a singlet at 8.50 ppm that 
corresponds to the proton of the triazole ring, H-3. Additionally, the methylene 
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protons in the α-position of the triazole belonging to the core,  
H-1, as well as the protons in the α- and β-positions of the triazole belonging to 
the dendrons, H-4 and H-5, were shifted downfield with respect to the signals 
observed in the dendron spectrum. They moved from 3.49 to 4.55 ppm (H-1), 
from 2.3 to 4.55 ppm (H-4) and from 1.70 to 1.95 ppm (H-5). The correct 
assignation of the peaks was confirmed by 1H-1H COSY and 1H-13C HSQC 
experiments (see annexes 8 & 9). 
 Furthermore, the 13C NMR shows two peaks that correspond to the 
carbon atoms of the triazole ring, C-2 and C-3, which appear at 137.9 and 128.7 
ppm, respectively.  
 The absence of dendron that had not reacted with the core was 
confirmed by FTIR and SEC (figure C5-4).  
 
Figure C5-4: FTIR spectra of a dendron and a dendrimer of bis-GMPA and SEC 
chromatogram of the dendrons and dendrimers of 3rd and 4th generation of bis-GMPA. 
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 The characteristic band at 2100 cm-1, which corresponds to the azide 
group of the dendron, is not visible in the FTIR spectrum of the dendrimer. SEC 
chromatograms show an only monomodal peak for the dendrimer of 3rd 
generation, and a peak with a small shoulder for the dendrimer of 4th 
generation, although this shoulder doesn’t correspond to the maximum of its 
dendron precursor. The polydispersity of the dendrimers was low, 1.02 and 1.05 
respectively using PMMA as a reference, in accordance with their dendritic 
nature. 
 In summary, bis-GMPA dendrimers of small or medium generations can 
be easily synthesized following a convergent pathway by means of CuAAC. The 
two dendrimers showed very few defects and were synthesized with good 
yields.  
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5.1.1.2- Bis-MPA dendronized hyperbranched polymers (DHPs) 
 The typical synthesis of high generation dendrimers using either the 
divergent or convergent method requires many steps followed in all cases by 
complicated purification processes making them long and tedious. In this 
context, hyperbranched polymers were developed as an alternative to 
dendrimers. These polymers are easily obtained in only one step. Although they 
are polydisperse compounds, their properties, size and terminal groups are very 
similar in different batches. Today, a lot of commercial hyperbranched polymers 
is available.[80] 
 Recently, dendronized hyperbranched polymers (DHPs) have been 
investigated. They consist on a core based on a hyperbranched polymer of small 
or medium generation which is decorated with peripheral dendrons. Following 
this strategy, high generation dendritic macromolecules with low polydispersity 
can be obtained quite easily. The term pseudodendrimer was also introduced to 
describe them.[87-89] 
 In our case, commercial bis-MPA hyperbranched polymers of 2nd, 3rd and 
4th generation were decorated with bis-MPA dendrons of 3rd generation with 
peripheral glycine moieties following a double stage convergent synthetic 
pathway (figure C5-5). 
 In a first step, bis-MPA commercial hyperbranched polymers were 
allowed to react with 4-pentynoic acid according to Steglich’s esterification 
conditions (in the presence of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide  
   
 
 
 
                                                          
[80] a) Y.H. Kim et al., J. Am. Chem. Soc., 1990, 112, 4592; b) Y. Zheng et al., Chem. Soc. Rev., 
2015, 44, 4091. 
[87] A. Lederer et al., Angew. Chem. Int. Ed., 2015, 54, 12578. 
[88] C. Lach et al., Macromolecules, 1998, 31, 2381. 
[89] A. Lederer et al., Macromol. Rapid Commun., 2012, 33, 1440. 
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Figure C5-5: Synthesis of the three bis-MPA dendronized hyperbranched polymers of 
generations 2+3, 3+3 and 4+3. 
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hydrochloride (EDC·HCl) and DPTS) to insert peripheral alkyne groups at the 
periphery of the polymers, HP-[G2,3,4]-≡ (figure C5-5, general procedure XI)). An 
excess of the acid (1.25 mole per mole of hydroxyl groups) was used to favor a 
complete functionalization of the terminal hydroxyl groups. In this specific case, 
EDC·HCl was preferred to DCC as coupling agent as it induces the formation of a 
water soluble urea derivative that can be easily removed by several washings 
with aqueous solutions. The hyperbranched polymers were further purified by 
precipitation into hexanes.[210] 
 The so prepared hyperbranched polymers HP-[G2,3,4]-≡ were grafted 
with the previously synthesized 3rd generation of the bis-MPA dendrons with t-
Boc glycine moieties at the periphery and with an azide group at the focal point 
(see section 4.1.1.1, p. 95). As before, the Cu(I) catalytic species was formed “in 
situ” by reduction of Cu(II) salts by (L)-ascorbate in presence of TBTA (figure C5-
5, general procedure XII)). An excess of the corresponding dendron (1.2 mole of 
dendron per mole of alkyne group) was used to favor a high level of dendron 
grafting. The catalytic system was removed by washings with aqueous solutions, 
including a KCN solution, and filtrated through silica gel in order to remove the 
catalytic system. Then, the DHP[G 2+3, 3+3, 4+3](NHBoc) were precipitated into 
a mixture of hexanes and ethyl acetate (9/1) to remove the unreacted dendron.  
 Finally, the t-Boc protecting groups of the terminal amino groups were 
removed under acidic conditions (HCl 3M) in ethyl acetate, forming the 
ammonium salts that precipitated in the reaction medium. Hydrochloric acid 
was then removed under vacuum. The final products were recovered by 
centrifugation and washed with pure ethyl acetate to remove remaining acid 
traces. DHP[G2+3](NH3+Cl-), DHP[G3+3](NH3+Cl-) and DHP[G4+3](NH3+Cl-) were 
obtained with global yields between 49 and 55 %. 
                                                          
[210] M. Lomba, L. Oriol, R. Alcalá, C. Sánchez, M. Moros, V. Grazú, J.L. Serrano, J.M. de la 
Fuente, In situ photopolymerization of biomaterials by thiol-yne click chemistry, Macromol. 
Biosci., 2011, 11, 1505-1514. 
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 All the final DHPs and their respective intermediates were characterized 
by 1H and 13C nuclear magnetic resonance (NMR) and Fourier transform infrared 
spectroscopy (FTIR). Additionally, size exclusion chromatography (SEC) were 
performed for the hyperbranched polymers bearing terminal alkyne groups and 
with the DHPs bearing terminal t-Boc protected amino groups. Elemental 
analysis (EA) was performed with the DHPs with t-Boc protected and 
unprotected amino groups (see chapter 7 for the complete chemical 
characterization of the derivatives). 
 1H NMR was used to confirm the completion of the reactions (figure C5-
6). The correct insertion of the alkyne groups was confirmed by the apparition 
of a peak at 1.94 ppm, corresponding to the protons of the alkyne groups H-13’, 
and two other signals at 2.54 and 2.44 ppm that corresponded to the methylene 
protons in the α- and β-positions of the alkyne groups H-10’ and H-11’, 
respectively.  
 The grafting of the bis-MPA dendrons after the CuAAC was verified by the 
apparition of a new peak at 7.41 ppm that corresponded to the proton of the 
triazole rings, H-13. Additionally, four other peaks corresponding to the bis-MPA 
dendrons appeared in the spectra. They corresponded to the methyl groups of 
the t-Boc protecting groups, H-27 (1.43 ppm), the methylene protons in the β-
position of the triazole rings, H-15 (1.89 ppm), the methylene protons in the α-
position of the amino groups, H-26 (3.87 ppm) and the protons belonging to the 
amido groups, N-H (5.48 ppm).  
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Figure C5-6: Full 1H NMR spectrum of DHP[G3+3](NHBoc) (A) and enlargements of the 
1H NMR spectra of the 3 hyperbranched polymers HP[G2,3,4]-≡ (B) and the 3 
dendronized hyperbranched polymers DHP[G2+3,3+3,4+3](NHBoc) (C) recorded in 
CDCl3 at 400 MHz. 1H-1H COSY experiments were carried out to confirm the correct 
peak assignation (see annexes 10). 
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 The 1H NMR spectrum also permitted to estimate the proportion of 
alkyne groups and dendrons that could be effectively grafted onto the 
hyperbranched polymer cores. 
 After the insertion of the terminal alkyne groups, the relative integration 
of the peaks corresponding to the protons in the α- and β-positions of the 
alkyne groups (H-10’ and H-11’) were compared with the relative integration of 
the peak corresponding to the methyl groups of the hyperbranched polymer  
(H-7). This allowed to estimate that the hyperbranched polymer of 2nd 
generation could be grafted with an average of 15 terminal peripheral alkyne 
groups while the 3rd and 4th generation ones could be grafted with an average of 
31 and 61 peripheral alkyne groups, respectively. These values correspond to 
degrees of functionalization between 94 % and 96 %.  
After the CuAAC reaction, the peaks corresponding to these methylene 
protons are downfield shifted and move from 2.54 and 2.44 ppm (H-10’ and H-
11’) to 2.73 and 2.96 ppm (H-10 and H-11), respectively. In the case of 
DHP[G2+3](NHBoc) and DHP[G3+3](NHBoc), no remaining signals could be 
observed at 2.44 and 2.54 ppm, leading to affirm that all their terminal alkyne 
groups were grafted with bis-MPA dendrons. However, in the case of 
DHP[G4+3](NHBoc), remaining signals at 2.44 and 2.54 ppm could be observed 
and by comparing the relative integrations, it was estimated that 87 % of the 
alkyne groups could be grafted with dendrons. Thus, after the two reactions, an 
average of 15 dendrons, 31 dendrons and 53 dendrons were respectively 
grafted on the hyperbranched polymers of 2nd, 3rd and 4th generation, and this 
correspond to 120, 248 and 424 terminal amino groups. 
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 Other characterization studies were carried out to control the correct 
synthesis of the final DHPs. In 13C NMR, the signals corresponding to the carbon 
atoms belonging of the triazole rings, C-12 and C-13, appeared at 122.1 and 
145.2 ppm together with peaks corresponding to the hyperbranched polymer 
core (in orange) and to the peripheral dendrons (in green) (figure C5-7).  
 
Figure C5-7: 13C NMR spectra of DHP[G3+3](NH3+Cl-)248 recorded in (CD3)2SO at 75 MHz. 
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 According to the FTIR spectra (figure C5-8), the insertion of the terminal 
alkyne groups was confirmed by the disappearance of the stretching band of the 
O-H bonds at 3387 cm-1 and the apparition of the bands at 3309 and 2119 cm-1 
corresponding to the stretching of the ≡C-H and C≡C bonds, respectively. After 
the CuAAC reaction, these two bands were no longer visible and a band at 3354 
cm-1 corresponding to the stretching of the N-H bond appeared and the band 
corresponding to the stretching of the C=O bonds (near 1700 cm-1) was 
modified due to the introduction of carbamate groups. Finally, after removing 
the t-Boc protecting groups, the stretching band of the N-H bonds became 
much larger, and an only peak due to the C=O bonds of the ester groups could 
be seen. 
Figure C5-8: FTIR spectra of HP[G3]-(OH)32, HP[G3]-(≡)31, DHP[G3+3](NHBoc)248 and 
DHP[G3+3](NH3+Cl-)248. 
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 SEC chromatograms show peaks much sharper and at lower retention 
times (figure C5-9) than the corresponding commercial hyperbranched polymers 
(HPs), which show broad peaks with several maxima. Additionally, no peak 
corresponding to free bis-MPA dendron can be observed in the chromatograms. 
The polydispersity of the three DHPs was calculated finding values between 1.13 
and 1.22 using PMMA as a reference. The grafting of monodisperse dendrons 
on hyperbranched polymers of small and medium generations contributes to 
the low polydispersity of the final compounds.  
 
Figure C5-9: SEC chromatograms of HP[G2,3,4](OH), HP[G2+3,3+3,4+3](NHBoc) and  
N3-[bisMPA,G3]-(NHBoc)8. 
 Following this novel procedure, high generation bis-MPA dendronized 
hyperbranched polymers (DHPs) could be easily synthesized. These 
macromolecules, also called pseudodendrimers, present a high number of 
terminal ammonium groups (up to 424) and show a low polydispersity. 
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5.1.2. Properties  
 Both types of globular dendritic derivative were considered so as to be 
employed as gene delivery carriers. For this reason, properties such as 
bicompatibility, their response to pH changes and aggregation in water were 
studied.  
5.1.2.1. Bicompatibility 
 These studies carried out in the laboratories of the Center for Biomedical 
Research of Aragon (CIBA) in collaboration with Dr. M. Pilar Martín-Duque and 
Dr. Rebeca González-Pastor. Further details of these studies as well as deeper 
research belong to the thesis work  and are gathered in her thesis report.[184] 
Part of these studies are already published in Bioconjugate Chemistry.[211] This 
article is added at the end of this chapter for supporting information. 
 The biocompatibility of non-viral vectors used for gene delivery is 
undoubtedly an essential issue. However, only few dendrimers are both 
biocompatible and highly efficient gene vectors.[212] Indeed, classical dendrimers 
                                                          
[184] R. González, Estudio de dendrímeros y nanopartículas de oro para su uso en 
tratamientos antitumorales, 2017, Universidad de Zaragoza. 
[211] A. Lancelot, R. González-Pastor, A. Concellón, T. Sierra, P. Martín-Duque, J.L. Serrano, 
DNA transfection to mesenchymal stem cells using a novel type of pseudodendrimer based on 
2,2-bis(hydroxymethyl)propionic acid, Bioconjugate Chem., 2017, In press, DOI: 
10.1021/acs.bioconjchem.7b00037 
[212] a) Y. Wang, L.Li, N. Shao, Z.hu, H.Chen, L. Xu, C. Wang, Y. Cheng, J. Xiao, Triazine-
modified dendrimer for efficient TRAIL gene therapy in osteosarcoma, Acta Bioamat., 2015, 
17, 115-124; b) A. Kobayashi, Y. Yokoyama, Y. Osawa, R. Miura, H. Mizunuma, Gene therapy 
for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in 
mouse models, Cancer Gene Ther., 2016, 23, 24-28; c) y. Wang, M. Wang, H. Chen, H. Liu, Q. 
Zhang, Y. Chen, Fluorinated dendrimer for TRAIL gene therapy in cancer treatment, J. Mater. 
Chem. B, 2016,4, 1354-1360; d) L.Y. Lim, P.Y. Koh, S. Somani, M. Al Robaian, R. Karim, Y.L. Yean, 
J. Mitchell, R.J. Tate, R. Edrada-Ebel, D.R. Blatchford, M. Mullin, C. Dufès, Tumor regression 
following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes, 
Nanomedicine, 2015, 1445-1454. 
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such as naked PAMAMs, PPIs, etc. usually showed high gene transfection gene 
efficacy but notable cytotoxicity whereas others like bis-MPA based dendrimer 
derivatives showed high biocompatibility but low gene transfection 
efficiency.[213] 
 The cytotoxicity of the bis-GMPA dendrimers and bis-MPA DHPs was 
studied with human cervix cancer cells HeLa and mouse mesenchymal stem 
cells (MSCs) (figure C5-10). 
 All the derivatives were biocompatible for these two cell lines. Thus, the 
cell viability measured for the bis-MPA DHPs was high and appeared superior to 
85 % in all the cases. The bis-GMPA dendrimers also showed elevated 
biocompatibility with cell viabilities superior to 75 % in both cases. 
 
Figure C5-10: Cell viability measured for HeLa cells and MSCs after 72 hours after 72h 
with 1 mg/mL of globular dendritic derivatives. 
 Additionally, the amounts of copper that might have remained in the 
compounds were measured by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES) (table C5-1). Indeed, copper is quite cytotoxic and might 
                                                          
[213] a) M. Breunig, U. Lungwitz, R. Liebl, A. Goepferich, Breaking up the correlation between 
efficacy and toxicity for nonviral gene delivery, Proc. Natl. Acad. Sci. USA., 2007, 104, 14454–
14459; b) L. Jin X. Zeng, M. Liu, Y. Deng, N. He, Current progress in gene delivery technology 
based on chemical methods and nano-carriers, Theranostics, 2014, 4, 240–255. 
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accumulate in the tissues, limiting the long-term biocompatibility of the 
compounds.  
Table C5-1: Amount of copper remaining in the globular dendritic derivatives measured 
by ICP-AES. aThe limit of quantification (LOQ) for this technique was of 15 ppm.  
globular dendritic 
derivatives 
amount of copper 
(µg/mg) 
D[G3](NH3+Cl-)24 16 
D[G4](NH3+Cl-)48 54 
DHP[G2+3](NHBoc)120 < LOQa 
DHP[G3+3](NHBoc)248 < LOQ 
DHP[G4+3](NHBoc)424 < LOQ 
 The amounts of copper that remained in all the dendritic derivatives 
were really low and always far below the recommended dietary allowance.[214] 
  
                                                          
[214]Dietary Reference Intakes Tables and Application, The national academy of sciences, 
engineering, medicine, Table DRI Values Summary- A com 
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5.1.2.2 pH change response 
 The “proton sponge ability” of the dendrimers at pH values comprised 
between 7.4 and 5.0 is entailed during the endosomal escape process and favor 
transfection efficiency.[49] It is known that a large portion of 2nd and 3rd amino 
groups in the backbone of the synthetic vectors clearly promotes this ability.[215] 
Thus, the buffering effect of the two bis-GMPA dendrimers and the three bis-
GMPA DHPs was determined and compared to water and commercial PAMAM 
dendrimer as negative and positive controls, respectively (figure C5-11). 
 To decrease the pH from 7.5 to 5.0, 15 μL of HCl 0.1M are required in the 
case of water (in blue) whereas 130 μL of HCl 0.1 M are required for PAMAM (in 
red). Surprisingly, and although bis-MPA DHPs only contain primary amino 
groups, they show a “proton sponge ability” close to that of PAMAM and better 
than that of the bis-GMPA dendrimers. Indeed, between 90 and 100 µL of HCl 
0.1 M are required to decrease the pH in the case of the DHPs while 30 and 50 
μL are required for the bis-GMPA dendrimers of respectively 3rd and 4th 
generation. Interestingly, the 4th generation bis-GMPA dendrimer shows better 
proton sponge abilities than the 3rd generation one. 
                                                          
[49] a) A.K. Varkouhi et al., J. Control. Release, 2011, 151, 220; b) J. Behr, Chimia, 1997, 51, 34. 
[215] a) J.C. Sunshine, D.Y. Peng, J.J. Green, Uptake and transfection with polymeric 
Nanoparticles are dependent on polymer end-group structure, but largely independent of 
nanoparticle physical and chemical properties, Mol. Pharm., 2012, 9, 3375-83; b) J. Zhou, J. 
Wu, N. Hafdi, J.P. Behr, P. Erbacher, L. Peng L, PAMAM dendrimers for efficient siRNA delivery 
and potent gene silencing, Chem. Comm., 2006, 22, 2362-2364; c) A. Akinc, M. Thomas, A.M. 
Klibanov, R. Langer, Exploring polyethylenimine-mediated DNA transfection and the proton 
sponge hypothesis, J. Gene Med., 2005, 657-663; d) D. Ouyang, H. Zhang, H.S. Parekh, S.C. 
Smith, The effect of pH on PAMAM dendrimer–siRNA complexation — Endosomal 
considerations as determined by molecular dynamics simulation, Biophys. Chem., 2011, 158, 
2–3, 126–133. 
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Figure C5-11: “Proton sponge” titration curves of the bis-GMPA dendrimers, bis-MPA 
DHPs and commercial PAMAM in presence of 0.1 M NaCl. 
 In order to explain the good proton sponge ability of the DHPs, 
DHP[G3+3](NH3+Cl-)248 was titrated with NaOH (0.1 M). The pH of the solution 
was measured after each addition of NaOH (figure C5-12-A). As it can be 
observed in the curve, the pH changes were smooth. This observation confirms 
some theoretical calculations[216] that predict different pKa values for each 
terminal amino groups of the N3-[bisMPA,G3]-(NH3+Cl-)8 dendron, ranged from 
6.19 to 7.99 (figure C5-12-B). Due to the important electrical repulsions between 
the terminal ammonium groups located at the periphery of the dendron, the 
dissociation of the ammonium group is favored at lower pH, reducing the basic 
character of the terminal amino groups. As a consequence, some primary amino 
groups change from their neutral form to their protonated at endosomal pH 
values and disturb the normal pH decrease of the endosome, acting as a “proton 
sponge”. 
 The poorer proton sponge ability of DHP[G4+3](NH3+Cl-)424 in comparison 
with the two other DHPs may be explained by the lowest dendron density on 
                                                          
[216] Calculations performed by MarvinSketch program (www.chemaxom.com). 
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this hyperbranched polymer core. The electrostatic repulsions between the 
terminal ammonium groups are lower and, as a consequence, their basicity is 
higher. They change from their neutral form to their protonated form at higher 
pH and are therefore less sensitive to the pH changes that take place in the 
endosomes. 
 
Figure C5-12: Acid-base titration of DHP[G3+3](NH3+Cl-)248 (A) and D[G4](NH3+Cl-)48 (C); 
colorcurves represent the pH values after each addition of NaOH while grey curves 
represent the derivative pH curves. Representations of N3-[bisMPA,G3](NH2)8 (B) and 
N3-[bisGMPA,G3](NH2)8 (D) dendrons with pKa values of their terminal amino groups 
and internal amido groups calculated with MarvinSketch program. 
 D[G4](NH3+Cl-)48 was also titrated with NaOH (0.1M) (figure C5-12-C). The 
derivative of the curve clearly shows two distinct maxima: one corresponding to 
pH = 4-6 and the other one corresponding to pH = 8-9. This observation does 
not confirm the theoretical calculations that predicted pKa values for the 
terminal amino groups comprised between 6.25 and 7.87 (figure C5-12-D). 
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These results suggest that the insertion of amido groups in the internal 
branches of the dendrimers modified the protonation of the peripheral amino 
groups. 
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5.1.2.3- Aggregation in water 
 The globular dendritic derivatives were observed by TEM in order to 
study the morphology they adopt in water and their ability to self-aggregate 
(figure C5-13).  
 
Figure C5-13: TEM images of the bis-GMPA dendrimers and the bis-MPA DHPs at 1 
mg/mL in distilled water.  
 Both bis-GMPA dendrimers appear as spherical objects with average 
diameters around 10.42 ± 2.63 for D[G3](NH3+Cl-)24 and 14.32 ± 2.94 nm for 
D[G4](NH3+Cl-)48.The bis-MPA DHPs appear as spherical objects with average 
diameters around 7.52 ± 4.21, for DHP[G2+3](NH3+Cl-)120, 9.80 ± 2.71 for 
DHP[G3+3](NH3+Cl-)248 and 13.47 ± 3.50 nm for DHP[G4+3](NH3+Cl-)424. 
 The diameters measured for the bis-MPA DHPs reveal that they form 
unique and independent molecules dispersed in solution like the “green peas” 
culinary model described by Fréchet.[58] This observation is in accordance with 
                                                          
[58]  J.M.J Fréchet, Science, 1994, 263, 1710. 
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the literature. While the commercial hyperbranched polyester can aggregate in 
water forming bigger nanoobjects stabilized by lipophilic interactions and/or H 
bonds,[217]  the surface of amino terminated DHPs is positively charged and their 
aggregation must be impeded by electrostatic repulsion between molecules. 
 In contrast, bis-GMPA dendrimers, give rise to TEM images of rounded 
nanoobjects the diameter of which is too big to correspond to an only molecule. 
This indicates that self-aggregation must have occured. Indeed, these 
dendrimers can fold upon themselves to adopt a conical shape and several 
folded dendrimers can self-assemble to form a sphere. This sphere must be 
stabilized by the H bonds between the internal amide groups of the dendrimers 
and destabilized by the electrostatic repulsion between the terminal ammonium 
groups (figure C5-14). 
 
Figure C5-14: Self-assembly of the dendrimers into bigger spheres. 
  
  
                                                          
[217] a) M. Prabaharan, J.J. Grailer, S. Pilla, D.A Steeber, S. Gong, Folate-conjugated 
amphiphilic hyperbranched block copolymers based on Boltorn® H40, poly(l-lactide) and 
poly(ethylene glycol) for tumor-targeted drug delivery, Biomaterials, 2009, 30, 3009-19; b) G. 
Chen, L. Wang, T. Cordie, C. Vokoun, K.W. Eliceiri, S. Gong, Multi-functional self-fluorescent 
unimolecular micelles for tumor-targeted drug delivery and bioimaging, Biomaterials, 2015, 
47, 41-50. 
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 To conclude, two bis-GMPA dendrimers and three bis-MPA dendronized 
hyperbranched polymers (DHPs) were synthesized. Both compounds present 
numerous peripheral cationic ammonium groups to effectively complex pDNA 
and siRNA. Moreover, as they are biocompatible and as they present proton 
sponge abilities, they are good candidates to be explored as gene transfection 
agents.  
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5.2 - Gene transfection 
 
 The ability of both, bis-GMPA and bis-MPA globular dendritic derivatives, 
to transfect genetic material was studied. The dendriplexes formation and their 
characteristics were studied as well as their transfection efficiency. The bis-
GMPA dendrimers and bis-MPA dendronized hyperbranched polymers (DHPs) 
were used to transfect both pDNA and siRNA. 
 For pDNA transfection, plasmid enhanced green fluorescent protein 
(pEGFP) was chosen.  This small plasmid (4733 base pairs) induces the 
fabrication of a green fluorescent protein by the cells that permits to attest the 
efficiency of the gene transfection and facilitates the comparison between 
various non-viral vectors, including commercial agents.  
 For siRNA transfection, green fluorescent protein specified small 
interfering RNA (siGFP) and luciferease specified small interfering RNA (siLuc) 
with approximately 20 and 21 base pairs respectively were chosen. siGFP 
silences the production of GFP by epithelial cells and siLuc silences the 
production of luciferease by cancerous cells. After gene transfection, the 
decrease of fluorescence or luminescence allows attesting the efficiency of the 
gene silencing and facilitates the comparison of various non-viral vectors with 
commercial agents. 
 These studies herein detailed were carried out in collaboration with the 
Center for Biomedical Research of Aragon (CIBA) in collaboration with Dr. M. 
Pilar Martín-Duque and Rebeca González-Pastor whom performed gel 
retardation and transfection assays. Complementary investigations such as 
dendriplexes stability and cellular internalization are gathered in the thesis 
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report of Rebeca González-Pastor[184] and in one article[ 218 ] published in 
“Bioconjugate Chemistry” inserted at the end of this chapter.  
  
                                                          
[184] R. González, Estudio de dendrímeros y nanopartículas de oro para su uso en 
tratamientos antitumorales, 2017, Universidad de Zaragoza. 
[218] A. Lancelot, R. González-Pastor et al., Bioconjugate Chem., 2017, In press, DOI: 
10.1021/acs.bioconjchem.7b00037 
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5.2.1- Dendriplex formation and characterization 
5.2.1.1- Dendriplex formation 
 The electrostatic complexation of pDNA  and siRNA  by the two bis-GMPA 
dendrimers of 3rd and 4th generation and the three bis-MPA DHPs of the 
generations 2+3, 3+3 and 4+3 give rise to the formation of dendrimer/nucleic 
acid complexes, i.e. dendriplexes. Their formation was studied by agarose gel 
retardation assays and ζ potential measurements. 
Agarose gel retardation assays 
 Electrophoresis studies were carried out with the two bis-GMPA 
dendrimers to observe the migration of the negatively charged genetic material 
to the positive pole at different ratios weightdendrimer/weightpDNA or siRNA 
(wdend./wpDNA or siRNA). When the genetic materials are totally and strongly 
complexed by the dendritic derivatives, they don’t move and any remaining 
trace is observed at the same level than the free genetic material (figure C5-15). 
 The bis-GMPA dendrimer of 3rd generation, D[G3](NH3+Cl-)24, can complex 
the pDNA from a ratio (wdend./wpDNA) 50/1 and fails to totally complex the siRNA 
at any of the ratios tested. The dendrimer of 4th generation, D[G4](NH3+Cl-)48, 
shows much better complexation abilities and can totally complex the pDNA 
from a ratio (wdend./wpDNA) 5/1 and the siRNA from a ratio (wdend./wsiRNA) of 80/1. 
As previously described in the literature for other dendritic derivatives,[219] the 
dendrimer of the highest generation showed better siRNA and pDNA 
complexation abilities than the smallest one. Contrary to the flexible circular 
pDNAs, siRNA strands are rigid. Therefore, they cannot wrap around the 
                                                          
[219] L. Albertazzi, F.M. Mickler, G.M. Pavan, F. Salomone, G. Bardi, M. Panniello , E. Amir, T. 
Kang, K.L. Killops, C. Bräuchle, R.J. Amir, C.J. Hawker, Enhanced bioactivity of internally 
functionalized cationic dendrimers with PEG cores, Biomacromolecules, 2012, 13, 4089-4097. 
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dendritic derivatives and more dendritic macromolecules are required to 
effectively complex all the siRNA, as previously observed in the literature.[220] 
 
 
Figure C5-15: Gel retardation of pDNA (up) and siRNA (down) with increasing 
concentrations of 3rd and 4th generation bis-GMPA dendrimers. The N/P ratio 
corresponds to the number of N+ peripheral atoms of the dendritic derivatives 
required to complex all the P- atoms of the genetic material. 
 Electrophoresis studies were also carried out with the three bis-MPA 
DHPs at different ratios (wdend./wpDNA or siRNA) to estimate their pDNA and siRNA 
complexation abilities (figure C5-16). The two biggest DHPs, DHP[G3+3] 
(NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424, show similar complexation abilities. 
They can totally complex the pDNA at ratios (wdend./wpDNA) superior or equal to 
3/1 for and the siRNA at ratios (wdend./wsiRNA) superior or equal to 25/1. The 
smallest DHP, DHP[G2+3](NH3+Cl-)120, shows lower complexation abilities. It can 
totally complex pDNA and siRNA starting from ratios (wdend./wpDNA or siRNA) equal 
to 5/1 and 200/1, respectively. In addition, and as observed before for the bis-
GMPA dendrimers, siRNA is fully complexed by the DHPs at higher ratios 
(wdend./wpDNA or siRNA) than pDNA. 
                                                          
[220] S. Biswas, V.P. Torchilin, Dendrimers for siRNA Delivery, Pharmaceuticals, 2013, 6, 161-
183. 
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Figure C5-16: Gel retardation assays of pDNA (up) and siRNA (down) with increasing 
concentrations of the three bis-MPA DHPs. The N/P ratio corresponds to the number 
of N+ peripheral atoms of the dendritic derivatives required to complex all the P- atoms 
of the genetic material. 
  Even if D[G4]-(NH3+Cl-)48 has much less terminal protonated amino 
groups than the DHPs (48 versus 120, 248 and 424), it shows similar abilities to 
complex pDNA (N/P ratios 6 versus 7 or 4). On the other hand, it possess 
superior abilities than DHP[G2+3](NH3+Cl-)120 to complex siRNA (N/P ratio 80 
versus 140). These results can be explained by the higher flexibility of bis-GMPA 
dendrimers, which allows them to easily wrap pDNA or siRNA, when compared 
with the rigid unimolecular micelles formed by the DHPs. 
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ζ potential titration 
 The ζ potential of different solutions of genetic material with increasing 
quantity of bis-GMPA dendrimers or bis-MPA DHPs was measured (figure  
C5-17).  
 
Figure C5-17: ζ potential of dissolutions of pDNA and siRNA and bis-GMPA dendrimers 
(up) and of dissolution of pDNA and bis-MPA DHPs (down) at different (wdend./wpDNA or 
siRNA) ratios.  
 In all cases, the global charge of the particles in solution changes from 
negative values at low (wdend./wpDNA or siRNA) ratios to positive values at high ratios 
drawing curves that present two slopes. The first pronounced slope corresponds 
to the neutralization of the negative charges of the genetic material by the 
dendrimers. When the majority of the negative charges of the pDNA or the 
siRNA are neutralized, the slope of the curve becomes much smoother.  
 According to this technique, it was determined that D[G4](NH3+Cl-)48 
could complex pDNA at a ratio (wdend./wpDNA) equal to 8.0 and siRNA at a ratio 
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(wdend./wsiRNA) equal to 21.4, and D[G3](NH3+Cl-)24 could complex pDNA at a ratio 
(wdend./wpDNA) equal to 22.3. Likewise, DHP[G3+3](NH3+Cl-)248 and 
DHP[G4+3](NH3+Cl-)424 could complex pDNA ratios (wdend./wpDNA) equal to 5.6 an 
5.4, respectively, whereas DHP[G2+3](NH3+Cl-)120 could complex pDNA at a ratio 
equal to 24.9.  
 The (wdend./wpDNA) ratios determined by this technique turn to be lower 
than those determined by the agarose gel retardation assays but the results 
show similar trends. The biggest bis-GMPA dendrimer D[G4](NH3+Cl-)48 can 
form complexes with pDNA at lower ratios than the smallest dendrimer, 
D[G3](NH3+Cl-)24, and DHP[G3+3](NH3+Cl-)248 and DHP[G4+3] 
(NH3+Cl-)424 can complex pDNA at ratios smaller than DHP[G2+3](NH3+Cl-)120. 
Also, pDNA is complexed by the all the derivatives at lower ratios than siRNA. 
Additionally, and as observed with the agarose gel retardation assay, 
D[G4](NH3+Cl-)48 has similar abilities to complex pDNA than DHP[G3+3] 
(NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424. 
 At the end of the titration, the ζ potential values of the dendriplexes were 
ranged between + 21.6 and + 28.9 mV. The highest values were obtained for the 
two biggest bis-MPA DHPs with pDNA (+ 25.2 and + 28.9 mV) and for the biggest 
bis-GMPA dendrimers with pDNA (+ 25.6 mV). These values are promising: first, 
they are sufficiently elevated to promote good cellular internalization favoring 
interactions between the dendriplexes and the cellular membrane while, 
second, as they remain moderated, they should not break down the membrane 
inducing cell death.[221] 
 The differences observed between agarose gel retardation assays and ζ 
potential titration might be explained by the conditions employed to perform 
                                                          
[221] E. Fröhlich, The role of surface charge in cellular uptake and cytotoxicity of medical 
nanoparticles, Int. J. Nanomedicine, 2012, 7, 5577–5591. 
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the studies. In particular, the retardation assays were carried out during long 
time (45 min) and with high voltage applied (95 V) whereas ζ potential 
measurements were carried out during shorter time (2-3 min) and with lower 
voltage applied. Moreover, the ζ potential is a value determined for the totality 
of the sample whereas the gel agarose assay permits to separate the fully 
complexed, partially complexed and uncomplexed genetic material. Thus, the 
average ζ potential of the solution can be positive although all pDNA or siRNA 
are not fully complexed. For example, the D[G4](NH3+Cl-)48/siRNA  dendriplexes 
showed a ζ potential equal to + 19.2 mV (figure C5-17) at the ratio 50/1 whereas 
two populations, corresponding to fully complexed and partially complexed 
siRNA, were observed in agarose gel retardation assay (figure C5-15). 
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5.2.1.2- Morphological studies 
Dendriplexes based on bis-GMPA dendrimers 
 The hydrodynamic diameter of the dendriplexes formed by the 
dendrimers and the pDNA or siRNA were measured by DLS at the ratios 
(wdend./wpDNA) 10/1 and 100/1 for pDNA and at the ratios (wdend./wsiRNA) 50/1 and 
100/1 for siRNA (table C5-2). The results are given employing two mathematical 
data treatments: the intensity average and the number average hydrodynamic 
diameter.  
Table C5-2: Hydrodynamic diameters, dH, and ζ potential of the dendriplexes at 
different (wdend./wpDNA or siRNA) ratios at 1 mg/mL. 
 
dendriplexes 
DLS (DH, nm) ζ potential 
(mV)  number intensity 
pDNA 
D[G3](NH3+Cl-)24/pDNA 
10/1 97.2 ± 6.9 
97.2 ± 6.9 
327.3 ±25.5 - 13.2 
D[G3](NH3+Cl-)24/pDNA 
100/1 56.9 ± 11.3 76.7 ± 18.6 + 18.6 
D[G4](NH3+Cl-)48/pDNA 
10/1 55.7 ± 3.6 
57.2 ± 3.7 
 243.7 ±20.9 + 12.4 
D[G4](NH3+Cl-)48/pDNA  
100/1 40.2 ± 15.7 84.7 ± 21.9 + 22.5 
siRNA 
D[G4](NH3+Cl-)48/siRNA 
50/1 56.6 ± 6.9 63.1 ± 9.2 + 19.2 
D[G4](NH3+Cl-)48/siRNA 
100/1 126.3 ± 22.8 178.8 ± 29.4 +20.7 
 With respect to dendriplexes formed with pDNA, two size-populations of 
aggregates were measured upon applying the intensity average data treatment 
at the ratio (wdend./wpDNA) 10/1: diameters bigger than 250 nm and diameters 
smaller than 100 nm. The dendriplexes have a low ζ potential (-13.2 and + 12.4 
mV) that promote the self-aggregation of dendriplexes. When the proportion of 
dendrimer increases, ratio of 100/1, the ζ potential of the dendriplexes is higher 
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and this impedes dendriplex aggregation.[222] Thus, only a population of small 
objects was detected in both, number and intensity averages, with diameters 
smaller than 100 nm.  
 The D[G3](NH3+Cl-)24/pDNA dendriplexes formed at the ratio 10/1 were 
bigger, more polydisperse and with a negative ζ potential because all the pDNA 
was not complexed at this ratio in agreement with the agarose gel retardation 
assays (figure C5-15, p. 230). 
 For dendriplexes formed with siRNA, only a size-population was detected 
for D[G4](NH3+Cl-)48/siRNA dendriplexes in number and in intensity average 
diameters, regardless the (wdend./wsiRNA) ratio. Small aggregates were identified 
at the ratio 50/1, with average diameter ca. 60 nm, whereas bigger and more 
polydisperse aggregates with average diameters ca. 120-180 nm were identified 
at the ratio 100/1.  
 The results obtained from DLS measurements were in general confirmed 
by cryoTEM observation (figure C5-18), although the dendriplexes appeared 
with smaller diameters in the latter.  
 In the case of the dendriplexes formed with pDNA, two size-population 
distributions of spherical objects are observed for the dendriplexes at the ratio 
10/1. Big nanoobjects with sizes between 120 and 300 nm and small 
nanoobjects, more abundant, with sizes between 15 and 35 nm or between 30 
and 70 nm for D[G3](NH3+Cl-)24/pDNA and D[G4](NH3+Cl-)48/pDNA dendriplexes, 
respectively. At the ratio 100/1, an only population distribution of spherical 
dendriplexes is observed for the D[G4](NH3+Cl-)48/pDNA dendriplexes with sizes 
comprised between 30 and 120 nm. In contrast to DLS measurements, two size- 
 
                                                          
[222] I.C. Bellettini, S.J. Fayad, V.G. Machado, E. Minatti, Properties of polyplexes formed 
through interaction between hydrophobically-modified poly(ethylene imine)s and calf thymus 
DNA in aqueous solution, soft matter, 2017, ASAP, DOI: 10.1039/c6sm02835g. 
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population distribution of spherical objects are observed for D[G3] 
(NH3+Cl-)24/pDNA dendriplexes, one with sizes between 15 and 40 nm and 
another scarce one with sizes superior to 200 nm.  
 As for dendriplexes formed with siRNA, D[G4](NH3+Cl-)48/siRNA 
dendriplexes at the ratio 50/1, at which the siRNA strands are not fully 
complexed by the dendrimer, appear as a mixture of objects with two different 
morphologies, either spherical or elongated, whose sizes ranged from 35 to 60 
nm. At the ratio 100/1, all the siRNA was complexed by the dendrimer and this 
result in an only size-population of elongated objects with sizes ca. 50-120 nm. 
As siRNA is more rigid than pDNA, it cannot wrap the dendrimers and this must 
induce the formation of bigger and less spherical aggregates.  
 
Figure C5-18: CryoTEM images of the dendriplexes at different (wdend./wpDNA or siRNA) 
ratios at 1 mg/mL. 
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Dendriplexes based on bis-MPA DHPs 
 The hydrodynamic diameter of the dendriplexes formed by the bis-MPA 
DHPs and the pDNA or siRNA was measured by DLS at the ratios (wdend./wpDNA) 
equal to 10/1 and 100/1 and at the ratio (wdend./wsiRNA) 50/1 (table C5-3). The 
results are given employing two mathematical data treatments: the intensity 
average and the number average. 
Table C5-3: Hydrodynamic diameters and ζ potential of the dendriplexes at different 
(wdend./wpDNA or siRNA) ratios at 1 mg/mL. 
 
dendriplexes 
DLS (DH nm) ζ potential 
(mV)  number intensity 
pDNA 
DHP[G2+3](NH3+Cl-)120/pDNA 
10/1 18.0 ± 0.1 121.9 ± 42.6 - 17.2 
DHP[G2+3](NH3+Cl-)120/pDNA 
100/1 69.6 ± 12.1 87.8 ± 18.7 + 18.7 
DHP[G3+3](NH3+Cl-)248/pDNA 
10/1 38.5 ± 3.3 
40.3 ± 3.6 
186.3 ± 17.9 + 17.5 
DHP[G3+3](NH3+Cl-)248/pDNA  
100/1 112.7 ± 16.3 127.6 ± 19.5 + 27.4 
DHP[G4+3](NH3+Cl-)424/pDNA 
10/1 39.0 ± 4.3 75.3 ± 36.5 +18.8 
DHP[G4+3](NH3+Cl-)424/pDNA  
100/1 41.9 ± 4.6 63.9 ± 27.4 +23.2 
siRNA DHP[G3+3](NH3
+Cl-)248/siRNA 
50/1 47.8 ± 2.8 
48.9 ± 2.9 
160.7 ± 13.5 X 
 For DHP[G2+3](NH3+Cl-)120/pDNA and DHP[G3+3](NH3+Cl-)248/pDNA, at 
the ratio (wdend./wpDNA) 10/1, two size-population distributions were detected. A 
population of aggregates with sizes around ca. 20-40 nm according to the 
number average data treatment and another population of aggregates with 
sizes around ca. 120-190 nm employing the intensity average data treatment. 
When the amount of DHPs increased up to the ratio 100/1, an only population 
of dendriplexes with sizes around ca. 70 - 90 nm and ca. 110 - 130 nm was 
detected, respectively.   
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 The DHP[G4+3](NH3+Cl-)424/pDNA dendriplexes appeared as a unique 
size-population in both number and intensity averages with sizes around ca. 40 - 
75 nm at the ratio 10/1 and with sizes around ca. 40 - 60 nm at the ratio 100/1. 
This DHP clearly induces the formation of smaller and stable dendriplexes with 
positive ζ potential even at the lowest ratios.  
 The dendriplexes formed with siRNA, DHP[G3+3](NH3+Cl-)248/siRNA, 
showed two size-population distributions at the ratio (wdend./wpDNA) 50/1 
applying the intensity average data treatment, a big one with sizes ca. 160 nm 
and a smaller one with size ca. 50 nm. Only the population of small aggregates 
was detected applying the number average data treatment. 
 CryoTEM observations (figure C5-19) showed good agreement with DLS 
measurements. All the dendriplexes containing pDNA appear as spherical 
aggregates with sizes close to those measured by DLS. DHP[G2+3] 
(NH3+Cl-)120/pDNA dendriplexes have diameters around 160 nm at the ratio 
(wdend./wpDNA) 10/1 and diameters around 130 nm at the ratio 100/1 while 
DHP[G3+3](NH3+Cl-)248/pDNA dendriplexes have diameters around 70 nm at the 
ratio 10/1 and diameters around 100 nm at the ratio 100/1 and, finally, 
DHP[G4+3](NH3+Cl-)424/pDNA dendriplexes have diameters around 70 nm at the 
ratio 10/1 and diameters around 50 nm at the ratio 100/1.  
 In all the cases, an additional population, less represented, composed of 
spherical aggregates with sizes superior to 200 nm were observed and 
corresponded to the aggregation of various dendriplexes. The proportion of this 
second population is higher in the case of DHP[G2+3](NH3+Cl-)120/pDNA 
dendriplexes as it can be observed in the cryoTEM images (figure C5-19-A). 
 In the case of the dendriplexes containing siRNA (figure C5-19 B), two 
aggregate size-populations were observed for DHP[G2+3](NH3+Cl-)120/siRNA 
dendriplexes with sizes smaller than the ones measured by DLS. In any case, the 
small aggregate population appears as spherical objects with size ca. 30 - 40 nm 
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and the biggest one presents a more ovoidal shape with sizes ca. 60 - 90 nm. As 
occurred in the case of the bis-GMPA dendrimer, the siRNA dendriplexes 
showed a less spherical shape.  
 
Figure C5-19: CryoTEM images of the dendriplexes at different (wdend./wpDNA) ratios (A) 
and (wdend./wsiRNA) ratios (B) at 1 mg/mL. 
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 In all cases, the dendriplexes formed by the bis-MPA DHPs and the bis-
GMPA dendrimers show sizes ranged from ca. 20 nm to 200 nm, and this may 
indicate that various dendritic compounds are involved during the formation of 
one dendriplex. The dendriplexes formed by the bis-MPA DHPs and pDNA 
appeared to be in general bigger than the ones formed by the bis-GMPA 
dendrimers. Fortunately, in each series, spherical dendriplexes showing sizes 
comprised between 50 and 100 nm with positive ζ potential, containing either 
pDNA or siRNA, were formed. These ideal characteristics should permit the 
dendriplexes cellular internalization by means of endocytic pathway.[223]  
 
  
                                                          
[223] A.P.R. De Garibay, Endocytosis in gene therapy with non-viral vectors, Wien. Med. 
Wochenschr., 2016, 166, 227-235. 
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5.2.2- siRNA and pDNA transfection 
 
 In vitro gene transfection was carried out with the bis-GMPA dendrimer 
of 4th generation, D[G4](NH3+Cl-)48, and with the two biggest bis-MPA DHPs, 
DHP[G3+3](NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424 as they presented better 
complexation abilities and formed less polydisperse dendriplexes with higher  
ζ potential.  
 For pDNA transfection, pEGFP plasmid was chosen. GFP is a green 
fluorescent protein and cells effectively transfected with this plasmid would 
emit green fluorescence. For siRNA transfection, siGFP and siLuc strands were 
chosen and transfection assays were performed with cells producing GFP or 
luciferase. When the cells were effectively transfected, they stopped producing 
GFP or luciferease and the global fluorescence or luminescence of the cells 
decreased.  
 Transfection efficiencies obtained with the different dendritic derivatives 
were compared to FuGene®, Lipofectamine 2000® and/or TransIT-X2® 
commercial agents. 
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5.2.2.1- siRNA transfection 
siRNA transfection was studied for D[G4](NH3+Cl-)48/siGFP and 
DHP[G3+3](NH3+Cl-)248/siGFP and DHP[G4+3](NH3+Cl-)424/siGFP dendriplexes 
with epithelial kidney cells from dog expressing GFP (MDCK-GFP), and for 
D[G4](NH3+Cl-)48/siLuc, DHP[G3+3](NH3+Cl-)248/siLuc and DHP[G4+3] 
(NH3+Cl-)424/siLuc dendriplexes with cancerous human ovary cells expressing 
luciferease (SOKV3-Luc) (figure CIV-20). Transfection efficiency was compared 
with that obtained for commercial Lipofectamine® 2000 based complexes. 
Although transfection values were lower than the ones obtained after 
transfection with Lipofectamine® 2000, bis-GMPA dendrimers and bis-MPA 
DHPs could reduce the fluorescence or luminescence of the cells, proving the 
effective GFP and luciferease gene silencing. D[G4](NH3+Cl-)48/siGFP and 
D[G4](NH3+Cl-)48/siLuc dendriplexes could reduce these proteins expression by 
up to 12 and 21 % respectively while DHP[G3+3](NH3+Cl-)248/siGFP and 
DHP[G3+3](NH3+Cl-)248/siLuc could reduce the expression of these proteins by 
up to 6 and 13 % respectively. No significant differences were observed when 
gene silencing was performed with either DHP[G3+3](NH3+Cl-)248 or 
DHP[G4+3](NH3+Cl-)424.  
In all cases, the cell viability after the transfection was high proving that 
the reduction of the fluorescence or the luminescence was due to siRNA 
transfection and not to cell death. 
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Figure C5-20: Reduction of GFP expression (A & C) and luciferease expression (B & D) 
48 hours after transfection with D[bisGMPA,G4](NH3+Cl-)48, DHP[G3+3](NH3+Cl-)248 and 
DHP[G3+3](NH3+Cl-)424 in MDCK-GFP and SOKV3-Luc cells at different (wdend./wsiRNA) 
ratios. Lipofectamine® 2000 was used as a positive control. Scale bar = 500 µM. The 
relative fluorescence of each sample (indicated in white at the right photo corner) was 
measured by flow cytometry. 
 
Bis-GMPA and bis-MPA globular dendritic derivatives for gene delivery 
245 
Surprisingly, the transfection efficiencies obtained with D[G4](NH3+Cl-)48 
for both, GFP and luciferease, are higher at the ratio (wdend./wsiRNA) 50/1 than at 
the ratio 100/1, although siRNA appears to be not totally complexed at this 
lower ratio. Nevertheless, at the ratio 50/1, the dendriplexes formed are smaller 
(average diameters close to 60 nm) and more spherical (figura C5-18, p. 237). 
These characteristics appear to be more appropriate to promote the cellular 
uptake of the dendriplexes, and the subsequent gene silencing than those of 
dendriplexes ay the ratio 100/1, which are bigger (with sizes superior to 100 
nm) and less spherical .  
 D[G4](NH3+Cl-)48 shows better siRNA transfection efficiency in both cell 
lines than the two bis-MPA DHPs. This dendrimer could reach a siRNA 20 % 
transfection efficiency at the ratio (wdend./wsiRNA) (50/1) with cancerous cells, and 
12 % with epithelial cells. The differences observed for the gene silencing 
obtained for the bis-GMPA dendrimers and the bis-MPA DHPs are difficult to 
explain and can be due to different parameters such as cellular uptake, siRNA 
release, etc.  
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5.2.2.2- pDNA transfection 
 pDNA transfection experiments were first performed with cancerous 
human HeLa cells with the D[G4](NH3+Cl-)48/pEGFP dendriplexes and with 
DHP[G3+3](NH3+Cl-)248/pEGFP and DHP[G4+3](NH3+Cl-)424/pEGFP dendriplexes. 
Transfection efficiencies were compared to those obtained for two commercial 
gene vectors (Lipofectamine® 2000 and FuGene®). 
 As for pEGFP transfection with HeLa cells (figure C5-21), some green cells 
could be observed in all the cases 48 hours after transfection proving the 
expression of the EGFP protein, and consequently a positive gene transfection. 
Nevertheless, the transfection levels remained low and inferior to the level 
obtained with FuGene® and Lipofectamine® 2000. 
 
Figure C5-21: GFP expression at 48 hours after transfection with D[G4](NH3+Cl-)48 (A) 
and DHP[G3+3](NH3+Cl-)248 and DHP[G3](NH3+Cl-)424 (B) in HeLa cells at different  
(wdend/DHPs./wpEGFP) ratios. FuGene® and Lipofectamine® 2000 were used as a positive 
control. Scale bar = 100 µm. 
 pEGFP transfection efficiency does not increase when the ratio 
(wdend./WpEGFP) increases. However, D[G4](NH3+Cl-)48/pEGFP and DHP[G4+3] 
(NH3+Cl-)424/pEGFP dendriplexes can positively transfect HeLa cells with pEGFP 
starting from ratios lower (10/1) than DHP[G3+3](NH3+Cl-)248/pEGFP 
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dendriplexes that showed positive transfection at ratios superior or equal to 
50/1. 
 pEGFP transfection was also carried out with mesenchymal stem cells 
(MSCs) from mousse origin with DHP[G3+3](NH3+Cl-)248/pEGFP and 
DHP[G4+3](NH3+Cl-)248/pEGFP dendriplexes. As they can still differentiate, MSCs 
show high potential to treat a large variety of diseases after transplantation. In 
particular, ex-vivo gene transfected MSCs can be used to favor their 
transplantation or locally induce the expression of therapeutic genes.[224]  
 Transfection experiments with MSCs were carried out with 
DHP[G3+3](NH3+Cl-)248/pEGFP and DHP[G4+3](NH3+Cl-)424/pEGFP dendriplexes 
at three ratios (wDHPs./wDNA) 50/1, 100/1 and 200/1 and compared with two 
commercial agents: Lipofectamine® 2000 and TransIT-X2® as positive references 
(figure C5-22-A). 
 48 hours after transfection, green cells were observed in all cases proving 
that the two bis-MPA DHPs could effectively transfect pDNA in MSCs. In 
particular, the GFP expression obtained after transfection with DHP[G4+3] 
(NH3+Cl-)424/pEGFP at the ration 200/1  reaches levels similar than the ones 
obtained after transfection with the complexes based on the commercial 
agents.  
  
 
                                                          
[224] C. Madeira, R.D. Mendes, S.C. Ribeiro, J.S. Boura, M.R. Aires-Barros, C.L. Da Silva, J.M.S. 
Cabral, Nonviral gene delivery to mesenchymal stem cells using cationic liposomes for gene 
and cell therapy, J. Biomed. Biotechnol., 2010, 2010, ID 735349. 
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Figure C5-22: (A) GFP expression 48 hours after transfection with DHP[G3+3] 
(NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424 in MSCs at different  (wdend./wpEGFP) ratios. 
Lipofectamine 2000® was used as a positive reference control. Scale bar = 100 µm. (B) 
Relative fluorescence and cell viability of the samples 48 hours after transfection. 
 For both DHP based dendriplexes, the levels of the GFP relative 
fluorescence measured after transfection increase with the (wdend./wpEGFP) ratio 
(figure C5-22-B). The excellent biocompatibility of the bis-MPA DHPs with MSCs 
allows the use of dendriplexes with an elevated proportion of DHPs that have 
favored the pDNA transfection without affecting the cell viability.  
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 Moreover, the GFP relative fluorescence levels measured after the pEGFP 
transfection with DHP[G4+3](NH3+Cl-)424/pEGFP dendriplexes were higher than 
the ones measured after transfection with the DHP[G3+3] 
(NH3+Cl-)248/pEGFP regardless the (wdend./wpEGFP) ratio. Thus, the dendriplexes 
formed by DHP[G4+3](NH3+Cl-)424 at high (wdend./wpEGFP) ratios that contain an 
elevated quantity of DHPs have shown the best transfection efficiency. Their 
smaller size (ca. 40-60 nm) might favor their internalization within the cells 
while the higher quantity of DHPs might favor their endosomal escape by 
proton sponge effect. 
 The cell viability was controlled after transfection (figure C5-22-B). 
Whereas Lipofectamine® 2000 based dendriplexes showed low biocompatibility 
values (20 %), DHPs dendriplexes showed high biocompatibility values (> 90 %) 
similar to complexes containing the commercial TransIT-X2®. In conclusion, 
DHP[G4+3](NH3+Cl-)424 shows similar transfection abilities for MSCs than two 
commercial agents and similar biocompatibility than TransIT-X2® and much 
higher biocompatibility than Lipofectamine® 2000.  
 The dendritic systems described herein show an interesting potential as 
vehicles to transfect siRNA and pDNA. In all cases, higher transfection 
efficiencies were obtained when the dendriplexes presented a small size close 
to 50 nm that might promote their cellular internalization. The small bis-GMPA 
dendrimers have shown better abilities than the bis-MPA DHPs to transfect 
siRNA whereas the bis-MPA DHPs were more efficient as pDNA vectors. These 
latter could even reach the transfection levels of two commercial agents with 
MSCs. 
  
Chapter 5 
250 
5.3- General remarks 
Summary of results 
 Two bis-GMPA dendrimers of 3rd and 4th generation and three bis-MPA 
dendronized hyperbranched polymers (DHPs) of 5th, 6th and 7th generation with 
numerous terminal glycine moieties were synthesized. They showed high 
monodispersity and few defects.  
 The dendritic systems herein presented could complex and transfect 
pDNA and siRNA to cells. Better siRNA transfection efficiency was obtained 
employing the bis-GMPA dendrimers with HeLa cancerous cells whereas better 
pDNA transfection was obtained employing the bis-MPA DHPs with 
mesenchymal stem cells. In this last case, the dendritic systems were as efficient 
as two commercial agents.  
Conclusion 
 Effective gene transfection can be performed with dendritic systems 
based on both polyester and poly(amidoester) architectures that show high 
bicompatibility. In particular, dendronized hyperbranched polymers (DHPs) 
appear as innovative systems as high generation dendritic systems can be 
reached avoiding long and tedious synthesis.  
Future investigation 
 Dendronized hyperbranched polymers decorated with bis-GMPA might 
be investigated in gene transfection. Moreover, other commercial 
hyperbranched polymers containing internal amino groups, might be used as 
cores, such as polyester amide (Hybrane®) or poly(amidoamine) (Helux®). 
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 In this chapter, the hybrid dendritic-linear-dendritic block copolymers 
(HDLDBCs) and the dendronized hyperbranched polymers (DHPs), previously 
presented in this thesis report, are described as antimalarial drug nanocarriers. 
 First, the encapsulation abilities and the targeting abilities of the 
nanocarriers are described. Second, the activity of the dendritic 
nanocarrier/antimalarial drug conjugates against the parasite replication is 
evaluated. The influence of heparin coating on these abilities is also 
commented. 
  
Chapter 6 
254 
  
Bis-MPA and bis-GMPA HDLDBCs and bis-MPA DHPs as antimalarial nanocarriers 
255 
 Malaria is an infectious disease caused by Plasmodium type parasites 
principally affecting red blood cells (RBCs). It generally causes fever, headaches, 
muscular and articulation pains and digestive troubles and may also cause brain 
disorders, coma and/or death in some more severe cases. This disease, 
transfected to human via anopheles mosquito bites, has affected humanity for 
ages, and references dealing with it were found in documents dated from antic 
Egypt and China. Nowadays, it affects around 200 million people (~3% of the 
world population) almost exclusively spread in tropical regions and caused 
around 430 000 death in 2015, most of them being children under 15 with low 
economic resources.[225] 
 Four Nobel prizes were given to award important discoveries related with 
this disease: Ronald Ros (1902), Alphonse Laveran (1907), Paul Hermann Müller 
(1948) and Youyou Tu (shared with William Campbell and Satoshi Ōmura, 2015). 
Thanks to research, deaths attributed to malaria are decreasing since the last 
decades. Indeed, many efforts have been made to limit anopheles mosquito 
effects in the region infected by malaria by the use of mosquito nets and/or 
repellents and also by killing the mosquitoes. Prophylactic treatments also allow 
limiting the spread of the disease.[226] 
 Various drugs have been developed and used along History to treat 
malaria (figure C6-1). Quinine, an alkaloid extracted from South American trees, 
which inhibits the enzymatic activity of the parasite, was the first drug used by 
the Europeans to treat this illness. Indeed, Jesuits started to use it during the 
XVII century to eradicate the disease from Rome. However, this drug is highly 
toxic and can cause cinchonism and severe or even lethal nervous, cardiac and  
 
                                                          
[225] a) X. Fernández-Busquets, a short (Hi)story of Malaria, IBEC seminars; b) WHO, Malaria 
fact sheet N°94. 
[226] a) https://nobelprize.org; b) UNICEF & WHO, Achieving the malaria MDG target: 
reversing the incidence of malaria 2000–2015, 2015, ISBN 978-92-4-150944-2. 
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Figure C6-1: Representation of various common antimalarial drugs: quinine, 
artemisinin, chloroquine, primaquine and quinacrine. 
blood disorders. It has been gradually replaced since the XX century by other 
derivatives such as chloroquine, quinacrine (also called mepacrine) and 
primaquine.[227] 
 Chloroquine was developed during the World War II. It is still the most 
common drug used to prevent and treat malaria. It binds to heme residues that 
appear after hemoglobin digestion by the parasites, forming a complex highly 
toxic that induces cell death and impedes parasites replication. Chloroquine has 
important side effects, affecting the eyes, the brain, the ears, the skin, and the 
digestive system. When overdosed, it causes patient death.[227] 
 Quinacrine was used by the American soldiers during the World War II. 
Its mechanism of action against the parasites is not well understood although it 
is known that it binds with DNA and may affect the parasites’ cell membranes. 
Quinacrine is far to be a first choice drug. It is more toxic than quinine and 
chloroquine and presents common serious side effects such as brain and 
psychological disorders, digestive issues and yellow skin coloration.[227] 
                                                          
[227] a) WHO, Guidelines for the treatment of malaria, 2006, b) WHO, Prescribing information: 
drugs used in parasitic diseases - 2nd Edition, 1995. 
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 Primaquine was developed at the same period and is used to prevent 
disease infection and relapse. Indeed, although plasmodium principally affects 
red blood cells, it is also located in the liver in a dormant stage that may induce 
a new blood infection even after being cured. Its mechanism of action against 
the parasites remains unknown. Primaquine is less toxic than the other drugs 
but generally triggers nauseas, vomiting and painful stomach cramps.[227] 
 More recently, at the end of the XX century, artemisinin was re-
introduced to treat malaria. This drug was isolated from a plant used in the 
Chinese traditional medicine for ages. Contrary to the other drugs, this one is 
well tolerated by the patients. Nevertheless, it is much more expensive that the 
other ones and its administration is challenging due to its low pharmacokinetical 
properties.[227,228] 
 The multiple side effects of these drugs are actually due to the little or 
inexistent abilities they present to target parasite infected red blood cells. 
Moreover, drug resistances have risen and forced the World Health 
Organization (WHO) to restrain the use of new artemisinin to chloroquine or 
quinine resistant infections. Thus, in the Institute for Bioengineering of 
Catalonia (IBEC) and in the Institute for Global Health (ISGlobal), Dr. Xavier 
Fernàndez-Busquets and collaborators are employing nanomedicine benefits in 
order to improve the targeting and efficacy of current antimalarial drugs to 
infected red blood cells.[229]  
 With this aim, antimalarial drugs have been encapsulated within 
nanoaggregates based on liposomes[230] and polymers[231] containing peripheral 
                                                          
[228] N.J. White, Artemisinin: current status, Trans. R. Soc. Trop. Med. Hyg., 1994, 88 Suppl. 1, 
S3-4. 
[229] X. Fernàndez-Busquets, Novel strategies for Plasmodium-targeted drug delivery, Expert 
Opin. Drug Deliv., 2016, 13, 919-922 
[ 230 ] E. Moles, K. Moll, J.H. Ch'ng, P. Parini, M. Wahlgren, X. Fernàndez-Busquets, 
Development of drug-loaded immunoliposomes for the selective targeting and elimination of 
rosetting Plasmodium falciparum-infected red blood cells, J. Control. Release, 2016, 241, 57-67 
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amino groups. In particular, in a previous mutual collaboration, two hybrid 
dendritic-linear-dendritic block copolymers (HDLDBCs) based on Pluronic® F-127 
and bis-MPA dendrons were successfully used to encapsulate chloroquine and 
primaquine. The HDLDBCs showed good targeting abilities for infected red 
blood cells and could enhance the drug activities against the parasite in vitro 
and in vivo.[95]  
 Another strategy developed by Fernàndez-Busquets’s group consists on 
exploiting the use of polysaccharides as both antimalarial agents and as 
targeting agents for infected red blood cells.[232] In particular, heparin (figure  
C6-2) has shown both antimalarial activity and targeting abilities.[233] Hence, the 
heparin coating  of the surface of liposomes containing primaquine favored the 
targeting abilities of the liposome conjugate and enhanced the activity of the 
drug in vitro.[ 234] The anticoagulant properties of heparin have hinder its 
development as antimalarial drug. However, it has been demonstrated that the 
complexation of heparin with polycationic derivatives permits controlling this 
issue.[235,236] 
                                                                                                                                                                          
[231] P. Urbán, J.J. Valle-Delgado, N. Mauro, J. Marques, A. Manfredi, M. Rottmann, E. Ranucci, 
P. Ferruti, Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to 
Plasmodium, J. Control. Release, 2014, 177, 84-95. 
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 27, 7940. 
[232] J. Marques, E. Vilanova, P.A.S Mourão, X. Fernàndez-Busquets, Marine organism sulfated 
polysaccharides exhibiting significant antimalarial activity and inhibition of red blood cell 
invasion by Plasmodium, Sci. Rep., 2016, 6, 24368. 
[233]M.J. Boyle, J.S. Richards, P.R. Gilson, W. Chai, J.G. Beeson, Interactions with heparin-like 
molecules during erythrocyte invasion by Plasmodium falciparum merozoites, Blood, 2010, 
115, 4559-4568. 
[234] J. Marques, E. Moles, P. Urbán, R. Prohens, M.A. Busquets, C. Sevrin, C. Grandfils, X. 
Fernàndez-Busquets, Applications of heparin as a dual agent with antimalarial and liposome 
targeting activities towards Plasmodium-infected red blood cells, nanomedicine, 2014, 10, 
1719-1728. 
[235] X. Fernàndez-Busquets, Heparin-functionalized nanocapsules: enabling targeted delivery 
of antimalarial drugs, Future Med. Chem., 2013, 5, 737-9. 
[236 ] K.T. Al-Jamal, W.T. Al-Jamal, K. Kostarelos, J.A. Turtonc, A.T. Florence, Anti-angiogenic 
poly-L-lysine dendrimer binds heparin and neutralizes its activity, Res. Pharm. Sci., 2012, 2, 9-
15. 
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Figure C6-2: Chemical structure of the most common repetitive units of heparin 
sodium salt polysaccharide. 
 According to these results, two ideas have been planned to search for 
novel nanocarriers for the targeted delivery of antimalarial drugs: 
 - As a continuation of the research on HDLDBCs the potential of HDLDBCs 
 bearing bis-MPA and bis-GMPA dendrons previously presented in chapter 
 4 (figure C6-3-A) has been investigated. Chloroquine (CQ), primaquine 
 (PQ) and quinacrine (QN), three low molecular weight drugs, have been 
 encapsulated in order to enhance their targeting to parasite infected red 
 blood cells and activity against the parasite replication. 
  - The three dendronized hyperbranched polymers (DHPs) previously 
 described in chapter 5 (figure C6-3-B), which form unimolecular micelles in 
 water and have demonstrated ability to form complexes with polyanionic 
 biopolymers (i.e. DNA or RNA),[ 237 ] have been selected to prepare 
 nanocarriers for the three antimalarial drugs, in which the targeting effect is 
 reinforced by complexation with heparin. 
 A part of the studies described in this chapter (heparin complexation, 
targeting assays and antimalarial activity assays) were carried out in the 
laboratories of the Institute for Bioengineering of Catalonia (IBEC) and the 
Barcelona Institute for Global Health (ISGlobal) in collaboration with Dr. Xavier 
Fernàndez-Busquets during a 2 months stay financed by the Ministerio de 
Educación, Cultura y Deporte (MECD - scholarship with reference AP2012-5210). 
                                                          
[237] A.C. Rodrigo, A. Barnard, J. Cooper, D.K. Smith, Self-assembling ligands for multivalent 
nanoscale heparin binding, Angew. Chem. Int. Ed., 2011, 50, 4675-4679. 
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Figure C6-3: Chemical structures of the HDLDBCs and the DHPs used as antimalarial 
drugs nanocarriers. 
 In particular, the study of the plasmodium growing inhibition activity of 
the dendritic nanocarrier/drug conjugates was performed by Elisabet Martí 
Coma-Cros and belongs to her thesis work. These results will be discussed at the 
end of this chapter in order to evaluate the potential of the dendritic 
nanocarriers to deliver antimalarial drugs. 
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6.1- Hybrid dendritic-linear-dendritic block 
copolymers (HDLDBCs) 
 
 The abilities of the HDLDBCs to encapsulate chloroquine, primaquine and 
quinacrine have been studied as well as their targeting abilities to infected red 
blood cells. The three antimalarial drugs have been encapsulated in their 
hydrophilic and lipophilic forms.  
6.1.1- Chloroquine, primaquine and quinacrine 
encapsulation  
 Chloroquine, primaquine and quinacrine are generally administrated to 
patients in their hydrophilic salt form (CQs, PQs and QNs). Interestingly, their 
lipophilic base form (CQb, PQb and QNb) can be easily prepared starting from 
the commercial hydrophilic salt form. The encapsulation of both forms of the 
drugs into the dendritic nanocarriers may improve their pharmacokinetics 
properties when compared to the free drugs. 
6.1.1.1- Preparation of the lipophilic base form of the drugs 
 After dissolution of the commercial (Sigma-Aldrich®) salt form of the 
drugs in water, NaOH (pellets) was added to the solution until pH 12 was 
reached. During this process, the drugs pass from their hydrophilic salt forms to 
their lipophilic base forms. Insoluble in water, this form precipitates and can be 
recovered by extraction with dichloromethane. The evaporation of the solvent 
yields the pure drugs in their lipophilic base forms with excellent yields, 
between 91 and 99 % (figure C6-4). 
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Figure C6-4: Preparation of the lipophilic base forms of CQ, PQ y QN. 
 The correct preparation of the lipophilic base forms of the drugs was first 
of all controlled by the different solubility of the two forms: the hydrophilic 
form can be solubilized in polar solvent, such as water, whereas the lipophilic 
base form is only soluble into apolar organic solvents, such as dichloromethane. 
Furthermore, Fourier transform infrared spectroscopy (FTIR), 1H nuclear 
magnetic resonance (NMR) spectroscopies and elemental analysis were 
performed to observe the differences between the two forms of the drugs. 
 In FTIR, the bands corresponding to the stretching vibration of the N-H 
bond (near 3270 cm-1) changed when the amines were protonated or not. They 
passed from really large and unsymmetrical bands in the cases of N+-H forms to 
more narrow and symmetrical bands in the case of the N-H forms (figure C6-5). 
 
Figure C6-5: FTIR spectra of chloroquine (CQ) in its hydrophilic salt form (up) and in its 
lipophilic base form (down). 
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 In 1H NMR, the C-H protons adjacent to the N atoms appear upfield 
shifted when the drugs pass from their salt form to their base form (figure C6-6). 
In the case of chloroquine, H-1 shifts from 3.31 to 3.25 ppm while H-2 and H-3 
appear more resolved and shift from 2.30 to 1.91 ppm. In the case of 
primaquine, H-4 and H-5 shift, respectively, from 3.21 and 2.33 ppm to 3.14 and 
2.09 ppm. Finally, in the case of quinacrine, H-6 shifts from 4.53 to 3.98 ppm 
while H-7 and H-8 appear more resolved and shift from 2.93 to 2.19 ppm.  
 
Figure C6-6: 1H NMR spectra of chloroquine (up), primaquine (middle) and quinacrine 
(down) in their salt and base forms and the respective structure of their salt from. 
Protons whose 1H NMR signal were modified during the process are highlighted.  
 In elemental analysis, as the phosphate and chloride counterions were 
eliminated during the preparation of the lipophilic base form, the organic 
content of the three drugs increased (table C6-1). Additionally, this treatment 
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allowed to increase the purity of the drugs, experimental values were measured 
closer to the theoretical ones for the lipophilic base forms than for the 
commercial hydrophilic salt forms. 
Table C6-1: Experimentally measured elemental analysis of C, H and N compared with 
the theoretic calculated ones for the three drugs in their hydrophilic salt and lipophilic 
base forms. 
 % C % H % N % other 
chloroquine 
hydrophilic 
salt form 
th. 41.9 6.25 8.1 43.75 
exp. 39.6 6.5 7.8 16.1 
lipophilic 
base form 
th. 67.6 8.2 13.1 11.1 
exp. 67.5 8.45 13.0 11.05 
primaquine 
hydrophilic 
salt form 
th. 36.9 5.9 9.2 48.0 
exp. 38.8 6.1 9.35 45.75 
lipophilic 
base form 
th. 69.5 8.2 16.2 6.1 
exp. 67.85 9.0 16.5 6.65 
quinacrine 
hydrophilic 
salt form 
th. 58.4 6.8 8.9 25.9 
exp. 54.25 7.1 8.3 30.35 
lipophilic 
base form 
th. 69.1 7.6 10.5 12.8 
exp. 67.7 7.8 9.9 14.6 
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6.1.1.2 - Drugs encapsulation  
 The hydrophilic salt forms (CQs, PQs and QNs) and the lipophilic base 
forms (CQb, PQb and QNb) of the three drugs were encapsulated within the 
micelles formed by bisMPA-[PLU]-bisMPA and bisGMPA-[PLU]-bisGMPA) 
according to the oil-in-water technique (figure C6-7).[95] 
 
Figure C6-7: Encapsulation procedures for the antimalarial drugs in their hydrophilic 
salt forms (up) and their lipophilic base forms (down). 
 The HDLDBC was dissolved in water (see section 4.2.2.2, p. 152) and the 
drugs in water or dichloromethane according to their hydrophilicity. The 
samples were vigorously stirred in order to form an emulsion from which the 
organic solvent was slowly evaporated, using a ventilation system, until a clear 
aqueous solution was obtained. The feeding ratio was of 1/1 (wdrug/wHDLDBC) (see 
chapter 7 for detailed protocol).   
 The hydrophilic form of the drugs that was not encapsulated within the 
dendritic nanocarriers was removed by dialysis. The quantity of drug that could 
be effectively encapsulated within the nanocarriers was indirectly determined 
by measuring the UV absorbance of the dialysis waters.  
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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 The lipophilic forms of the drugs that were not encapsulated within the 
nanocarriers precipitated in the solution at pH 10 after the evaporation of 
dichloromethane and were removed by filtration. The quantity of drugs 
encapsulated within the nanocarriers was directly measured by dissolving an 
aliquot of the nanocarrier/drug complexes in dimehtyl sulfoxide. In this solvent 
the drugs were quickly released outside the nanocarriers and their 
concentrations were measured by UV absorbance.  
 The amounts of drugs encapsulated within the HDLDBC based 
nanocarriers was calculated in weight and in amount of substance while the 
encapsulation efficiencies (EE) were calculated by dividing the quantity of drugs 
encapsulated by the quantity used to perform the encapsulation (table C6-2). 
 Regarding to the hydrophilic salt forms of the drugs, the quantities of all 
the three drugs (CQs, PQs and QNs) were high. Slightly higher quantities of PQs 
and QNs could be encapsulated within the two HDLDBCs (EE between 41 and 44 
%) than CQs (EE between 31 and 35 %). Both HDLDBCs show similar 
encapsulation efficiencies. 
 Regarding to the lipophilic base forms of the drugs, the quantities of PQb 
encapsulated remained high and its EE, 43 %, was similar to the ones obtained 
for its hydrophilic salt form. Unfortunately, the quantities of CQb and QNb 
encapsulated were really lower and their EE were below 5 %. 
 All the solutions containing the HDLDBC/antimalarial drug conjugates 
were freeze-dried in order to facilitate their transport and conservation. After 
re-dissolution of the solid HDLDBC/drug conjugate, the correct encapsulation 
was checked again. In the case of the drugs in their hydrophilic form, it was 
asserted by comparing the fluorescence emission spectra of the free drugs in 
water with the one of the drugs encapsulated within the bisGMPA-[PLU]-
bisGMPA HDLDBC. In all cases, differences are observed in the two spectra, 
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proving that interactions occurred between the nanocarrier and the hydrophilic 
drugs (see annexes 11). In the case of the drugs in their lipophilic form, the 
absence of any precipitate after the re-dissolution of the solids obtained after 
freeze-drying while containing low-water soluble drugs assessed the correct 
drug encapsulation.  
Tables C6-2: Amount of antimalarial drugs encapsulated within the HDLDBCs based 
nanocarriers in their hydrophilic salt forms (up) and in their lipophilic base forms 
(down). aEE means encapsulation efficiency. 
 bisMPA-[PLU]-bisMPA 
 drug 
mg drug 
/ 
mg HDLDBC 
mol drug 
/ 
mol 
HDLDBC 
EEa 
(%) 
hydrophilic 
salt form 
chloroquine 0.348 17.75 35 
primaquine 0.412 25.92 41 
quinacrine 0.423 17.26 43 
lipophilic 
base form 
chloroquine 0.075 3.83 4 
primaquine 0.427 26.86 43 
quinacrine 0.009 0.37 1 
 bisGMPA-[PLU]-bisGMPA 
 drug 
mg drug 
/ 
mg HDLDBC 
mol drug 
/ 
mol 
HDLDBC 
EEa 
(%) 
hydrophilic 
salt form 
chloroquine 0.307 16.33 31 
primaquine 0.408 26.76 41 
quinacrine 0.475 20.20 44 
lipophilic 
base form 
chloroquine 0.055 2.92 3 
primaquine 0.431 28.27 43 
quinacrine 0.008 0.34 1 
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6.1.2- In vitro targeting studies 
 
 
 In a previous work, in vitro targeting experiments were carried out with 
two HDLDBC labeled with commercial rhodamine B that showed that bisMPA-
[PLU]-bisMPA was preferentially internalized within the infected red blood 
cells.[95]  
6.1.2.1- Labeling with rhodamine B 
 In order to confirm the targeting abilities of the different systems 
towards parasite infected red blood cells, the two HDLDBCs were fluorescently 
labeled by encapsulating the low-water soluble modified rhodamine B, 
RhB(C17)2, (see section 4.3.2.2, p. 181). Its encapsulation was carried out 
according to the oil-in-water technique in a way similar than that employed to 
encapsulate the antimalarial drugs in their lipophilic base forms (see p.). With a 
feeding ratio of 1/0.3 (wHDLDBC/wLR), no precipitate appeared after the 
encapsulation process and it was assumed that all RhB(C17)2 was encapsulated 
within the HDLDBC.  
 As before, the time-persistence of the RhB(C17)2 labeling was controlled 
by dialysis of a solution of bisMPA-[PLU]-bisMPA/RhB(C17)2 conjugate against a 
volume 100 times higher of distilled water (“sink conditions”) (figure C6-8). After 
3 days, more than 90 % of RhB(C17)2 remained encapsulated within the micelles 
asserting the correct labeling. In contrast, after 72 hours only 30 % of 
commercial water soluble rhodamine B remained entrapped within the bisMPA-
[PLU]-bisMPA/RhB conjugate. 
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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Figure C6-8: RhB(C17)2 and RhB releases curves from bisMPA-PLU-bisMPA/RhB(C17)2 
and bisMPA-PLU-bisMPA/RhB.   
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6.1.2.2- Targeting experiments 
 The targeting ability of RhB(C17)2 labeled bisMPA-[PLU]-bisMPA and 
bisGMPA-[PLU]-bisGMPA  nanocarriers to infected red blood cells, was then 
investigated by fluorescence microscopy (figure C6-9). In this experiment, the 
red blood cells were treated with Hoechst (blue stain) that mark DNA. Healthy 
red blood cells that do not have DNA remain free of Hoechst whereas the DNA 
belonging to the plasmodium parasites is stained in blue. Thus, the infected red 
blood cells (blue fluorescence) can be easily distinguished from the healthy ones 
(no fluorescence). The RhB(C17)2 labeled HDLDBC appears in red. 
 
Figure C6-9: Fluorescence microscopy images of the HDLDBC/RhB(C17)2  conjugates at 
75 μg/mL after 90 minutes incubation. Infected RBCs appear in blue (Hoechst 
marking), HDLDBC/RhB(C17)2  conjugates appear in red. 
 Interestingly, all the infected red blood cells have internalized the labeled 
HDLDBCs and only a small portion of healthy red blood cells have internalized 
some labeled HDLDBC. These results confirm the previous targeting results 
obtained for bisMPA-[PLU]-bisMPA[95] and extend them to bisGMPA-[PLU]-
bisGMPA. 
 The good HDLDBCs targeting abilities may be explained by the 
modifications that the red blood cell membrane suffer after the parasite 
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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infection. Indeed, after having entered into a red blood cell, the parasite rapidly 
modifies the membrane of its host cell by means of effector proteins. Among 
other modifications, the cell membrane becomes much more permeable in 
order to favor the entry of nutrients into the cells.[238] Besides, the presence of 
new proteins from parasites origin at the membrane of the infected red blood 
cells might also favor some specific interactions between these modified 
membranes and the HDLDBCs.  
 The HDLDBCs appear as promising dendritic nanocarriers for the delivery 
of antimalarial drugs. On the one hand, they can encapsulate antimalarial 
chloroquine, primaquine and quinacrine in their hydrophilic salt form and 
primaquine in its lipophilic base form. On the other hand, they are favorably 
internalized within infected red blood cells and this must therefore increase the 
drug targeting of the encapsulated antimalarial drugs. 
  
                                                          
[238] a) P.R. Gilson, S.A. Chisholm, B.S. Crabb, T.F. de Koning-Ward, Host cell remodelling in 
malaria parasites: a new pool of potential drug targets, Int. J. Parasitol., 2017, 47, 119–127; b) 
K. Kirk, H.A. Horner, B.C. Elford, J.C. Ellory, C.I. Newbold, Transport of diverse substrates into 
malaria-infected erythrocytes via a pathway showing functional characteristics of a chloride 
channel, J. Biol. Chem., 1994, 269, 3339–3347. 
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6.2- Dendronized hyperbranched 
polymers (DHPs) coated with heparin 
 
 The unimolecular micelles formed by the biocompatible bis-MPA based 
dendronized hyperbranched polymers (DHPs) can be used as nanocarriers for 
drug delivery.[145,152,153,212] Moreover, their numerous peripheral cationic groups 
afford the possibility to conjugate them with polyanionic polymers. In particular, 
glycodendrimers have improved the targeting and/or activity of encapsulated 
anti-malarial primaquine[239] and chloroquine[240].  
 Accordingly, the DHPs DHP[G2+3](NH3+Cl-)120, DHP[G3+3](NH3+Cl-)248 and 
DHP[G4+3](NH3+Cl-)424 have been used to encapsulate chloroquine, primaquine 
and quinacrine in their hydrophilic and lipophilic forms in order to increase their 
targeting abilities and their antiparasite activity, as it has been carried out with 
the HDLDBCs. Furthermore, these DHP/drug conjugates have been coated with 
heparin (figure C6-10).[226] 
                                                          
[145] A. Carlmark et al., Chem. Soc. Rev., 2013, 42, 5858. 
[152] O.L. Padilla de Jesús et al., Bioconjugate Chem. 2002, 13, 453. 
[153] C. Kontoyianni et al., Macromol Biosci., 2008, 8, 871. 
[212] a) M. Prabaharan et al., Biomaterials, 2009, 30, 3009; b) G. Chen et al., Biomaterials, 
2015, 47, 4. 
[239] D. Bhadra , A.K. Yadav, S. Bhadra, N.K. Jain, Glycodendrimeric nanoparticulate carriers of 
primaquine phosphate for liver targeting, Int. J. Pharm., 2005, 295, 221–233. 
[240] D. Bhadra, S. Bhadra, N.K. Jai, PEGylated peptide dendrimeric carriers for the delivery of 
antimalarial drug chloroquine phosphate, Pharm. Res., 2006, 23, 623–633. 
[226] J. Marques et al., Sci. Rep., 2016, 6, 24368. 
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Figure C6-10: Schematic representation of the DHP/antimalarial drug conjugates 
coated with heparin.  
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6.2.1- Chloroquine, primaquine and quinacrine encapsulation 
 Chloroquine, primaquine and quinacrine were encapsulated within the 
DHPs following the oil-in-water method as described for the HDLDBCS (see 
section 6.1.1.2, p. and chapter 7 for the detailed protocol).  
 Taking into account the data obtained during the encapsulation of the 
antimalarial drugs within the HDLDBCs, and in order to avoid the unnecessary 
waste of drugs, the hydrophilic forms of the antimalarial drugs were 
encapsulated within the three DHPs, DHP[G2+3](NH3+Cl-)120, DHP[G3+3] 
(NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424, at a feeding ratio of 0.5/1 (wdrug/wDHP) 
whereas their lipophilic base forms were encapsulated at a feeding ratio of 
0.75/1 (wPQb/wDHP) for PQb, 0.50/1 (wCQb/wDHP) for CQb and 0.1/1 (wQNb/wDHP) 
for QNb.  
 The amount of drug encapsulated within the DHPs was calculated in 
weight and mole ratios, and the encapsulation efficiencies were calculated by 
dividing the quantity of drug encapsulated by the quantity used to perform the 
encapsulation (table C6-3). 
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Tables C6-3: Amount of antimalarial drugs encapsulated within the DHPs based 
nanocarriers in their hydrophilic salt forms (up) and in their lipophilic base forms 
(down). aEE means encapsulation efficiency. 
  DHP[G2+3](NH3+Cl-)120 
 drug 
mg drug 
/ 
mg DHP 
mol drug 
/ 
mol DHP 
EEa 
(%) 
Hydrophilic  
salt form 
chloroquine 0.158 14.06 38 
primaquine 0.190 20.86 38 
quinacrine 0.129 9.18 26 
Lipophilic 
base form 
chloroquine 0.393 34.98 78 
primaquine 0.388 42.59 55 
quinacrine 0.007 0.50 7 
 DHP[G3+3](NH3+Cl-)248 
 drug 
mg drug 
/ 
mg DHP 
mol drug 
/ 
mol DHP 
EEa 
(%) 
Hydrophilic  
salt form 
chloroquine 0.318 58.57 65 
primaquine 0.127 28.85 26 
quinacrine 0.233 34.32 46 
Lipophilic 
base form 
chloroquine 0.404 74.41 81 
primaquine 0.230 52.20 31 
quinacrine 0.012 1.77 13 
 DHP[G4+3](NH3+Cl-)424 
 drug 
mg drug 
/ 
mg DHP 
mol drug 
/ 
mol DHP 
EEa 
(%) 
Hydrophilic  
salt form 
chloroquine 0.246 78.84 49 
primaquine 0.214 84.59 43 
quinacrine 0.229 58.70 46 
Lipophilic 
base form 
chloroquine 0.395 126.60 82 
primaquine 0.239 94.48 32 
quinacrine 0.007 1.79 7 
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 All the drugs in their hydrophilic salt forms, CQs, PQs and QNs, can be 
encapsulated within the DHPs nanocarriers with high efficiencies, 26 to 49 %. 
The two biggest DHPs, DHP[G3+3](NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424, show 
better encapsulation efficiencies than the smallest one. With respect to the 
lipophilic base forms of the drugs, high quantities of CQb can be encapsulated 
within the DHPs, showing encapsulation efficiencies between 78 and 82 %. 
Interestingly, the quantities of CQb encapsulated were higher than the 
quantities obtained with CQs. In the same manner, high quantities of PQb can 
be encapsulated within these nanocarriers. Unfortunately, and as observed for 
the HDLDBCs, QNb shows low level of encapsulation within the DHPs.  
 In general, DHP[G3+3](NH3+Cl-)248 and DHP[G4+3](NH3+Cl-)424 show higher 
encapsulation efficiencies than the smallest nanocarrier DHP[G2+3](NH3+Cl-)120 
for all the drugs, either in their hydrophilic or lipophilic form.  
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6.2.2- Heparin complex formation  
 Heparin (Hep) (figure C6-2, p.) belongs to the family of the 
glycoaminoglycan and it is constituted of a repetition of various disaccharide 
units. Under physiological pH, heparin is negatively charged and can form 
complexes when mixed with polycationic dendrimers.[236,237] For this study, 
heparin sodium salt from porcine intestinal mucosa (≥ 180 U.S. Pharmacopeial 
(USP) units/mg) has been employed. Its molecular weight varies from 6 000 to 
30 000 Da, with most chains being in the range of 17 000 to 19 000 Da, and 
presents an average of 2.3 negative charges per disaccharide unit at 
physiological pH although 4 sites are available.[241] 
The formation of complexes with heparin was determined by the 
methylene blue (MB) spectroscopic competition assay.  Heparin/MB complexes 
display an indigo color (absorption at λmax = 565 nm). The addition of the 
corresponding DHP promotes the competition between DHP and MB to 
complex heparin. When all heparin is complexed by the DHP, MB is released and 
remains free in solution displaying a turquoise color (absorption at λmax = 665 
nm). The representation of the intensity ratio between the absorbance at 665 
nm and the absorbance at 565 nm (A665/A565), and versus the wDHP/wHep ratio 
permits to calculate the parameters that define the DHP/Hep complex 
formation, i.e. EC50, the effective ratio at which 50 % of heparin is complexed by 
the DHP, and EC100, the effective ratio at which 100 % of heparin is complexed by 
the DHPs (see chapter 7 for detailed protocol). The complexation experiments 
were carried out for the empty DHP nanocarriers as well as for the drug-loaded 
DHP nanocarriers.  
                                                          
[236] K.T. Al-Jamal et al., Res. Pharm. Sci., 2012, 2, 9. 
[237] A.C. Rodrigo et al., Angew. Chem. Int. Ed., 2011, 50, 4675-4679. 
[241] a) www.sigmaaldrich.com, ref. product H4784; b) R.A. Gelman, J.Blackwell, Heparin-
polypeptide interactions in aqueous solution, Arch. Biochem. Biophys., 1973, 159, 427-33. 
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6.2.2.1 Bis-MPA DHP-heparin complexes  
 The study of the formation of the complexes between heparin and the 
three DHPs by the MB spectroscopic competition assay is represented in figure 
C6-11.  
 
Figure C6-11: Heparin complexation by the DHPs studied according to the MB 
spectroscopic assay. The EC100 corresponded to the ratio A665/A565 ratio measured for 
free MB control in water. 
 In all cases, the ratio A665/A565 reached a threshold that corresponded to 
the absorbance intensity of the free MB control in water, proving that heparin 
can be entirely complexed by the three DHPs. The biggest DHP, DHP[G4+3] 
(NH3+Cl-)424 shows better heparin complexation abilities than the two other 
DHPs and can totally complex heparin from a (wDHP/wHep) ratio  of 2.5/1 whereas 
the two other DHPs can totally complex heparin from a ratio 3.0/1. Assuming 
that the average molecular weight of heparin used for this study is close to 18 
000 Da and that 4 possible negative charges are present for each disaccharide 
units (corresponding to 6.20 x 10-3 negative charge per mole of heparin), the +/- 
charges ratio at which all heparin is complexed by the DHPs were calculated: 1.2 
for DHP[G4+3](NH3+Cl-)424 and 2.0 for DHP[G3+3](NH3+Cl-)248 and DHP[2+3] 
(NH3+Cl-)120. These values are slightly lower than the ones obtained for the pDNA 
complexation (N/P between 7 and 4, figure C5-16, p. 231), certainly due to the 
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lower molecular weight of heparin. EC50 and EC100 values are gathered in table 
C6-4. 
6.2.2.2 - DHP/drug -heparin complexes 
 The ability of the different DHPs loaded with the hydrophilic drugs to 
form complexes with heparin was first investigated. The EC50 and EC100 values 
are gathered in table C6-4. 
Table C6-4: EC50 and EC100 (wDHP/wHep) ratios determined according to the MB 
spectroscopic competition assay for the three DHPs without drugs and with the 
antimalarial drugs encapsulated within them. The curves obtained for the MB 
spectroscopic competition assays are depicted in annexes 12. 
 DHP[G2+3](NH3+Cl-)120 
 no drug CQs PQs QNs 
EC50 1.2/1 3.0/1 2.9/1 1.2/1 
EC100 3.0/1 7.5/1 7.5/1 4.5/1 
 DHP[G3+3](NH3+Cl-)248 
 no drug CQs PQs QNs 
EC50 1.2/1 2.6/1 1.8/1 1.2/1 
EC100 3.0/1 4.5/1 4.5/1 3.5/1 
 DHP[G4+3](NH3+Cl-)424 
 no drug CQs PQs QNs 
EC50 0.5/1 1.9/1 1.9/1 1.2/1 
EC100 2.5/1 4.5/1 4.5/1 3.0/1 
 
 As a general observation, the encapsulation of the antimalarial drugs in 
their hydrophilic salt form increases slightly the amount of DHP/drug necessary 
to complex the heparin.  
 Comparing the different DHPs, the heparin-complex formation is less 
altered for the two biggest DHPs. For instance, the (wDHP/wHep) ratios at which 
the EC100 are reached for DHP[G4+3](NH3+Cl-)424/hydrophilic drug and 
DHP[G3+3](NH3+Cl-)248/hydrophilic drug conjugates increase, respectively, from 
Chapter 6 
280 
2.5/1 and 3.0/1 for the DHPs without drug to 3.5/1 and 4.5/1 after drug 
encapsulation. DHP[G2+3](NH3+Cl-)120, the smallest DHP, is more affected by the 
incorporation of the drugs and can totally complex heparin at ratios ranged 
from 4.5/1 to 7.5/1 after drug encapsulation.  
 Comparing the different drugs encapsulated within the DHPs, hydrophilic 
quinacrine (QNs) was the drug that less disturbed the formation of complexes 
between the DHPs and heparin, showing an increase of 0.5 points for the EC100 
(wDHP/wHep) ratios for the two biggest DHPs and of 1.5 point for the smallest 
one. Hydrophilic chloroquine (CQs) and primaquine (PQs) disturb a little more 
the formation of the complexes and the EC100 is reached from ratios comprised 
between 4.5/1 and 7.5/1. 
 At this point, it resulted necessary to confirm that the differences 
observed for heparin complexation between the DHPs without drug and DHPs 
with encapsulated hydrophilic drugs were actually due to drug encapsulation 
and not to the presence of free drug in solution. For this purpose, three MB 
spectroscopic competition assays were carried out with DHP[G4+3](NH3+Cl-)424 
in the presence of free CQs, PQs and QNs. In these conditions, the EC100 was 
reached for a ratio (wDHP/wHep) 2.5/1, which is exactly the same than that 
determined for the DHP alone (table C6-4).  
 Subsequently, the ability of the different DHP/lipophilic drug conjugates 
containing chloroquine (CQb) and primaquine (PQb) to form complexes with 
heparin was investigated according to the same assay. Unlike the 
DHP/hydrophilic drug conjugates, the two encapsulated lipophilic drugs 
strongly affected the formation of complexes (figure C6-12). 
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Figure C6-12: Heparin complexation by DHP[G4+3]/CQb and  DHP[G4+3]/PQb studied 
according to the MB spectroscopic competition assay. The EC100 corresponded to the 
ratio A665/A565 ratio measured for free MB control in water. 
Table C6-5: Percentage of complexed heparin by the three DHPs/lipophilic base drugs 
conjugates at the ratio (wDHP/wHep) 40/1. 
 DHP[G2+3] DHP[G3+3] DHP[G4+3] 
DHPs/CQb 48 % 52 % 47 % 
DHP/PQb 45 % 25 % 30 % 
Even at high (wDHP/wHep) ratios, i.e. ≥ 40/1, more than 10 times higher 
than the ratios at which heparin is totally complexed by the DHPs alone, 
uncomplexed heparin remained present in the samples. At the ratio 40/1, 
between 25 and 52 % of heparin was complexed by the DHPs (table C6-5). The 
encapsulation of lipophilic chloroquine (CQb) within the DHPs limits the 
heparin-complex formation is less extent than the introduction of lipophilic 
primaquine (PQb), and this although higher quantities of CQb than PQb were 
encapsulated within the DHPs (table C6-3). 
 As a summary, the three bis-MPA DHPs can form complexes with heparin 
by means of electrostatic interactions starting from low (wDHP/wHep) ratios. The 
insertion of antimalarial drugs in their hydrophilic form within the DHPs only 
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slightly affects the formation of complexes with heparin. It still occurs from low 
ratios, demonstrating the effective post-functionalization of the nanocarrier/ 
antimalarial drug conjugates with heparin. In contrast, the presence of 
antimalarial drugs in their lipophilic form within the DHPs disturbs the heparin 
complexation that is uncompleted even at high ratios thus blocking their post-
functionalization with heparin. 
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6.2.3- Morphological studies 
 Preliminary transmission electron microscopy (TEM) (figure C6-13) and 
cryogenic transmission electron microscopy (cryoTEM) (figure C6-14) 
observation was conducted to determine how the size and morphology of the 
unimicellar micelles formed by DHP[G4+3](NH3+Cl-)424 were affected by the 
encapsulation of the primaquine drug in its hydrophilic salt form (PQs) and by 
the formation of the complexes with heparin (Hep).  
 In TEM images, the diameter of the spherical aggregates slightly 
increases after the encapsulation of hydrophilic primaquine or after the 
formation of the complexes with heparin. Whereas the unimolecular micelles 
formed by the DHP in water have an average size around 13.5 ± 3.5 nm, the 
DHP[G4+3](NH3+Cl-)424/PQs conjugates have average sizes around 18.7 ± 7.5 nm 
and DHP[G4+3](NH3+Cl-)424/Hep complexes have an average size around 23.5 ± 
5.5 nm. Finally, DHP[G4+3](NH3+Cl-)424/PQs/Hep complexes are the biggest 
ones; they have an average size around 26.2 ± 6.2 nm. The higher polydispersity 
observed is due to the formation of a second size-population of bigger 
aggregates with sizes close to 50 nm that must correspond to the self-
aggregation of various unimolecular micelles. 
 Additionally, the complexes formed with heparin were observed in 
cryoTEM. Like in TEM images, two size-population distributions are observed in 
these images. An abundant population of small aggregates, with diameters ca. 
20 - 35 nm are visible for DHP[G4+3](NH3+Cl-)424/Hep and ca. 15 - 40 nm for 
DHP[G4+3](NH3+Cl-)424/PQs/Hep, together with another scarce size-population 
of bigger spherical aggregates with sizes ca. 60 - 90 nm.  
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Figure C6-13: TEM images of the aggregates formed by DHP[G4+3](NH3+Cl-)424 
DHP[G4+3](NH3+Cl-)424/PQs, DHP[G4+3](NH3+Cl-)424/Hep and DHP[G4+3](NH3+Cl-)424/ 
PQs/Hep at 1 mg/mL in water. 
 
Figure C6-14: CryoTEM images of the complexes formed by DHP[G4+3](NH3+Cl-)424/ 
Hep and DHP[G4+3](NH3+Cl-)424/PQs/Hep at 1 mg/mL in water.   
 Interestingly, the unimolecular micelles formed by DHP[G4+3](NH3+Cl-)424 
in water are only slightly affected by the encapsulation of the hydrophilic 
primaquine (PQs) and by the formation of the complexes with heparin (Hep). 
Their sizes remained small and only little aggregation between the dispersed 
particles is observed. These dendritic nanocarriers show attractive size and 
morphologic characteristics that should favor red blood cells internalization.  
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6.2.4- In vitro targeting studies  
 In order to confirm the targeting abilities of the different bis-MPA DHP 
towards parasite infected red blood cells, it was necessary to label the DHPs 
with a fluorescent probe. For this purpose rhodamine B fluorophore was 
covalently linked to DHP[G3+3](NH3+Cl-)248. 
6.2.4.1- Synthesis of a bis-MPA DHP labeled with rhodamine B 
 The synthetic pathway is depicted in figure C6-15 (see section 5.1.1.2, p. 
208, general procedure XII). The hyperbranched polyester of 3rd generation with 
an average of 31 alkyne groups at its periphery, HP[G3]-≡31, was decorated with 
3rd generation bis-MPA dendrons with 8  terminal glycine moieties and 
rhodamine B by means of two steps copper(I) azide-alkyne cycloaddition 
(CuAAC). In the first step, HP[G3]-≡31 was decorated with the dendrons but 
using an amount below the stoichiometric ratio, i.e. 0.77 mol of dendron per 1 
mol of alkyne group. This allowed to ensure the presence of free alkyne groups 
after the 1st CuAAC. The catalytic system was then removed by various washings 
with aqueous solutions and the final DHP was precipitated into a mixture of 
hexanes and ethyl acetate in order to remove the dendrons that had not 
reacted. In the second step, a CuAAC was carried out with N3-RhB, a rhodamine 
B derivative bearing an azide group (the synthesis of this derivatives is described 
in the section 4.3.3.2, p. 181). An excess of dye was used to ensure the sufficient 
labeling of the DHP (1.7 mol of dye per 1 mol of alkyne group). After completion 
of the reaction, the catalytic system and the excess of dye were removed by 
several washings with aqueous solutions and by dialysis against methanol in 
order to obtain pure DHP[G3+3](NHBoc,RhB). Finally, the t-Boc protecting 
groups of the terminal amino groups were removed as before, in acidic 
conditions in ethyl acetate yielding the ammonium salts that precipitated from 
the reaction mixture. Pure dendronized hyperbranched polymer of generation 
3+3 covalently labeled with rhodamine B, DHP[G3+3](NH3+Cl-,RhB) was 
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obtained as a pink solid with a yield of 52 %, which is slightly lower than the one 
obtained for the DHP without dye (71 %). 
 
Figure C6-15: Synthesis of the bis-MPA DHP covalently labeled with rhodamine B. aThe 
2 steps CuAAC was carried out in the same conditions described for the synthesis of 
the bis-MPA DHPs, general procedure XII detailed in the chapter 7). 
 As in the case of the DHPs without fluorescent label, 1H-NMR (figure  
C6-16) and FTIR spectroscopy were employed to confirm the formation of the 
final triazole rings. The complete chemical characterization data are gathered in 
chapter 7. 
 As before, the 1H-NMR spectrum shows a peak at 7.40 ppm that 
corresponds to the proton of the triazole ring, H-13. The methylene protons 
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closed to the triazole ring (H-10, H-11, H-14 and H-15) are downfield shifted. 
Additionally, peaks with low intensities corresponding to the aromatic protons 
of the dye can be observed between 6.5 and 8.5 ppm as well as a doublet 
corresponding to the methylene protons in the α-position of the N atoms of the 
dye, H-29, at 3.61 ppm. In the FTIR spectrum, the band corresponding to the 
stretching of the azide bond at 2100 cm-1 disappears completely while the two 
bands corresponding to the stretching of the bonds of the alkyne groups, ≡C-H 
and C≡C at 3292 and 2119 cm-1 respectively, are no longer observed. 
 
Figure C6-16: 1H NMR spectrum of DHP[G3+3](NHBoc,RhB) recorded at 400 MHz in 
CDCl3. 
 The degree of functionalization of the bis-MPA hyperbranched polymers 
by the dendrons and then, by the rhodamine dye was calculated by 1H-NMR. As 
for the DHPs without dye, the methylene protons in the α- and β-positions of 
the alkyne groups (H-10’ and H-11’) or the proton of the triazole rings (H-10 and 
H-11) can be used to determine the degree of dendrons and dye grafting (figure 
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C6-17). When they are in the α- and β-positions of the alkyne groups, their 
corresponding peaks appear at 2.55 and 2.45 ppm and, after the formation of 
the triazole rings, they are downfield shifted to 2.90 and 3.19 ppm, respectively. 
Therefore, and as before, the degree of functionalization of the hyperbranched 
polymer can be determined by comparing the relative intensity of the different 
peaks. The degree of dendron functionalization during the 1st CuAAC step is 
equal to 78 % while the degree of rhodamine dye functionalization during the 
2nd step is equal to 100 %. Thus, pure DHP of generation 3+3 bearing an average 
of 24 bis-MPA dendrons and labeled by 7 rhodamine dye moieties were 
obtained.   
 
Figure C6-17: 1H-NMR spectra from 2.4 to 3.3 ppm of the DHP[G3+3] after the grafting 
of the bis-MPA dendrons (left) and after the grafting of rhodamine B dye (right). 
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6.2.4.2- Targeting experiments 
 Before carrying any targeting experiments, the abilities of 
DHP[G3+3](NH3+Cl-,RhB) to form complexes with heparin was controlled by the 
methylene blue (MB) spectroscopic competition assay (see annexes 13). As this 
DHP has less dendrons and, as a consequence less peripheral glycine moieties 
than its respective DHP without dye (192 versus 248 terminal amino groups), it 
forms complexes with heparin at higher (wDHP/whep) ratios. The EC50 and EC100 
vales are 1.5 and 6.0, respectively, which correspond to a +/- charge ratios of 0.8 
and 3.2. Nevertheless, this DHP is still a good heparin binder and targeting 
experiments with heparin complexes could be conducted. 
 The abilities of DHP[G3+3](NH3+Cl-,RhB) and its relative heparin 
complexes containing different quantities of heparin (5, 10 and 15 %w) to target 
parasites infected RBCs were studied by fluorescence microscopy and by flow 
cytometry (figure C6-18). The infected RBCs were stained by Hoechst and 
appear in blue. DHP[G3+3](NH3+Cl-,RhB) and its respective complexes appear in 
red. 
 The fluorescence microscopy images show that DHP[G3+3](NH3+Cl-,RhB) 
is located in all the infected RBCs and only inside them. Moreover, the DHP is 
specifically located in the same area than the parasites within the infected cells. 
These results were confirmed by flow cytometry assays where more than 90 % 
of the infected red blood cells show red fluorescence whereas less than 10 % of 
the healthy ones show red fluorescence. As the DHP showed excellent 
properties for its own, the addition of heparin that specifically binds the 
infected RBCs didn’t seem necessary for targeting.  
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Figure C6-18: Fluorescence microscopy images (A) of DHP[G3+3](NH3+Cl-,RhB) with 0, 
5, 10 and 15 %w of heparin at 150 μg/mL after 90 minutes incubation. Infected RBCs 
appeared in blue and DHP[G3+3](NH3+Cl-,RhB) appeared in red. (B) Percentage of DHP 
and complexes internalized within the infected (left) and healthy (right) red blood cells 
(RBCs) determined by flow cytometry assay. 
 An additional experiment was performed in which the targeting abilities 
of the complexes were conducted with DHP[G3+3](NH3+Cl-,RhB)-Hep, in which 
the heparin is covalently marked with fluorescein isothiocyanate (Hep-FITC) 
(figure C6-19).  
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Figure C6-19: Fluorescence microscopy images of DHP[G3+3](NH3+Cl-,RhB)-Hep with 10 
and 15 %w of heparin at 150 μg/mL after 90 minutes incubation. Infected red blood 
cells appear in blue, DHP[G3+3](NH3+Cl-,RhB) appears in red and Hep-FITC appears in 
green. 
 Green fluorescence due to heparin and red one due to the DHP were 
both located in the infected red blood cells confirming the entry of the whole 
DHP-Hep complexes within the infected red blood cells.  
 As it has occurred with the HDLDBCs, the cellular uptake of the DHPs into 
the parasite infected red blood cells is favored when compared with the cellular 
uptake of the non-infected ones. Thus, these two series of dendritic 
nanocarriers appear as alluring nanocarriers to deliver and increase the 
targeting of antimalarial drugs.  
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6.3- In vitro plasmodium growing 
inhibition assays (GIAs) 
 
 Preliminary studies have been undertaken in order to evaluate, the 
potential of the dendritic/antimalarial drug conjugates to inhibit plasmodium 
growing in infected RBCs for the conjugates based on DHP[G4+3](NH3+Cl-)424 and 
on bisGMPA-[PLU]-bisGMPA.  
 First, the inhibition the replication of plasmodium was evaluated by 
measuring the plasmodium growth after being exposed to various 
concentrations of the corresponding dendritic derivative/chloroquine and 
dendritic derivative/primaquine conjugates for 48 hours and compare to the 
growth after exposition to the free drugs. The half-maximal inhibition effective 
concentrations (IC50), which represents the concentrations at which the parasite 
growth decreases by 50% was evaluated for the dendritic derivatives/drug 
conjugates and their respective free drug control (table C6-6). The Growing 
inhibition assays curves are gathered in annexes 14. 
Table C6-6: IC50 determined from the GIAs for the DHP[G4+3]/antimalarial drug 
conjugates, HDLDBC/antimalarial drug conjugates and for the free drugs controls.  
 hydrophilic  salts form lipophilic  base form 
primaquine free PQs  DHP[G4+3] HDLDBC free PQs  DHP[G4+3] HDLDBC 
IC50 15.5 µM 24.7 µM 22.9 µM 20.9 µM 20.7 µM 24.7 µM 
chloroquine free CQs  DHP[G4+3] HDLDBC free CQs  DHP[G4+3]  
IC50 33.4 nM 72.9 nM 37.2 nM 37.8 nM 81.7 nM  
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 In almost all the cases, the encapsulation of the antimalarial drugs 
within the dendritic nanocarriers, in either their hydrophilic salt form or 
lipophilic salt form, does not affect negatively their activity 
 Second, the DHP[G4+3](NH3+Cl-)424/QNs-Hep conjugate was chosen to 
perform a preliminary plasmodium growing inhibition assay (GIA) when 
combined with heparin. The complex was prepared at a ratio (wDHP/wHep) 5/1 at 
which all heparin is complexed. The plasmodium growing inhibition activity of 
plasmodium was measured after being exposed to the DHP[G4+3](NH3+Cl-)424/ 
QNs/Hep conjugate during 48 hours and the IC50 values were determined for all 
the drug conjugates and their respective free drug control (table C6-7). The GIAs 
curves are gathered in annexes 15. 
Table C6-7: IC50 determined from the GIA of the DHP[G4+3]/QNs-Hep conjugate. 
Quinacrine free QNs control 
free QNs 
& Hep 
DHP[G4+3] 
/Hep 
DHP[G4+3] 
/QNs 
DHP[G4+3] 
/QNs/Hep 
IC50 54.7 nM 132.2 nM - 72.9 nM 35.0 nM 
 Interestingly, the activity of the drug is enhanced after the formation of 
the conjugate with heparin. 
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6.4- General remarks 
Summary of results 
 The HDLDBCs based on commercial Pluronic® F127 and either bis-MPA or 
bis-GMPA dendrons and together with the bis-MPA DHPs, previously described 
chapters 4 and 5, respectively, can encapsulate three antimalarial drugs: 
chloroquine, primaquine and quinacrine. Furthermore, the polycationic DHPs 
can form complexes with heparin, a polyanionic polysaccharide, by means of 
electrostatic interactions from low (DHP/Heparin) ratios.  
 The HDLDBCs as well as the DHPs and DHP/heparin complexes labeled 
with rhodamine B fluorophore have shown interesting abilities to target red 
blood cells infected by the parasite that provokes malaria and subsequent cell 
internalization.   
 The antimalarial activity of the drugs was in general maintained after 
their encapsulation within the dendritic systems. The post-functionalization 
with heparin of DHP/quinacrine conjugate have enhanced the drug activity. 
Conclusions 
 The HDLDBCs and the DHPs are promising nanocarriers for the delivery of 
antimalarial drugs. They are able to enhance the drug targeting to infected red 
blood cells without showing a decrease of the drug activity.  
Future investigation 
 The promising results obtained for antimalarial drug delivery might be 
corroborate in order to extend the study to in vivo experiments. It might be 
interesting to perform in vitro studies in which parasite infected red blood cells 
are exposed 90 min to the drugs and drug nanocarriers. Moreover, the 
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administration of DHP/drug/heparin systems may be extended to chloroquine 
and primaquine in order to observe if the activity of these drugs could be 
improved as well. Following this idea, the pharmacokinetics of the drugs when 
encapsulated within the DHP or within the heparin post-functionalized DHPs 
might give critical results before making in vivo experiments.  
  
Chapter 6 
296 
 
  
 
 
Chapter 7 
Experimental part 
  
  
Experimental part 
299 
7.1- Synthesis  and  chemical 
characterization 
 
7.1.1- Materials and equipments 
 The reactive were purchased form Sigma-Aldrich® or from Acros TM. In 
particular, the commercial bis-MPA hyperbranched polymers of generation 2, 3 
and 4, camptothecin, hydrophilic chloroquine salt, hydrophilic primaquine salt 
and hydrophilic quinacrine salt were purchased from Sigma-Aldrich®. 
Rhodamine B fluorophore was purchased from Acros TM. 
 Organic solvents and silica gel were purchased from Sigma-Aldrich® or 
Scharlab S.L.; dichloromethane was distilled before use. Inorganic salts and 
mineral acids were purchased from Scharlab S.L. Bases were purchased from 
Panreac AppliChem®. 
 The dialysis membranes of cellulose acetate with 1000, 2000 or 3500 Da 
cut-off were purchased from Spectra/Por®. 
 1H nuclear magnetic resonance (NMR) and 13C NMR experiments were 
performed using a Bruker AV-500 (1H: 500 MHz, 13C: 125 MHz), Bruker AV-400 
(1H: 400 MHz, 13C: 100 MHz) or a Bruker AMX300 (1H: 300 MHz, 13C: 75 MHz) 
spectrometer employing deuterated chloroform (CDCl3), deuterated 
dichloromethane (CD2Cl2), deuterated methanol (CD3OD), deuterated dimethyl 
sulfoxide ((CD3)2SO) or deuterated water (D2O) as solvents. The chemical shifts 
are given in ppm relative to TMS and the coupling constants in Hz. The solvent 
residual peak was used as internal standard. 
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 Mass spectrometry (MS) were performed using an ESI Bruker Esquire 
300+ or a Bruker Microflex system employing the MALDI-TOF technique with 
nitrogen laser (337 nm) and ditranol as matrix (expect otherwise specified).  
 Fourier transformed infrared (FTIR) spectra were performed using a 
Bruker Vertex 70 spectrophotometer in ATR mode and recorded between 4000 
and 600 cm–1 or using a FTIR ATI-Mattson Genesis series II while the sample 
were suspended in nujol in NaCl cells and recorded between 4000 cm-1 and 600 
cm-1. 
 Elemental analysis (EA) were performed with a Perkin-Elmer 2400 series 
II microanalyser. 
 Size exclusion chromatography (SEC) were performed on a Waters 
e2695 Alliance system with two Styragel columns HR4 and HR1 (500 and 104 Å 
of pore size) in series and a Waters 2424 evaporation light scattering detector. 
The sample was dissolved into THF (HPLC grade) at the concentration of 1 
mg·mL–1. The flow rate was set at 1 mL·min–1 and the temperature at 35 °C. 
PMMA was used as standard for calibration. 
 The pH of the solutions was measured after each addition by a Hanna HI 
8424 pH meter with a HI 1110B electrode.   
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7.1.2- Bis-MPA and bis-GMPA dendrons 
7.1.2.1- bis-MPA dendrons 
 
General procedure I): growing up esterification reaction of the bis-MPA 
dendrons 
 
 Alcohol was dissolved into dry dichloromethane. Bis-MPA(monomer)* 
(1.10, 1.05 or 1.50 mol per hydroxyl groups according to the dendron 
generation) and DPTS (0.40 mol per hydroxyl groups) were added. The reaction 
mixture was stirred under argon atmosphere and was cooled down to 0ºC. A 
solution of DCC (1.10, 1.05 or 1.50 mol per hydroxyl group according to the 
dendron generation) in dry dichloromethane was added drop wise. The reaction 
mixture was allowed to stir under argon atmosphere overnight at room 
temperature. The white precipitate, N,N’-dicyclohexylurea (DCU), was filtered 
off and the solvent was evaporated under vacuum to get a mixture of oil and 
solid. DCU was newly precipitated into hexane and filtered off. The solvent was 
evaporated under reduce pressure. The crude product was purified on silica gel 
(mixtures of hexane and ethyl acetate). 
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General procedure II): deprotection of the terminal hydroxyl groups 
 
 Dowex 50 WX2 hydrogen form 50.100 (mesh) (50 % mass equivalent) was 
washed by stirring it in MeOH and was recovered using filtration. Ketonide 
protected dendron (1.00 mol) was dissolved into MeOH. Washed Dowex resin 
H+ was added and the reaction was stirred during 5, 10 or 24 hours according to 
the dendron generation. The resin was filtered off and the solvent was 
evaporated under vacuum to obtain the corresponding pure product. 
General procedure III): functionalization of the dendron with t-Boc protected 
glycine moieties 
 
 Alcohol (1.00 mol) was dissolved into dry dichloromethane. t-Boc Glycine 
(1.25 mol per hydroxyl groups) and DMAP (0.40 mol per hydroxyl groups) were 
added to it. The reaction mixture was stirred under argon atmosphere and 
cooled down to 0ºC. DCC (1.25 mol per hydroxyl groups) was dissolved into dry 
dichloromethane and was added drop wise to the reaction mixture. It was 
stirred at room temperature under argon atmosphere during 24 hours. The 
white precipitate, N,N’-dicyclohexylurea (DCU), was filtered off and the solvent 
was evaporated under vacuum to get a mixture of oil and solid. DCU was newly 
precipitated into a mixture of hexane and ethyl acetate (7:3) and filtered off. 
The solvent was evaporated under reduce pressure.  The crude product was 
purified twice on silica gel with mixtures of hexane and ethyl acetate (ramp 
from 7:3 to 4:6) to get a white solid. 
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General procedure IV): functionalization of the dendron with stearic acid (C17 
alkyl chains) 
 
 Alcohol (1.00 mol) was dissolved into dry dichloromethane. Stearic acid 
(1.50 mol per hydroxyl groups) and DMAP (0.4 mol per hydroxyl groups) were 
added to it. The reaction mixture was stirred under argon atmosphere and 
cooled down to 0ºC. DCC (1.50 eq. per hydroxyl groups) was dissolved into dry 
dichloromethane and was added drop wise to the reaction mixture. It was 
stirred at room temperature under argon atmosphere during 2 days. The white 
precipitate, N,N’-dicyclohexylurea (DCU), was filtered off and the solvent was 
evaporated under vacuum to get a mixture of oil and solid. DCU was newly 
precipitated into hexane and filtered off. The solvent was evaporated under 
reduce pressure. The crude product was purified by two successive 
precipitations into cold acetone.  
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ketal-protected bis-MPA(monomer), 
named as bis-MPA(monomer)*  
O
O
HO
O
1 2
3
4
5
6
 
2,2-Bis(hydroxymethyl)propionic acid (60.00 g, 447.33 mmol, 1.00 eq.) was dissolved in 
dry acetone (300 mL). 2,2 dimethoxypropane (82.51 mL, 670.99 mmol, 1.50 eq.) and 
TsOH,H2O (4.26 g, 22.37 mmol, 0.05 eq.) were added. The reaction mixture was stirred 
at room temperature during 2 hours. Then, the reaction was neutralized by adding a 
solution of NH3/EtOH (1:1) (6 mL). The solvent was evaporated under vacuum. The 
white solid was dissolved in AcOEt (100 mL) and was washed twice with distillated 
water. The organic phase was dried over anhydrous MgSO4. The solvent was 
evaporated under vacuum to get a white powder (54.07 g, 69 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.21 (s, 3H, H-3), 1.41 (s, 3H, H-6), 1.44 (s, 3H, H-6’), 
3.67 (d, J = 12 Hz, 2H, H-4), 4.19 (d, J = 12 Hz, 2H, H-4’), 9.95 (bs, COOH). 
13C NMR (100 MHz, CDCl3) δ (ppm): 18.4 (C-3), 21.9 (C-6), 25.2 (C-6’), 41.8 (C-2), 65.8 
(C-4), 98.3 (C-5), 180.2 (C-1).  
MS (ESI+): m/z (%) 196.9 (100) [C8H14O4,Na]+, 174.0 (33) [C8H14O4,H]+.  
FT-IR (νmax/cm-1, nujol): 3126 (COO-H st), 2924-2854 (C-H st), 1722 (C=O st), 1460 (CH2, 
CH3 δ).  
EA (%): Found: C, 55.4; H, 8.4. Calc. for C8H14O4: C, 55.2; H, 8.1%. 
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6-azidohexan-1-ol 
N3
OH1
2
3
4
5
6  
6-chlorohexan-1-ol (19.53 mL, 146 mmol, 1.00 eq.) was dissolved in DMF (60 mL). 
NaN3 (19.99 g, 307 mmol, 2.10 eq.) was added. The reaction mixture was stirred at 140 
ºC during 36 hours. Water (400 mL) was added. The product was extracted tree times 
using Et2O (3 x 200 mL). Organic phases were collected, put together, washed twice 
using brine (2 x 200 mL) and dried over anhydrous MgSO4. Solvent was evaporated to 
give an orange oil. The crude product was purified on silica gel (hexane : ethyl acetate 
= 7:3) to give a light yellow oil (15.32 g, 73 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.34 (m, 4H, H-3 and H-4), 1.56 (m, 4H, H-2 and  
H-5), 1.76 (bs, -OH), 3.24 (t, J = 6.8 Hz, 2H, H-1), 3.61 (t, J = 6.4 Hz, 2H, H-6).  
13C NMR (400 MHz, CDCl3) δ (ppm): 25.3 (C-4), 26.4 (C-3), 28.7 (C-5), 32.5 (C-2), 51.3  
(C-1), 62.6 (C-6). 
MS (ESI+): m/z (%) 166.0 (100) [C6H13N3O1,Na]+.  
FTIR (νmax/cm-1, nujol): 3339 (O-H st), 2936-2861 (C-H st), 2097 (N3 st), 1456 (CH2, CH3 
δ). 
 EA (%): Found: C, 49.7; H, 9.2; N, 29.5. Calc. for C6H13N3O1: C, 50.3; H, 9.15; N, 29.35. 
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N3-[bisMPA,G1]-(ketal)1 
N3
O1
2
3
4
5
6
O
O
O
7
8
9
10 11
12
 
General procedure I) 6-azidohexan-1-ol (12.68 g, 88.58 mmol, 1.00 eq.);  
bis-MPA(monomer)* (16.97 g, 97.44 mmol, 1.10 eq.); DPTS (10.43 g, 35.43 mmol, 0.40 
eq.); DCC (20.10 g, 97.44 mmol, 1.10 eq.); dry DCM (250  + 50 mL);time of reaction: 
overnight.  The crude product was purified on silica gel (hexane : ethyl acetate = 8:2) to 
give a light yellow oil (25.68 g, 94 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.18 (s, 3H, H-9), 1.38 (s, 3H, H-12), 1.40 (m, 4H,  
H-3 and H-4), 1.42 (s, 3H, H-12’), 1.61 (m, 2H, H-2) 1.67 (m, 2H, H-5), 3.26 (t, J = 6.8 Hz, 
2H, H-1), 3.64 (d, J = 11.6 Hz, 2H, H-10), 4.14 (t, J =6.6 Hz, 2H, H-6), 4.18 (d, J = 11.6 Hz, 
2H, H-10’).  
13C NMR (100 MHz, CDCl3) δ (ppm): 18.7 (C-9), 22.7 (C-12), 24.6 (C-12’), 25.4 (C-4), 26.3 
(C-3), 28.4 (C-5), 28.7 (C-2), 41.8 (C-8), 51.3 (C-1), 64.6 (C-6), 66.0 (C-10), 98.0 (C-11), 
174.3 (C-7).  
MS (ESI+): m/z (%): 322.1 (15) [C14H25N3O4,Na]+, 300.0 (52) [C14H25N3O4,H]+, 272.0 (100) 
[C14H25N1O4,H]+. 
FTIR (νmax/cm-1, nujol): 2939-2864 (C-H st), 2096 (N3 st), 1731 (C=O st), 1455 (CH2, CH3 
δ), 1259 (CO-O st), 1160 (O-C-C st).  
EA (%): Found: C, 55.9; H, 8.7; N, 13.8. Calc. for C14H25N3O4: C, 56.2; H, 8.4; N, 14.0. 
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General procedure II) N3-[bisMPA,G1]-(ketal)1 (25.68 g, 85.78 mmol, 1.00 eq.); ion 
exchange resin Dowex H+ (12.50 g, 50 % mass equivalent); MeOH (350 mL). Time of 
reaction: 5 hours. The product was obtained as a colorless oil (20.86 g, 97 %). 
1H NMR (300 MHz, CDCl3) δ (ppm): 1.05 (s, 3H, H-9), 1.39 (m, 4H, H-3 and H-4),  1.61 
(m, 2H, H-2), 1.67 (m, 2H, H-5), 3.02 (bs, -OH), 3.25 (t, J = 6.9 Hz, 2H, H-1), 3.68 (dd,  
J = 11.2 Hz and J = 5.7 Hz, 2H, H-10), 3.87 (dd, J = 11.2 Hz and J = 5.7 Hz, 2H, H-10’), 
4.14 (t, J = 6.6 Hz, 2H, H-6). 
13C NMR (100 MHz, CDCl3): δ (ppm)17.0 (C-9), 25.3 (C-4), 26.2 (C-3), 28.3 (C-5), 28.6  
(C-2), 49.1 (C-8), 51.2 (C-1), 64.8 (C-6), 67.9 (C-10), 175.9 (C-7).  
MS (ESI+): m/z(%): 282.0 (100) [C11H21N3O4,Na]+, 232.0 (72) [C11H21NO4,H]+. 
FTIR (νmax/cm-1, nujol): 3381 (O-H st), 2925-2855 (C-H st), 2097 (N3 st); 1727 (C=O st), 
1462 (CH2,CH3 δ), 1237 (CO-O st), 1131 (O-C-C st).  
EA (%): Found: C. 50.4; H, 8.2; N, 16.4. Calc. for C11H21N3O4: C. 50.95; H. 8.2; N. 16.2.  
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General procedure I) N3-[bisMPA,G1]-(OH)2 (16.78 g, 64.70 mmol, 1.00 eq.);  
Bis-MPA(monomer)* (24.80 g, 142.35 mmol, 2.10 eq.); DPTS (15.24 g, 51.76 mmol, 
0.80 eq.); DCC (29.24 g, 142.35 mmol, 2.10 eq.); dry DCM (280  + 70 mL); time of 
reaction: overnight.  The crude product was purified on silica gel (hexane : ethyl 
acetate = 7:3) to give a colorless oil (36.19 g, 98 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.14 (s, 6H, H-13), 1.28 (s, 3H, H-9), 1.35 (s, 6H,  
H-16), 1.39 (m, 4H,H-3 and H-4), 1.41 (s, 6H, H-16’), 1.60 (m, 2H, H-2) 1.65 (m, 2H, H-5), 
3.27 (t, J = 7.2 Hz, 2H, H-1), 3.62 (d, J = 12.8 Hz, 4H, H-14), 4.11 (t, J = 6.8 Hz, 2H, H-6), 
4.15 (d, J = 12.0 Hz, 4H, H-14’), 4.32 (s, 4H, H-10). 
13C NMR (100 MHz, CDCl3) δ (ppm): 17.7 (C-9), 18.5 (C-13), 22.2 (C-16), 25.0 (C-16’), 
25.5 (C-4), 26.3 (C-3), 28.4 (C-5), 28.7 (C-2), 42.0 (C-12), 47.0 (C-8), 51.3 (C-1), 65.2  
(C-6), 65.3 (C-10), 65.9 (C-14), 98.1 (C-15), 172.6 (C-7), 173.5 (C-11).  
MS (MALDI+): m/z (%): 594.3 (100) [C27H45N3O10, Na]+. 
 FTIR (νmax/cm-1, nujol): 2940-2868 (C-H st), 2097 (N3 st), 1736 (C=O st), 1457 (CH2, CH3 
δ), 1252 (CO-O st), 1155 (O-C-C).  
EA (%): Found: C, 56.5; H, 7.8; N, 7.0. Calc. for C27H45N3O10: C, 56.7; H, 7.9; N, 7.35.  
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General procedure II) N3-[bisMPA,G1]-(ketal)2 (36.20 g, 63.30 mmol, 1.00 eq.); ion 
exchange resin Dowex H+ (18.00 g, 50 % mass equivalent); MeOH (400 mL); time of 
reaction: 10 hours. The pure product was obtained as a white solid (28.96 g, 93 %). 
1H NMR (400 MHz, CD3OD) δ (ppm): 1.05 (s, 6H, H-13), 1.30 (s, 3H, H-9), 1.40 (m, 4H, 
H-3 and H.4), 1.61 (m, 2H, H-2) 1.65 (m, 2H, H-5), 3.30 (t, J = 6.9 Hz, 2H, H-1), 3.64 
(ABq, J = 10.8 Hz, Δ νAB = 26.7 Hz, 8H, H-14), 4.26 (t, J = 6.8 Hz, 2H, H-6), 4.43 (ABq, J = 
11.2 Hz, Δ νAB = 15.1 Hz, 4H, H-10). 
13C NMR (100 MHz, CDCl3) δ (ppm): 17.1 (C-13), 18.1 (C-9), 25.4 (C-3), 26.3 (C-4), 28.3 
(C-5), 28.7 (C-2), 46.3 (C-8), 49.7 (C-12), 51.3 (C-1), 64.8 (C-10), 65.4 (C-6), 68.0 (C-14), 
173.0 (C-7), 175.2 (C-11). 
MS (MALDI+) m/z (%): 514.3 (100) [C21H37N3O10,Na]+. 
FTIR (νmax/cm-1, nujol): 3283 (O-H st), 2923-2854 (C-H st), 2098 (N3 st), 1731 (C=O st), 
1462 (CH2, CH3 δ), 1241 (CO-O st), 1137 (O-C-C st).  
EA (%): Found: C, 51.5; H, 7.6; N, 8.7. Calc. for C21H37N3O10: C. 51.3; H, 7.6; N, 8.55.  
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General procedure I) N3-[bisMPA,G2]-(OH)4 (15.00 g, 30.52 mmol, 1.00 eq.); bis-
MPA(monomer)* (31.89 g, 183.11 mmol, 6.00 eq.); DPTS (14.37 g, 48.82 mol, 1.60 eq.); 
DCC (37.74 g, 183.11 mmol, 6.00 eq.); dry DCM (260 + 90 mL); time of reaction: 
overnight. The crude product was purified twice on silica gel (hexane : ethyl acetate =  
ramp from 7:3 to 6:4) to give a colorless gel (26.75 g, 79 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.14 (s, 12 H, H-17), 1.25 (s, 3H, H-9), 1.26 (s, 6H, H-
13), 1.35 (s, 12H, H-20), 1.40 (m, 16H, H-3, H-4 and H-20’), 1.60 (m, 2H, H-2) 1.65 (m, 
2H, H-5), 3.27 (t, J = 6.6 Hz, 2H, H-1), 3.61 (d, J = 12 Hz, 8H, H-18), 4.10 (t, J = 7.2 Hz, 2H, 
H-6), 4.13 (d, J = 12.4 Hz, 8H, 18’), 4.27 (m, 12H, H-10 and H-14). 
13C NMR (100 MHz, CDCl3) δ (ppm): 17.1 (C-9), 17.7 (C-13), 18.4 (C-17), 22.0 (C-20), 
25.1 (C-20’), 25.4 (C-4), 26.3 (C-3), 28.3 (C-5), 28.7 (C-2), 42.0 (C-16), 46.6 (C-8), 46.8  
(C-12), 51.3 (C-1), [64.9-65.4-65.9] (C-10, C-14 and C-18), 66.0 (C-6), 98.1 (C-19), 171.8 
(C-11) , 172.1 (C-7), 173.4 (C-15). 
MS (MALDI+) m/z(%): 1138.7 (100) [C53H85N3O22,Na]+, 1115.7 (84) [C53H85N3O22,H]+.  
FTIR (νmax/cm-1, nujol): 2991-2940-2876 (C-H st), 2097 (N3 st), 1739 (C=O st), 1457 (CH2, 
CH3 δ), 1253 (CO-O st), 1155 (O-C-C).  
EA (%): Found: C, 57.05; H, 7.9; N, 3.7. Calc. for C53H85N3O22: C, 57.0; H, 7.7; N. 3.8. 
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General procedure II) N3-[bisMPA,G3]-(OH)8 (22.88 g, 20.51 mmol, 1.00 eq.); ion 
exchange resin Dowex H+ (11.00 g, 50 % mass equivalent); MeOH (300 mL). Time of 
reaction: 24 hours. The pure product was obtained as a white solid (17.45 g, 89 %). 
1H NMR (CD3OD, 300 MHz) δ (ppm): 1.09 (s, 12H, H-17), 1.24 (s, 6H, H-13), 1.25 (s, 3H, 
H-9), 1.39 (m, 4H, H-3 and H-4), 1.57 (m,2H, H-2), , 1.65 (m, 2H, H-5), 3.26 (t, J = 6.8 Hz, 
H-1), 3.64 (ABq, J = 12 Hz, ΔνAB = 32.0 Hz, 16H, H-18), 4.18 (t, J = 6.6 Hz, 2H, H-6), 4.29 
(m, 12H, H-10 and H-14). 
13C NMR (CD3OD, 75 MHz) δ (ppm): 17.3 (C-17), 18.2 (C-9), 18.3 (C-13), 26.7 (C-4), 27.5 
(C-3), 29.6 (C-5), 29.8 (C-2), 48.0 (C-8 and C-12), 51.8 (C-16), 52.4 (C-1), 65.9 (C-18), 
66.2 (C-14), 66.7 (C-10), 67.4 (C-6), 173.8 (C-11), 174.1 (C-7), 176.0 (C-15). 
MS (MALDI+) m/z (%): 978.5 (100) [C41H69N3O22,Na]+. 
FTIR (νmax/cm-1, nujol): 3289 (O-H st), 2924-2853 (C-H st), 2099 (N3 st), 1732 (C=O st), 
1461 (CH2, CH3 δ), 1237 (CO-O st), 1131 (O-C-C st). 
EA (%): Found: C, 51.8; H, 7.3; N, 4.6. Calc. for C41H69N3O22: C, 51.5; H, 7.3; N, 4.4. 
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General procedure III) N3-[bisMPA,G2]-(OH)4 (2.50 g, 5.09 mmol, 1.00 eq.); Glyboc(OH) 
(4.46 g, 25.45 mmol, 5.00 eq.); DMAP (0.99 g, 8.14 mmol, 1.6 eq.); DCC (5.25 g, 25.45 
mmol, 5.00 eq.); dry DCM (110 + 35 mL); time of reaction: 24 hours.  The crude 
product was purified twice on silica gel (hexane : ethyl acetate = 7:3) to get a white 
solid (2.80 g, 49 %). 
1H (300 MHz, CDCl3) δ (ppm): 1.25 (s, 6H, H-13), 1.27 (s, 3H, H-9), 1.45 (m, 40H, H-3,  
H-4 and H-19) 1.59 (m, 2H, H-2) 1.68 (m, 2H, H-5), 3.29 (t, J = 6.6 Hz, 2H, H-1), 3.89 (d, J 
= 5.7 Hz, 8H, H-16), 4.13 (t, J = 6.6 Hz, 2H, H-6), 4.27 (m, 12H, H-10 and H-14), 5.25 (bs, 
-NH). 
13C (75 MHz, CDCl3) δ (ppm): [17.7-17.9] (C-9 and C-13), 25.4 (C-4), 26.3 (C-3), 28.3  
(C-5 and C-19), 28.7 (C-2), 42.2 (C-16), 46.4 (C-12), 46.6 (C-8), 51.3 (C-1), [65.5-65.7]  
(C-6, C-10 and C-14), 80.0 (C-18), 155.8 (C-17), 170.0 (C-15), [171.8-172.2] (C-7 and  
C-11). 
MS (MALDI+) m/z (%): 1147.2 (100) [C49H81N7O22,Na]+ 
 FTIR (νmax/cm-1, ATR): 3394 (N-H st), 2918 (C-H st), 2100 (N3 st), 1741 (C=O st ester), 
1703 (C=O st carbamate), 1516 (N-H δ), 1471 (CH2, CH3 δ), 1247 (CO-O st), 1153  
(N-CO-O st), 1130 (O-C-C st). 
EA (%): Found: C. 52.6; H. 7.3; N, 8.55. Calc. for C49H81N7O22: C, 52.5; H, 7.3; N, 8.75.  
SEC (ref PMMA): Mw 1352 g.mol-1; Ð 1.02.  
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General procedure III) N3-[bisMPA,G3]-(OH)8 (15.00 g, 15.69 mmol, 1.00 eq.); 
Glyboc(OH) (27.49 g, 156.91 mmol, 10.00 eq.); DMAP (6.13 g, 50.21 mmol, 3.20 eq.); 
DCC (32.37 g, 156.91 mmol, 10.00 eq.); dry DCM (300 + 90 mL); time of reaction: 24 
hours. The crude product was purified four times on silica gel (hexane : ethyl acetate = 
ramp from 7:3 to 4:6) to get a white solid (25.70 g, 74 %). 
 1H NMR (400 MHz, CDCl3) δ (ppm): 1.24 (s, 12H, H-17), 1.25 (s, 6H, H-13), 1.28 (s, 3H, 
H-9), 1.43 (s, 72H, H-23), 1.46 (m, 4H, H-3 and H-4,), 1.61 (m, 2H,H-2), 1.67 (m, 2H,  
H-5), 3.27 (t, J = 6.8 Hz, 2H, H-1), 3.88 (d, J = 6 Hz, 16H, H-20), 4.12 (t, J = 7.2 Hz, 2H,  
H-6), 4.25 (m, 28H, H-10, H-14 and H-18), 5.29 (bs, -NH). 
13C NMR (75 MHz, CDCl3) δ (ppm): [17.4-17.7] (C-9, C-13 and C-17), 25.4 (C-4), 26.3  
(C-3), 28.3 (C-5 and C-23), 28.7 (C-2), 42.2 (C-20), 46.3 (C-16), 46.4 (C-8), 46.6 (C-12), 
51.1 (C-1), [65.2-66.1] (C-6, C-10, C-14 and C-18), 79.8 (C-22), 155.8 (C-21), 170.0  
(C-19), [171.4-171.9] (C-7, C-11 and C-15).  
MS (MALDI+) m/z (%): 2236.3 (100) [C97H157N11O46,Na]+. 
FTIR (νmax/cm-1, ATR): 3383 (N-H st), 2980-2941 (C-H st), 2102 (N3 st), 1742 (C=O st 
ester), 1717 (C=O st carbamate), 1520 (N-H δ), 1475 (CH2, CH3 δ), 1367 (C-N st), 1250 
(CO-O st), 1155 (N-CO-O st), 1140 (O-C-C st). 
EA (%): Found: C. 53.4; H. 7.7; N, 6.9. Calc. for C97H157N11O46: C, 52.6; H, 7.15; N, 7.0.  
SEC: (ref PMMA): Mw 2469 g.mol-1;  Ð 1.02. 
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General procedure I) Bis-MPA(monomer)* (10.00 g, 53.1 mmol, 1.00 eq.); propargyl 
alcohol (3.23 mL, 55.8 mmol, 1.05 eq.); DPTS (6.24 g, 21.2 mmol, 0.40 eq.); DCC (10.96 
g, 53.1 mmol, 1.05 eq.), dry DCM (80 + 20 mL); time of reaction: overnight. The crude 
product was purified on silica gel (hexane:ethyl acetate = 7:3) to give a light grey oil 
(10.77 g, 90 %). 
1H (400 MHz, CDCl3) δ (ppm): 1.18 (s, 3H, H-6), 1.36 (s, 3H, H-9), 1.40 (d, 3H, H-9’), 2.46 
(t, J = 2.4 Hz, 1H, H-1), 3.63 (d, J = 12 Hz, 2H, H-7), 4.17 (d, J = 12 Hz, 2H, H-7’), 4.71  
(d, J = 2.4 Hz, 2H, H-3). 
13C (100 MHz, CDCl3) δ (ppm): 18.3 (C-6), 22.5 (C-9), 24.5 (C-9’), 41.8 (C-5), 52.3 (C-3), 
65.8 (C-7), 74.9 (C-1), 77.4 (C-2), 98.0 (C-8), 173.3 (C-4).  
MS (ESI+) m/z (%): 235.0 (13) [C11H16O4,Na]+, 213.0 (31) [C11H16O4,H]+.  
FTIR (νmax/cm-1, nujol): 3273 (≡C-H st), 2993 (C-H st), 2129 (C≡C st), 1739 (C=O st), 1456 
(CH2, CH3 δ). 
EA (%): Found: C, 61.6; H, 7.7. Calc. for C11H16O4: C, 62.3; H, 7.6. 
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General procedure II) ≡-[bisMPA,G1]-(ketal)1 (10.55 g, 49.71 mmol, 1.00 eq.); Dowex 
resin H+ (5.22 g, 50 %mass equivalent); MeOH (150 mL); time of reaction: 5 hours. The 
pure product was obtained as a colorless oil (8.47 g, 99 %).  
1H (400 MHz, CDCl3) δ (ppm): 1.09 (s, 3H, H-6), 2.50 (t, J = 2.4 Hz, 1H, H-1), 3.04 (bs,  
-OH), 3.71 (d, J = 10.6 Hz, 2H, H-7), 3.90 (d, J = 10.6 Hz, 2H, H-7’), 4.74 (d, J = 2.4 Hz, 2H, 
H-3). 
13C (100 MHz, CDCl3) δ (ppm): 17.0 (C-6), 49.3 (C-5), 52.4 (C-3), 67.6 (C-7), 75.2 (C-1), 
77.3 (C-2), 175.0 (C-4).  
MS (ESI+) m/z (%): 194.9 (100) [C8H12O4,Na]+.  
FTIR (νmax/cm-1, nujol): 3293 (O-H st), 2945 (C-H st), 2128 (C≡C st), 1730 (C=O st), 1461 
(CH2, CH3 δ).  
EA (%): Found: C, 55.4; H, 7.3; Calc. for C8H12O4: C, 55.8, H, 7.0. 
  
Chapter 7 
316 
≡-[bisMPA,G2]-(ketal)2 
O
O
O
O1
2 3
4 5
6
7
O
O
8 9
10
11
O
O
O
O
12
13
 
General procedure I) ≡-[bisMPA,G1]-(OH)2 (6.87 g, 38.7 mmol, 1.00 eq.); bis-
MPA(monomer)* (15.3 g, 81.3 mmol, 2.10 eq.); DPTS (9.11 g, 30.7 mmol, 0.80 eq.); 
DCC (16.77 g, 81.3 mmol, 2.10 eq.), dry DCM (160 + 40 mL); time of reaction: 
overnight. The crude product was purified on silica gel (hexane : ethyl acetate = 7:3) to 
obtain a white powder (18.57 g, 99 %).  
1H (300 MHz, CDCl3): δ 1.16 (s, 6H, H-10), 1.20 (s, 3H, H-6), 1.39 (s, 6H, H-13), 1.41  
(s, 6H, H-13’), 2.47 (t, J = 2.4 Hz, 1H, H-1), 3.62 (d, J = 12.3 Hz, 4H, H-11), 4.16 (d, J = 
12.0 Hz, 4H, H-11’), 4.33 (s, 4H, H-7), 4.72 (d, J = 2.4 Hz, 2H, H-3). 
13C (75 MHz, CDCl3): δ 17.6 (C-6), 18.5 (C-10), 22.2 (C-13), 24.9 (C-13’), 42.0 (C-9), 46.8 
(C-5), 52.6 (C-3), 65.2 (C-7), 65.9 (C-11), 75.2 (C-1), 77.2 (C-2), 98.1 (C-12), 171.8 (C-4), 
173.5 (C-8).  
MS (MALDI+) m/z (%): 507.2 (100) [C24H36O10,Na]+.  
FTIR (νmax/cm-1, nujol): 3249 (≡C-H st), 2923 (C-H st), 2121 (C≡C st), 1733 (C=O st), 1458 
(CH2, CH3 δ).  
EA (%): Found: C, 59.9; H, 8.1; Calc. for C24H36O10: C, 59.5; H, 7.5. 
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General procedure II) ≡-[bisMPA,G2]-(ketal)2 (17.17 g, 35.44 mmol, 1.00 eq.); ion 
exchange resin Dowex H+ (8.59 g, 50 %mass equivalent); MeOH (200 mL); time of 
reaction: 10 hours. The pure product was obtained as a white powder (13.03 g, 91 %). 
1H (400 MHz, CD3OD) δ (ppm): 1.15 (s, 6H, H-10), 1.31 (s, 3H, H-6), 2.96 (t, J = 2.4 Hz, 
1H, H-1), 3.64 (ABq, J = 11.2 Hz, ΔνAB = 25.3 Hz, 8H, H-11), 4.29 (ABq, J = 10.8 Hz, ΔνAB = 
9.8 Hz, 4H, H-7),  4.76 (d, J = 2.4 Hz, 2H, H-3). 
13C (100 MHz, CD3OD) δ (ppm): 17.3 (C-10), 18.1 (C-6), 40.5 (C-9), 47.9 (C-5), 51.8 (C-3), 
65.8 (C-11), 66.4 (C-7), 76.7 (C-1), 78.6 (C-2), 173.7 (C-4), 175.9 (C-8). 
MS (MALDI+) m/z (%): 427.2 (100) [C18H28O10,Na]+.  
FTIR (νmax/cm-1, nujol): 3403 (O-H st), 2923 (C-H st), 2125 (C≡C st), 1732 (C=O st), 1461 
(CH2, CH3 δ).  
EA (%): Found: C, 53.2; H, 7.45. Calc. for C18H28O10: C, 53.5; H, 7.0. 
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General procedure IV) ≡-[bisMPA,G1]-(OH)2 (3.00 g, 17.49 mmol, 1.00 eq.); stearic acid 
(14.93 g, 52.47 mmol, 3.00 eq.); DMAP (1.71 g, 13.99 mmol, 0.80 eq.); DCC (10.83 g, 
52.47 mmol, 4.00 eq.); dry DCM (120 + 30 mL); time of reaction: 2 days. The pure 
product was obtained as a white powder (7.73 g, 63%).  
1H (CDCl3, 300 MHz) δ (ppm): 0.88 (t, J = 6.3 Hz, 6H, H-12), 1.25 (m, 59H, H-6 and H-11), 
1.59 (m, 4H, H-10), 2.30 (t, J = 7.5 Hz, 4H, H-9), 2.45 (t, J = 2.1 Hz, 1H, H-1), 4.23 (ABq,  
J = 11.4 Hz, ΔνAB = 6.0 Hz, 4H, H-7), 4.71 (d, J = 2.1 Hz, 2H, H-3). 
13C (CDCl3, 75 MHz) δ (ppm): 14.1 (C-12), 17.7 (C-6), 22.7 (C-11), 24.9 (C-10), [29.1-
29.7] (C-11), 31.9 (C-11), 34.1 (C-9), 46.4 (C-5), 52.5 (C-3), 65.1 (C-7), 75.1 (C-1), 77.2 
(C-2), 172.1 (C-4), 173.2 (C-8). 
MS (MALDI+) m/z (%): 727.6 (100) [C44H80O6,Na]+. 
FTIR (νmax/cm-1, ATR): 3924 (≡C-H st), 2916 (C-H st), 2129 (C≡C st), 1734 (C=O st), 1473 
(CH2, CH3 δ), 1250 (CO-O st), 1132 (O-C-C st). 
EA: (%) Found: C, 75.5; H, 11.65. Calc. for C44H80O6: C, 74.95; H, 11.4. 
SEC: (ref PMMA): Mw 1211 g.mol-1;  Ð 1.02. 
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General procedure IV) ≡-[bisMPA,G2]-(OH)4 (1.50 g, 3.71 mmol, 1.00 eq.); stearic acid 
(6.33 g, 22.26 mmol, 6.00 eq.); DMAP (7.25 g, 5.94 mmol, 1.60 eq.); DCC (4.59 g, 22.27 
mmol, 6.00 eq.); dry DCM (90 + 10 mL). The pure product was obtained as a white 
powder (3.67 g, 67 %).  
1H (400 MHz, CDCl3) δ (ppm): 0.88 (t, J = 6.6 Hz, 12H, H-16), 1.25 (m, 121 H, H-6, H-10 
and H-15), 1.58 (m, 8H, H-14), 2.29 (t, J = 7.5 Hz, 8H, H-13), 2.50 (t, J = 2.4 Hz, 1H, H-1), 
4.19 (ABq, J = 10.5 Hz, ΔνAB = 6.8 Hz, 8H, H-11), 4.26 (ABq, J  = 8.1 Hz, ΔνAB = 12.0 Hz,  
H-7), 4.72 (d, J = 2.4 Hz, H-3). 
13C (100 MHz, CDCl3) δ (ppm): 14.1 (C-16), 17.4 (C-6), 17.8 (C-10), 22.7 (C-15), 24.8  
(C-14), [29.1-29.7] (C-15), 31.9 (C-15), 34.0 (C-13), 46.4 (C-9), 46.7 (C-5), 52.8 (C-3), 
65.0 (C-11), 65.6 (C-7), 75.4 (C-1), 77.1 (C-2), 171.4 (C-4), 172.0 (C-8), 173.1 (C-12).  
MS (MALDI+): m/z (%): 1492.4 (100) [C90H164O14,Na]+.  
FTIR (νmax/cm-1, ATR): 3292 (≡C-H st), 2916 (C-H st), 2141 (C≡C st), 1736 (C=O st), 1472 
(CH2, CH3 δ), 1236 (CO-O st), 1119 (O-C-C st).  
EA (%): Found: C, 74.0; H, 11.6. Calc. for C90H164O14: C, 73.5, H, 11.2.  
SEC: (ref PMMA): Mw 2428 g.mol-1;  Ð 1.02. 
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7.1.2- Bis-GMPA dendrons 
General procedure V): growing up amide coupling reaction of the bis-GMPA 
dendrons 
 
 Amine (1.00 mol) was dissolved into a mixture of dry dimethylformamide 
and dry dichloromethane. Bis-GMPA(monomer)* (1.20, 1.50 and 1.75 mol per 
amino groups according to the dendron generation), HOBt (1.20, 1.50 and 1.75 
mol per amino groups according to the dendron generation) and DMAP (1.4 mol 
per amino groups) were added to it. The reaction mixture was stirred under 
argon atmosphere and cooled down to 0ºC. DCC (1.20, 1.50 and 1.75 mol per 
amino groups according to the dendron generation) was dissolved into dry 
dichloromethane and was added drop wise to the reaction mixture. It was 
stirred at room temperature under argon atmosphere during 24 hours. The 
white precipitate, N,N’-dicyclohexylurea (DCU), was filtered off and the solvent 
was evaporated under vacuum to get an orange oil. Remaining DCU and HOBt 
were precipitated into a mixture of hexane and ethyl acetate and filtered off. 
The organic phase was washed 3 times with brine, dried over anhydrous MgSO4 
and the solvent were evaporated. Remaining HOBt was precipitated into cold 
AcOEt (-16ºC) and filtered off. The solvent was evaporated under reduce 
pressure. The crude product was purified on silica gel. In the case of the 3rd 
generation, the crude product was precipitate into a mixture of hexane and 
ethyl acetate before purification on silica gel. 
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General procedure VI): deprotection of the terminal amino groups 
 
 t-Boc protected dendron (1 mol) was dissolved into ethyl acetate. HCl 
into ethyl acetate (3M) was carefully added to it. The reaction mixture was 
stirred at room temperature during 1 hour. A white precipitate appeared. The 
reaction mixture was diluted into ethyl acetate and was stirred during another 
30 min. Then, it was stirred under vacuum to remove the hydrochloric acid. The 
white residue was recovered by centrifugation and was washed twice with pure 
ethyl acetate.  
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Bis-MPA (20.00 g, 149.2 mmol, 1.00 eq.) was dissolved into DMF (100 mL). KOH (10.20 
g, 179.0 mmol, 1.20 eq.) was added to it. The reaction was stirred at 100ºC during 1 
hour. Then, BnBr (26.55 mL, 223.7 mmol, 1.50 eq.) was added drop wise. The reaction 
mixture was stirred overnight at 100ºC. A white precipitate appeared. It was filtered 
off. Water (450 mL) was added to the filtrate and the product was extracted three 
times with ethyl acetate, (3 x 200 mL) and then washed three times with brine (3 x 150 
mL) to give a yellow oil. The crude product was recristalized into toluene to get white 
crystals (23.20 g, 69 %). 
 1H (400 MHz, CDCl3) δ (ppm): 1.02 (s, 3H, H-8), 2.82 (bs, -OH), 3.74 (d, J = 10.8 Hz, 2H, 
H-9), 3.94 (d, J= 11.2 Hz, 2H, H-9’), 5.21 (s, 2H, H-5), 7.36 (m, 5H, H-1, H-2 and H-3). 
13C (100 MHz, CDCl3) δ (ppm): 17.1 (C-8), 49.2 (C-7), 66.7 (C-5), 68.6 (C-9), 127.9 (C-3), 
128.3 (C-1), 128.6 (C-2), 135.6 (C-4), 175.7 (C-6). 
MS (ESI+) m/z (%): 246.8 (100) [C12H16O4,Na]+. 
FTIR (νmax/cm-1, nujol): 3352 (O-H st), 2923-2853 (C-H st and arC-H), 1701 (C=O st). 
EA (%): Found: C, 63.9; H, 7.3. Calc. for C12H16O4: C, 64.3; H, 7.2.  
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BnOOC-[bisMPA,G1]-(OH)2 (10.00 g, 44.62 mmol, 1.00 eq.) was dissolved into dry DCM 
(230 mL). Glyboc(OH) (19.54 g, 111.56 mmol, 2.50 eq.) and DPTS (10.51 g, 35.70 mmol, 
0.80 eq.) were added to it. The reaction mixture was stirred under argon atmosphere 
and cooled down to 0ºC. DCC (22.99 g, 111.56 mmol, 2.50 eq.) was dissolved into dry 
DCM (70 mL) and was added drop wise to the reaction mixture. The reaction mixture 
was stirred at room temperature overnight. The white precipitate, N,N’-
dicyclohexylurea (DCU), was filtered off and the solvent was evaporated under vacuum 
to get a mixture of oil and solid. DCU was newly precipitated into a mixture of hexane : 
ethyl acetate (10:2) (240 mL) and was filtered off. The solvents were evaporated under 
reduce pressure. The crude powder was purified on silica gel (hexane : ethyl acetate = 
8:2) to get a colorless oil (22.00 g, 92 %). 
1H (300 MHz, CDCl3) δ (ppm): 1.27 (s, 3H, H-8), 1.45 (s, 18 H, H-14), 3.81 (d, J = 4Hz, 4H, 
H-11), 4.31 (ABq, J = 10.8 Hz, ΔνAB = 22.4 Hz, 4H, H-9), 5.03 (bs, -NH), 5.17 (s, 2H, H-5), 
7.36 (m, 5H, H-1, H-2 and H-3). 
13C (75 MHz, CDCl3) δ (ppm): 17.9 (C-8), 28.3 (C-14), 42.2 (C-11), 46.3 (C-7), 65.8 (C-9), 
67.0 (C-5), 80.0 (C-13), 128.3 (C-3), 128.5 (C-1), 128.6 (C-2), 135.4 (C-4), 155.7 (C-12), 
169.9 (C-10), 172.1 (C-6). 
MS (ESI+) m/z (%): 561 (42) [C26H38N2O10,Na]+. 
FTIR (νmax/cm-1, ATR): 3379 (N-H st), 2980-2932 (C-H st and C-Har st), 1757 (C=O st 
aliphatic ester), 1720 (C=O st aromatic ester), 1690 (C=O st carbamate), 1512 (N-H δ), 
1456 (CH2, CH3 δ), 1365 (C-N st), 1250 (CO-O st), 1153 (N-CO-O st), 1132 (O-C-C st). 
EA (%): Found: C, 57.8; H, 7.2; N, 5.4. Calc. for C26H38N2O10: C, 58.0; H, 7.1; N, 5.2. 
  
Chapter 7 
324 
t-Boc protected Bis-GMPA(monomer), 
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BnOOC-[bisMPA,G1]-(NHBoc)2 (16.75 g, 31.10 mmol, 1.00 eq.) was dissolved into ethyl 
acetate (150 mL) under argon atmosphere. Pd/C (837 mg, 0.05 eq. in weight) was 
added carefully to the reaction mixture. Firstly, three cycles of argon - vacuum were 
made and secondly three cycles vaccum-H2 were made. The reaction mixture was 
stirred overnight under H2 pressure using a globe. Then, it was filtered on celite© with 
ethyl acetate flow. The solvent was evaporated under reduce pressure to give a 
colorless gel (13.39 g, 96 %). 
1H (400 MHz, CDCl3) δ (ppm): 1.26 (s, 3H, H-3), 1.43 (s, 18H, H-9), 3.89 (d, J = 5.6 Hz, 
4H, H-6), 4.32 (ABq, J = 11.2 Hz, ΔνAB = 23.7 Hz, 4H, H-4), 5.27 (bs, -NH). 
13C (100 MHz, CDCl3) δ (ppm): 17.9 (C-3), 28.3 (C-9), 42.2 (C-6), 45.9 (C-2), 65.8 (C-4), 
80.2 (C-8), 156.0 (C-7), 170.1 (C-5), 176.1 (C-1). 
MS (ESI+) m/z (%): 471 (100) [C19H32N2O10,Na]+. 
FTIR (νmax/cm-1, ATR): 3381 (N-H st), 2980-2937 (C-H st), 1745 (C=O st aliphatic ester), 
1699 (C=O st carbamate), 1522 (N-H δ), 1458 (CH2, CH3 δ), 1367 (C-N st), 1250 (CO-O 
st), 1151 (N-CO-O st), 1140 (O-C-C st). 
EA (%): Found: C, 50.6; H, 7.5; N, 5.9. Calc. for C19H32N2O10: C, 50.9; H, 7.2; N, 6.25. 
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General procedure III) N3-[bisMPA,G1]-(OH)2A (3,69 g, 14.2 mmol, 1.00 eq.); 
Glyboc(OH) (6.23 g, 35.6 mmol, 2.50 eq.); DPTS (3.35 g, 11.4 mmol, 0.80 eq.); DCC 
(7.33 g, 35.6 mmol, 2.50 eq.); dry DCM (85 + 15 mL); time of reaction: 24 hours. The 
crude product was purified on silica gel (hexane : ethyl acetate = 8:2) to get a colorless 
and viscous oil  (7.50 g, 92 %). 
A The synthesis of N3-[bisMPA,G1]-(OH)2 is described at page 307. 
1H (300 MHz, CDCl3) δ (ppm): 1.24 (s, 3H, H-9), 1.37 (m, 4H, H-3 and H-4), 1.44 (s, 18H, 
H-15), 1.60 (m, 2H, H-2), 1.64 (m, 2H, H-5), 3.27 (t, J = 6.8 Hz, 2H, H-1), 3.88 (d, J = 5.3 
Hz, 4H, H-12), 4.12 (t, J = 6.6Hz, 2H, H-6), 4.32 (ABq, J = 11.1 Hz and ΔνAB = 21.6 Hz, 4H, 
H-10), 5.08 (bs, -NH). 
13C (100 MHz, CDCl3) δ (ppm): 18.0 (C-9), 25.4 (C-4), 26.3 (C-3), 28.3 (C-5 and C-15), 
28.7 (C-2), 42.2 (C-12), 46.2 (C-8), 51.3 (C-1), 65.2 (C-6), 65.7 (C-10), 80.0 (C-14), 156.7 
(C-13), 170.0 (C-11), 172.4 (C-7). 
MS (ESI+) m/z (%): 596 (24) [C25H43N5O10,Na]+. 
FT-IR (cm-1, ATR): 3410-3339 (N-H st), 2984-2949-2872 (C-H st), 2093 (N3 st), 1771-
1757 (C=O st ester), 1722-1688 (C=O st carbamate), 1539-1510 (N-H δ), 1472 (CH2, CH3 
δ), 1367 (C-N st), 1228 (CO-O st), 1161 (N-CO-O st), 1128 (O-C-C st). 
EA (%): Found: C, 52.7; H, 7.6; N, 12.0. Calc. for C25H43N5O10: C, 52.35; H, 7.6; N, 12.2. 
SEC (ref PMMA): Mw 747 g.mol-1; Ð: 1.01. 
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N3-[bisGMPA,G1]-(NHBoc)2 (4.54 g, 7.91 mmol, 1.00 eq.) was dissolved into AcOEt (15 
mL). A dissolution of HCl 3M into AcOEt (15 mL) was added to it. It was stirred at room 
temperature during 4 hours. A precipitate appeared. AcOEt (100 mL) was added to the 
reaction mixture and it was stirred at room temperature for 1 hour more. Then, it was 
stirred under vacuum to remove HCl vapors. Ethyl acetate was removed under reduce 
pressure. The white precipitate was washed by being newly dispersed into ethyl 
acetate and stirred during 15 min. The ethyl acetate was evaporated under reduce 
pressure to give a white powder (2.67 g, 76 %). 
1H (400 MHz, CD3OD) δ (ppm): 1.31 (s, 3H, H-9), 1.43 (m, 4H, H-3 and H-4), 1.61 (m, 2H, 
H-2), 1.65 (m, 2H, H-5), 3.89 (s, 4H, H-12), 4.16 (t, J = 6.4 Hz, 2H, H-6), 4.45 (ABq, J = 
19.2 Hz, ΔνAB = 7.0 Hz, 4H, H-10). 
note: H-1 signal (~3.2 ppm) is overlapped with the CH3 signal of CD3OD but the 
correlation between H-1 and H-2 is observed in 1H-1H COSY and the correlation 
between H-1 and C-1 is observed in 1H-13C HSQC. 
13C (100 MHz, CD3OD): δ (ppm): 17.9 (C-9), 26.5 (C-4), 27.3 (C-3), 29.4 (C-5), 29.7 (C-2), 
40.9 (C-12), 47.5 (C-8), 52.3 (C-1), 66.6 (C-6), 67.7 (C-10), 168.3 (C-11), 173.8 (C-7). 
MS (ESI+) m/z (%): 374.1 (100) [C20H30N2O6,H]+. 
FTIR (νmax/cm-1, ATR): 3441-2505 (N-H+), 2943-2860-2702-2625 (C-H st), 2097 (N3 st), 
1744 (C=O st ester), 1605-1574 (N-H+ δ), 1466 (CH2, CH3 δ), 1420 (C-N st), 1224 (CO-O 
st), 1137 (O-C-C st). 
EA (%): Found: C, 40.1; H, 6.6; N, 14.2. Calc. for C15H29Cl2N5O6: C, 40.4; H, 6.55; N, 15.7. 
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General procedure V) N3-[bisGMPA,G1]-(NH3+Cl-)2 (3.59 g, 8.04 mmol, 1.00 eq.); Bis-
GMPA(monomer)* (7.96 g, 17.70 mmol, 2.20 eq.); HOBt,nH2O (2.71 g, 17.70 mmol, 
2.20 eq.); DMAP (2.42 g, 19.82 mmol, 2.80 eq.); DCC (3.65 g, 17.70 mmol, 2.20 eq.); dry 
DMF (40 mL); dry DCM (90 + 10 mL). The crude product was purified on silica gel 
(hexane : ethyl acetate = ramp from 5:5 to 2:8) to obtain a white powder (7.64 g,  
77 %).  
1H (400 MHz, CDCl3) δ (ppm): 1.27 (s, 3H, H-9), 1.29 (s, 6H, H-15), 1.41 (m, 4H, H-3 and 
H-4), 1.45 (m, 36H, H-21), 1.62 (m, 2H, H-2), 1.67 (m, 2H, H-5), 3.29 (t, 2H, J = 6.8Hz,  
H-1), 3.91 (d, J = 5.6Hz, 8H, H-18), 3.98 (d, J = 5.2Hz, 4H, H-12), 4.15 (t, J = 6.4 Hz, 2H, 
H-6), 4.17 (m, 2H, H-10), [4.17-4.38] (m, 10H, H-10’ and H-16), 5.29 (bs, -NHBoc), 7.08 
(bs, -NHCO). 
13C (100 MHz, CDCl3) δ (ppm): 17.8 (C-15), 18.1 (C-9), 25.4 (C-4), 26.3 (C-3), 28.3 (C-5 
and C-21), 28.7 (C-2), 41.0 (C-18), 42.4 (C-12), 46.1 (C-8), 46.3 (C-14), 51.3 (C-1), 64.9 
(C-16), 65.3 (C-10), 66.5 (C-6), 80.1 (C-20), 155.9 (C-19), 169.6 (C-17), 170.3 (C-11), 
172.5 (C-7), 172.8 (C-13). 
MS (MALDI+) m/z (%): 1256 (100) [C53H87N9O24,Na]+. 
FTIR (νmax/cm-1, ATR): 3379 (N-H st), 2980-2943-2864 (C-H st), 2098 (N3 st), 1742  
(C=O ester st), 1699 (C=O st carbamate), 1676 (C=O st amide), 1520 (N-H δ), 1458 (CH2, 
CH3 δ), 1367 (C-N st), 1246 (CO-O st), 1155 (N-CO-O st). 
EA (%): Found: C, 52.2; H, 7.5; N, 10.1. Calc. for C53H87N9O24: C, 51.6; H, 7.1; N, 10.2. 
SEC (ref PMMA): Mw 1581 g.mol-1; Ð: 1.02.  
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General procedure VI) N3-[bisGMPA,G2]-(NHBoc)4 (6.00 g, 2.58 mmol, 1.00 eq.); HCl 
3M into ethyl acetate (20 mL); ethyl acetate (10 mL). The pure product was obtained 
as a white powder (3.77 g, 81 %). 
1H (400 MHz, CD3OD) δ (ppm): 1.27 (s, 3H, H-9), 1.37 (s, 6H, H-15), 1.43 (m, 4H, H-3 
and H-4), 1.62 (m, 2H, H-2), 1.69 (m, 2H, H-5), 3.93 (m, 8H, H-18), 3.96 (m, 4H, H-12), 
4.16 (t, J = 6.8 Hz, 2H, H-6), 4.32 (ABq, J = 11.6 Hz, ΔνAB = 9.4 Hz, 4H, H-10), 4.45 (ABq,  
J = 11.2 Hz, 8H, H-16), 8.35 (bs, -NHCO). 
note: H-1 signal (~3.2 ppm) is overlapped with the CH3 signal of CD3OD but the 
correlation between H-1 and H-2 is observed in 1H-1H COSY and the correlation 
between H-1 and C-1 is observed in 1H-13C HSQC (see annexes 1). 
13C (100 MHz, CD3OD) δ (ppm): 17.8 (C-15), 18.1 (C-9), 26.5 (C-4), 27.3 (C-3), 29.4 (C-5), 
29.7 (C-2), 41.1 (C-18), 42.1 (C-12), 47.3 (C-14), 47.6 (C-8), 52.3 (C-1), 66.6 (C-6), 67.2 
(C-10), 68.5 (C-16), 168.2 (C-17), 170.9 (C-11), 174.0 (C-7), 174.9 (C-13).  
MS (MALDI+) m/z (%): 834.7 (100) [C33H55N9O16,H]+. 
FTIR (νmax/cm-1, ATR): 3222 (N-H st), 2941-2861 (C-H st and bs N-H+ st), 2098 (N3 st), 
1747 (C=O st ester), 1662 (C=O st amide and N-H+ δ), 1541 (N-H δ), 1478 (CH2, CH3 δ), 
1407 (C-N st), 1246 (CO-O st), 1138 (O-C-C st) . 
EA (%): Found: C, 39.9; H, 6.5; N, 12.9. Calc. for C33H59Cl4N9O16: C, 40.5; H, 6.1; N, 12.9. 
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General procedure V) N3-[bisGMPA,G2]-(NH3+Cl-)4 (2.00 g, 2.04 mmol, 1.00 eq.);  
Bis-GMPA(monomer)* (5.50 g, 12.25 mmol, 6.00 eq.); HOBt,nH2O (1.88 g, 12.25 mmol, 
6.00 eq.); DMAP (1.40 mg, 11.43 mmol, 5.60 eq.); DCC (2.53 g, 12.25 mmol, 6.00 eq.); 
dry DMF (33 mL); dry DCM (56 + 10 mL). The crude product was purified on silica gel 
(DCM : MeOH = 95:5) to obtain a white solid (3.88 g, 74 %).  
1H (400 MHz, CDCl3) δ (ppm): 1.25 (s, 6H, H-15), 1,26 (s, 3H, H-9), 1.28 (s, 12H, H-21), 
1.44 (m, 76H, H-3, H-4 and H-27), 1.61 (m, 2H, H-2), 1.66 (m, 2H, H-5), 3.27 (t, 2H,  
J = 6.8 Hz, H-1), 3.90 (d, J = 5.2 Hz, 16H, H-24), 3.95 (d, J = 5.2 Hz, 4H, H-12), 4.00 (d,  
J = 5.2 Hz, 8H, H-18), 4.13 (t, J = 6.4 Hz, 2H, H-6), [4.20-4.38] (m, 28H, H-10, H-16 and  
H-22), 5.42 (bs, -NHBoc), 7.19 (bs, -NHCO). 
13C (75 MHz, CDCl3) δ (ppm): 17.7 (C-21), 18.0 (C-15), 18.3 (C-9), 25.3 (C-4), 26.2 (C-3), 
28.3 (C-5 and C-27), 28.6 (C-2), 41.3 (C-24), 42.3 (C-12 and C-18), 46.0 (C-8 and C-14), 
46.1 (C-20), 51.2 (C-1), 65.2 (C-22), 66.4 (C-6, C-10 and C-16), 80.0 (C-26), 156.0 (C-25), 
170.6 (C-11, C-17 and C-23), 172.5 (C-7), 172.8 (C-13 and C-19). 
MS (MALDI+) m/z (%) : 2580 (100) [C109H175N17O52,Na]+. 
FTIR (νmax/cm-1, ATR): 3356 (N-H st), 2978-2928-2854 (C-H st), 2106 (N3 st), 1742-1718 
(C=O ester st), 1699 (C=O carbamate st), 1664 (C=O amide st), 1528 (N-H δ), 1458 (CH2, 
CH3 δ), 1367 (C-N st), 1250 (CO-O st), 1157 (N-CO-O st). 
EA (%): Found: C, 51.3; H, 7.3; N, 9.6. Calc. for C109H175N17O52: C, 51.2; H, 6.9; N, 9.3. 
SEC (ref PMMA): Mw 2966 g.mol-1; Ð: 1.02 
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General procedure VI) N3-[bisGMPA,G3]-(NHBoc)8 (1.50 g, 5.86x10-1 mmol, 1.00 eq.); 
HCl 3M into ethyl acetate (10 mL); ethyl acetate (5 mL). The pure product was 
obtained as a white powder was obtained (1.12 g, 93 %). 
1H (400 MHz, CD3OD) δ (ppm): 1.28 (s, 3H, H-9), 1.33 (s, 6H, H-15), 1.38 (s 12H, H-21), 
1.43 (m, 4H, H-3 and H-4), 1.62 (m, 2H, H-2), 1.69 (m, 2H, H-5), 3.93 (s, 16H, H-24), 3.97 
(s, 4H, H-12), 4.01 (s, 8H, H-18), 4.16 (t, J = 6.4 Hz, 2H, H-6), 4.32 (m, 12H, H-10 and  
H-16), 4.45 (ABq, 16H, H-22). 
note: H-1 signal (~3.2 ppm) is overlapped with the CH3 signal of CD3OD but the 
correlation between H-1 and H-2 is observed in 1H-1H COSY and the correlation 
between H-1 and C-1 is observed in 1H-13C HSQC.  
13C (100 MHz, CD3OD): δ 17.8 (C-21), 18.1 (C-9 and C-15), 26.6 (C-4), 27.4 (C-3), 29.4  
(C-5), 29.8 (C-2), 41.2 (C-24), 42.2 (C-12 and C-18), 47.4 (C-14 and C-20), 47.7 (C-8), 
52.4 (C-1), 66.5 (C-6), 67.2 (C-10), 67.8 (C-16), 68.5 (C-22), 168.3 (C-23), 170.8 (C-11), 
171.1 (C-17), 174.1 (C-7), 175.0 (C-19), 175.2 (C-13). 
MS (MADLI+, DHB) m/z (%): 1775.2 (100) [C69H111N17O36,Na]+. 
FTIR (νmax/cm-1, ATR): 3342 (N-H st), 2984-2928 (C-H and bs N-H+), 2091 (N3 st), 1755 
(C=O st ester), 1659 (C=O st amide and N-H+ δ), 1541 (N-H δ), 1475 (CH2, CH3 δ), 1406 
(C-N st), 1236 (νas CO-O), 1171 (O-C-C st). 
EA (%): Found: C, 39.7; H, 6.5; N, 11.5. Calc. for C69H119Cl8N17O36: C, 40.5; H, 5.9; N, 
11.6. 
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General procedure V) N3 -[bisGMPA,G3]-(NH3+,Cl-)8 (1.02 g, 4.99x10-1 mmol, 1.00 eq.); 
Bis-GMPA(monomer)* (3.14 g, 6.92 mmol, 14.00 eq.); HOBt,nH2O (1.07 g, 6.92 mmol, 
14.00 eq.); DMAP (878 mg, 7.19 mmol, 14.4 eq.); DCC (1.44 g, 6.92 mmol, 14.00 eq.); 
dry DMF (7 mL); dry DCM (63 mL) The crude product was dissolved in ethyl acetate (30 
mL) and hexane (70 mL) was added slowly under agitation until the formation of a gel. 
This operation was repeated twice. Then, it was purified on silica gel (DCM : MeOH = 
ramp from 95:5 to 9:1) to obtain a white solid (2.29 g, 88 %).  
1H (400 MHz, CDCl3) δ (ppm): [1.24-1.28] (m, 45H, H-9, H-15, H-21 and H-27) 1.45 (s, 
148H, H-3, H-4 and H-33), 1.61 (m, 4H, H-2 and H-5), 3.27 (t, 2H, J = 7.2 Hz, H-1), 3.88 
(m, 32H, H-30), 3.98 (m, 28H, H-12, H-18 and H-24), 4.11 (t, J = 6.4 Hz, 2H, H-6), [4.20-
4.45] (m, 60H, H-10, H-16, H-22 and H-28), 5.55 (bs, -NHBoc), 7.38 (bs, -NHCO). 
13C (100 MHz, CDCl3) δ (ppm): [17.7-18.0] (C-9, C-15, C-21 and C-27), 25.3 (C-4), 26.3 
(C-3), 28.3 (C-5 and C-33), 28.3 (C-2), 41.3 (C-30), 42.3 (C-12, C-18 and C-24), [46.0-
46.1] (C-8, C-14, C-20 and C-26), 51.3 (C-1), 65.3 (C-28), [66.3-66.5] (C-6, C-10, C-16 and 
C-22), 80.0 (C-32), 156.1 (C-31), 169.6 (C-29), [170.2-170.3] (C-11, C-17 and C-23), 
172.6 (C-7),  [172.9-173.2] (C-13, C-19 and C-25). 
MS (MALDI+, DCTB) m/z (%): 5220.2 (100) [C221H351N33O108,Na]+. 
FTIR (νmax/cm-1, ATR): 3362 (N-H st), 2978-2930-2852 (C-H st), 2098 (N3 st), 1749 (C=O 
st ester), 1695 (C=O st carbamate), 1668 (C=O st amide), 1520 (N-H δ), 1456 (CH2, CH3 
δ), 1367 (C-N st), 1284 (CO-O st), 1155 (N-CO-O st). 
EA (%): Found: C, 52.2; H, 7.1; N, 8.8. Calc. for C221H351N33O108: C, 51.1; H, 6.8; N, 8.9. 
SEC (ref PMMA): Mw 4463 g.mol-1; Ð: 1.04. 
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General procedure VI) N3-[bisGMPA,G4]-(NHBoc)16 (708 mg, 1.36x10-1 mmol, 1.00 eq.); 
HCl 3M into ethyl acetate (10 mL); ethyl acetate (5 mL). The pure product was 
obtained as a white powder (506 mg, 89 %). 
1H (400 MHz, CD3OD) δ (ppm): 1.23 (s, 3H, H-9), 1.28 (s, 6H, H-15), 1.33 (s, 12H, H-21) 
1.38 (s, 24H, H-27), 1.43 (m, 4H, H-3 and H-4), 1.62 (m, 2H, H-2), 1.69 (m, 2H, H-5), 3.95 
(s, 32H, H-30), 4.01 (m, 28H, H-12, H-18 and H-24), 4.16 (t, J = 6.4 Hz, 2H, H-6), 4.33 (m, 
28H, H-10, H-16 and H-22), 4.46 (m, 32H, H-28), 8.35 (bs, -NHCO). 
note: H-1 signal (~3.2 ppm) is overlapped with the CH3 signal of CD3OD but the 
correlation between H-1 and H-2 is observed in 1H-1H COSY and the correlation 
between H-1 and C-1 is observed in 1H-13C HSQC.  
13C (100 MHz, CD3OD) δ (ppm): [17-9-18.2] (C-9, C-15, C-21 and C-27), 26.6 (C-4), 27.4 
(C-3), 29.4 (C-5), 29.8 (C-2), 41.2 (C-30), 42.2 (C-12, C-18 and C-24), [47.3-47.7] (C-8,  
C-14, C-20 and C-26), 52.4 (C-1), 66.4 (C-6), [67.2-67.9] (C-10, C-16 and C-22), 68.5  
(C-28), 168.3 (C-29), [170.8-171.3] (C-11, C-17 and C-23), 174.2 (C-7), [174.9-175.3]  
(C-13, C-19 and C-25). 
FTIR (νmax/cm-1, ATR): 3318 (N-H st), 2986-2883-2615 (C-H and bs N-H+), 2102 (N3 st), 
1744 (C=O ester st), 1655 (C=O st amide and N-H+ δ), 1539 (N-H st), 1479 (CH2, CH3 δ), 
1410 (C-N st), 1230 (CO-O st), 1176 (O-C-C st). 
EA (%): Found: C, 39.4; H, 6.5; N, 10.7. Calc. for C141H239Cl16N33O76: C, 40.5; H, 5.8; N, 
11.1. 
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7.1.3- Amphiphilic dendritic derivatives for 
camptothecin delivery 
 
7.1.3.1- Amphiphilic Janus dendrimers 
General procedure VII): copper(I) azide-alkyne cyloaddition reaction (CuAAC) 
for the synthesis of the Janus dendrimers 
 
 Pre-hydrophilic azido-dendron (1.00 mol) and lipophilic alkyno-dendron 
(1.20 or 1.50 mol) were dissolved into dimethylformamide (7 mL) in a Schlenk 
flask. 3 cycles vacuum-argon were made to remove O2. The reaction mixture 
was allowed to stir under argon atmosphere at 45ºC. CuSO45.H2O (0.1 mol), L-
ascorbate (0.2 mol) and TBTA (0.1 mol) were dissolved into DMF (3 mL) in a 
second Schlenk flask. 3 cycles vacuum-Argon were made in order to remove O2 
and the copper solution was stirred at 45ºC during 15 min. Then, it was added 
through a cannula to the previous azide-alkyne reaction mixture. The reaction 
mixture was stirred at 45ºC during 2 days. Then, brine was added (100 mL) and 
the product was extracted 2 times with ethyl acetate (2 x 70 mL). The organic 
phase was washed three times with brine (3 x 100 mL), once with a KCN 
aqueous solution (15 mg into 100 mL of water) and twice with brine (2 x 100 
mL), dried over anhydrous MgSO4 and the solvent was evaporated under reduce 
pressure. Finally, the crude product was purified on silica gel (refer to the 
product to see the solvents that were employed and their proportions.  
 The t-Boc protective groups were removed according to the general 
procedure VI) (see page 321). 
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General procedure VII) N3-[bisMPA,G2]-(NHBoc)4 (1,531 g, 1.36 mmol, 1.00 eq.);  
≡-[bisMPA,G1]-(C17)2 (1,439 g, 2.04 mmol, 1.50 eq.); CuSO4, 5H2O (34 mg, 0.12 mmol, 
0.10 eq), (L)-ascorbate (46 mg, 0.23 mmol, 0.20 eq.), TBTA (61mg, 0.12 mmol, 0,10 
eq.). The crude product was purified on silica gel (hexane : ethyl acetate = ramp from 
7:3 to 5:5) to give a white solid (1.896 g, 76 %). 
1H (300 MHz, CDCl3) δ (ppm): 0.89 (t, J = 6Hz, 6H, H-31), 1.27 (m, 70H, H-8, H-12, H-17, 
H-25 and H-30), 1.43 (m, 2H, H-16), 1.46 (s, 36H, H-1), 1.58 (m, 4H, H-29), 1.67 (m, 2H, 
H-15), 1.96 (m, 2H, H-18), 2.27 (t, J = 7.8 Hz, 4H, H-28), 3.91 (d, J = 5.7 Hz, 8H, H-4), 
4.13 (t, J = 6.6 Hz, 2H, H-14), 4.25 (m, 16H, H-6, H-10 and H-26), 4.38 (t, J = 7.2 Hz, 2H, 
H-19), 5.24 (s, 2H, H-22), 5.28 (bs, -NHBoc), 7.63 (s, 1H, H-20). 
13C (100 MHz, CDCl3) δ (ppm): 14.1 (C-31), [17.7-17.9] (C-8, C-12 and C-25), 22.7 (C-30), 
24.9 (C-29), 25.3 (C-17), 26.1 (C-16), 28.3 (C-1 and C-15), [29.1-29.7] (C-30), 30.1 (C-18), 
31.9 (C-30), 34.1 (C-28), 42.3 (C-4), 46.3 (C-24), 46.4 (C-11), 46.6 (C-7), 50.2 (C-19), 58.4 
(C-22), 65.0 (C-26), 65.4 (C-10), 65.6 (C-14), 65.7 (C-6), 80.0 (C-2), 123.7 (C-20), 142.4 
(C-21), 155.8 (C-3), 170.1 (C-5), [172.2-172.8] (C-9, C-13 and C-23), 173.3 (C-27). 
MS (MALDI+) m/z (%):  1848.1 (100) [C93H161N7O28,Na]+. 
FTIR (νmax/cm-1, ATR): 3393 (N-H st), 2978-2918-2851 (C-H st), 1738 (C=O st ester), 
1724 (C=O st carbamate), 1514 (N-H δ), 1468 (CH2-, CH3 δ), 1367 (C-N st), 1250  
(CO-O st as), 1155 (N-CO-O st), 1130 (O-C-C st). 
EA (%): Found C. 60.92; H. 8.43; N. 5.34. Calcd for C93H161N7O28: C. 61.20; H. 8.89;  
N. 5.37.  
SEC (ref PMMA): Mw 2702 g.mol-1; Ð: 1.02. 
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General procedure VII) N3-[3G]-(glyBoc)8 (1.200 g, 5.67x10-1 mmol, 1.00 eq.);  
≡-[1G]-(C17) (600 mg, 8.51x10-1 mmol, 1.00 eq.); CuSO4, 5H2O (16.7 mg, 5.67x10-2 
mmol, 0.10 eq); (L)-ascorbate (22.5 mg, 1.13x10-1 mmol, 0.20 eq.); TBTA (30.1 mg, 
5.67x10-2 mmol, 0.10 eq.); dry DMF (10 mL). The crude product was purified on silica 
gel (hexane : ethyl acetate = ramp from 6:4 to 4:6) to give a white solid (1.344 g, 81 %). 
1H (400 MHz, CDCl3) δ (ppm):0.87 (t, J = 6Hz, 6H, H-35), 1.27 (m, 80H, H-8, H-12, H-16, 
H-29 and H-34), 1.43 (m, 76H, H-1, H-20 and H-21), 1.56 (m, 4H, H-33), 1.69 (m, 2H,  
H-19), 1.96 (m, 2H, H-22), 2.25 (t, J = 7.8 Hz, 4H, H-32), 3.91 (d, J = 5.7 Hz, 16H, H-4), 
4.13 (t, J = 6.6 Hz, 2H, H-18), 4.25 (m, 32H, H-6, H-10, H-14 and H-30), 4.36 (t, J = 7.2 
Hz, 2H, H-23), 5.25 (s, 2H, H-26), 5.27 (bs, -NHBoc), 7.62 (s, 1H, H-24). 
13C (100 MHz, CDCl3) δ (ppm): 14.1 (C-35), [17.5 - 17.9] (C-8, C-12, C-16 and C-29), 22.6 
(C-34), 24.8 (C-33), 25.3 (C-21), 26.1 (C-20), 28.3 (C-1 and C-19), [29.1-29.7] (C-34), 30.1 
(C-22), 31.9 (C-34), 31.9 (C-32), 42.2 (C-4), [46.3-46.7] (C-7, C-11, C-15 and C-28), 50.3 
(C-23), 58.3 (C-26), 65.0 (C-30), 65.4 (C-10 and C-14), 65.6 (C-6), 66.1 (C-18), 79.9 (C-2), 
123.8 (C-24), 142.2 (C-25), 155.9 (C-3), 170.1 (C-5), [171.5-172.8] (C-9, C-13, C-17 and 
C-27), 173.2 (C-31).  
MS (MALDI+) m/z (%): 2939.1 (100) [C141H237N11O52,Na]+.  
FTIR (νmax/cm-1, ATR): 3373 (N-H st), 2980-2926-2854 (C-H st), 1738 (C=O st ester), 
1720 (C=O st carbamate), 1516 (N-H δ), 1464 (CH2, CH3 δ), 1367 (C-N st), 1232  
(CO-O st as), 1151 (N-CO-O st), 1132 (O-C-C st). 
EA (%): Found C. 57.90; H. 8.02; N. 5.27; Calcd for C141H237N11O52: C. 58.03; H. 8.19;  
N. 5.28. 
SEC (ref PMMA): Mw 3653 g.mol-1; Ð: 1.02. 
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General procedure VII) N3-[bisMPA,G2]-(NHBoc)4 (1.027 g, 9.24x10-1 mmol, 1.00 eq.); 
≡-[bisMPA,G2]-(C17)4 (1.630 g, 1.10 mmol, 1.20 eq.); CuSO4,5H2O (27 mg, 9.24x10-2 
mmol, 0.10 eq); (L)-ascorbate (37 mg, 1.85x10-1 mmol, 0.20 eq.) and TBTA (49 mg, 
9.24x10-2 mmol, 0.10 eq.) into dry DMF (10 mL). The crude product was purified on 
silica gel (hexane : ethyl acetate; ramp from 8:2 to 6:4) to give a white solid (1.641 g, 
69 %). 
1H (CDCl3, 300 MHz) δ (ppm): 0.88 (t, J = 6.3 Hz, 12H, H-35), 1.24 (m, 130H, H-8, H-12, 
H-25, H-29 and H-34), 1.39 (m, 4H, H-16 and H-17), 1.44 (s, 36H, H-1), 1.57 (m, 8H, H-
33), 1.65 (m, 2H, H-15), 1.93 (m, 2H, H-18), 2.28 (t, J = 7.5 Hz, 8H, H-32), 3.89 (d, J = 5.7 
Hz, 8H, H-4), 4.07 – 4.31 (m, 26H, H-6, H-10, H-14, H-26 and H-30), 4.37 (t, J = 7.2 Hz, 
2H, H-19), 5.24 (s, 2H, H-22), 5.25 (bs, -NHBoc), 7.69 (s, 1H, H-20). 
13C (CDCl3, 100 MHz) δ (ppm): 14.1 (C-35), 17.5 (C-29), [17.7-17.9] (C-8, C-12 and C-25), 
22.7 (C-34), 24.8 (C-33), 25.2 (C-17), 26.1 (C-16), 28.3 (C-1 and C-15), [29.1-29.7] (C-34), 
30.1 (C-18), 31.9 (C-34), 34.0 (C-32), 42.3 (C-4), 46.4 (C-28), 46.4 (C-7), 46.6 (C-24), 46.6 
(C-11), 50.2 (C-19), 58.4 (C-22), [64.9 – 65.7] (C-6, C-10, C-14, C-26 and C-30), 79.9 (C-
2), 124.0 (C-20), 142.0 (C-21), 155.8 (C-3), [170.0-172.2] (C-5, C-9, C-13, C-23 and C-27), 
173.2 (C-31).  
MS (MALDI+) m/z (%): 2612.8 (100) [C139H245N7O36,Na]+. 
FTIR (νmax/cm-1, ATR): 3404 (N-H st), 2960-2918-2851 (C-H st), 1740 (C=O st ester), 
1707 (C=O st carbamate), 1524 (N-H δ), 1470 (CH2, -CH3 δ), 1367 (C-N st), 1252 (CO-O 
st as), 1159 (N-CO-O st), 1140 (O-C-C st). 
EA: Found C, 64.54; H, 9.54; N, 3.78; Calcd for C139H245N7O36: C. 64.45; H. 9.53; N. 3.78.  
SEC (ref PMMA): Mw 3743 g.mol-1; Ð: 1.02. 
  
Experimental part 
337 
(NHBoc)8[bisMPA,G3]-[bisMPA,G2](C17)4 
O
O
O
O
O
N
N N
O
O
O
O
OO
O
O
OO
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
NH
BocHN
BocHN
BocHN
BocHN
BocHN
BocHNc
BocHN
O
O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24 25
26
27 28
29
30
31
33 34
35
O
O
O
O
O
O
O
O
(CH2)14
(CH2)14
(CH2)14
(CH2)14
32
36
37
38 39
 
General procedure VII) N3-[bisMPA,G3]-(NHBoc)8 (960 mg, 0.45 mmol, 1.00 eq.);  
≡-[bisMPA,G2]-(C17) (1000 mg, 0.68 mmol, 1.50 eq.); CuSO4,5H2O (13.36 mg, 4.5x10-1 
mmol, 0.10 eq.); (L)-ascorbate (17.97 mg, 9.0x10-1 mmol, 0.20 eq.) and TBTA (24.05 
mg, 4.5x10-1 mmol,0.10 eq.) into DMF (10 mL). The crude product was purified on silica 
gel (hexane : ethyl acetate = ramp from 8:2 to 5:5) to give a white solid (1.604 g, 92 %). 
1H (300 MHz, CDCl3) δ (ppm): 0.87 (t, J = 8.0 Hz, 12H, H-39), 1.24 (m, 142H, H-8, H-12, 
H-16, H-29, H-33 and H-38), 1.43 (m, 76H, H-1, H-20 and H-21), 1.57 (m, 8H, H-37), 1.67 
(m, 2H, H-19), 1.93 (m, 2H, H-22), 2.28 (t, J = 6.0 Hz, 8H, H-36), 3.88 (d, J = 4.0 Hz, 16H, 
H-4), [4.13-4.25] (m, 42H, H-6, H-10, H-14, H-18, H-30 and H-34), 4.36 (t, J = 6.9 Hz, 2H, 
H-23), 5.23 (s, 2H, H-26), 5.36 (bs, -NHBoc), 7.68 (s, 1H, H-24). 
13C (75 MHz, CDCl3) δ (ppm): 14.1 (C-39), [17.5-17.8] (C-8, C-12, C-16, C-29 and C-33), 
22.6 (C-38), 24.8 (C-37), 25.3 (C-21), 26.1 (C-20), 28.3 (C-1 and C-22), [29.1 - 29.7]  
(C-38), 30.1 (C-19), 31.9 (C-38), 34.0 (C-36), 42.2 (C-4), [46.3-46.7] (C-7, C-11, C-15,  
C-28 and C-32), 50.2 (C-23), 58.4 (C-26), [64.9 - 66.0] (C-6, C-10, C-14, C-18, C-30 and  
C-34), 79.9 (C-2), 124.1 (C-24), 141.9 (C-25), 155.9 (C-3), [170.1-172.1] (C-5, C-9, C-13, 
C-17, C-27 and C-31), 173.2 (C-35).  
MS (MALDI+) m/z (%): 3706.5 (100) [C187H321N11O60,Na]+.  
FTIR (νmax/cm-1, ATR): 3391 (N-H st), 2978-2918-2849 (C-H st), 1740 (C=O st ester), 
1724 (C=O st carbamate), 1516 (N-H δ), 1468 (δ-CH2-, δas -CH3), 1367 (C-N st), 1250 
(CO-O st as), 1155 (N-CO-O st), 1142 (O-C-C st).  
EA (%): Found C, 60.95; H, 8.64; N, 4.17; Calcd for C187H321N11O60: C, 60.97; H, 8.78;  
N, 4.18.  
SEC (ref PMMA): Mw 4590 g.mol-1; Ð: 1.02. 
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General procedure VII) N3-[bisGMPA,G2]-(NHBoc)4 (1000 mg, 8.10x10-1 mmol, 1.00 
eq.); ≡-[bisMPA,G1]-(C17)2 (686 mg, 9.72x10-1 mmol, 1.20 eq.), CuSO4,5H2O (20.23 mg, 
8.10x10-2 mmol, 0.10 eq.); (L)-ascorbate (32.11 mg, 1.62x10-2 mmol, 0.20 eq.) and 
TBTA (42.97 mg, 8.10x10-2 mmol, 0.10 eq.) into dry DMF (10 mL). The crude product 
was purified on silica gel (DCM : MeOH = ramp from 98:2 to 95:5) to give a yellow solid 
(1193 mg, 76 %). 
1H (400 MHz, CDCl3) δ (ppm): 0.86 (t, J = 6.8Hz, 6H, H-33), 1.20 (s, 3H, H-27), 1.23 (m, 
59H, H-14 and H-32), 1.27 (s, 6H, H-8), 1.35 (m, 4H, H-18 and H-19), 1.42 (s, 36H, H-1), 
1.54 (m, 4H, H-31), 1.63 (m, 2H, H-17), 1.92 (m, 2H, H-20), 2.23 (t, J = 7.6 Hz, 4H, H-30), 
3.91 (d, J 0 5.6 Hz, 8H, H-4), 3.96 (d, J = 4.8 Hz, 4H, H-10), 4.11 (t, J = 6.4 Hz, 2H, H-16), 
4.19 (ABq, J = 11.2 Hz, ΔνAB = 18.5 Hz, 4H, H-28), [4.24-4.39] (m, 14H, H-4, H-12 and H-
21), 5.23 (s, 2H, H-24), 5.27 (bs, -NHBoc), 7.10 (bs, -NHCO), 7.59 (s, 1H, H-22).  
13C (100 MHz, CDCl3) δ (ppm): 14.1 (C-33), [17.7-17.9] (C-8, C-14 and C-27), 22.7 (C-32), 
24.9 (C-31), 25.3 (C-18), 26.1 (C-19), 28.3 (C-1 and C-17), [29.1-29.7] (C-32), 30.1 (C-20), 
31.9 (C-32), 34.1 (C-30), 41.1 (C-10), 42.4 (C-4), [46.1-46.3] (C-7, C-13 and C-26), 50.2 
(C-21), 58.4 (C-24), [65.0-65,7] (C-6, C-12, C-16 and C-28), 80.1 (C-2), 123.7 (C-22), 
142.4 (C-23), 155.9 (C-3), 170.3 (C-5), [172.5-173.2] (C-9, C-11, C-15, C-25 and C-29). 
MS (MALDI+) m/z (%): 1962.3 (100) [C97H167N9O30,Na]+.  
FTIR (νmax/cm-1, ATR): 3366 (N-H st), 2980-2916-2851 (C-H st), 1744 (C=O st ester), 
1717 (C=O st carbamate), 1664 (C=O st amide), 1528 (N-H δ), 1468 (CH2, CH3 δ), 1367 
(C-N st), 1254 (CO-O st), 1157 (N-CO-O st). 
EA: Found C. 61.3; H. 9.4; N. 6.8; Calcd for C97H167N9O30: C. 60.1; H. 8.7; N. 6.5. 
SEC (ref PMMA): Mw 2718 g.mol-1; Ð: 1.02. 
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General procedure VII) N3-[bisGMPA,G3]-(NHBoc)8 (600 mg, 2.35x10-1 mmol, 1.00 eq.); 
≡-[bisMPA,G1]-(C17)2 (199 mg, 2.82x10-1 mmol, 1.20 eq.), CuSO4,5H2O (6.92 mg, 
2.35x10-2 mmol, 0.10 eq.); (L)-ascorbate (9.30 mg, 4.69x10-2 mmol, 0.20 eq.) and TBTA 
(12.45 mg, 2.35x10-2 mmol, 0.10 eq.) into dry DMF (10 mL). The crude product was 
purified on silica gel (DCM : MeOH = ramp from 95:5 to 90:1) to give a yellow solid 
(646 mg, 84 %).  
1H (400 MHz, CD2Cl2) δ (ppm): 0.87 (t, J = 8.0 Hz, 6H, H-39), 1.21 (s, 3H, H-33), 1.26 (m, 
65H, H-14, H-20 and H-38), 1.28 (s, 12H, H-8), 1.37 (m, 4-H, H-24 and H-25), 1.42 (s, 
72H, H-1), 1.54 (m, 8H, H-37), 1.64 (m, 2H, H-22), 1.91 (m, 2H, H-27), 2.24 (t, J = 7.6 Hz, 
4H, H-36), 3.88 (d, J = 6.0 Hz, 16H, H-4), 3.95 (d, J = 5.6 Hz, 4H, H-16), 4.00 (d, J= 5.2 Hz, 
8H, H-10), 4.11 (t, J = 6.4 Hz, 2H, H-22), 4.18 (ABq, J = 10.8 Hz, ΔνAB = 19.7 Hz, 4H, H-
34). [4.21-4.37] (m, 30H, H-6, H-12, H-18 and H-22), 5.22 (s, 2H, H-30), 5.46 (bs, -
NHBoc), 7.10 (bs, -NHCO), 7.62 (s, 1H, H-28). 
13C (100 MHz, CD2Cl2) δ (ppm): 14.5 (C-39), [18.1-18.7] (C-8, C-14, C-20 and C-33), 23.3 
(C-38), 25.4 (C-37), 25.8 (C-24), 26.6 (C-25), 28.6 (C-1), 28.8 (C-23), [29.7-30.3] (C-38), 
30.6 (C-26), 32.5 (C-38), 34.5 (C-36), [41.8-41.9] (C-10 and C-16), 42.9 (C-4), [46.6-46.8] 
(C-7, C-13 and C-19), 47.7 (C-32), 50.8 (C-1), 58.9 (C-30), [65.3-67.1] (C-6, C-12, C-18, C-
22 and C-34), 80.3 (C-2), 124.3 (C-28), 142.9 (C-29), 156.6 (C-3), [170.1-170.2] (C-11 
and C-17),170.8 (C-5), 173.1 (C-21), [173-2-173.6] (C-9, C.15 and C-35).  
FTIR (νmax/cm-1, ATR): 3360 (N-H st), 2980-2928-2854 (C-H st), 1747 (C=O st ester), 
1713 (C=O st carbamate), 1670 (C=O st amide), 1518 (N-H δ), 1466 (CH2, CH3 δ), 1367 
(C-N st), 1250 (CO-O st), 1157 (N-CO-O st). 
EA: Found C. 57.0; H. 8.5; N. 7.7; Calcd for C153H255N17O58: C. 56.4; H. 7.9; N. 7.3. 
SEC (ref PMMA): Mw 4056 g.mol-1; Ð: 1.02  
Chapter 7 
340 
(NHBoc)8[bisGMPA,G3]-[bisMPA,G2](C17)4 
O
N N
NHBoc
O
BocHN
O
O
O
O
NH
O
O N
H
BocHN
O
O
O
O O
NH
O
BocHN
O
BocHN
O
O
O
O
NH
O
O
O
O
N
H O
BocHN
BocHN
O
O
O
O
O
N
H O
O
O
O
O
NH
O
O
O
O
O
N O
O
O
O
OO
O
O
O
O
O
O
O
1
2
3 4 5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27 28 29 30
3132
33
34 3536
37
38
39
40
41 42 43
(CH2)14
(CH2)14
(CH2)14
(CH2)14
 
General procedure VII) N3-[bisGMPA,G3]-(NHBoc)8 (1000 mg, 3.91x10-1 mmol, 1.00 
eq.); ≡-[bisMPA,G2]-(C17)4 (690 mg, 4.69x10-1 mmol, 1.20 eq.), CuSO4,5H2O (11.53 mg, 
3.91x10-2 mmol, 0.10 eq.); (L)-ascorbate (15.50 mg, 7.82x10-2 mmol, 0.20 eq.) and 
TBTA (20.75 mg, 3.91x10-2 mmol, 0.10 eq.) into dry DMF (10 mL). The crude product 
was purified on silica gel (DCM : MeOH = ramp from 98:2 to 95:5) to give a yellow solid 
(1070 mg, 68 %).  
1H (CDCl3, 400 MHz) δ (ppm): 0.86 (t, J = 6.4 Hz, 12H, H-43), [1.16-1.26] (m, 130H, H-14, 
H-20, H-33, H-37 and H-42), 1.27 (s, 12H, H-8), 1.37 (m, 4H, H-24 and H-25), 1.44 (s, 
72H, H-1), 1.56 (m, 8H, H-41), 1.63 (m, 2H, H-23), 1.92 (m, 2H, H-26), 2.27 (t, J = 7.6 Hz, 
8H, H-40), 3.88 (d, J = 5.6 Hz, 16H, H-4), 3.94 (d, J = 5.2 Hz, 4H, H-16), 3.98 (d, J = 5.2 Hz, 
8H, H-10), 4.11 (t, J = 6.0 Hz, 2H, H-22), 4.12 (ABq, J = 11.2 Hz, ΔνAB = 9.8 Hz, 8H, H-38), 
[4.19-4.37] (m, 34H, H-6, H-12, H-18, H-27 and H-34), 5.22 (s, 2H, H-30), 5.25 (bs, -
NHBoc), 7.19 (bs, -NHCO), 7.67 (s, 1H, H-28). 
13C (CDCl3, 100 MHz) δ (ppm): 14.1 (C-43), [17.7 -18.3] (C-8, C-14, C-20, C-33 and C-37), 
22.7 (C-42), 24.8 (C-41), 25.2 (C-24), 26.0 (C-25), 28.3 (C-1 and C-23), [29.1-29.7] (C-42), 
30.1 (C-28), 31.9 (C-42), 34.0 (C-40), [41.2-41.3] (C-10 and C-16), 42.3 (C-4), [46.0-46.6] 
(C-7, C-13, C-19, C-32 and C-36), 50.1 (C-27), 58.4 (C-30), [64.9-66.7] (C-6, C-12, C-18, C-
22, C-34 and C-38), 80.0 (C-2), 124.1 (C-28), 141.9 (C-29), 156.0 (C-3), [169.5-173.1] (C-
5, C-9, C-11, C-15, C-17, C-21, C-31, C-35 and C-39). 
MS (MALDI+) m/z (%): 4046-4067 (100) [C199H339N17O66,Na]+. 
FTIR (νmax/cm-1, ATR): 3362 (N-H st), 2976-2918-2851 (C-H st), 1744 (C=O st ester), 
1717 (C=O st carbamate), 1663 (C=O st amide), 1526 (N-H δ), 1470 (CH2, CH3 δ), 1367 
(C-N st), 1252 (CO-O st), 1159 (N-CO-O st).  
EA: Found C. 60.1; H. 8.9; N. 6.2; Calcd for C199H339N17O66: C. 59.4; H. 8.5; N. 5.9. 
SEC (ref PMMA): Mw 4952 g.mol-1; Ð: 1.02.  
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General procedure VI) (NHBoc)4[bisMPA,G2]-[bisMPA,G1]-(C17)2 (500 mg, 0.27 mmol, 
1 eq.) and HCl 3M into ethyl acetate (20 mL) into ethyl acetate (5 mL). The product was 
obtained as a white solid (430 mg, 99 %). 
1H NMR (400 MHz, CD3OD) δ (ppm): 0.90 (t, J = 6.4Hz, 6H, H-28),  1.24 (s, 3H, H-22), 
1.29 (m, 59H, H-9 and H-27), 1.31 (s, 6H, H-5), 1.46 (m, 4H, H-13 and H-14), 1.56 (m, 
4H, H-26), 1.69 (m, 2H, H-12), 1.94 (m, 2H, H-15), 2.26 (t, J = 7.2Hz, 4H, H-25), 3.94 (s, 
8H, H-1), 4.16 (t, J = 6.4 Hz, 2H, H-11), 4.22 (ABq, J = 10.8 Hz, ΔνAB = 26.0 Hz, 4H, H-23), 
4.32 (ABq, J = 11.2 Hz, ΔνAB = 17 Hz, 4H, H-7), 4.44 (m, 10H, H-16 and H-3), 5.25 (s, 2H, 
H-19), 8.06 (s, 1H, H-17).  
13C NMR (75 MHz, CDCl3) δ (ppm): 14.1 (C-28), [17.7-17-9] (C-5, C-9 and C-22), 22.7  
(C-17), 24.9 (C-26), 25.3 (C-13), 26.1 (C-14), 28.3 (C-12), [29.1-29.7] (C-27), 30.1 (C-15), 
31.9 (C-27), 34.1 (C-1 and C-25), [46.0-46.3] (C-4, C-8 and C-21), 50.3 (C-16), 58.4  
(C-19), [64.7-65.5] (C-3, C-7, C-11 and C-23), 123.7 (C-17), 142.3 (C-18), 167.6 (C-2), 
[172.0-173.6] (C-6, C-10, C-20), 173.3 (C-24).  
MS (MALDI+) m/z (%): 1447.1 (100) [C73H129N7O20,Na]+;  1425.1 (16) [C73H129N7O20,H]+. 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs N-H+ st), 2959-2918-2851 (C-H st), 1736 (C=O st 
ester), 1589 (N-H+ δ), 1468 (CH2, CH3 δ), 1379 (C-N st), 1236 (CO-O st as), 1134  
(O-C-C st).  
pH (1 mg·mL-1 in distilled water): 3.54. 
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General procedure VI) (NHBoc)8[bisMPA,G3]-[bisMPA,G1](C17)2 (1000 mg, 0.27 mmol, 
1.00 eq.) and HCl 3M into ethyl acetate (5 mL) into ethyl acetate (3 mL) The product 
was obtained as a white solid (737 mg, quantitative yield).  
1H (400 MHz, CD3OD) δ (ppm): 0.90 (t, J = 6.4Hz, 6H, H-32), 1.24 (s, 3H, H-26), 1.29 (m, 
65H, H-9, H-13 and H-31), 1.33 (s, 12H, H-5), 1.45 (m, 4H, H-17 and H-18), 1.56 (m, 4H, 
H-30), 1.70 (m, 2H, H-16), 1.95 (m, 2H, H-19), 2.27 (t, J = 7.2Hz, 4H, H-29), 3.96 (s, 16H, 
H-1), 4.16 (t, J = 6.8 Hz, 2H, H-15), 4.22 (ABq, J = 11.2 Hz, ΔνAB = 28.7 Hz, 4H, H-27), 4.33 
(m, 12H, H-7 and H-11), 4.45 (m, 18H, H-3 and H-20), 5.26 (s, 2H, H-23), 8.08 (s, 1H,  
H-21). 
13C (100 MHz, CD3OD) δ (ppm): 14.1 (C-32), [18.1-18.2] (C-5, C-9, C-13 and C-26), 23.7 
(C-31), 26.0 (C-30), 26.5 (C-17), 27.1 (C-18), 28.3 (C-16), [29.5-31.2] (C-31), 33.1 (C-19), 
34.8 (C-29), 41.1 (C-1), [47.5-48.1] (C-4, C-8, C-12 and C-25), 51.3 (C-20), 58.9 (C-23), 
[65.9-67.7] (C-7, C-11, C-15 and C-27), 67.6 (C-3), 126.2 (C-21), 143.6 (C-22), 168.3  
(C-2), [173.2-174.0] (C-6, C-10, C-14 and C-24), 174.6 (C-28). 
MS (MALDI+) m/z (%): 2140.1 (100) [C101H173N11O36,Na]+. 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs N-H+ st), 2962-2922-2852 (C-H st), 1738 (C=O st 
ester), 1593 (N-H+ δ), 1468 (CH2, CH3 δ), 1373 (C-N st), 1229 (CO-O st as), 1130  
(O-C-C st). 
pH (1 mg·mL-1 in distilled water): 3.72. 
 
 
  
Experimental part 
343 
(NH3+Cl-)4[bisMPA,G2]-[bisMPA,G2](C17)4 
O
O
O
O
O
N
N N
O
O
O
O
OO
O
O
OO
O
O
O O
O
O
1
2
3
4
5
6
7
8 10
11
12
13
14
15
16
17
18
19
20 21
22
23
25
24
26 27
28
29
30 31
-
-Cll
++H3N
-
-Cll
++H3N
-
-Cll
++H3N
9
O
O
O
O
O (CH2)14
(CH2)14
(CH2)14
(CH2)14
32
O
O
-
-Cll
++H3N
  
General procedure VI) (NHBoc)4[bisMPA,G2]-[bisMPA,G2]-(C17)4 (470 mg, 0.18 mmol, 
1.00 eq.); HCl 3M into ethyl acetate (20 mL) into ethyl acetate (5 mL).The pure product 
was obtained as a white solid (423 mg, quantitative yield).  
1H NMR (400 MHz, CD3OD, 40 ºC) δ (ppm): 0.90 (t, J = 6.4Hz, 12H, H-32), 1.21 (s, 6H, H-
26), 1.30 (m, 124H, H-5, H-9, H-22 and H-31), 1.43 (m, 4H, H-13 and H-14), 1.60 (m, 8H, 
H-30), 1.70 (m, 2H, H-12), 1.94 (m, 2H, H-15), 2.32 (t, J = 7.6 Hz, 8H, H-29), 3.93 (m, 8H, 
H-1), 4.18 (m, 10H, H-11 and H-27), [4.18-4.50] (m, 18H, H-3, H-7, H-16, H-23), 5.27 (s, 
2H, H-19), 8.00 (s, 1H, H-17). 
13C NMR (75 MHz, CDCl3): δ (ppm) 14.0 (C-32), [17.5-17.7] (C-5, C-9, C-22 and C-26), 
22.6 (C-31), 24.8 (C-30), 25.3 (C-13), 26.1 (C-14), 28.3 (C-12), [29.1-29.7] (C-31), 30.2 
(C-15), 31.9 (C-31), 34.0 (C-1 and C-29), [46.0-46.6] (C-4, C-8, C-21 and C-25), 50.2  
(C-16), 58.3 (C-19), [64.8-65.3] (C-3, C-7, C-11, C-23 and C-27), 124.1 (C-17), 142.0 (C-
18), 167.5 (C-2), [171.9-172.3] (C-6, C-10, C-20 and C-24), 173.1 (C-28). 
MS (MALDI+) m/z (%): 2212.8 (100) [C119H213N7O28,Na]+; 2155.7 (7) [C117H210N6O27,Na]+. 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs N-H+ st), 2959-2918-2851 (C-H st), 1738 (C=O st 
ester), 1585 (N-H+ δ), 1468 (CH2, CH3 δ), 1385 (C-N st), 1236 (CO-O st as), 1134  
(O-C-C st).  
pH (1 mg·mL-1 in distilled water): 3.08. 
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General procedure VI) (NHBoc)8[bisMPA,G3]-[bisMPA,G2](C17)4 (1282 mg, 0.35 mmol, 
1.00 eq.); HCl 3M into ethyl acetate (25 mL) into ethyl acetate (8 mL). The pure product 
was obtained as a white solid (430 mg, 96 %).  
1H NMR (400 MHz, CD3OD, 35ºC) δ (ppm): 0.90 (t, J = 6,8Hz, 12H, H-36), 1.21 (s, 6H,  
H-30), 1.25 (m, 124H, H-9, H-13, H-26 and H-35), 1.34 (s, 12H, H-5), 1.45 (m, 4H, H-17 
and H-18), 1.60 (m, 8H, H-34), 1.70 (m, 2H, H-16), 1.96 (m, 2H, H-19), 2.33 (t, J = 7.2Hz, 
8H, H-33), 3.95 (s, 16H, H-1), 4.16 (m, 10H, H-15 and H-31), [4.28-4.38] (m, 16H, H-7,  
H-11 and H-27), 4.45 (m, 18H, H-3 and H-20), 5.28 (s, 2H, H-23), 8.07 (s, 1H, H-21). 
13C NMR (75 MHz, CDCl3): δ (ppm) 14.1 (C-36), [17.6-18.3] (C-5, C-9, C-13, C-26 and  
C-30), 22.7 (C-35), 24.9 (C-34), 25.3 (C-17), 26.2 (C-18), 28.3 (C-16), [29.1-29.7] (C-35), 
30.2 (C-19), 31.9 (C-35), 34.0 (C-1 and C-33), [46.1-46.6] (C-4, C-8, C-12, C-25 and C-29), 
50.0 (C-20), 58.3 (C-23), [64.7-64.3] (C-3, C-7, C-11, C-15, C-27 and C-31), 124.0 (C-21), 
142.0 (C-22), 167.7 (C-2), [173.4-171.9] (C-6, C-10, C-14, C-24 and C-28), 173.1 (C-32).  
MS (MALDI+) m/z (%): 2905.0 (100) [C147H257N11O44,Na]+; 2847.9 (13) 
[C145H254N11O43,Na]+.  
FTIR (νmax/cm-1, ATR): 3000-2600 (bs N-H+ st), 2959-2916-2849 (C-H st), 1736 (C=O st 
ester), 1601 (N-H+ δ), 1470 (CH2, CH3 δ), 1377 (C-N st), 1236 (CO-O st as), 1136 
(O-C-C st). 
pH (1 mg·mL-1 in distilled water): 3.21. 
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General procedure VI) (NHBoc)4-[bisGMPA,G1]-[bisMPA,G2]-(C17)2 (214 mg, 1.11x10-1 
mmol, 1.00 eq.); HCl 3M into AcOEt (10 mL) into ethyl acetate (5 mL). The product was 
obtained as a white solid (187 mg, quantitative yield). 
1H NMR (400 MHz, CDCl3) δ (ppm): 0.90 (t, J = 6.4Hz, 6H, H-30), 1.24 (s, 3H, H-24), 1.27 
(s, 3H, H-11), 1.29 (s, 56H, H-29),  1.37 (s, 6H, H-5), 1.43 (m, 4H, H-15 and H-16), 1.55 
(m, 4H, H-28), 1.66 (m, 2H, H-14), 1.94 (m, 2H, H-17), 2.26 (t, J = 7.2 Hz, 4H, H-27), 3.94 
(s, 8H, H-3), 3.96 (s, 4H, H-9), 4.13 (t, J = 6.4 Hz, 2H, H-13), 4.21 (ABq, J = 11.2 Hz, ΔνAB = 
24.8 Hz, 4H, H-25), 4.31 (m, 4H, H-9), [4.37-4.47] (m, 10H, H-3 and H-18), 7.36 (bs, -
NHCO), 8.06 (s, 1H, H-19). 
13C NMR (75 MHz, CD3OD) δ (ppm): 14.5 (C-30), [17.8-18.2] (C-5, C-11 and C-24), 23.7 
(C-29), 26.0 (C-28), 26.4 (C-15), 27.0 (C-16), 29.4 (C-14), [30.2-31.4] (C-29), 31.1 (C-17), 
33.1 (C-29), 34.8 (C-29), 41.1 (C-1), 42.1 (C-7), [47.4-47.6] (C-4, C-10 and C-23), 51.3 (C-
18), 58.9 (C-21), [66.2-68.4] (C-3 and C-9), 67.3 (C-9), 68.5 (C-3), 126.1 (C-19), 143.5 (C-
20), 168.3 (C-2), [170.9-174.9] (C-6, C-8, C-12, C-22 and C-26).   
MS (MALDI+): m/z (%): [C77H135N9O22,Na]+ 1561.5 (100). 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs N-H+ st), 2953-2916-2851 (C-H st), 1742 (C=O st 
ester), 1657 (C=O st amide and N-H+ δ), 1543 (N-H δ), 1470 (CH2, CH3 δ), 1229  
(CO-O st), 1134 (O-C-C st). 
pH (1 mg·mL-1 in distilled water): 3.20. 
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(NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1](C17)2 
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General procedure VI) (NHBoc)8-[bisGMPA,G3]-[bisMPA,G1]-(C17)2 (424 mg, 1.30x10-1 
mmol, 1.00 eq.) and HCl 3M into ethyl acetate (10 mL) into ethyl acetate (5 mL). The 
product was obtained as a white solid  (313 mg, quantitative yield). 
1H (400 MHz, CD3OD) δ (ppm): 0.90 (t, J = 6.8 Hz, 6H, H-36), 1.24 (s, 3H, H-30), 1.27 (s, 
3H, H-17), 1.29 (m, 56H, H-35), 1.32 (s, 6H, H-11), 1.38 (s, 12H, H-5), 1.44 (m, 4H, H-21 
and H-22), 1.55 (m, 4H, H-34), 1.67 (m, 2H, H-20), 1.94 (m, 2H, H-23), 2.26 (t, 4H,  
J = 7.2 Hz, H-33), 3.95 (s, 16H, H-1), 3.97 (s, 4H, H-13), 4.01 (s, 8H, H-7), 4.13 (t,  
J = 6.4 Hz, 2H, H-19), 4.21 (ABq, J = 11.2 Hz, ΔνAB = 27.7 Hz, 4H, H-31), 4.32 (m, 12H, H-9 
and H-16), 4.45 (m, 18H, H-3 and H-24), 5.26 (s, 2H, H-27), 8.08 (s, 1H, H-25). 
13C (100 MHz, CD3OD) δ (ppm):14.5 (C-36), [17.8-18.2] (C-5, C-11, C-17 and C-30), 23.7 
(C-35), 26.0 (C-34), 26.4 (C-21), 27.0 (C-22), 29.4 (C-20), [30.1-30.8] (C-35), 31.1 (C-23), 
33.1 (C-35), 34.8 (C-33), 41.2 (C-1), 42.2 (C-7 and C-13), [47.4-47.6] (C-4, C-10, C-16 and 
C-29), 51.4 (C-24), 58.9 (C-27), [66.2-66.4] (C-19 and C-31), 67.2 (C-15), 67.8 (C-9), 68.5 
(C-3), 126.2 (C-25), 143.5 (C-26), 168.3 (C-2), [170.8-171.1] (C-8 and C-14),  
[174.0-174.1] (C-19 and C-28), [174.6-175.2] (C-6, C-14 and C-32).  
FTIR (νmax/cm-1, ATR): 3600-2600 (bs N-H+ st), 2920-2852 (C-H st), 1745 (C=O st ester), 
1653 (C=O st amide and N-H+ δ), 1537 (N-H δ), 1468 (CH2, CH3 δ), 1229 (CO-O st). 
pH (1 mg·mL-1 in distilled water): 3.66. 
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General procedure VI) (NHBoc)8-[bisGMPA,G2]-[bisMPA,G3]-(C17)4 (290 mg, 7.20x10-2 
mmol, 1.00 eq.) and HCl 3M into ethyl acetate (10 mL) into ethyl acetate (5 mL). The 
pure product was obtained as a white solid (253 mg, quantitative yield). 
 
1H NMR (400 MHz, CD3OD) δ (ppm): 0.90 (t, J = 6.8Hz, 12H, H-40), 1.20 (s, 6H, H-34), 
[1.28-1.33] (m, 124H, H-11, H-17, H-30 and H-39), 1.38 (s, 12H, H-5), 1.43 (m, 4H, H-21 
and H-22), 1.59 (m, 8H, H-38), 1.67 (m, 2H, H-20), 1.95 (m, 2H, H-23), 2.33 (t, J = 7.2Hz, 
8H, H-37), 3.94 (s, 16H, H-1), 3.97 (m, 4H, H-13), 4.00 (m, 8H, H-9), 4.13 (m, 10H, H-19 
and H-35), 4.27 (ABq, 4H, H-31), 4.32 (m, 12H, H-9 and H-15), 4.45 (m, 18H, H-19 and 
H-24), 8.08 (bs, -NHCO). 
13C NMR (100 MHz, CDCl3) δ (ppm): 14.5 (C-40), [17.8-18.3] (C-5, C-11, C-17, C-30 and 
C-34), 23.8 (C-39), 26.1 (C-38), 26.4 (C-21), 27.1 (C-22), 29.4 (C-23), [30.2-30.9] (C-31), 
31.2 (C-20), 33.1 (C-39), 34.9 (C-37), 41.2 (C-1), 42.2 (C-7 and C-13), [47.4-47.9] (C-4, C-
10, C-16, C-29 and C-33), 51.4 (C-24), 59.1 (C-27), [66.3-68.6] (C-3, C-9, C-15, C-19, C-31 
and C-35), 126.3 (C-25), 143.5 (C-26), 168.3 (C-2), [170.8-175.3] (C-6, C-8, C-12, C-14, C-
18, C-28 and C-32). 
MS (MALDI+) m/z (%): 3248.6 (100) [C159H275N17O50,Na]+. 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs N-H+ st), 2959-2918-2851 (C-H st), 1738 (C=O st 
ester), 1653 (C=O st amide and N-H+ δ), 1539 (N-H δ) 1470 (CH2, CH3 δ), 1217 (CO-O st 
as), 1132 (O-C-C st). 
pH (1 mg·mL-1 in distilled water): 3.33. 
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7.1.3.2 - Amphiphilic hybrid dendritic-linear-dendritic blocks copolymers 
(HDLDBCs) 
General procedure VIII): copper(I) azide-alkyne cyloaddition reaction (CuAAC) 
for the synthesis of the HDLDBCs 
 
 Alkyne functionalized F-127 Pluronic (1.00 mol) and pre-hydrophilic 
dendrons (2.60 mol) were dissolved into dimethylformamide (8 mL) in a Schlenk 
flask. 3 cycles vacuum-argon were made to remove the O2. The reaction mixture 
was allowed to stir under argon atmosphere at 45ºC. CuSO45.H2O (0.40 mol), L-
ascorbate (0.80 mol) and TBTA (0.40 mol) were dissolved into DMF (5 mL) in a 
second Schlenk flask. 3 cycles vacuum-argon were made in order to remove the 
O2 and the copper solution was stirred at 45ºC during 15 min. Then, it was 
added through a cannula to the previous azide-alkyne reaction mixture. The 
reaction mixture was stirred at 45ºC during 2 days under argon atmosphere. 
Then, hot brine (100 mL) was added to the reaction mixture and the product 
was extracted 3 times with dichloromethane (3 x 100 mL). Organic phases were 
washed two times with hot brine (2 x 100 mL), dried over anhydrous MgSO4 and 
the solvent was evaporated under reduce pressure to give a yellow solid. The 
crude product was precipitated into cold diethyl ether and allowed to decant 
overnight at 4ºC. It was filtered and washed with cold diethyl ether to give a 
white powder. Finally, the product was dialyzed (cellulose membrane, 1000 Da) 
against methanol during 24 hours to give a light yellow solid. 
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General procedure IX): deprotection of the terminal amino groups  
 
 t-Boc protected HDLDBC (1 mol) was dissolved into ethyl acetate. HCl 
(3M into ethyl acetate) was carefully added to it. The reaction mixture was 
stirred at room temperature during 45 min. A white gel appeared. The reaction 
mixture was diluted into ethyl acetate and was stirred during another 30 min. 
Then, it was stirred under vacuum to remove the hydrochloric acid and the 
solvent was evaporated under reduce pressure. The gel was washed firstly with 
pure ethyl acetate and secondly with pure methanol. In each case, the solution 
was stirred under vacuum to remove the residual hydrochloric acid and then, 
the solvent was evaporated under reduce pressure to obtain a dried gel.  
  
Chapter 7 
350 
4-propargyloxybenzoate 
O
O
O
1 2 3
4
5 6
7
8
9
 
4-hydroxybenzoate (5.00 g, 32.9 mmol, 1.00 eq) was dissolved into DMF (100 mL). 
K2CO3 (6.82 g, 49.4 mmol, 1.50 eq.) was added to it. The reaction mixture was heated 
up to 105ºC.  Propargyl bromide (80% in toluene) (4.74 mL, 36.1 mmol, 1.10 eq.) was 
added drop wise. The reaction was stirred at 105ºC overnight. The reaction was cooled 
down to room temperature and a mixture of water and brine (3:1) (400 mL) was added 
to it. The product was extracted two times with AcOEt (2 x 200 mL). The organic 
phases were washed two times with a mixture of water and brine (1:1) (2 x 200 mL), 
dried over anhydrous MgSO4 and the solvent was evaporated under vacuum. The 
crude product was purified on silica gel (hexane : ethyl acetate = ramp from 9:1 to 8:2) 
to give a light orange solid (4.34 g, 69 %). 
1H (400 MHz, CDCl3) δ (ppm): 2.55 (t, J = 2.4 Hz, 1H, H-1), 3.88 (s, 3H, H-9), 4.75 (d,  
J = 2.4 Hz, 2H, H-3), 6.99 (dt, J1 = 9.2 Hz, J2 = 2.8 Hz, 2H- H-5), 8.01 (dt, J1 = 9.2 Hz,  
J2 = 2.8 Hz, 2H, H-6). 
13C (100 MHz, CDCl3) δ (ppm): 51.9 (C-9), 55.8 (C-3), 76.0 (C-1), 77.8 (C-2), 114.4 (C-5), 
122.4 (C-7), 131.5 (C-6), 161.1 (C-4), 166.6 (C-8). 
FTIR (νmax/cm-1, ATR): 3246 (≡C-H st), 2959 (C-H st), 2129 (C≡C-H st), 1705 (C=O st 
ester), 1286-1250 (CO-O st), 1175(C-O-C st). 
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4-propargyloxybenzoate (4.13 g, 21.75 mmol, 1.00 eq) was dissolved into MeOH (133 
mL). Distilled water (66 mL) is slowly added. The reaction mixture was cooled down to 
0ºC. LiOH (3.65 g, 87.04 mmol, 4.00 eq.) was slowly added. The reaction mixture was 
slowly heated up to reflux temperature and stirred during 6 hours. It was diluted with 
NaOH (2M in water) in an ice bath. HCl (12M in water) is carefully added to pH 1. A 
white precipitate appeared. It was filtered and washed with HCl (0.5M in water) (2.59 
g, 81 %). 
1H (400 MHz, (CD3)2SO): δ 3.61 (t, J = 2.0 Hz, 1H, H-1), 4.88 (d, J = 2.0 Hz, 2H, H-3), 7.10 
(d, J= 8.8 Hz, 2H, H-5), 7.92 (d, J = 8.8 Hz, 2H, H-6), 12.69 (bs, -COOH). 
13C (100 MHz, (CD3)2SO): δ 55.7 (C-3), 78.1 (C-1), 78.8 (C-2), 114.7 (C-5), 123.7 (C-7), 
131.3 (C-6), 160.8 (C-4), 166.9 (C-8). 
FTIR (νmax/cm-1, ATR): 3244 (≡C-H st), 3200-2300 (O-H st), 2825 (C-H st), 2131 (C≡C-H 
st), 1672 (C=O st acid), 1296-1242 (CO-O st), 1182 (C-O-C st). 
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Pluronic® F-127 (10.00 g, 0.794 mmol, 1.00 eq) was heated during 2 hours at 105ºC to 
remove the water that are contained inside the polymer. It was cooled to room 
temperature and dissolved into a mixture of dry dichloromethane : dry 
tetrahydrofurane (1:1) (20 mL) and stirred at 45ºC under argon atmosphere. DMAP 
(118 mg, 0.953 mmol, 1.20 eq.) and 4-propargyloxybenzoic acid (560 mg, 3.12 mmol, 
4.00 eq.) were added to it. DCC (655 mg, 3.12 mmol, 4.00 eq.) was dissolved into dry 
tetrahydrofurane (1 mL) and added drop wise. The reaction mixture was stirred at 
45ºC under argon atmosphere during 48 hours. The white precipitate, N,N’-
dicyclohexylurea (DCU), was filtered off and the product was precipitate into cold 
diethyl ether (1 L) and it was allowed to decant overnight at 4ºC. The white precipitate 
was recovered by filtration at atmospheric pressure and was washed with cold diethyl 
ether. Then, it was dissolved into toluene (20 mL) and filtered in order to remove the 
entrapped DCU that is insoluble in toluene. The solvent was evaporated under reduce 
pressure to obtain a white powder (8.47, 75 %). 
1H (CDCl3, 400 MHz) δ (ppm): 1.13 (m, 201H, H-1), 2.55 (t, J = 2.4 Hz, 2H, H-15), 3.37 
(m, 67H, H-2), [3.42-3.74] (m, ~1000H, H-3, H-4 and H-5), 3.79 (t, 4H, H-6), 4.41 (m, 8H, 
H-7), 4.72 (d, J = 2.4 Hz, 4H, H-13), 6.97 (dt, J = 9.2 Hz, J = 2.0 Hz, 4H, H-11), 7.99 (dt,  
J1 = 9.2 Hz, J = 9.2 Hz, J = 2.0 Hz, 4H, H-10). 
13C (CDCl3, 100 MHz) δ (ppm): [17.1-17.2] (C-1), 55.6 (C-13), [63.7-75.3] (C-2 to C-7), 
76.1 (C-15), 77.6 (C-14), 114.3 (C-11), 123.2 (C-9), 131.5 (C-10), 161.0 (C-12), 165.9  
(C-8).  
MS (MALDI+): distribution with max at m/z 13800. 
FTIR (νmax/cm-1, ATR): 3240 (≡C-H st), 2883 (C-H st), 1717 (C=O st ester), 1466 (CH2, CH3 
δ), 1279 (CO-O st), 1101 (C-O-C st). 
SEC (ref PMMA): 2 populations; Mw 17006 g.mol-1; Ð: 1.10.  
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General procedure VIII) ≡-(PLU)-≡ (2.000 g, 1.55x10-1 mmol, 1.00 eq.);  N3-
[bisMPA,G3]-(NHBoc)8 (891 mg, 4.03x10-1 mmol, 2.60 eq.); CuSO4,5H2O (32.8 mg, 
6.20x10-2 mmol, 0.40 eq), (L)-ascorbate (24.5 mg, 1.24x10-1mmol, 0.80 eq.) and TBTA 
(32.8 mg,  
6.20x10-2, 0.40 eq.) into DMF (12 mL). The product was obtained as a white powder 
(1.024 g, 38%).  
1H (400 MHz, CDCl3) δ (ppm): 1.13 (m, 201H, H-1), 1.23 (s, 18H, H-24G3), 1.28 (s, 12H, 
H-24G2), 1.33 (s, 6H, H-24G1), 1.43 (m, 152H, H-18, H-19 and H-30), 1.67 (m, 4H, H-20), 
1.95 (m, 4H, H-17), 3.39 (m, 67H, H-2), 3.44-3.74 (m, ~1000H, H-3, H-4 and H-5), 3.81 
(t, J = 4.8 Hz, H-6), 3.87 (d, J = 5.6 Hz, 32H, H-27), 4.11 (t, J = 6.4 Hz, 4H, H-7), [4.18-
4.29] (m, 56H, H-25), 4.37 (t, J = 7.2 Hz, 4H, H-16), 4.43 (t, J = 4.8 Hz, 4H, H-7) 5.25 (s, 
4H, H-13), 5.35 (bs, ~NH), 7.01 (d, J = 9.2 Hz, 4H, H-11), 7.67 (s, 2H, H-15), 8.00 (d, J = 
9.2Hz, 4H, H-10). 
13C NMR (75 MHz, CDCl3) δ (ppm): [17.3-17.8] (C-1 and C-24), 25.3 (C-19), 26.1 (C-18), 
28.3 (C-20 and C-30), 30.1 (C-17), 42.2 (C-25G3), [46.4-46.7] (C-23), 50.2 (C-16), [62.1-
75.3] (C-2 to C-7, C-13, C-21 and C-25G1,G2), 79.9 (C-29), 114.3 (C-11), 122.7 (C-15), 
123.1 (C-9), 131.7 (C-10), 143.4 (C-14), 155.8 (C-28), 162.0 (C-12), 166.1 (C-8), 170.0 (C-
26G3), [171.5-172.0] (C-21 and C-26G1,G2). 
MS (MALDI+): distribution with max at m/z 17550. 
FTIR (νmax/cm-1, ATR): 3321 (N-H st), 2974-2883 (C-H st), 1745 (C=O st ester), 1717 (C=O 
st carbamate), 1670 (C=O st amide), 1514 (N-H δ), 1466 (δ -CH2-, δas -CH3), 1101  
(C-O-C st). 
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(NHBoc)8[bisGMPA]-PLU-[bisGMPA](NHBoc)8 
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General procedure VIII) ≡-(PLU)-≡ (1.000 g, 7.74x10-1 mmol, 1.00 eq.); N3-
[bisGMPA,G3]-(NHBOC)8 (514 mg, 2.01x10-1 mmol, 2.60 eq.); CuSO4,5H2O (18.2 mg, 
6.19x10-2 mmol, 0.80 eq), (L)-ascorbate (24.05 mg, 1.24x10-1mmol, 1.60 eq.) and TBTA 
(32.8 mg, 6.19x10-2, 0.80 eq.) into dry DMF (12 mL). The product was obtained as a 
light yellow solid (855 mg, 61%).  
1H (400 MHz, CDCl3) δ (ppm): 1.11 (m, 201H, H-1), 1.26 (m, 36H, H-24), 1.41 (m, 152H, 
H-18, H-19 and H-31), 1.62 (m, 4H, H-20), 1.94 (m, 4H, H-17), 3.38 (m, 67H, H-2), [3.44-
3.74] (m, ~1000H, H-3, H-4 and H-5), 3.81 (t, 4H, J = 4.8 Hz, H-6), 3.88 (m, 32H, H-27G3), 
3.94 (m, 8H, H-27G1), 3.88 (m, 16H, H-27G2), 4.11 (t, J = 6.4 Hz, 4H, H-21), [4.18-4.35] 
(m, 60H, H-16 and H-25), 4.43 (t, J = 4.8 Hz, 4H, H-7) 5.29 (s, 4H, H-13), 5.35 (bs, 
~NHBoc), 7.02 (d, J = 8.8 Hz, 4H, H-11), 7.17 (bs, ~CONH), 7.82 (s, 2H, H-15), 8.00 (d, J = 
8.0 Hz, 4H, H-10). 
FTIR (νmax/cm-1, ATR): 3360 (N-H st), 2883 (C-H st), 1755 (C=O st ester), 1718 (C=O st 
carbamate), 1670 (C=O st amide), 1533 (N-H δ), 1468 (δ -CH2-, δas -CH3), 1101  
(C-O-C st). 
SEC (ref PMMA): 2 populations; Mw 19745 g.mol-1; Ð: 1.08. 
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(NH3+Cl-)8[bisMPA]-PLU-[bisMPA] (NH3+Cl-)8 
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General procedure IX) (NHBoc)8[bisMPA]-PLU-[bisMPA](NHBoc)8 (500 mg, 2.88x10-2 
mmol, 1.00 eq.) and  HCl (3M in ethyl acetate) (7 mL) into ethyl acetate (3 mL).The 
product was obtained as a colorless dried gel (470 mg, quantitative yield). 
1H NMR (400 MHz, CD3OD) δ (ppm): 1.14 (m, 201H, H-1), 1.34 (m, 42H, H-24), 1.43 (m, 
8H, H-18 and H-19), 1.67 (m, 4H, H-20), 1.96 (m, 4H, H-17), 3.46 (m, 67H, H-2),  
[3.44-3.74] (m, ~1000H, H-3, H-4 and H-5), 3.83 (m, 4H, H-6), 4.05 (m, 32H, H-27), 4.14 
(t, J = 5.6 Hz, 4H, H-21), [4.27-4.37] (m, 24H, H-25G1,G2), 4.41 (m, 4H, H-16), 4.46 (m, 
32H, H-25G3), 5.32 (s, 4H, H-13), 7.16 (d, J = 8.8 Hz, 4H, H-11), 8.02 (d, J = 8.8 Hz, H-10), 
8.21 (m, 2H, H-15). 
MS (MALDI+): distribution with max at m/z 16260. 
FTIR (νmax/cm-1, ATR): 3441 (N-H st), 2887 (C-H st), 1742 (C=O st ester), 1468 (CH2, CH3 
δ), 1103 (C-O-C st). 
pH (1 mg·mL-1 in distilled water): 3.82. 
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(NH3+Cl-)8[bisGMPA]-PLU-[bisGMPA](NH3+Cl-)8 
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General procedure IX) (NHBoc)8-[bisGMPA,G2]-PLU-[bi-GMPA,G2]-(NHBoc)8 (653 mg, 
3.62x10-2 mmol, 1.00 eq.) and  HCl (3 M in ethyl acetate) (7 mL) into ethyl acetate (3 
mL). The product was obtained as a light yellow dried gel (212) (615 mg, quantitative 
yield). 
1H (400 MHz, CD3OD) δ (ppm): 1.14 (m, 201H, H-1), 1.27 (s, 6H, H-24G1), 1.32 (s, 20H, 
H-18, H-19 and H-24G2), 1.39 (s, 24H, H-24G2), 1.64 (m, 4H, H-20), 1.95 (m, 4H, H-17), 
3.47 (m, 67H, H-2), 3.51-3.73 (m, ~1000H, H-3, H-4 and 5), 3.84 (t, J = 4.8 Hz, 4H, H-6), 
3.96 (s, 8H, H-27G0), 4.00 (s, 16H, H-27G1), 4.03 (s, 32H, H-27G2), 4.12 (t, J = 6.0 Hz, 4H, 
H-21), 4.31 (m, 24H, H-25G0,G1), 4.45 (m, 40H, H-7, H-16 and H-25G3) 5.30 (s, 4H, H-13), 
7.38 (d, J = 8.8 Hz, 4H, H-11), 8.23 (d, J = 8.8 Hz, 4H, H-10), 8.19 (s, 2H, H-15). 
13C NMR (125 MHz, CD3OD) δ (ppm): [17.4-18.3] (C-1 and C-24), 26.3 (C-19), 26.9  
(C-18), 29.3 (C-20), 31.1 (C-17), 41.5 (C-25G2), 42.2 (C-25G0,G1), 47.3 (C-23), 51.3 (C-16), 
[62.6-76.8] (C-2 to C-7, C-13, 21 and C-25), 115.9 (C-11), 124.2 (C-9), 125.8 (C-15), 
132.8 (C-10), 140.4 (C-14), 163.7 (C-12), 167.6 (C-8), 168.8 (C-26G2), [170.8-171.2]  
(C-26G0,G1), 174.0 (C-21), [174.7, 175.0] (C-28). 
FTIR (νmax/cm-1, ATR): 2885 (C-H st), 1751 (C=O st ester), 1663 (C=O st amide and N-H+ 
δ), 1545 (N-H δ), 1468 (CH2-, CH3 δ), 1099 (C-O-C st). 
pH (1 mg·mL-1 in distilled water): 3.43. 
  
Experimental part 
357 
7.1.4- Globular dendritic derivatives for gene 
transfection 
 
7.1.4.1- Bis-GMPA dendrimers 
General procedure X): copper(I) azide-alkyne cyloaddition reaction (CuAAC) for 
the synthesis of the 3-arms dendrimers 
  
 Tripropargylamine (1.00 mol) and azido-dendron (1.10 mol) were 
dissolved into dimethylformamide (7 mL) in a Schlenk flask. 3 cycles vacuum-
argon were made to remove the O2. The reaction mixture was allowed to stir 
under argon atmosphere at 45ºC. CuSO45.H2O (0.3 or 1.5 mol), L-ascorbate (0.6 
or 3.0 mol) and TBTA (0.3 mol) were dissolved into DMF (3 mL) in a second 
Schlenk flask. 3 cycles vacuum-Argon were made in order to remove the O2 and 
the copper solution was stirred at 45ºC during 15 min. Then, it was added 
through a cannula to the previous azide-alkyne reaction mixture. The reaction 
mixture was stirred at 45ºC during 2 days. Then, brine was added (100 mL) and 
the product was extracted 2 times with ethyl acetate (2 x 70 mL). The organic 
phase was washed three times with brine (3 x 100 mL), once with a KCN 
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aqueous solution (15 mg into 100 mL of water) and twice with brine (2 x 100 
mL), dried over anhydrous MgSO4 and the solvent was evaporated under reduce 
pressure. Finally, the crude product was precipitated into a mixture of hexane 
and ethyl acetate (refer to the product to see the solvents proportion, 100 mL); 
the crude product was first dissolved into ethyl acetate and then, hexane was 
slowly added into the dissolution. The product was recovered by centrifugation 
and the solid was washed once with the same mixture of hexane and ethyl 
acetate. Finally, the product was dialyzed against methanol (cellulose acetate, 
MW 1000 Da) to give a white or light yellow powder. 
 The t-Boc protective groups were removed according to the general 
procedure VI) (see page 321). 
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D[bisGMPA,G3](NHBoc)24 and D[bisGMPA,G4]-(NHBoc)48 
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D[bisGMPA,G3](NHBoc)24 
General procedure X) Triporpargylamine amine (6.71 μL, 4.74x10-2 mmol, 1.00 eq.); 
N3-[bisGMPA,G3]-(NHBoc)8 (400 mg, 1.57x10-1 mmol, 3.30 eq.); CusO4.5H2O (17.8 mg, 
7.11x10-2 mmol, 1.50 eq.), (L)-ascorbate (28.2 mg, 1.42x10-2 mmol, 3.00 eq.); TBTA 
(7.53 mg, 1.42x10-2 mmol, 0.30 eq.); dry DMF (10 mL). The crude product was purified 
by precipitation into a mixture of hexane and ethyl acetate (4:6) and by dialysis against 
methanol to give a white powder (313 mg, 85 %). 
For 1H and 13C number, refer to the scheme CVI-1. 
1H (400 MHz, CDCl3) δ (ppm): [1.22-1.27] (m, 63H, H-12), 1.38 (m, 12H, H-6 and H-7), 
1.42 (m, 216H, H-19), 1.63 (m, 6H, H-8), 1.93 (m, 2H, H-5), 3.70 (m, 6H, H-1), 3.88 (d,  
J = 5.2 Hz, 48H, H-15[G3]), 3.94 (d, J = 4.4 Hz, 6H, H-15[G1]), 3.98 (d, J = 4.0 Hz, H-
15[G2]), 4.11 (m, 6H, H-9), [4.19-4.34] (m, 90H, H-13 and H-4), 5.48 (-NHBoc), 7.33  
(-NHCO), 7.82 (s, 3H, H-3). 
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13C (100 MHz, CDCl3) δ (ppm): [17.8-18.3] (C-12), 25.2 (C-7), 26.0 (C-6), 28.3 (C-8 and  
C-19), 30.1 (C-5), 41.3 (C-15[G1,2]), 42.3 (C-15[G2]), [46.0-46.1] (C-11), 46.8 (C-1), 50.2  
(C-1), [65.2-66.5] (C-9 and C-13), 80.0 (C-16), 123.0 (C-3), 156.1 (C-17), 169.6 (C-
14[G3]), [170.3-171.1] (C-14[G1,G2]), 172.6 (C-10), 172.9 (C-16). 
Note: The signals of the carbons C-1, C-2, C-3 and C-4 could not be observed in the 13C 
NMR spectrum. However, coupling signals between H-1 and C-1, H-2 and C-2 and H-4 
and C-4 were observed in 1H-13C HSQC experiment.  
FTIR (νmax/cm-1, ATR): 3375 (N-H st), 2979-2927-2868 (C-H st), 1749 (C=O st ester), 
1699 (C=O st carbamate), 1660 (C=O st amide), 1522 (N-H δ), 1457 (CH2, CH3 δ), 1366 
(C-N st), 1287 (CO-O st), 1161 (N-CO-O st). 
EA (%): Found: C, 51.2; H, 6.9; N, 9.2. Calc. for C335H532N52O156: C, 51.7; H, 6.9; N, 9.4. 
SEC (ref PMMA): Mw 6895 g.mol-1; Ð: 1.05. 
 
D[bisGMPA,G4]-(NHBoc)48 
General procedure X) Triporpargylamine amine (3,45 μL, 2.33x10-2 mmol, 1.00 eq.); 
N3-[bisGMPA,G4]-(NHBoc)16 (400 mg, 7.69x10-1 mmol, 3.30 eq.); CusO4.5H2O (8.73 mg, 
3.50x10-2 mmol, 1.50 eq.), (L)-ascorbate (13.9 mg, 7.00x10-2 mmol, 3.00 eq.); TBTA 
(3.71 mg, 7.00x10-3 mmol, 0.30 eq.); dry DMF (10 mL). The crude product was purified 
by precipitation into a mixture of hexane and ethyl acetate (5:5) (100 mL) and by 
dialysis against methanol to give a light yellow powder (287 mg, 78 %). 
For 1H and 13C number, refer to the scheme CVI-1. 
1H (400 MHz, CDCl3) δ (ppm): [1.22-1.28] (m, 135H, H-12), 1.43 (m, 444H, H-17, H-6 
and H-7), 1.64 (m, 6H, H-8), 1.96 (m, 6H, H-5), 3.69 (m, 6H, H-1), 3.89 (m, 96H, H-
15[G4]), 3.98 (m, 84H, H-15[G1,2,3]), 4.12 (m, 6H, H-9), [4.17-4.40] (m, 180H, H-13), 
4.35 (m, 6H, H-4), 5.54 (-NHBoc), 7.70 (s, 3H, H-3). 
13C (100 MHz, CDCl3) δ (ppm): [17.7-18.8] (C-12), 28.3 (C-19), 42.4 (C-15[G4]), 42.4 (C-
15[G1,2,3]), 46.0 (C-11), [65.3-66.1] (C-9 and C-13), 80.0 (C-18), 156.1 (C-17), 170.1 (C-
14G3), [169.6-173.1] (C-10, C-14 and C-16). 
Note: The signals of the carbons C-1 to C-9 could not be observed in the 13C NMR 
spectrum and their 1H-13C correlations could not be observed in the 1H-13C HSQC 
spectrum. 
FTIR (νmax/cm-1, ATR): 3367 (N-H st), 2978-2927 (C-H st), 1749 (C=O st ester), 1699 (C=O 
st carbamate), 1675 (C=O st amide), 1525 (N-H δ), 1469 (CH2, CH3 δ), 1369 (C-N st), 
1249 (CO-O st), 1159 (N-CO-O st). 
EA (%): Found: C, 52.0; H, 7.3; N, 8.0. Calc. for C672H1062N100O324: C, 51.3; H, 6.8; N, 8.9. 
SEC (ref PMMA): Mw 13102 g.mol-1; Ð: 1.05. 
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D[bisGMPA,G3](NH3+Cl-)24 and D[bisGMPA,G4]-(NHBoc)48 
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D[bisGMPA,G3](NH3+Cl-)24 
General procedure VI) D-[bisGMPA,G3](NHBoc)8 (154 mg, 7.38x10-2 mmol, 1.00 eq.); 
HCl 3M into ethyl acetate (5 mL); ethyl acetate (5 mL). The product was obtained as a 
white powder (123 mg, quantitative yield). 
1H (500 MHz, CD3OD) δ (ppm): 1.28 (s, 9H, H-12[G0]), 1.33 (s, 18H, H-12[G1]), 1.38  
(s, 36H, H-12[G2]), 1.43 (m, 12H, H-6 and H-7), 1.68 (m, 6H, H-8), 1.99 (m, 6H, H-5), 3.95 
(s, 48H, H-15[G2]), 3.97 (s, 12H, H-15[G0]), 4.01 (s, 24H, H-15[G1]), 4.15 (m, 6H, H-9), 4.33 
(m, 36H, H-13[G0,1]), 4.46 (m, 48H, H-13[G2]), 4.52 (m, 12H, H-1 and H-4), [8.26-8.34]  
(bs, N-H), 8.42 (s, 3H, H-3). 
13C (125 MHz, CD3OD) δ (ppm): [17.9-18.2] (C-12), 26.4 (C-7), 27.1 (C-6), 29.4 (C-8), 
31.2 (C-5), 41.2 (C-15[G2]), 42.2 (C-15[G0,1]), [47.4-47.9] (C-1 and C-11), 51.6 (C-4), 66.4 
(C-9), [67.2-68.6] (C-13), 128.7 (C-3), 137.9 (C-2), 168. 3 (C-14[G2]), [170.8-174.1] (C-10 
and C-14[G0,G1]) [174.0-175.2] (C-16). 
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FTIR (νmax/cm-1, ATR): 3600-2600 (bs N-H+ st), 2947-2633 (C-H st), 1749 (C=O st ester), 
1655 (C=O st and N-H+ δ), 1545 (N-H δ), 1473 (CH2, CH3 δ), 1379 (C-N st), 1221 (CO-O 
st). 
 
D[bisGMPA,G4]-(NH3+Cl-)48 
General procedure VI) D-[bisGMPA,G4](NHBoc)16 (163 mg, 1.04x10-2 mmol, 1.00 eq.); 
HCl 3M into ethyl acetate (5 mL); ethyl acetate (5 mL). The product was obtained as a 
white powder (131 mg, quantitative yield). 
1H (500 MHz, CD3OD) δ (ppm): 1.23 (s, 9H, H-12[G1]), 1.28 (s, 18H, H-12[G2]), 1.33  
(s, 36H, H-12[G3]), 1.38 (s, 72H, H-12[G4]), 1.45 (m, 12H, H-6 and H-7), 1.68 (m, 6H, H-
8), 1.99 (m, 6H, H-5), 3.96 (s, 96H, H-15[G4]), 4.01 (m, 84H, H-15[G1,2,3]), 4.15 (m, 6H, 
H-9), 4.33 (m, 84H, H-13[G1,2,3]), 4.46 (m, 96H, H-13[G4]), 4.56 (m, 12H, H-1 and H-4),  
[8.24-8.33] (bs, N-H), 8.44 (s, 3H, H-3). 
Note: Some 1H signals can be detected near 3.77 ppm, they result to the degradation of 
the bis-GMPA dendrons but they do not integrate for more than 5 % percent of the 
total of the bis-GMPA dendrons.  
13C (125 MHz, CD3OD) δ (ppm): [17.9-18.2] (C-12), 26.4 (C-7), 27.1 (C-6), 29.4 (C-8), 
31.2 (C-5), 41.2 (C-15[G4]), 42.3 (C-15[G1,2,3]), [47.4-47.7] (C-1 and C-11), 51.6 (C-4),  
[65.7-68.6] (C-9 and C-13), 128.9 (C-3), 137.7 (C-2), 168.3 (C-14[G4]), [170.9-174.1]  
(C-10 and C-14[G1,2,3]) [175.0-177.0] (C-16). 
FTIR (νmax/cm-1, ATR): 3600-2600 (bs N-H+ st), 3391 (N-H st), 2935-2615 (C-H st), 1749 
(C=O st ester), 1655 (C=O st and N-H+ δ), 1545 (N-H δ), 1477 (CH2, CH3 δ), 1385 (C-N st), 
1211 (CO-O st). 
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7.1.4.2 - Bis-MPA dendronized hyperbranched polymers (DHPs) 
General procedure XI): Alkyne functionalization of the commercial 
hyperbranched polyesters 
 Commercial hyperbranched polyesters (1.00 mol) were dissolved into dry 
THF. DPTS (0.50 mol per hydroxyl groups) and 4-pentynoic acid (1.25 mol per 
hydroxyl groups) were dissolved in dry THF. The reaction mixture was stirred 
under argon atmosphere and was cooled down to 0ºC. EDC·HCl (1.25 mol per 
hydroxyl groups) was added. The mixture was stirred under argon atmosphere 
at room temperature for 72 h. Then, the solvent was evaporated and the 
resulting product was dissolved in dichloromethane (100 mL) and washed twice 
with water (70 mL) and once with brine (70 mL). The organic layer was dried 
over anhydrous MgSO4 and the dichloromethane was partially evaporated. The 
solution was carefully precipitated into cold hexane and recovered by further 
centrifugation at 4000 rpm for 30 min. The alkyne functionalized hyperbranched 
polymer was washed twice with cold hexane. 
General procedure XII): copper(I) azide-alkyne cyloaddition reaction (CuAAC) 
for the synthesis of the DHPs 
 Alkyne functionalized hyperbranched polymer (1.00 mol) and N3-
[bisMPA,G3]-(NHboc)8 (1.20 mol per mol of alkyne group) were dissolved into 
dimethylformamide in a Schlenk flask. 3 cycles vacuum-argon were made to 
remove O2 and the reaction mixture was allowed to stir at 45ºC under argon 
atmosphere.  CuSO45.H2O (0.10 mol per mol of alkyne group), (L)-ascorbate 
(0.20 mol per mol of alkyne group) and TBTA (0.10 mol per mol of alkyne grous) 
were added to the copper dissolution. 3 cycles vacuum-Argon were made in 
order to remove the O2 and the copper solution was stirred at 45ºC until it 
became yellow. Then, it was added through a cannula to the previous azide-
alkyne reaction mixture. The reaction mixture was stirred under argon 
atmosphere at 45ºC during 2 days. Brine (250 mL) was added to the reaction 
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mixture and the product was extracted 3 times with ethyl acetate (3 x 150 mL). 
The organic phases were collected and combined and washed 3 times with 
brine (3 x 200 mL). The organic phase was dried over anhydrous MgSO4 and the 
solvent was evaporated under reduce pressure to give a yellow oil. The crude 
product was filtrated through silica gel (DCM 100%) and the solvent was 
evaporated under reduced pressure to give a light yellow oil. The product was 
then dissolved in ethyl acetate (250 mL) and was washed twice with a solution 
of KCN (15 mg) in water (150 mL) and twice with brine (150 mL). The organic 
phase was dried over anhydrous MgSO4 and concentrated by evaporation under 
reduced pressure. The product was precipitated by pouring into a mixture of 
hexane and ethyl acetate (9:1) and recovered by filtration. The products were 
obtained as white solids. 
 The t-Boc protective groups were removed according to the general 
procedure VI) (see page 321). 
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HP[G2]-≡ 
General procedure XI) HP[G2]-(OH)16 (1.25 g, 0.74 mmol, 1.00 eq.); DPTS (1.79 g, 5.72 
mmol, 12.00 eq.); 4-pentynoic acid (1.40 g, 14.29 mmol, 19.20 eq.) and EDC·HCl (2.74 
g, 14.20 mmol, 19.20 eq.) into THF (100 mL). The product was obtained as a yellow 
solid (1.74 g, 81%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.24 (m, 36H, H-7), 1.99 (m, 15H, H-13), 2.44  
(m, 30H, H-11), 2.54 (m, 30H, H-10), 3.64 (m, 16H, H-2 and H-3), 4.24 (m, 56H, H-4 and 
H-8). 
13C NMR (CDCl3, 100 MHz) δ (ppm): 14.4 (C-11), 17.9 (C-7), 33.3 (C-10), 46.7 (C-6), 65.5 
(C-8), 69.5 (C-13), 82.5 (C-12), 171.3 (C-8 and C-9).  
FTIR (νmax/cm-1, KBr): 3287 (≡C−H st), 2122 (C≡C st), 1740 (C=O st), 1245 (CO-O st). 
SEC (ref PMMA): Mw 5000 g mol-1; ÐM = 1.20. 
HP[G3]-≡ 
General procedure XI) HP[G3]-(OH)32 (1.25 g, 0.35 mmol, 1.00 eq.); DPTS (1.73 g, 5.54 
mmol, 16.00 eq.); 4-pentynoic acid (1.36 g, 13.86 mmol, 39.60 eq.) and EDC·HCl (2.66 
g, 13.86 mmol, 39.60 eq.) into THF (100 mL). The product was obtained as a yellow 
solid (1.66 g, 78%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.24 (m, 84H, H-7), 1.99 (m, 31H, H-13), 2.44  
(m, 64H, H-11), 2.54 (m, 64H, H-10), 3.64 (m, 16H, H-2 and H-3), 4.24 (m, 120H, H-4 
and H-8). 
13C NMR (CDCl3, 100 MHz) δ (ppm): 14.4 (C-11), 17.9 (C-7), 33.3 (C-10), 46.7 (C-6), 65.5 
(C-8), 69.5 (C-13), 82.5 (C-12), 171.3 (C-8 and C-9). 
FTIR (νmax/cm-1, KBr): 3285 (≡C−H st), 2119 (C≡C st), 1740 (C=O st), 1243 (CO-O st). 
SEC (ref PMMA): Mw 7700 g mol-1; ÐM 1.43. 
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HP[G4]-≡ 
General procedure XI) HP[G4]-(OH)64 (1.25 g, 0.17 mmol, 1.00 eq.); DPTS (1.71 g, 5.46 
mmol, 32.00 eq.); 4-pentynoic acid (1.34 g, 13.66 mmol, 80.35 eq.) and EDC·HCl (2.62 
g, 13.66 mmol 80.35 eq.) into THF (100 mL). The product was obtained as a yellow 
solid (1.33 g, 64%). 
1H NMR (CDCl3, 400 MHz) δ (ppm): 1.24 (m, 180H, H-7), 1.99 (m, 61H, H-13), 2.44  
(m, 128H, H-11), 2.54 (m, 128H, H-10), 3.64 (m, 16H, H-2 and H-3), 4.24 (m, 248H, H-4 
and H-8). 
13C NMR (CDCl3, 100 MHz) δ (ppm): 14.4 (C-11), 17.9 (C-7), 33.3 (C-10), 46.7 (C-6), 65.5 
(C-8), 69.5 (C-13), 82.5 (C-12), 171.3 (C-8 and C-9). 
FTIR (νmax/cm-1, KBr): 3287 (≡C−H st), 2121 (C≡C st), 1741 (C=O st), 1243 (CO-O). 
SEC (ref PMMA): Mw 15600 g mol-1; ÐM 1.91. 
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DHPs[G 2+3, 3+3, 4+3](NHBoc) 
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DHP[G2+3](NHBoc) 
General procedure XII). HP[G2]-≡ (208 mg, 7x10-2 mmol, 1.00 eq.); N3-[bisMPA,G3]-
(NHBoc)8 (3.00 g, 1.36 mmol, 19.2 eq.); CuSO4,5H2O (33 mg, 1.13x10-1 mmol, 1.60 eq.); 
(L)-ascorbate (48 mg, 2.30x10-1 mmol, 6.40 eq.) and TBTA (60 mg, 1.13x10-1 mmol, 1.60 
eq.) into dimethylformamide (15 mL). The product was obtained as a white solid  
(1.755 g, 65 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.24  (411H, m, H-7, H-16, H-17 and H-22), 1.45 
(1080H, s, H-28), 1.60 (30H, m, H-18), 1.90 (30H, m, H-15), 2.73 (30H, m, H-10), 2.97 
(30H, m, H-11), 3.63 (16H, m, H-2 and H-3), 3.87 (240 H, d, J = 4.8 Hz, H-25), 4.26 
(506H, m, H-4, H-8, H-19 and H-23), 4.43 (30H, m, H-14), 5.46 (bs, -NHBoc), 7.41 (15H, 
s, H-13). 
 13C NMR (75 MHz, CDCl3) δ (ppm): [17.5-17.7] (C-7 and C-22), 20.8 (C-11), 25.3 (C-17), 
26.2 (C-16), 28.3 (C-18 and C-27), 30.2 (C-15), 33.3 (C-10), 42.2 (C-24), [46.4-46.6] (C-6 
and C-21), 50.0 (C-14), [65.4-65.6] (C-8, C-19, C-23), 79.8 (C-26), 121.2 (C-12), 145.9  
(C-13), 155.9 (C-25), [170.1- 171.5-171.8-172.1] (C-5, C-9, C-20 and C-24).  
FTIR (νmax/cm-1, ATR): 3367 (N-H st), 2988-2935 (C-H st), 1738 (C=O st ester), 1711 (C=O 
st carbamate), 1514 (N-H δ), 1470 (CH2, CH3 δ), 1367 (C-N st), 1248 (CO-O st), 1155 (N-
CO-O st), 1142 (O-C-C st).  
EA (%): Found: C, 53.1; H, 7.6; N, 6.3; Calc. for C1603H2539N165O749: C, 53.3; H, 7.1; N, 6.4. 
SEC (ref PMMA): Mw 32698 g.mol-1; ÐM 1.16. 
  
Chapter 7 
368 
DHP[G3+3](NHBoc) 
General procedure V) HP[G3]-≡ (215 mg, 3.53x10-2 mmol, 1.00 eq.); N3-[bisMPA,G3]-
(NHBoc)8 (3.00 g, 1.36 mmol, 38.4 eq.); CuSO4,5H2O (33 mg, 1.13x10-1 mmol, 3.20 eq.); 
(L)-ascorbate (48 mg, 2.30x10-1 mmol, 6.40 eq.) and TBTA (60 mg, 1.13x10-1mmol, 1.60 
eq.) into dimethylformamide (15 mL). The product was obtained as a white solide 
(1.937 g, 71 %).  
1H NMR (400 MHz, CDCl3) δ (ppm): 1.24 (859H, m, H-7, H-16, H-17 and H-22), 1.43 
(2232H, s, H-28), 1.65 (62H, m, H-18), 1.89 (62H, m, H-15), 2.73 (62H, m, H-10) 2.86 
(62H, m, H-11), 3.64 (16H, m, H-2 and H-3), 3.87 (496H, m, H-25), 4.26 (1050H, m, H-4, 
H-8, H-19 and H-23), 4.44 (62H, m, H-14), 5.48 (bs, -NHBoc), 7.42 (31H, s, H-13).  
13C NMR (75 MHz, CDCl3) δ (ppm): [17.5-17.8] (C-7 and C-22), 20.8 (C-11), 25.3 (C-17), 
26.2 (C-16), 28.3 (C-18 and C-27), 30.2 (C-15), 33.3 (C-10), 42.2 (C-24), [46.4-46.7] (C-6 
and C-21), 50.0 (C-14), [65.4-65.6] (C-8, C-19, C-23), 79.8 (C-26), 121.2 (C-12), 145.8 (C-
13), 155.9 (C-25), [170.1-171.5-171.8-172.0] (C-5, C-9, C-20 and C-24). 
FTIR (νmax/cm-1, ATR):  3354 (N-H st), 2986-2947 (C-H st), 1736 (C=O ester st), 1711 
(C=O st carbamate), 1518 (N-H δ), 1462 (CH2, CH3 δ), 1367 (C-N st), 1244 (CO-O st), 
1155 (N-CO-O st), 1124 (O-C-C st). 
EA (%): Found: C, 53.2; H, 7.35; N, 6.5; Calc. for C3317H5247N341O1550: C, 53.3; H, 7.1; N, 
6.4.  
SEC (ref PMMA): Mw 42745 g.mol-1; ÐM 1.14. 
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DHP[G4+3](NHBoc) 
General procedure XII) HP[G4]-≡ (217 mg, 1.78x10-2 mmol, 1.00 eq.); N3-[bisMPA,G3]-
(NHBoc)8 (3.00 g, 1.36 mmol, 76.8 eq.); CuSO4,5H2O (33 mg, 1.13x10-1mmol, 6.40 eq.); 
(L)-ascorbate (48 mg, 2.30x10-1mmol, 12.80 eq.); TBTA (60 mg, 1.13x10-1mmol, 6.40 
eq.). The product was obtained as a white solid (1.834 g, 77 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.27 (1505H, m, H-7, H-16, H-17 and H-22), 1.43 
(3816H, s, H-28), 1.66 (106H, m, H-18), 1.90 (106H, m, H-15), 2.44 (16H, m, H-11’) 2.54 
(16H, m, H-10’), 2.73 (106H, m, H-10) 2.96 (106H, m, H-11), 3.64 (16H, m, H-3 and H-4), 
3.87 (848H, m, H-25), 4.26 (1838H, m, H-4, H-8, H-19 and H-23), 4.43 (106H, m, H-14), 
5.51 (bs, -NHBoc), 7.41 (53H, s, H-13). 
13C NMR (75 MHz, CDCl3) δ (ppm): [17.5-17.8] (C-7 and C-22), 20.8 (C-11), 25.3 (C-17), 
26.2 (C-16), 28.3 (C-18 and C-27), 30.2 (C-15), 33.3 (C-10), 42.2 (C-24), [46.4-46.6] (C-6 
and C-21), 50.0 (C-14), [65.4-65.6] (C-8, C-19, C-23), 79.8 (C-26), 121.2 (C-12), 145.8  
(C-13), 155.9 (C-25), [170.0- 171.5-171.8-172.0] (C-5, C-9, C-20 and C-24).  
FTIR (νmax/cm-1, ATR):  3393 (N-H st), 2980-2932 (C-H st), 1740 (C=O st ester), 1713 
(C=O st carbamate), 1512 (N-H δ), 1460 (CH2, CH3 δ), 1365 (C-N st), 1244 (CO-O st), 
1155 (N-CO-O st), 1136 (O-C-C st). 
EA (%): Found: C. 53.3; H. 7.2; N. 6.4. Calc. for C5761H9077N583O2688: C, 53.4; H, 7.1; N, 
6.3. 
SEC (ref PMMA): Mw 58703 g.mol-1; ÐM 1.21. 
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DHPs[G2+3,G3+3,G4+3](NH3+Cl-) 
O
O O
OO
O
O
O
O
O
O
O
O
O O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
O
NH3
+Cl
-
N N
N
OO
X
O
O
O
NH3
+Cl
-
NH3
+Cl
-
NH3
+Cl
-
NH3
+Cl-
NH3
+Cl
-
NH3
+Cl
-
NH3
+Cl
-
O
OO1 2 3 54 6
7
8
9
10 11 12 13
14
15
16
17
18
19
20
10'
11'
21
22
23
13'
24
 
DHP[G2+3](NH3+Cl-) 
General procedure VI) DHP[G2+3](NHBoc) (873 mg, 2.42x10-2 mmol) and HCl 3M into 
ethyla acetate (20 mL) into ethyl acetate (5 mL). The product was obtained as a white 
powder (688 mg, quantitative yield). 
1H NMR (400 MHz, CD3OD) δ (ppm): 1.34 (351H, m, H-7 and H-22), 1.44 (60H, m, H-16 
and H-17), 1.70 (30H, m, H-18), 1.94 (30H, m, H-15), 2.76 (30H, m, H-10), 3.02 (30H, m, 
H-11), 3.66 m (16H, m, H-2 and H-3), 3.98 (240H, m, H-25), 4.17 (30H, m, H-19), 4.35 
(236H, m, H-4, H-8 and H-23[G1,2]), 4.46 (270H, m, H-14 and H-23[G3]) 7.94 (15H, s,  
H-13). 
13C NMR (75 MHz, C2D6SO) δ (ppm): [17.1-17.4] (C-7 and C-22), 21.1 (C-11), 25.3 (C-17), 
25.6 (C-16), 27.9 (C-18), 29.8 (C-15), 32.8 (C-10), [45.9-46.3] (C-6, C-24 and C-21), 49.3 
(C-14), 65.7 (C-8, C-19, C-23), 122.1 (C-12), 145.1 (C-13), 167.1 (C-20[G3]),  
[171.6-172.1] (C-5, C-9 and C-20[G0,1,2]). 
FTIR (νmax/cm-1, ATR): 3000-2600 (N-H+ st), 2984-2941 (C-H st), 1732 (C=O st ester), 
1605-1514 (N-H+ δ), 1472 (CH2, CH3 δ), 1369 (C-N st), 1236 (CO-O st), 1128 (O-C-C st).  
EA (%) Found: C, 41.5; H, 6.8; N, 7.9; Calc. for C1003H1699N165Cl120O509: C, 42.3; H, 6.0;  
N, 8.1. 
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DHP[G3+3](NH3+Cl-) 
General procedure VI) DHP[G3+3]-(NHBoc) (1287 mg, 1.72x10-2 mmol) and HCl 3M 
into ethyl acetate (20 mL) into ethyl acetate (5 mL). The product was obtained as a 
white powder (1014 mg, quantitative yield). 
1H NMR (400 MHz, CD3OD) δ (ppm): 1.35 (735H, m, H-7 and H-22), 1.43 (124H, m,  H-
16 and H-17), 1.71 (62H, m, H-18), 1.93 (62H, m, H-15), 2.77 (62H, m, H-10),  3.00 (62H, 
m, H-11), 3.68 (16H, m, H-2 and H-3), 3.99 (496H, m, H-25), 4.17 (62H, m, H-19), 4.35 
(492H, m, H-4, H-8 and H-23[1,2G]), 4.46 (558H, m, H-14 and H-23[3G]), 7.94 (31H, s, 
H-13). 
13C NMR (75 MHz, C2D6SO) δ (ppm): [17.1-17.4] (C-7 and C-22), 24.8 (C-11), 25.6 (C-16), 
27.9 (C-18), 30.0 (C-15), 32.8 (C-10), [45.9-46.3] (C-6, C-24 and C-21), 49.3 (C-14), 65.7 
(C-8, C-19, C-23), 122.1 (C-12), 145.1 (C-13), 167.1 (C-20[G3]), [171.6-172.1] (C-5, C-9 
and C-20[G0,1,2]). 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs, N-H+ st), 3001-2851 (C-H st), 1734 (C=O st ester), 
1605-1510 (N-H+ st), 1474 (CH2, CH3 δ), 1302 (C-N st), 1223 (CO-O st), 1126 (O-C-C st).  
EA (%): Found: C, 41.5; H, 7.0; N, 7.6; Calc. for C2077H3507N341O1054: C, 42.3; H, 6.0;  
N, 8.1. 
DHP[G4+3](NH3+Cl-) 
General procedure VI) DHP[G4+3]-(NHBoc) (1184 mg, 9.14x10-3 mmol) and HCl 3M 
into ethyl acetate (20 mL) into ethyl acetate (5 mL).The product was obtained as a 
white powder (937 mg, quantitative yield). 
1H NMR (400 MHz, CD3OD) δ (ppm): 1.35 (1293H, m, H-7 and H-22), 1.45 (212H, m,  
H-16 and H-17), 1.70 (106H, m, H-18), 1.95 (106H, m, H-15), 2.34 (16H, m, H-11’), 2.48 
(16H, m, H-12’), 2.78 (106H, m, H-10) 3.02 (106H, m, H-11), 3.68 (16H, m, H-2 and H-3), 
3.99 (848H, m, H-25), 4.17 (106H, m, H-19), 4.35 (884H, m, H-4, H-8 and H-23[1,2G]), 
4.47 (954H, H-14 and H-23[3G]), 7.94 (53H, s, H-13). 
13C NMR (75 MHz, C2D6SO) δ (ppm): [17.2-17.5] (C-7 and C-22), 21.1 (C-11), 24.8 (C-17), 
25.7 (C-16), 28.0 (C-18), 29.8 (C-15), 32.9 (C-10), [46.0-46.3] (C-6, C-24 and C-21), 49.3 
(C-14), 65.8 (C-8, C-19, C-23), 122.1 (C-12), 145.2 (C-13), 167.2 (C-20[G3]),  
[171.6-172.2] (C-5, C-9 and C-20[G0,1,2]). 
FTIR (νmax/cm-1, ATR): 3000-2600 (bs, N-H+ st), 2999-2947 (C-H st), 1730 (C=O st ester), 
1605-1514 (N-H+ δ), 1472 (CH2, CH3 δ), 1369 (C-N st), 1225 (CO-O st), 1128 (O-C-C st). 
EA (%): Found: C, 41.9; H, 6.7; N, 7.6; Calc. for C3641H6105Cl424N583O1840: C. 42.65; H, 6.0; 
N, 8.0. 
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7.1.5- Other derivatives 
 
7.1.5.1- Rhodamine B derivatives 
 
azido rhodamine B (N3-RhB) 
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Rhodamine B (1.00g, 2.09 mmol, 1.00 eq.) was dissolved into dry dichloromethane (70 
mL). 6-azidohexan-1-ol (602 mg, 4.18 mmol, 2.00 eq.) and DPTS (492 mg, 1.67 mmol, 
0.80 eq.) were added to it. The reaction mixture was stirred at 45ºC under argon 
atmosphere. DCC (861 mg, 4.18 mmol, 2.00 eq.) was dissolved into dry 
dichloromethane (10 mL) and added drop wise to the reaction mixture. It was stirred 
at 45ºC under atmosphere overnight, protected from the light. Then, the white 
precipitate, N,N’-dicyclohexylurea (DCU), was filtered off. Dichloromethane was added 
(20 mL) to the filtrate. It was washed once with HCl 0.1 M (100 mL) and twice with 
brine (2 x 100 mL). The organic phase was dried over anhydrous MgSO4 and the 
solvent was evaporated under reduce pressure. The crude product was purified on 
silica gel (DCM : MeOH = ramp from 10:0 to 9:1) to give a purple solid (934 mg, 74 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.32 (t, J = 8 Hz, 12H, H-21), 1.49 (m ,4H, H-3 and 
H.4), 1.65 (m, 2H, H-2), 1.87 (m, 2H, H-5), 3.23 (t, J = 4 Hz, 2H, H-1), 3.63 (q, J = 8 Hz, H-
20), 4.02 (t, J = 8 Hz, 2H, H-6), 6.84 (d, J = 2.4 Hz, 2H, H-17), 6,90 (dd, J =9,6 Hz, J = 2.4 
Hz, 2H, H-19), 7.07 (d, 2H, H-18), 7.31 (dd, J = 7.6 Hz, J = 1.2 Hz, 1H, H-12), 7.74 (td, J = 
8.0 Hz, J = 1.2 Hz, 1H, H-10), 7.82 (td, J = 7.6 Hz, J = 1.2 Hz, 1H, H-11), 8.29 (dd, J = 8.0 
Hz, J = 1.2 Hz, 1H, H-9). 
13C NMR (75MHz, CDCl3) δ (ppm): 12.6 (C-21), 25.4 (C-4), 26.3 (C-3), 28.2 (C-5), 28.6 (C-
2), 46.2 (C-20), 51.3 (C-1), 65.5 (C-6), 96.5, 113.6, 114.3, 126.3, 128.5, 130.0, 130.3, 
130.4, 131.3, 133.1, 133.5, 155.5, 157.7, 165.1 (C-7). 
Note: the counter-ions are a mixture of C7H7SO3– and Cl–; C7H7SO3– was observed in 1H 
NMR (2.26 (s, 2.4H), 7.07 (d, J = 8.0 Hz, 1.6H), 7.90 (d, J = 8.0 Hz, 1.6H)), and 13C NMR 
(21.3, 127.0, 129.7, 139.4, and 158.9).  
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FTIR (νmax/cm-1, ATR): 2928-2852 (C-H st), 2095 (N3 st), 1715 (C=O st), 1645-1585 (C-
Car). 
MS (ESI+) m/z (%): 568.4 (100) [C34H42N5O3]+. 
EA (%):  Found: C, 66.3; H, 7.0; N, 10.0; S, 3.7; Calc. for C34H42N5O3+,Cl–/C7H7SO3–: C, 
66.8; H, 6.7; N, 9.9; S, 3.5. 
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N3-RhB (200 mg, 0.33 mmol, 1.00 eq.) and ≡-[bisMPA,G1]-(C17)2 (280 mg, 0.40 mmol, 
1.20 eq.)were dissolved into dimethylformamide (7 mL) in a Schlenk flask. 3 cycles 
vacuum-argon were made to remove the O2. The reaction mixture was allowed to stir 
under argon atmosphere at 45ºC. 3 cycles of vacuum–argon were made to remove O2. 
CuSO4.5H2O (9.8 mg, 0.03 mmol, 0.10 eq.), (L)-ascorbate (13.1 mg, 0.07 mmol, 0.20 
eq.) and TBTA (17.6 mg, 0.003 mmol, 0.01 eq.) were dissolved into dimethylformamide 
(3 mL) in a second Schlenk flask. 3 cycles vacuum-argon were made in order to remove 
the O2 and the copper solution was stirred at 45ºC during 15 min. Then, it was added 
through a cannula to the previous azide-alkyne reaction mixture. The reaction mixture 
was stirred at 45ºC during 1 day under argon atmosphere protected from the light. 
Then, brine (100 mL) was added to the reaction mixture. The product was extracted 
three times with ethyl acetate (3 x 70 mL). The organic phases were dried over 
anhydrous MgSO4 and the solvent was evaporated under reduced pressure. The crude 
product was purified on silica gel (DCM:MeOH = ramp from 100:0 to 92:8) to give a 
purple solid (199 mg, 46%). 
1H NMR (400 MHz, CDCl3) δ (ppm): 0.87 (t, J = 6.4 Hz, 6H, H-34), 1.24 (m, 59H, H-28 and 
H-33), 1.33 (m, 16H, H-1, H-19 and H-20), 1.42 (m, 2H, H-18), 1.55 (m, 4H, H-32), 1.88 
(m, 2H, H-21), 2.26 (t, J = 7.2 Hz, 4H, H-31), 3.65 (m, 8H, H-2),  4.00 (t, J = 6.0 Hz, H-17), 
4.20 (ABq, J = 11.2 Hz, ΔνAB = 17.4 Hz, 4H, H-29), 4.40 (t, J = 5.6 Hz, 2H, H-22), 5.24 (s, 
2H, H-25), 6.92 (m, 4H, H-4 and H-6), 7.08 (d, J = 9.6 Hz, 2H, H-7), 7.29 (d, J = 6.8 Hz, 
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1H, H-11), 7.74 (t, J = 8.0 Hz, 1H, H-13), 7.79 (t, J = 7.2 Hz, 1H, H-12), 7.97 (s, 1H, H-23), 
8.28 (d, J = 8.0 Hz, 1H, H-14). 
13C NMR (100 MHz, CDCl3) δ (ppm): 12.7 (C-1), 14.1 (C-34), 17.8 (C-28), 22.6 (C-33), 
24.8 (C-32), 25.2 (C-19), 26.1 (C-20), 28.12(C-18), [29.1-29.7] (C-33), 30.0 (C-21), 31.9 
(C-33), 34.0 (C-31), 46.3 (C-2), 50.7 (C-22), 58.2 (C-26), 64.9 (C-29), 65.5 (C-17), 96.5  
(C-4), 113.5 (C-6), 130.1, 130.2, 130.4, 131.3, 131.4, 133.0, 133.4, 155.5, 157.7, 158.8, 
165.1 (C-16), 172.6 (C-26), 173.2 (C-30). 
Note: The signals of the carbons C-23 and C-24 could not be observed in the 13C NMR 
spectrum. The 1H-13C correlation could be observed in the 1H-13C HSQC spectrum at 
7.97(1H signal)-125.6 (13C signal). 
FTIR (νmax/cm-1, ATR): 2916-2 851 (C–H st), 1 740-1 715 (C=O), 1 649-1 587 (C–Car).  
Note: a peak corresponding to water is observed at 3406 cm-1. 
MS (MALDI+) m/z (%): 1273.1 (100) [C78H122N5O8]+. 
EA (%): Found: C, 69.6; H, 9.4; N, 5.45; Calc. for C78H122N5O9Cl1: C, 71.6; H, 9.4; N, 5.35. 
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 First, HP[G3]-≡ (60.37 mg, 9.92x10-2 mmol, 1.00 eq.) and N3-[bisMPA,G3]-
(NHboc)8 (526 mg, 2.38x10-2 mmol, 24.00 eq.) were dissolved into dimethylformamide 
(4 mL) in a Schlenk flask. 3 cycles vacuum-argon were made to remove air and the 
reaction mixture was allowed to stir at 45ºC under argon atmosphere.  CuSO45.H2O 
(7.01 mg, 2.38x10-2 mmol, 2.40 eq.), (L)-ascorbate (9.42 mg, 4.76x10-2 mmol, 4.80 eq.) 
and TBTA (12.61 mg, 2.38x10-2 mmol, 2.40 eq.) were dissolved into 
dimethylformamide (3 mL). 3 cycles vacuum-Argon were made in order to remove the 
O2 and the copper solution was stirred under argon pressure at 45ºC during 15 min. 
Then, it was added through a cannula to the previous azide-alkyne reaction mixture. 
The reaction mixture was stirred under argon atmosphere at 45ºC during 2 days. The 
crude products were purified in the same manner than the one described in the 
general procedure XII). 
 Second, the obtained solids with free alkynes remaining, DHP[G3+3](NHBoc),-
(≡), (435 mg, 7.35x10-2 mmol, 1.00 eq.) and N3-RhB (53 mg, 1.88x10-2 mmol, 12.00 eq.) 
were dissolved into dimethylformamide (4 mL). 3 cycles vacuum-argon were made to 
remove air and the reaction mixture was stirred under argon atmosphere at 45ºC. 
CuSO4, 5.H2O (4.12 mg, 1.39x10-2 mmol, 2.40 eq.), (L)-ascorbate (5.51 mg, 2.78x10-2 
mmol, 4.80 eq.) and TBTA (3.70 mg, 6.98x10-2 mmol, 0.80 eq.) were dissolved into 
dimethylformamide (3 mL). 3 cycles vacuum-argon were made to remove air and the 
copper dissolutions were stirred under argon atmosphere at 45ºC during 15 min. Then, 
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it was added through a cannula to the previous azide-alkyne reaction mixture. The 
reaction mixture was stirred under argon atmosphere at 45ºC during 2 day keeping it 
away from the light. Then, a dissolution of NaHSO4 (saturated in water) (100 mL) was 
added to the reaction mixture. The product was extracted 3 times with a mixture of 
hexane and ethyl acetate (1:2). The organic phases were collected and combined 
together. They were washed 3 times with brine (3 x 150 mL), once with a solution of 
KCN (15 mg) in water (150 mL) and repetitively with brine (150 mL) until the aqueous 
phase remained colorless. The organic phases were dried over anhydrous MgSO4 and 
the solvent were evaporated to give dark pink solids. The crude products were dialyzed 
(cellulose membrane, 3500 Da) against methanol during 2 days to give the pure 
product as dark pink solid (349 mg, 50 %). 
1H NMR (400 MHz, CDCl3) δ (ppm): 1.24 (m, 796H, H-7, H-16, H-17, H-22 and H-30), 
1.42 (s, 1728H, H-28), 1.65 (m, 62H, H-18), 2.00 (m, 62H, H-15), 2.89 (m, 62H, H-10), 
3.17 (m, 62H, H-11), 3.64 (m, 72H, H-2, H-3 and H-29), 3.87 (m, 384H, H-24), 4.25 (m, 
854H, H-4, H-8, H-19 and H-23), 4.55 (m, 62H, H-14), 5.50 (bs, -NHBoc), [6.7-7.2] (bs, 
Har RhB), [7.30-8.29] (m, bs, H-13 and Har RhB).  
FTIR (νmax/cm-1, ATR): 3383 (N-H st), 2978-2933 (C-H st), 1740 (C=O st ester), 1713 (C=O 
st carbamate), 1512 (N-H δ), 1460 (CH2, CH3 δ), 1367 (C-N st), 1248 (CO-O st), 1157 (N-
CO-O st), 1130 (O-C-C st). 
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General procedure VI) DHP[G3+3](NHBoc),(RhB) (261 mg, 3.75x10-3 mmol) and HCl 3M 
into ethyl acetate (8 mL) into ethyl acetate (2 mL).The product was obtained as a pink 
solid (193 mg, quantitative yield). 
 1H NMR (400 MHz, CD3OD) δ (ppm): 1.34 (m, 796H, H-7, H-16, H-17, H-22 and H-26), 
1.70 (m, 62H, H-18), 1.95 (m, 62H, H-15), 2.77 (m, 62H, H-10), 3.03 (m, 62H, H-11), 3.67 
(m, 72H, H-2, H-3 and H-25), 3.98 (m, 384H, H-24), 4.16 (m, 62H, H-19), 4.34 (m, 408H, 
H-4, H-8 and H-23[G1,2]), 4.45 (m, 446H, H-14 and H-23[G3]), [6.7-7.2] (bs, Har RhB), 
[7.30-8.29] (bs, H-13 and m Har RhB). 
FTIR (νmax/cm-1, ATR): 3600-2600 (N-H+ st), 2947-2870 (C-H st), 1736 (C=O st ester), 
1512 (N-H+ δ), 1472 (CH2, CH3 δ), 1242 (CO-O st), 1132 (O-C-C st). 
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7.1.5.2- Antimalarial drugs in their base form 
 
General procedure XIII): synthesis of the lipophilic base antimalarial drugs 
forms starting from their hydrophilic salt forms 
 
 Commercial antimalarial drug in its salt form was dissolved into distilled 
water (25 mL) NaOH was added to brought pH up to 12. A precipitate appeared. 
The product was extracted 3 times with dichloromethane (3 x 10 mL). The 
organic phase was dried over anhydrous MgSO4 and the dichloromethane was 
evaporated under reduce pressure to give the pure antimalarial drug in its 
lipophilic base form. 
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Chloroquine base (CQb)  
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General procedure XIII). CQ-salt (1000 mg, 1.94 mmol). The pure product was 
obtained as a white solid (566 mg, 91 %). 
1H NMR (400 MHz, CD2Cl2) δ (ppm): 0.98 (t, J = 9.6 Hz, 6H, H-16), 1.30, (d, J = 6.4 Hz, 
3H, H-11), 1.59 (m, 2H, H-13), 1.65 (m, 1H, H-12), 1.74 (m, 1H, H-12’), 2.42 (t, J = 6.8 Hz, 
2H, H-14), 2.49 (q, J = 6.8 Hz, 4H, H-15), 3.71 (m, 1H, H-10), 5.47 (d, J = 6.8 Hz, 1H, N-H), 
6.46 (d, J = 5.2 Hz, 1H, H-2), 7.34 (dd, J = 9.2 Hz and J = 2.4 Hz, 1H, H-7), 7.75 (d,  
J = 8.8 Hz, 1H, H-8), 7.89 (d, J = 2Hz, 1H, H-5), 8.47 (d, J = 5.6 Hz, H-3). 
1H NMR (400 MHz, (CD3)2SO) δ (ppm): 0.89 (t, J = 7.2 Hz, 6H), 1.22 (d, J = 6.4 Hz, 3H), 
1.46 (m, 3H), 1.67 (m, 1H), 2.33 (t, J = 6.8 Hz, 2H), 3.38 (q, J = 7.6 Hz, 4H), 3.36 (s, 1H), 
3.70 (m, 1H), 6.49 (d, J = 5.6 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 7.41 (dd, J = 8.8 Hz and  
J = 2.0 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), 8.35 (s, 1H), 8.37 (d, J = 2.4 Hz, 1H). 
13C NMR (100 MHz, CD2Cl2) δ (ppm): 11.9 (C-16), 20.4 (C-11), 24.4 (C-13), 35.0 (C-12), 
47.3 (C-15), 48.9 (C-10), 53.0 (C-14), 99.9 (C-2), 118.1 (C-9), 122.2 (C-8), 125.2 (C-7), 
129.2 (C-5), 134.9 (C-6), [149.7-150.1] (C-1 and C-4), 152.6 (C-3).  
FTIR (ATR, cm-1): 3244 (N-H st), 2968 and 2800 (C-H C-Har st), 1466 (-CH2-, CH3 δ). 
EA (%): Found: C, 67.5; H, 8.45; N, 13.0; Calc. for C18H26N3Cl1: C, 67.6; H, 8.2; N, 13.1. 
 
Chloroquine salt (CQs) 
Commercial product (Aldrich), white solid. 
1H NMR (400 MHz, (CD3)2SO) δ (ppm): 0.89 (t, J = 7.2 Hz, 6H), 1.08 (d, J = 6.0 Hz, 3H), 
1.42 (m, 3H), 1.56 (m, 1H), 2.62 (m, 6H), 3.36 (s, 1H), 3.60 (m, 1H), 3.80 (bs), 6.38 (d,  
J = 5.6 Hz, 1H), 6.91 (d, J = 7.6 Hz, 1H), 7.28 (dd, J = 8.8 Hz and J = 2.4 Hz, 1H), 7.61 (d,  
J = 2.4 Hz, 1H), 8.22 (d, J = 5.6 Hz, 1H), 8.26 (d, J = 9.2 Hz, 1H). 
FTIR (ATR, cm-1): 3658-2052 (bs, N-H+ st), 2970 and 2865 (C-H, C-Har st) 1458 (-CH2-, 
CH3 δ).  
EA (%): Found: C, 39.6; H, 6.5; N, 7.8; Calc. for C18H32N3O8Cl1P2: C, 41.9; H, 6.25; N, 8.1. 
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General procedure XIII). PQ-salt (350 mg, 0.77 mmol). The product was obtained as a 
brown gel (199 mg, 99 %). 
1H NMR (400 MHz, CD2Cl2) δ (ppm): 1.29 (d, J = 6.4 Hz, 3 H, H-12), 1.56 (bs, H-13, H-14 
and  
-NH2), 1.70 (m, 1H, H-13), 2.68 (t, J = 6.8 Hz, 2H, H-15), 3.62 (qd, 1H, H-11), 3.87 (s, 3H, 
H-10), 6.06 (d, J = 7.6 Hz, 1H, -NH), 6.28 (d, J = 2.4 Hz, H-5), 6.35 (d, J = 2.4 Hz, 2H, H-7), 
7.31 (dd, J = 8 Hz and J = 4 Hz, 1H, H-2), 7.94 (dd, J = 8.0 Hz and J = 1.6 Hz, 1H, H-3), 
8.50 (dd, J = 4.4 Hz and J = 1.6 Hz, 1H, H-1). 
1H NMR (400 MHz, (CD3)2SO) δ (ppm): 1.21 (d, J = 6.0 Hz, 3 H), [1.35-1.71] (m, 4H), 2.54 
(t, J = 6.8 Hz, 2H), 3.59 (m, 1H), 3.82 (s, 3H), 6.12 (d, J = 8.4 Hz, 1H), 6.24 (d, J = 2.4 Hz, 
1H), 6.35 (d, J = 2.4 Hz, 1H), 7.42 (m, 1H), 8.07 (dd, J = 8.4 Hz and J = 1.6 Hz, 1H), 8.53 
(dd, J = 4.4 Hz and J = 1.6 Hz, 1H). 
13C NMR (100 MHz, CD2Cl2) δ (ppm): 20.8 (C-12), 30.9 (C-14), 34.6 (C-13), 42,8 (c-15), 
48.5 (C-11), 55.7 (C-10), 92.0 (C-7), 97.0 (C-5), 1223 (C-2), 130.5 (C-4), 130.5 (C-4), 
135.2 (C-3), 135.9 (C-9), 144.8 (C-1), 145.7 (C-8), 160.1 (C-6). 
FTIR (ATR, cm-1): 3385 (N-H st), 2933 and 2852 (C-H, C-Har st), 1456 (-CH2-, CH3 δ).  
EA (%): Found: C, 67.85; H, 9.0; N, 16.5; Calc. for C15H21N3: C, 69.5; H, 8.2; N, 16.2. 
 
Primaquine salt (PQs) 
Commercial product (Aldrich), orange solid. 
1H NMR (400 MHz, (CD3)2SO) δ (ppm): 1.22 (d, J = 6.4 Hz, 3 H), [1.55-1.73] (m, 4H), 2.78 
(t, J = 7.2 Hz, 2H), 3.66 (m, 1H), 3.82 (s, 3H), 4.89 (bs), 6.16 (d, J = 9.2 Hz, 1H), 6.29 (d,  
J = 2.4 Hz), 6.49 (d, J = 2.4 Hz, 1H), 7.43 (m, 1H), 8.08 (dd, J = 8.4 Hz and J = 1.6 Hz, 1H), 
8.54 (dd, J = 4.4 Hz and J = 1.6 Hz, 1H). 
FTIR (ATR, cm-1): 3416-2154 (bs, N-H+ st), 2866 (C-H, C-Har st).  
EA (%): Found: C, 38.8; H, 6.1; N, 9.35; Calc. for C15H21N3O9P2: C, 39.6; H, 5.9; N, 9.2. 
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General procedure XIII). QN-salt (1000 mg, 2.11 mmol). The pure product was 
obtained as a yellow gel (822 mg, 97 %). 
1H NMR (400 MHz, CD2Cl2) δ (ppm): 0.91 (t, J = 7.2 Hz, 6H, H-21), 1.28 (d, J = 6.4 Hz, 3H, 
H-16), 1.57 (m, 2H, H-18), 1.70 (m, 2H, H-17), 2.34 (td, J = 7.2 Hz and J = 1.2 Hz, 2H,  
H-19), 2.41 (q, J = 7.2 Hz, 4H, H-20), 3.97 (s, 3H, H-14), 4.05 (qd, 1H, H-15), 4.56 (d,  
J = 10.4 Hz, 1H, -NH), 7.27 (d, J = 2.8 Hz, H-11), 7.34 (dd, J = 9.2 Hz and J = 2.4 Hz, 1H,  
H-3), 7.41 (dd, J = 9.6 Hz and 2.8 Hz, 1H, H-9), 7.96 (d, J = 9.2 Hz, 1H, H-8), 8.02 (d,  
J = 2.0 Hz, 1H, H-5), 8.06 (d, J = 9.6 Hz, 1H, H-2). 
1H NMR (400 MHz, (CD3)2SO) δ (ppm): 0.75 (t, J = 6.8 Hz, 6H), 1.25 (m, 1H), 1.35 (m, 
3H), 1.56 (m, 1H), 1.73 (m, 1H), 2.15 (t, J = 6.4 Hz, 2H), 2.21 (q, J = 7.2 Hz, 4H), 3.94 (s, 
3H), 3.98 (m, 1H), 6.30 (d, J = 10.0 Hz, 1H), 7.38 (dd, J = 9.2 Hz and J = 2.0 Hz), 7.43 (dd, 
J = 9.6 Hz and J = 2.8 Hz, 1H), 7.59 (d, J = 2.4 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.92 (d,  
J = 2.0 Hz, 1H), 8.31 (d, J = 9.2 Hz, 1H). 
13C NMR (100 MHz, CD2Cl2) δ (ppm): 12.1 (C-21), 22.6 (C-16), 24.7 (C-17), 37.5 (C-18), 
47.4 (C-20), 53.3 (C-19), 56.1 (C-14), 56.6 (C-15), 99.9 (C-11), 117.9 (C-1), 119.9 (C-9), 
[124.9-125.1-125.2] (C-2, C-3 and C-9), 128.9 (C-5), 132.2 (C-8), 134.9 (C-4),  
[147.6-148.9] (C-6 and C-7), 149.9 (C-13), 156.7 (C-10).  
FTIR (ATR, cm-1): 3312 (N-H st), 2968 and 2800 (C-H C-Har st), 1466 (-CH2-, CH3 δ). 
EA (%): Found: C, 67.7; H, 7.8; N, 9.9; Calc. for C23H30N3OCl: C, 69.1; H, 7.6; N, 10.5. 
Quinacrine salt (QNs) 
Commercial product (Aldrich), yellow solid. 
1H NMR (400 MHz, (CD3)2SO) δ (ppm): 1.08 (t, J = 7.2 Hz, 6H), 1.58 (m, 2H), 1.64 (d, J = 
6.5 Hz, 3H), 1.82 (m, 1H), 2.08 (m, 1H), [2.86-3.01] (m, 6H), 4.00 (s, 3H), 4.53 (m, 1H), 
7.56 (dd, J = 9.2 Hz and J = 2.0 Hz), 7.71 (dd, J = 9.2 Hz and J = 1.0 Hz, 1H), 7.96 (d, J = 
9.2 Hz, 1H), 8.04 (d, J = 2.0 Hz, 1H), 8.43 (bs, 1H), 9.44 (bs, 1H), 10.07 (bs, 1H). 
FTIR (ATR, cm-1): 3533-2490 (bs, N-H+ st).  
EA (%): Found: C, 54.25; H, 7.1; N, 8.3; Calc. for C23H32N3OCl3: C, 58.4; H, 6.8; N, 8.9. 
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7.1.5.3- Tris(benzyltriazolylmethyl)amine (TBTA) 
Benzyl azide (BnN3) 
N3
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Sodium azide (2.09 g, 32.15 mmol, 1.10 eq.) was dissolved into dimethyl sulfoxide (200 
mL) at 50ºC. Benzyl bromide (3.47 mL, 29.23 mmol, 1.00 eq.) was added drop wise. 
The reaction mixture was stirred at 50ºC during 3 hours. Then, water (200 mL) was 
added to it and the product was extracted with diethyl ether (3 x 100 mL). The organic 
phase was washed with brine (3 x 100 mL) and was dried over anhydrous MgSO4. The 
solvent was evaporated under reduce pressure. The product was obtained as a light 
yellow oil (3.81 g, 98%). 
1H NMR (400 MHz, CDCl3) δ (ppm): 4.35 (s, 2H, H-5), [7.32-7.43] (m, 5H, H-1 to H-3). 
13C NMR (100 MHz, CDCl3) δ (ppm): 54.7 (C-5), 128.2 (C-3), 128.3 (C-1), 128.8 (C-2), 
135.3 (C-4). 
Tris(benzyltriazolylmethyl)amine (TBTA) 
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Tripropargylamine (1.26 mL, 8.89 mmol, 1.00 eq.) was dissolved into acetonitrile (15 
mL). Benzylbromide (3.82 g, 28.71 mmol, 4.50 eq.), 2,6-lutidine (1.03 mL, 8.89 mmol, 
1.00 eq.) and Cu(MeCN)4+,PF6- (129 mg, 3.6x10-1 mmol, 3.9x10-2 mmol) were 
successively added to the reaction mixture. The reaction mixture was stirred at room 
temperature during 2 days. The product precipitated as white needle crystals. It was 
recovered by filtration and was washed with cold methanol (2.00 g, 42 %).  
1H NMR (400 MHz, CDCl3) δ (ppm): 3.65 (s, 6H, H-8), 5.48 (s, 6H, H-5), [7.23-7.35]  
(m, 15H, H-1, H-2 and H-3), 7.62 (s, 3H, H-6). 
13C NMR (100 MHz, CDCl3) δ (ppm): 47.2 (C-8), 54.0 (C-5), 123.7 (C-6), 128.02 (C-3), 
128.5 (C-1), 129.0 (C-2), 135.4 (C-4), 144.5 (C-7). 
MS (ESI+) m/z (%): 553.0 (15) [C30H30N10,Na]+;  531.1 (100) [[C30H30N10,H]+. 
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7.2- Working protocols 
 
7.1.1- General working protocols and apparatus 
 Ultraviolet-visible absorbance measurements were performed with a 
Varian Cary50 Probe UV-visible spectrophotometer (unless otherwise specified) 
and Fluorescence measurements were performed with a Perkin Elmer LS 55 
fluorescent spectrophotometer (unless otherwise specified) using quartz cells. 
UV-Vis and fluorescence measurements were performed in distilled water or 
DMSO spectrophotometric grade (Sigma-Aldrich®). 
 Liophilization processes were performed with a Teslar Cryodos 50 
liofilizador. Samples were frozen in liquid nitrogen prior to liophilization. 
 Vigorous rotational stirring was performed with an IKA KS 130 basic 
orbital shaker. 
 Dynamic light scattering measurements of the amphiphilic Janus and 
pDNA/siRNA dendriplexes samples were performed with a Brookhaven 
Instruments Corporation 90 plus particle size analyzer with a laser with a 
wavelength of 658 nm at concentrations of 1 mg/mL and at 25ºC. Dynamic light 
scattering measurements of the HDLDBCs samples were performed with 
Malvern Instruments Nano ZS with a laser with a wavelength of 633 nm at 
concentrations of 1 mg/mL at 25, 37 and 45ºC. Dynamic light scattering 
measurements of the Pluronic® F-127 sample were performed in the same 
conditions but at a concentration of 2 mg/mL, i.e. > CMC. The samples were not 
filtrated before measurements and the results are given applying two 
mathematical data treatments, the intensity average and the number average.  
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 Transmission electron microscopy (TEM) images were obtained with a 
FEI TECNAI T20 with beam power 200kV using holey carbon film 300 mesh 
coppered grids provided by Agar Scientific Ltd. A droplet of an aqueous solution 
of the samples at the concentration of 1 mg/mL was deposited on the grid and 
let penetrate during 30 seconds; the excess of the aqueous solution was 
removed using a filter paper. A phosphotungstic acid, 3% aqueous solution was 
used as negative stain; a droplet of the stain solution was deposited on the 
sample grid and let penetrate during 10 seconds; the excess of the staining 
aqueous solution was removed using a filter paper. The grid was dried during at 
least 24 hours under atmospheric pressure. The average size of the different 
aggregates measured by TEM was obtained by comparing at least 100 
aggregates in at least 4 photos. 
 Cryogenic transmission electron microscopy (cryoTEM) images were 
obtained with a FEI TECNAI T20 with beam power 200kV using quantifoil carbon 
film 300 mesh coppered grid or lacey carbon film 300 mesh coppered grids 
provided by Agar Scientific Ltd. Quantifoil grids were previously ionized using a 
plasma cleaner whereas lacey carbon grids were previously ionized using UV 
light irradiation or using a glow-discharge apparatus. A droplet (60 μL) of an 
aqueous solution of the samples was deposited on the grid. Sample vitrification 
was automatically processed using a vitrobot (FEI) and performed in liquid 
ethane. A specific sample holder, Gatan for cold samples, was used to stock the 
grids in liquid nitrogen prior to observation with the microscope.  
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7.2.2- Study of the amphiphilic dendritic 
derivatives for camptothecin delivery 
 
Bis-GMPA dendrons degradation  
 The bis-GMPA dendrons degradation was observed by 1H NMR. 10 mg of 
the dendrons were dissolved into 0.7 μL of D2O or D2O+H2SO4. The samples 
were stocked at 37ºC while 1H NMR spectra were recorded at different times.  
Formation of the aggregates in water   
 As the majority of the Janus dendrimers could not be directly solubilized 
in water at room temperature, all the aggregates formed in water by the Janus 
dendrimers were prepared following the oil-in-water procedure.[95] Each Janus 
dendrimer was dissolved at a concentration of 1 mg/mL in dichloromethane, a 
volatile and water-immiscible solvent. An appropriate volume of distilled water 
was added to obtain a final concentration of 1 mg/mL in water. The mixtures 
were vigorously rotationally stirred at room temperature under ventilation until 
the organic solvent was completely evaporated. 
 The aggregates formed by the HDLDBCs and the Pluronic® F-127 were 
prepared taking advantages of the LCST of the materials. An appropriate volume 
of distilled water was added to each derivative in order to obtain a final 
concentration of 1 or 2 mg/mL in water. The samples were placed 30 min at 4ºC 
to favor the total dissolution of the derivatives in water. Then, they were slowly 
heated to room temperature.[193] 
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
[193] I Jiménez-Pardo, Hidrogeles termosensibles y fotopolimerizables derivados de Pluronic® 
para aplicaciones biomédicas, 2014, Univerisdad de Zaragoza. 
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Determination of the critical aggregation concentration (CAC) using the nile 
red technique 
 The CAC of the amphiphilic Janus dendrimers, HDLDBCs and Pluronic®  
F-127 was determined using nile red as a solvatochromic fluorophore which 
fluorescence spectrum (λext = 550 nm) is different according to the hydrophilicity 
of its environment.[191] Below the CAC, the nile red is in a hydrophilic 
environment, i.e. water, and presents low fluorescence emission (λmax = 653 
nm). In contrast, above the CAC, Nile red migrates to the lipophilic inner part of 
the aggregates and presents intense fluorescence emission (λmax ≈ 630 nm) 
(figure C7-1). 
 
Figure C7-1: Fluorescence spectra of Nile red after excitation at 550 nm in an 
hydrophilic environment, i.e. water, (λmax = 653 nm) and in an lipophilic environment, 
i.e. after encapsulation within (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2](C17)4 (λmax = 635 
nm). 
 The aqueous dissolution of the samples with a volume of 2 mL and an 
adequate concentrations ranging were prepared as described before (protocol 
A). Nile red was dissolved in ethanol at a concentration of 2.5 x 10–1 mM and 10 
µL of this solution was added to the dendritic derivatives solutions. In the 
specific case of (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G2](C17)4, the concentration of 
the Nile red solution was lower (0.83 x 10–1 mM) in order to avoid precipitation. 
                                                          
[191] M.C.A. Stuart, J. Phys. Org. Chem., 2005, 18, 929. 
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The mixtures were vigorously rotationally stirred at room temperature for 1 
hour in the dark with an orbital shaker. The emission spectrum of each sample 
dissolution was measured (λmax ≈ 660 nm or λmax2 = 635 nm) after excitation at 
λexc = 550 nm. 
 This technique was preferred to the pyrene technique[242] employed 
before in the Crystal Liquid and Polymers group due to interactions between the  
terminal amino groups of the dendritic derivatives and pyrene that modified the 
pyrene fluorescent properties. 
Encapsulations of camptothecin (CPT) and modified rhodamine B (RhB(C17)2) 
 The solvent diffusion technique was employed to encapsulate 
camptothecin (CPT) inside the aggregates.[203] Firstly, CPT was dissolved in 
DMSO and was added to the previously prepared aggregates under the 
following conditions: 100 µg of CPT per mg of dendritic derivatives were added 
and the volume of DMSO was adjusted to obtain a final concentration of CPT in 
DMSO of 200 µg/mL. The mixtures were stirred at 4 °C for 12 hours to allow CPT 
to reach the lipophilic core of the aggregates. DMSO was removed by dialysis 
against distilled water at 4 °C using a 1000 Dalton membrane. The volume of the 
samples after dialysis was measured. The non-encapsulated camptothecin 
precipitated during the dialysis and was removed by filtration to obtain the 
dendrimer/CPT conjugates.  
 The concentration of encapsulated camptothecin was directly measured 
by fluorescence (λmax = 436 nm and λexc = 368 nm) in DMSO. Two aliquots, 400 
μL each, were freeze-dried and then redissolved in DMSO for to break down the 
aggregates and allow the immediate and total release of camptothecin.  
                                                          
[242] J. Aguiar, P. Carpena, J.A. Molina-Bolıv́ar, C. Carnero Ruiz, On the determination of the 
critical micelle concentration by the pyrene 1:3 ratio method, J. Coll. Interface Sci., 2003, 258, 
116-122. 
[203] I. Jiménez-Pardo et al., Macromol. Biosci., 2015, 15, 1381. 
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 The encapsulation process was repeated at least two times for each 
dendritic derivatives/CPT conjugate.  
 The oil-in-water technique was employed to encapsulate modified 
rhodamine (RhB(C17)2) within the amphiphilic Janus. Each Janus dendrimer was 
dissolved at a concentration of 1 mg/mL in dichloromethane. An appropriate 
amount of RhB(C17)2 was added to each dissolution in order to obtain a 
concentration of RhB(C17)2 equal to 0.15 mg/mL in dichloromethane. Then, an 
appropriate volume of distilled water was added to obtain a final concentration 
of 1 mg/mL of amphiphilic Janus dendrimer in water. The mixtures were 
vigorously rotationally stirred at room temperature under ventilation until the 
organic solvent was completely evaporated. As any precipitate was observed in 
the final aqueous dissolution, it was assumed that all RhB(C17)2 was 
encapsulated. The encapsulation process was repeated at least two times for 
each dendritic derivatives/RhB(C17)2 conjugate. 
 The two previous encapsulation protocols were employed for the 
RhB(C17)2 and CPT co-encapsulation within the amphiphilic Janus dendrimers. 
Firstly, RhB(C17)2 was encapsulated within the dendrimers according to the oil-
in-water procedure and secondly, CPT was encapsulated within the 
dendrimers/RhB(C17)2 conjugates following the solvent diffusion procedure. 
The quantity of CPT that could be encapsulated within the dendritic 
nanocarriers was directly determined by fluorescence as explained before. As 
the excitation and maximal fluorescence emission wavelengths of CPT were 
lower (368 and 413 nm, respectively) than the ones of RhB(C17)2 (540 and 580 
nm respectively), any interference occurred during the measurements. 
 The encapsulation process was repeated at least two times for each 
dendritic derivatives/RhB(C17)2/CPT conjugate. 
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Modified rhodamine B (RhB(C17)2) and rhodamine B releases 
 The RhB(C17)2 release outside the dendrimer/RhB(C17)2 conjugates was 
studied by dialysis. 2 mL of the dendrimer/RhB(C17)2  conjugates containing 
0.15 mg/mL of encapsulated RhB(C17)2 were dialyzed against distilled water 
(200 mL) using a dialysis membrane (1000 Da cut-off). Aliquots (2mL) were 
withdrawn from the water dialysis at different times during 72 hours. The 
quantity of RhB(C17)2 in the water dialysis was measured by fluorescence at 
different times (λexc = 540 and λmax =580 nm). Additionally, unmodified water 
soluble rhodamine B fluorophore was encapsulated within (NH3+Cl-)4 
[bisGMPA,G2]-[bisMPA,G1](C17)2 in order to compare its release profile with 
RhB(C17)2. 
Evaluation of the anti-Hepatitis C activity of the dendritic derivatives/ 
camptothecin conjugates 
(protocol carried out by Rafael Clavería-Gimeno) 
 These biological studies were performed with the highly permissive cell 
clone Huh 7-Lunet, as well as Huh 7 cells containing subgenomic (HCV) 
replicons I389luc-ubi-neo/NS3-3'/5.1 (Huh 5-2), I377NS3-3'/wt (Huh 9-13), or 
I389/hygro-ubi-NS3-3/5.1 (a kind gift from Dr. V. Lohmann and Dr. R. 
Bartenschlager).[243] Briefly, this system allowed the efficient propagation of 
genetically modified HCV RNAs (replicons) in a human hepatoma cell line (Huh). 
                                                          
[243] a) J. Courcambeck, M. Bouzidi, R. Perbost, B. Jouirou, N. Amrani, P. Cacoub, G. Pepe, J.M. 
Sabatier, P. Halfon, Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms 
of drug resistance induced by R155Q, A156T, D168A and D168V mutations, Antiviral Therapy, 
2006, 11, 847-855; b) S. Susser, J. Vermehren, N. Forestier, M.W. Welker, N. Grigorian, C. 
Fuller, D. Perner, S. Zeuzem, C. Sarrazin, Analysis of long-term persistence of resistance 
mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or 
boceprevir, J. Clin. Virol., 2011, 52,321-327; c) K.J. Blight, J.A. McKeating, C.M. Rice, Highly 
permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication, J. Virol., 
2002, 76, 13001-13014; d) V. Lohmann, F. Korner, J. Koch, U. Herian, L. Theilmann, R. 
Bartenschlager, Replication of  subgenomic hepatitis C virus RNAs in a hepatoma cell line, 
Science, 1999,285,110-113. 
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The amount of RNA that has been transcribed and translated is determined 
through the quantification of a reporter contained in the replicon system 
(luciferase). The amount of luminescence detected (after adding the substrate 
specific for this enzyme) is proportional to the virus replication rate. Cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% 
heat-inactivated fetal bovine serum, 1x non-essential amino acids, 100 IU/mL 
penicillin, 100 µg/mL streptomycin, and 250 µg/mL geneticin (G418). 
 The antiviral assays for determining the efficacy of the dendritic 
derivative/CPT conjugates were performed as described in the literature.[243,244] 
Briefly, Huh5-2 cells were seeded at a density of 7.103 cells per well in a tissue 
culture-treated white 96-well view plate (Techno Plastic Products AG) in 
complete DMEM supplemented with 250 µg/mL G418. After incubation for 24 h 
at 37 °C, the medium was removed and two-fold serial dilutions in complete 
DMEM (without G418) of the dendritic derivative/CPT and dendritic derivatives/ 
RhB(C17)2/CPT conjugates were added in a total volume of 100 µL (final CPT 
concentrations from 1 or 2 µM to 0 µM). After 3 days of incubation at 37 °C, 
luciferase activity was determined using the Bright-Glo Luciferase Assay System 
(20 µL). The luciferase signal was measured using a Synergy HT 50 Multimode 
Reader (BioTek Instruments). Luciferase signal levels obtained in each assay 
were normalized using internal patterns previously determined in Huh5-2 cells. 
The 50 % effective concentration (EC50) was defined as the concentration of 
compound that reduced the luciferase signal by 50%.  
 The cytostatic assays for measuring the cell viability of all the dendritic 
derivatives/CPT and dendritic derivatives/RhB(C17)2/CPT conjugates were 
performed as described in the literature.[243,244] Briefly, Huh5-2 cell lines were 
seeded at a density of 7x103 cells per well of a 96-well plate in complete DMEM 
                                                          
[244] A. Urbani, R. Bazzo, M. C. Nardi, D. O. Cicero, R. De Francesco, C. Steinkuhler, G. Barbato, 
The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation, J. 
Biol. Chem. 1998, 273, 18760-18769. 
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(with the appropriate concentrations of G418 in the case of Huh 5-2). Serial 
dilutions of the dendrimer/CPT aggregates in complete DMEM (without G418) 
were added 24 h after seeding. Cells were allowed to proliferate for 3 days at 37 
°C. Cell culture medium was removed and cell number was determined by 
CellTiter 96 AQueous One Solution Cell Proliferation Assay. The 50% cytostatic 
concentration (CC50) was determined employing the dose–response equation 
(i.e., Hill equation). All experiments on Huh5-2 cells were carried out in triplicate 
and each experiment was repeated on three different days. 
Cellular uptake of the dendrimer/CPT and dendrimer/RhB(C17)2/CPT 
conjugates (protocol carried out by Rafael Clavería-Gimeno) 
 The cellular uptake of the dendrimer/CPT conjugates and dendrimer/ 
RhB(C17)2/CPT conjugate were studied by flow cytometric assays performed 
with an ImageStream X Amnis® Cytometer and the results were analyzed with 
an IDEAS® software. Cytometry assays were performed in a similar way that 
antiviral and cytostatic assays. After being seeded, cells were incubated with 
free CPT, dendrimer/CPT conjugates, dendrimer/RhB(C17)2  conjugates and 
dendrimer/RhB(C17)2/CPT conjugates with a concentration of 2 µM of CPT for 3 
days at 37ºC. A control treated only with DMEM was made. Then, cells were 
picked up in a volume of 200 µl and were washed three times with PBS by 
centrifugation at 1500 rpm. 30 μL of propidium iodide (PI) solution (1 mg/mL) 
was added to the cells and the samples were shaken in a vortex and incubated 
in darkness for 3 minutes to mark the cellular cycle before being introduced into 
the cytometer. RhB(C17)2  (λext = 507 nm, λdect = 529 nm) and PI (λext = 535 nm, 
λdect = 610 nm) were detected in two different channels. 
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7.2.3- Study of the globular dendritic derivatives 
for gene transfection 
 
Determination of the amount of copper in the globular dendritic derivatives 
after the CuAAC 
  The quantities of copper that remained entrapped in the final globular 
dendritic derivatives after the CuAAC were determined by inductively coupled 
plasma atomic emission spectroscopy (ICP-AES) performed on a Thermo 
elemental IRIS intrepid apparatus, with a limit of quantification (LOQ) of 15 
ppm. 
pH measurements 
 The pH of the solutions was measured after each addition by a Hanna HI 
8424 pH meter with a HI 1110B electrode.  
 The titrations were carried out by adding small volumes of NaOH (0.1 M) 
into an aqueous dissolution of the dendritic derivatives. After each addition of 
NaOH, the pH of the samples was measured. Theoretical pKA calculations were 
performed by MarvinSketch® program.[245] 
 The “buffer sponge” ability of the dendritic derivatives was determined 
by dissolving 4 mg of them into 20 mL of a 0.1 M NaCl aqueous dissolution. pH 
was set to 11 using NaOH (1M) and titrated to 3.2 by successive additions of 10 
μL of HCl 0.1M.[215a] 
                                                          
[245] Mª Elena Fuentes Paniagua, Tesis Mª Elena Fuentes Paniagua - Síntesis de 
marcromléculas dendríticas catiónicas de estructuras carbosilano y sus aplicaciones en 
biomedicina, 2015, Univerisdad de Alcalá de Henares,  
[215a] J.C. Sunshine et al., Mol. Pharm., 2012, 9, 3375. 
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Complexation of pDNA and siRNA by the globular dendritic derivatives 
(protocols carried out in collaboration with Rebeca González) 
 Dendriplexes were freshly prepared by adding pDNA or siRNA to 
dendritic derivatives solutions diluted in serum-free medium (SFM). The 
solutions were mixed by vigorous pipetting and incubated for 20 min at room 
temperature. Gel retardation assays[246] were performed to study pDNA and 
siRNA complexation by the dendritic derivatives. 15 μL of freshly prepared 
dendriplexes at different ratios, from 1:1 to 200:1 (w:w), containing 0.25 μg of 
pDNA (pEGFP)  or 0.3 µg siRNA (siGFP), were mixed with appropriate amounts 
of 6X loading buffer (Takara, UK) and then electrophoresed on a 0.8% (w/v) 
agarose gel in 1X TAE (40 mM TRIS/HCl, 1% acetic acid, 1 mM EDTA, pH 7.4) 
containing SyberSafe for 30 min at 95 V. The location of pDNA and siRNA in the 
gel was analyzed on a G:Box UV transilluminator (Syngene, UK).    
 Dendriplexes were freshly prepared by adding pDNA or siRNA to 
dendritic derivatives solutions diluted in a NaCl-HEPES buffer, containing 6 mM 
of HEPES buffer pH 7.4 and 144 mM of NaCl, filtered through a 0.2 μm pore size 
cellulose membrane 25 mm filter (ChemLab®). The solutions were mixed by 
vigorous pipetting and incubated for 30 min at room temperature. ζ potential 
measurements[246] were performed to study the pDNA and siRNA complexation 
with a MalvernTM Instruments Nano ZS using DTS 1070 folded capillary cells 
(provided by Iesmat, S.A.). The dendriplexes were prepared at a concentration 
of 10 µg/mL of pDNA or siRNA and with concentrations of pseudodendrimers 
comprised between 4.5 and 2000 µg/mL. Three measurements with a minimum 
of 10 scans were carried out for each sample.  
  
                                                          
[246] D. Shcharbin, E. Pedziwiatr, M. Bryszewska. How to study dendriplexes I: 
Characterization, J. Control. Release, 2009, 135, 186-97. 
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Biocompatibility of the bis-GMPA dendrons and globular dendritic derivatives 
(protocols carried out by Rebeca González) 
 Mesenchymal stem cells (MSCs) from mousse origin (Lonza) were grown 
in DMEM/F12 (Biowest) supplemented with 10% FBS (Gibco), 1% Penicillin/ 
Streptomycin/Amphotericin (Biowest) and 2 mM L-glutamine (Biowest) and 
maintained under hypoxic conditions (3% O2). Human cervix cancer cell line 
HeLa were maintained in DMEM High Glucose (w/Glutamine, Biowest) 
supplemented with 10% FBS and 1% Pencillin/Streptomycin/Amphotericin at  
37 ºC and 5% CO2 in a humidified atmosphere.[184] 
 For cytotoxicity evaluation, cells were seeded at a density of 5 × 103 cells 
per well in 96 multiwell culture plates. After 24 h incubation, the culture 
medium was removed and 100 μL of DMEMc with increasing concentrations of 
the corresponding dendritic derivatives were added (0.1–1 mg/mL). After  
24–72 h the solutions were replaced by 100 μL of fresh DMEM and 10 μL of 
Alamar Blue® dye solution (Thermo Fisher Scientific). Upon entering the cells, 
resazurin, the active ingredient of the dye, was reduced to resorufin, which 
produced very bright red fluorescence. After incubation for 3 h at 37 ºC, 
fluorescence was read (λext = 530, λem = 590) on a Synergy HT (BioTek, USA) plate 
reader. Untreated cells incubated with medium without dendritic derivatives 
were used as control and cytotoxicity is expressed as the relative viability of the 
cells compared to control cells (considered as 100% viability). Four replicates 
per concentration were assayed in each of the three independent experiments 
performed.  
  
                                                          
[184] R. González, Estudio de dendrímeros y nanopartículas de oro para su uso en 
tratamientos antitumorales, 2017, Universidad de Zaragoza. 
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In vitro transfection 
(protocols carried out by Rebeca González) 
 Mesenchymal stem cells (MSCs) from mousse origin (Lonza) were grown 
in DMEM/F12 (Biowest) supplemented with 10% FBS (Gibco), 1% Penicillin/ 
Streptomycin/Amphotericin (Biowest) and 2 mM L-glutamine (Biowest) and 
maintained under hypoxic conditions (3 % O2). Human cervix cancer cell line 
HeLa, MDCK-GFP (Madin-Darby Canine Kidney expressing GFP) and SKOV3-Luc 
derived from human ovarian carcinoma and expressing Luciferase (kindly 
obtained from Cancer Research-UK Cell services) were maintained in DMEM 
High Glucose (w/Glutamine, Biowest) supplemented with 10% FBS and 1% 
Pencillin/ Streptomycin/Amphotericin at 37 ºC and 5% CO2 in a humidified 
atmosphere.[184] 
 MSCs and HeLa were seeded at a density of 1 × 104 cells per well in 96-
well plates 24 h prior to in vitro transfection. In positive control experiments, 
pEGFP, siGFP and siLuc were mixed with Lipofectamine (Thermo Fisher 
Scientific) at a 3:1 w:w ratio in SFM. 50 µL of dendriplexes consisting of 0.1–0.4 
µg of pEGFP and the adjusted amount of dendritic derivatives to obtain the 
desired (wdend./wpDNA/siRNA) ratios were prepared in SFM. After incubation at 
room temperature for 20 min, complexes were added in duplicate to each well 
and incubated for 4 h. EGFP expression was evaluated by fluorescence 
microscopy (Olympus IX81 Olympus, Spain) at 24-48 h. For quantification of 
EGFP by flow cytometry, cells were seeded at a density of 5 × 105 cells per well 
in 6-well plates and incubated with 750 µL of dendriplexes with 5-100 nM siGFP 
for 4h. For quantification of Luciferase with Bright-Glo™ Assay Reagent 
(Promega), after 72h of transfection with siLuc, media was changed for 100 µL 
fresh complete DMEM, 100 µL of Bright-Glo™ Assay Reagent (lysis buffer and 
luciferin) were added and cells were lysed by pipetting. After 5 minutes, all the 
content was transferred to an opaque 96 well plate (Nunc) in dark. 
Luminiscence was read was read on a Synergy HT (Biotek). 
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7.2.4- Study of the dendritic derivatives as 
antimalarial nanocarriers 
 
Encapsulation of the antimalarial drug within the dendritic derivatives 
 The oil-in-water procedure was employed to encapsulate the hydrophilic 
form of the antimalarial drugs (PQ-salt, QN-salt and CQ-salt) within the 
HDLDBCs.[95] The HDLDBCs were dissolved into DCM at a concentration of 1 
mg/mL. An appropriate volume of a dissolution of the hydrophilic drugs in 
distilled water (1 mg/mL) was added to obtain final concentrations of HDLDBC 
of 1 mg/mL in water. The samples were vigorously rotationally stirred at room 
temperature under ventilation until complete evaporation of DCM (around 2 
hours). The non-encapsulated drugs were removed by dialysis (regenerated 
cellulose membrane, MW 1000 Da cut off) against distilled water (200 mL) at 
4ºC during 16h. The final volumes of the dissolutions were measured. The 
amounts of encapsulated drug were indirectly measured: the quantities of drugs 
were determined in the dialysis water by UV-VIS spectrometry (λCQs = 345 nm, 
λPQs =259 nm, λQns = 280 nm) and were subtracted to the initial quantity of drug.  
 The oil-in-water procedure was employed to encapsulate the hydrophilic 
form of the antimalarial drugs (PQ-salt, QN-salt and CQ-salt) within the DHPs 
was performed following the oil-in-water procedure. The DHPs and the 
hydrophilic drugs were dissolved into distilled water at the respective 
concentrations of 5 mg/mL of DHPs and 2.5 mg/mL of drugs. A volume of 
dichloromethane equivalent to the one of distilled water was added. The 
samples were vigorously rotationally stirred at room temperature under 
ventilation until complete evaporation of DCM. The non-encapsulated drugs 
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35, 7940. 
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were removed by dialysis (regenerated cellulose membrane, MW 1000 Da  
cut-off) against distilled water (200 mL) at 4ºC during 16h. The final volumes of 
the dissolutions were measured. The final volume of the dissolutions was 
measured. The amounts of encapsulated drugs were indirectly measured: the 
quantities of drugs were determined in the dialysis water by UV-VIS 
spectrometry (λCQs = 345 nm, λPQs =259 nm, λQns = 280 nm) and were subtracted 
to the initial quantity of drug.  
 The oil-in-water procedure was performed to encapsulate the 
hydrophobic form of the antimalarial drugs (PQ-base, QN-base and CQ-base) 
within the HDLDBCs. The HDLDBCs were dissolved in water at the concentration 
of 1.00 mg/mL. The lipophilic drugs were dissolved into dichloromethane at the 
concentration of 1.00 mg/mL and were mixed with the HDLDBCs dissolutions at 
the ratio (wHDLDBCs/wdrug) 1/1. The samples were vigorously rotationally stirred at 
room temperature under ventilation until complete evaporation of 
dichloromethane. NaOH (1 M in distilled water) was added to the dissolutions 
until pH 10 was reached. The non-encapsulated drugs precipitated and were 
removed by filtration through 0.2 μm pore size cellulose membrane 25 mm 
filter (ChemLab®). The final volumes of the dissolutions were measured. The 
amounts of encapsulated drugs were directly measured: the quantities of drugs 
were determined by withdrawing two aliquots of 100 µL, diluting them with 
1.90 mL of DMSO and measuring their UV-VIS absorbance (λCQb = 340 nm, λPQb = 
366 nm, λQnb = 420 nm).  
 The oil-in-water procedure was performed to encapsulate the 
hydrophobic form of the antimalarial drugs (PQ-base, QN-base and CQ-base) 
within the DHPs. The DHPs were dissolved in water at the concentration of 5.00 
mg/mL. The lipophilic drugs were dissolved into dichloromethane at the 
concentration of 2.50 mg/mL for CQ-base, 3.75 mg/mL for PQ-base and 0.50 
mg/mL for QN-base and were mixed with the DHPs dissolutions at the ratios 
(wHDLDBC/wCQb) 1/0.5, (wDHPs/wPQb) 1/0.75 and (wHDLDBC/wQNb) 1/0.1. The samples 
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were vigorously rotationally stirred at room temperature under ventilation until 
complete evaporation of dichloromethane. NaOH (1 M in distilled water) was 
added to the dissolutions until pH 10 was reached. The non-encapsulated drugs 
precipitated and were removed by filtration through 0.2 μm pore size cellulose 
membrane 25 mm filter (ChemLab®). The final volumes of the dissolutions were 
measured. The amounts of encapsulated drugs were directly measured: the 
quantities of drugs were determined by withdrawing two aliquots of 100 µL, 
diluting them with 1.90 mL of DMSO and measuring their UV-VIS absorbance 
(λCQb = 340 nm, λPQb = 366 nm, λQnb = 420 nm).  
Complexation of heparin by the DHPs 
 The formation of the complexes between the DHPs and heparin was 
studied employing the methylene blue (MB) spectroscopic competition assay 
process.[236] MB is a cationic metachromatic dye that presents a good affinity for 
polyanions. In particular, MB can complex heparin forming a complex that 
displays an indigo color (λmax = 565 nm). When a potential heparin binder is 
added to a MB/heparin complex dissolution, it may compete with MB and bind 
heparin; thus, MB would be released in the solution and displays its natural sky 
blue color (λmax = 665 nm) (figure C7-2).  
 In the Heparin/MB spectrum, two maximums can be observed, one at 
565 nm that corresponds to the MB/heparin complexes and another one at 665 
nm that correspond to the free MB in excess, assuring that all heparin is 
complexed by the MB. When all heparin was complexed by one DHP, MB was 
totally released in the medium and displayed the same UV/Vis spectra that the 
free MB. In addition, DHP/heparin complexes do not present absorbance 
between 400 and 800 nm that could have affected the presence of DHPs do not 
affect the same UV/Vis spectrum of MB.  
 
                                                          
[236] Al-Jamal KT et al., Results in Pharma Sci., 2012, 2, 9. 
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FigureC7-2: UV/Vis spectra of DHP/Heparin/MB (λmax = 665 nm), DHP/MB (λmax = 665 
nm), free MB (λmax = 665 nm), Heparin/MB (λmax = 565 nm) and DHP with heparin (no 
absorbance). 
 Samples containing heparin (10 µg/mL) and methylene blue (50 µM) was 
dissolved into TRIS.HCl pH 7.4 (10 mM) buffer were prepared in 96 multiwell 
culture plates and were gently rotationally stirred at room temperature for 15 
min to allow MB to fully complex heparin. Then, DHPs were added to the 
samples at different (wDHPs/wHep) ratios and the final sample volumes were 
adjusted to 150 μL. They were newly stirred for another 30 min. UV/Vis spectra 
was recorded between 400 and 800 nm with an EPOCH UV/Vis 
spectrophotometer. A665/A565 ratio was calculated to determine the 
complexation between the DHPs and heparin. The experiments were replicated 
in triplicate in the case of the DHPs alone and in duplicate with the DHPs 
containing the encapsulate antimalarial drugs in their salt and base form. 
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Parasite infected red blood cells targeting  
(protocols carried out in collaboration with Elisabet Martí Coma-Cros) 
 The oil-in-water procedure was employed to encapsulate modified 
rhodamine (RhB(C17)2) within the HDLDBCs.[95] Each HDLDBC was dissolved at a 
concentration of 1 mg/mL in water. RhB(C17)2 was dissolved in 
dichloromethane at a concentration of 0.15 mg/mL. An appropriate volume of 
the RhB(C17)2 solution was added to each HDLBC solution in order to obtain a 
(wHDLDBC/WRhB(C17)) ratio of 1/0.15. The mixtures vigorously rotationally stirred at 
room temperature under ventilation until the organic solvent was completely 
evaporated. As any precipitate was observed in the final aqueous dissolution, it 
was assumed that all RhB(C17)2  was encapsulated.  
 Parasite infected red blood cells targeting was studied by fluorescence 
microscopy.[95] Living P. falciparum cultures were synchronized to mature stages 
of the parasite (trophozoites). They were incubated with Hoechst during 30 
minutes in RPMIc in dark at room temperature to stain the parasite nuclei. After 
three washings with RPMIc, parasitemia was decreased to 2 %. Parasite infected 
red blood cells (pRBCs) were incubated during 90 min at 37ºC with gentle 
stirring in dark with the presence of 150 µg/mL of DHP[G3+3](NH3+Cl-,RhB)  with 
0, 5, 10 and 15 %w of heparin or with 75 µg/mL of HDLDBC/RhB(C17)2  
conjugates in RPMIc. After three washings with RPMIc, samples were observed 
in RPMIc in an 8 chambered borosilicate coverglass system in fluorescence 
microscopy. Hoechst fluorescence was observed at λ = 461 nm (λext = 340 nm), 
FITC fluorescence was observed at λ = 518 nm (λext =492 nm) and rhodamine 
fluorescence was observed at λ = 575 nm (λext = 558 nm). Time of exposure was 
of 100 ms for Hoechst and rhodamine derivatives fluorescence and of 1000 ms 
for FITC fluorescence. 
  
                                                          
[95] J. Movellan, P. Urbán et al., Biomaterials, 2014, 35 7940.  
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In vitro plasmodium growing inhibition assays (GIAs) (protocols carried out by 
Elisabet Martí Coma-Cros) 
 Plasmodium falciparum strains 3D7 was grown in vitro in human red 
blood cells (RBCs) type B, haematocrit 3%, using previously described 
conditions.[247] Parasites, thawed from glycerol stocks, were cultured at 37°C in 
T25 flasks with RBCs in Roswell Park Memorial Institute (RPMI) complete 
medium and incubated under a gas mixture of 92% N2, 5% CO2, and 3% O2. 
Culture was synchronize with 5% sorbitol lysis[248 and maintained below 5% 
parasitemia by dilution with washed RBCs.  
 For standard growth inhibition assays (GIAs), parasitemia was adjusted 
to 1.5% parasitemia with more than 90% of rings stages after sorbitol 
synchronization. 150 µL of living parasite in complete medium with different 
concentrations of free drug and dendrimer encapsulating drug were plated in 
96-well plate and incubated for 48h at 37°C, at same gas mixture than 
maintenance. Parasitemia was determined by fluorescent-assisted cell sorting 
(FACS) after staining pRBCs DNA with Syto 11 a nucleic acid dye dilution 1:1000 
for FACS Calibur.  
 
 
 
                                                          
[247] C. Lambros, J.P. Vanderber, Synchronization of Plasmodium falciparum erythrocytic 
stages in culture, J. Parasitol., 1979, 65, 418-420. 
[248] P. Urbán, J. Estelrich, A. Cortés, X. Fernàndez-Busquets A nonovector with complete 
discrimination for targeted delivery to Plasmodium falciparum versus non-infected red blood 
cells in vitro, J. Control. Release, 2011, 151, 202-211. 
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Resumen de la tesis 
 
Introducción 
 
 El transporte y la liberación controlada de fármacos y la terapia génica 
son nuevas herramientas que permiten tratar enfermedades de manera más 
específica limitando los efectos secundarios de los tratamientos. En ambos 
casos, se requiere el empleo de vectores para transportar los genes o los 
fármacos. Estos vectores tienen que proteger su carga del sistema inmune, 
dirigirla de manera específica hacia las células enfermas y liberarla, reduciendo 
por lo tanto las dosis necesarias para obtener un efecto terapéutico y los 
efectos secundarios de las terapias. Además, en el caso del transporte de 
fármacos se puede emplear nuevos fármacos que no pueden ser inyectados 
directamente al paciente por su falta de solubilidad o su inestabilidad en el 
suero fisiológico.[1,2] 
 Dentro de la familia de los polímeros, los dendrímeros presentan 
características muy interesantes para convertirlos en buenos vectores para el 
transporte de genes y de fármacos. De hecho, al contrario de los polímeros 
lineares, los dendrímeros se sintetizan por etapas sucesivas formando 
macromoléculas hiperramificadas que tienen una topología repetitiva en forma 
de árbol. Sus estructuras finales están perfectamente controladas y se obtiene 
macromoléculas uniformes y monodispersas que presentan un alto número de 
grupos terminales en su superficie. Además, presentan unas propiedades muy 
interesantes tales como alta solubilidad,  baja viscosidad, forma tridimensional 
globular que contiene huecos en su estructura capaces de contener moléculas 
pequeñas, etc. 
                                                          
[1] V.P. Torchilin, Nat. Rev. Drug. Discov. 2014, 13, 813. 
[2] H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, D.G. Anderson, Nat. Rev. Genet. 
2014, 15, 541. 
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 Los dendrímeros de tipo polilisina (PLL), poliamidoamina (PAMAM), 
polipropileneimina (PPI) y poliésteres (bis-MPA) han sido ampliamente   
 
 
Figura 1: Representación esquemática de algunas derivados dendríticos. 
investigados para sus aplicaciones en nanomedicina. Dado la dificultad de 
sintetizar dendrímeros globulares de altas generaciones, se han sintetizado e 
investigado nuevos derivados dendríticos: polímeros hiperramificados y 
polímeros hiperramificados dendrónizados (DHPs), dendrímeros Janus, híbridos 
de copolímeros bloque dendrítico-lineal-dendrítico (HDLDBCs), etc. (figura 1).[3] 
 Los dendrímeros de tipo Janus y los HDLDBCs son particularmente 
interesantes para el transporte de fármacos. Estas estructuras permiten la 
síntesis de macromoléculas anfífilas que pueden autoensamblarse en agua 
formando nanoestructuras cuyo núcleo es lipófilo y cuya periferia es hidrófila. 
Por una parte, pueden encapsular unos fármacos lipófilos en su núcleo y por lo 
tanto aumentar su solubilidad en medios acuosos y, por otra parte, pueden 
encapsular unos fármacos hidrófilos en su periferia aumentado su actividad. 
Previamente en nuestro grupo de investigación, unos dendrímeros de tipo Janus 
y HDLDBCs, ambos anfífilos, basados en bis-MPA han sido sintetizados para el 
                                                          
[3] F. Vögtle, G. Richardt, N. Werner, Dendrimer chemistry, concepts, synthesis, properties, 
applications, 2009, WILEY-VCH Verlag GmbH & Co. Weinheim. 
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transporte de dos fármacos lipófilos insolubles en agua, la plitidepsina y la 
camptotecina, y dos hidrófilos, la primaquina y la cloroquina, para el 
tratamiento de diversos cánceres, de la hepatitis C y de la malaria.[4,5,6] 
 Los dendrímeros de bis-MPA funcionalizados con aminas terminales en su 
periferia han sido utilizados también en terapia génica. Así, se han utilizado 
polímeros hiperramificados y macromoléculas dendríticas iónicas o covalentes 
basadas en bis-MPA. Estas estructuras presentan buenas propiedades para 
formar complejos con el ADN pero su eficiencia en transfección génica sigue 
siendo nula o limitada.[7,8,9] 
Objetivos 
 En esta tesis doctoral, se ha empleado derivados dendríticos del ácido 
2,2-bis-hidroximetilpropiónico (bis-MPA) funcionalizados en su periferia con 
glicina y otros derivados dendríticos originales derivado del ácido 2,2-bis-
gliciloximetilpropiónico (bis-GMPA) para sus aplicaciones en terapia génica y en 
transporte de fármacos (figura 2). 
 
Figura 2: Representación del ácido 2,2-bis-hidroximetilpropiónico (bis-MPA) y 
del ácido 2,2-bis-gliciloximetilpropiónico (bis-MPA). 
                                                          
[4] E. Fedeli, A. Lancelot, J.L. Serrano, P. Calvo, T. Sierra, New J. Chem. 2015, 39, 1960. 
[5] I. Jiménez, R. González, A. Lancelot, R. Clavería, A. Velázquez, O. Abián, M.B. Ros, T. Sierra, 
Macromol. Biosci. 2015, 15, 1381. 
[6] J. Movellan, P. Urbán, E. Moles, J.M. de la Fuente, T. Sierra, J.L. Serrano, X. Fernàndez, 
Biomaterials, 2014, 35, 7940. 
[7] J. Movellan, R. González, P. Martín, T. Sierra, J.M. de la Fuente, J.L. Serrano, Macromol. 
Biosci. 2015, 15, 657. 
[8] A. Barnard, P. Posocco, S. Pricl, M. Calderon, R. Haag, M.E. Hwang, V.W.T. Shum, D.W. Pack, 
D.K. Smith, J. Am. Chem. Soc. 2011, 133, 20288. 
[9] R. Reul, J. Nguyen, T. Kissel, Biomaterials 2009, 30, 5815. 
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 En un primer lugar, se han sintetizado y empleado siete dendrímeros de 
tipo Janus y dos híbridos de copolímeros bloque dendrítico-lineal-dendrítico 
(HDLDBCs) anfífilos basados en bis-MPA y bis-GMPA para el transporte un 
fármaco lipófilo, la camptotecina, y se ha evaluado su potencial para el 
tratamiento in vitro de la hepatitis C. 
 En un segundo lugar, se han sintetizado y empleado dos dendrímeros 
globulares de bis-GMPA y tres polímeros hiperramificados dendronizados 
(DHPs) de bis-MPA para su uso como vectores sintéticos de siARN y pADN. 
 En un tercer lugar, se ha empleado los HDLDBCs basados en bis-MPA y 
bis-GMPA y los DHPs basados en bis-MPA sintetizados previamente para formar 
complejos con la heparina y encapsular tres fármacos antimaláricos, cloroquina, 
primaquina y quinacrina en sus formas hidrófila y lipófila, los cuales son. 
Sistemas anfifílos para el transporte de la camptotecina, fármaco usado como 
antiviral en el tratamiento de la hepatitis C 
 
 La camptotecina es un inhibidor alostérico de la protease NS3 
perteneciendo al virus de la hepatitis C y por lo tanto impide la replicación de 
este virus. Sin embargo, este fármaco lipófilo presenta una baja solubilidad en 
agua, una inestabilidad al suero fisiológico y una elevada citotoxicidad.[10] 
 Para superar estos inconvenientes, se ha planteado encapsular el 
fármaco dentro de nuevos sistemas dendrítico anfifílos, conteniendo un bloque 
lipófilo y un otro bloque hidrófilo. Por eso, se han sintetizado los siguientes 
sistemas dendríticos de tipo Janus y los siguientes HDLDBCs basados en 
Pluronic® F-127 (figura 3): 
 
 
                                                          
[10] O. Abián, S. Vega, J. Sancho, A. Velázquez-Campoy, Allosteric Inhibitors of the NS3 
Protease from the Hepatitis C Virus. PLoS ONE. 2013, 8, e69773.,  
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- (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1]-(C17)2 
 - (NH3+Cl-)4[bisMPA,G2]-[bisMPA,G2]-(C17)4 
- (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G1]-(C17)2  
 - (NH3+Cl-)8[bisMPA,G3]-[bisMPA,G2]-(C17)4 
 - (NH3+Cl-)4[bisGMPA,G2]-[bisMPA,G1]-(C17)2 
 - (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G1]-(C17)2  
 - (NH3+Cl-)8[bisGMPA,G3]-[bisMPA,G2]-(C17)4 
dendrímeros  
de tipo Janus 
  
- (NH3+Cl-)8[bisMPA,G3]-PLU-[bisMPA,G3](NH3+Cl-)8 
- (NH3+Cl-)8[bisGMPA,G3]-PLU-[bisGMPA,G3](NH3+Cl-)8 
HDLDBCs 
 Todos los derivados anfifílos sintetizados pudieron auto-ensamblarse en 
agua formando diversos agregados supramoleculares tales como micelas 
esféricas o ovoidales, bicapas flexibles o rígidas y vesículas. 
 
Figura 3: Representación esquemática de los derivados dendríticos sintetizados 
y fotos de microscopia de transmisión de electrones de los diversos agregados 
que forman en agua. Barra de escala = 50 nm. 
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 Se ha logrado encapsular la camptotecina dentro de 8 de los 9 derivados 
dendríticos sintetizados, aumentando la solubilidad y la estabilidad del 
fármaco lipófilo en medio acuoso. Los dendrímeros de tipo Janus constituidos 
por el dendrón hidrófilo de bis-GMPA (serie B) han demostrado la mayor 
capacidad para encapsular el fármaco con una eficiencia de encapsulación (EE) 
siendo entre el 54 y el 60 % mientras que la EE ha sido entre el 29 y el 46 % por 
los HDLDBCs (serie C) y entre el 0 y el 14 % por los dendrímeros de tipo Janus 
constituidos por el dendrón hidrófilo de bis-MPA (serie A). Claramente, la 
presencia del dendrón de bis-GMPA ha favorecido la encapsulación del fármaco 
dentro de los agregados supramoleculares y la estabilidad del conjugado 
“derivado dendrítico/fármaco” formado.  
 Además, se ha observado durante ensayos in vitro un aumento de la 
actividad antiviral del fármaco encapsulado, en respeto a la actividad del 
fármaco libre, cuando estaba encapsulado dentro de los dendrímeros de tipo 
Janus constituidos por el dendrón de bis-MPA hidrófilo (serie A) y dentro de los 
HDLDBCs (serie C). 
  De todos los sistemas estudiados, el HDLDBC, (NH3+Cl-)8[bisGMPA,G2]-
PLU-[bisGMPA,G2](NH3+Cl-)8, aparece como el mejor vector para el transporte 
de la camptotecina para tratar la hepatitis C, dado que presenta una buena 
eficiencia de encapsulación del fármaco (46 %) y que ha permitido mejorar la 
actividad del fármaco. 
 En un estudio paralelo, se ha sintetizado un nuevo fluoróforo lipófilo, 
derivado de un fluoróforo comercial: la rodamina B. Este fluoróforo original ha 
demostrado su potencial para marcar eficazmente por simples interacciones 
lipófilas, los agregados de tipo Janus sin alterar su formación, su morfología y la 
actividad del fármaco encapsulado. 
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Sistemas dendríticos globulares para su uso como vectores sintéticos de siARN 
y pADN 
 Para transfectar siARN y pADN, se ha sintetizado dos series de derivados 
dendríticos globulares con numerosos cationes localizados en su periferia. Los 
cationes de los derivados dendríticos forman interacciones electrostáticas con 
los grupos fosfato aniónicos del siARN o del pADN permitiendo su transporte y 
protección hacía las partes internas de las células. Por eso, se ha sintetizado los 
siguientes dendrímeros de bis-GMPA y polímeros hiperramificados 
dendronizados (DHPs) de bis-MPA con glicinas terminales (figura 3): 
 - D[bisGMPA,G2] (NH3+Cl-)24  
 - D[bisGMPA,G3] (NH3+Cl-)48 
dendrímeros  
de bis-GMPA 
  
- DHP[bisMPA,G2+3](NH3+Cl-)120 
- DHP[bisMPA,G3+3](NH3+Cl-)248 
- DHP[bisMPA,G4+3](NH3+Cl-)424 
bis-MPA DHPs 
con glicinas 
terminales 
 
Figura 3: Polímeros hiperramificados dendronizados (DHPs) basados en bis-MPA 
y dendrímeros basados en bis-GMPA para su uso como transportadores de 
pADN y siARN.  
 La biocompatibilidad de todos los derivados dendríticos ha sido 
comprobada en varias líneas celulares y todos los derivados han podido formar 
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complejos con pADN y siARN, llamados “dendriplexos”. Sin embargo, los 
derivados dendríticos de las generaciones más altas de ambas series, 
D[bisGMPA,G3] (NH3+Cl-)48 y DHP[bisMPA,G4+3](NH3+Cl-)424 han formado 
complejos más pequeños y con una carga superficial más altas, características 
favorables a una eficiente transfección génica.[2]  
 En cuanto a la transfección del siARN, el dendrímero de bis-GMPA, 
D[bisGMPA,G3](NH3+Cl-)48, ha presentado los mejores resultados, 
transfectando el siARN en células cancerígenas con una eficiencia igual al 
cuarto de la eficiencia de la lipofectamina® 2000, un agente comercial, e igual al 
séptimo de la eficiencia de este mismo agente en células no tumorales.  
 En cuanto a la transfección de pADN, el DHP basado en bis-MPA, 
DHP[bisMPA,G3+3](NH3+Cl-)424, ha presentado los mejores resultados. Si la 
transfección génica no fue muy eficiente en células cancerígenas, este derivado 
dendrítico ha conseguido transferir el pADN en células madre mesenquimatosas 
con la misma eficiencia que la lipofectamina® 2000 y el Transit-X2®, 
presentando además una mejor biocompatibilidad que el primer agente 
comercial. Estos DHPs han sido los primeros derivados dendríticos basados en 
bis-MPA que pudieron demonstrar una eficiencia de transfección de pADN 
similar a la de dos agentes comerciales. 
Sistemas dendríticos para el transporte de fármacos antimaláricos 
 Una amplia librería de fármacos se ha usado para el tratamiento de la 
malaria. No obstante, estos fármacos presentan un direccionamiento 
insuficiente hacía los glóbulos rojos infectados por el parásito responsable de la 
malaria. En consecuencia, unas altas dosis de fármacos son necesarias para 
tratar la enfermedad, lo cual resulta en numerosos y penosos efectos 
secundarios para los pacientes y en la aparición de cepas de parásitos 
resistentes a los tratamientos. 
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 Con el fin de mejorar su direccionamiento y su actividad, tres fármacos 
antimaláricos, la cloroquina (CQ), la primaquina (PQ) y la quinacrina (QN), han 
sido encapsulados tanto en su forma de sal (soluble en agua) como en su forma 
básica (insoluble en agua) dentro de los tres DHPs basados en bis-MPA y de los 
dos HDLDBCs basados en bis-MPA y bis-GMPA presentados anteriormente en 
esa memoria (figura 4). 
 Todos los derivados dendríticos estudiados han podido encapsular los 
tres fármacos en sus formas hidrófilas y la primaquina en su forma base con 
buenas eficiencias de encapsulación (EE entre el 26 y el 44 %). Solo los DHPs 
han sido capaces encapsular la cloroquina en su forma básica (EE entre el 78 y el 
82 %) mientras que no se ha conseguido encapsular la quinacrina en su forma 
básica en ninguno de los derivados estudiados. 
 
Figura 4: Representación esquemática de los derivados dendríticos 
dendronizados para la formación de complejos con heparina (Hep) y el 
transporte de fármacos antimaláricos (cloroquina (CQ), primaquina (PQ) y 
quinacrina (QN)). Barra de escala = 200 nm. 
 En paralelo, la formación de complejos con la heparina y los DHPs ha 
sido estudiada. La heparina es un polímero que tiene una actividad antimalárica 
y se dirige con preferencia hacia los glóbulos rojos infectados con el parásito 
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responsable de la malaria.[11] Los tres DHPs han sido capaces de formar 
complejos basados en interacciones electrostáticas con la heparina. 
Similarmente a lo observado con anterioridad con el ADN, el DHP más grande 
DHP[bisMPA,G4+3](NH3+Cl-)424 ha presentado las mejores eficiencias para 
formar los complejos con la heparina. La presencia de los fármacos 
encapsulados en sus formas salinas dentro de los DHPs retarda levemente la 
formación de los complejos con heparina mientras que la presencia de los 
fármacos encapsulados en sus formas básicas impide la formación de los 
complejos con heparina. El tamaño de los complejos es pequeño (inferior a 50 
nm) lo cual es interesante para su internalización eficaz dentro de los glóbulos 
rojos infectados.[12] 
 Tanto los DHPs como los HDLDBCs han demostrado un buen 
direccionamiento hacia los glóbulos rojos infectados por el parásito, siendo 
casi exclusivo por los DHPs. En la mayoría de los casos, se ha conseguido 
mantener la actividad de los fármacos en comparación con la de los fármacos 
libres. Además, se ha conseguido mejorar la actividad de la quinacrina 
encapsulada dentro de un DHP mientras estaba asociada con la heparina 
demostrando el potencial de los complejos “DHP/heparina” para transportar 
fármacos antimaláricos. Sería relevante seguir con estos estudios, probando si la 
formación de los complejos DHP/heparina, permite mejorar la actividad de la 
cloroquina y de la primaquina. 
 
 
  
                                                          
[11] J. Marqués, E. Moles, P. Urbán, R. Prohens, M.A. Busquets, C. Sevrin, C. Grandfils, X. 
Fernàndez-Busquets, nanomedicine 2014, 10, 1719. 
[12] P.R. Gilson, S.A. Chisholm, B.S. Crabb, T.F. de Koning-Ward, Int. J. Parasitol. 2017, 47, 119. 
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Conclusiones 
 En esta tesis doctoral, se ha estudiado el potencial de nuevos sistemas 
dendríticos de tipo poliéster basados en el ácido 2,2’-bis-hidroximetilpropiónico 
(bis-MPA) o de tipo poli(esteramido) basados en el ácido 2,2’-bis-
gliciloximetilpropiónico (bis-GMPA) para su aplicación como transportadores de 
material genético como de fármacos. Todos los sistemas sintetizados, 
dendrímeros globulares y Janus, copolímeros bloques híbrido dendrítico-lineal-
dendrítico (HDLDBCs) y polímeros hiperramificados dendronizados (DHPs), han 
demostrado su biocompatibilidad y biodegradabilidad. 
 En terapia anti-hepatitis C, los derivados dendríticos de tipo Janus y 
HDLDBCs han podido encapsular la camptotecina, un fármaco lipófilo, y mejorar 
su actividad contra la replicación del virus del la hepatitis C. En particular, los 
HDLDBCs han demostrado un buen balance, mejorando a la vez la solubilidad 
del fármaco en agua y su actividad. 
 En terapia génica, los derivados dendríticos de tipo dendrímero globular y 
DHPs, han permitido la transfección de pADN y de siARN. En particular, los 
polímeros hiperramificado dendronizados (DHPs) basados en bis-MPA han 
destacado como compuestos innovadores para la síntesis de sistemas 
dendríticos de alta generación con aplicaciones en terapia génica que pueden 
competir con los agentes comerciales.  
 En terapia antimalárica, los derivados dendríticos basados en bis-MPA y 
bis-GMA han demostrado su potencial para encapsular fármacos antimaláricos y 
su alta selectividad hacia los glóbulos rojos infectados con el parásito 
plásmodium, responsable de la enfermedad. Además, los DHPs han podido 
formar complejos con la heparina, un polisacárido que favorece el 
direccionamiento de los transportadores de fármacos antimaláricos hacia los 
glóbulos rojos infectados, mejorando su actividad.  
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 La adición de cadenas lipófilas mediante un dendrón de bis-MPA sobre la 
rodamina permite marcar de manera eficaz y duradera varios agregados 
basados en sistemas dendríticos sin necesidad de emplear química covalente y 
sin alterar sus propiedades biológicas. 
  
 
 
Annexes 
 
 
 Annexes 1: 1H-1H COSY and 1H-13C HSQC NMR experiments of  
N3-[bisGMPA,G1]-(NH3+Cl-)4. 
  
  
Annexes 2: 1H-1H COSY of (NH3+Cl-)4 [bisMPA,G2]-[bisMPA,G1](C17)2. 
  
  
Annexes 3: 1H-1H COSY of (NH3+Cl-)4 [bisGMPA,G2]-[bisMPA,G1](C17)2. 
  
 Annexes 4: 13C-NMR spectra of (NHBoc)4[bisMPA,G2]-[bisMPA,G1](C17)2 and the two 
starting dendrons (NH3+Cl-)4[bisGMPA,G2]-N3 and (C17)2[bisMPA,G1]-(≡) in CDCl3 and 
(NH3+Cl-)4[bisMPA,G2]-[bisMPA,G1](C17)2 in CD3OD, at 75 or 100 MHz. 
  
 Annexes 5: 1H-1H COSY of bisGMPA-PLU-bisGMPA recorded in CD3OD at 500 MHz. 
 bis-MPA/bis-MPA series with CPT 
 [G2]-[G1] [G3]-[G1] [G3]-[G2] 
number 160 nm 140 nm 120 nm 
intensity 400 - 800 nm 800 - 1400 nm 600 - 1500 nm 
 bis-GMPA/bis-MPA series with CPT 
 [G1]-[G1] [G2]-[G1] [G2]-[G1] 
number 45 nm 140 nm 25 nm 
intensity 100 - 900 nm 500 - 700 nm 100 - 700 nm 
 HDLDBCs with CPT 
 bisMPA-[PLU]-bisMPA bisGMPA-[PLU]-bisGMPA 
number 15 nm (100%) 12 nm (100%) 
intensity 30 nm (24 %) 150 - 250 nm (76 %) 
40 nm (8 %) 
220 - 300 nm (92 %) 
Annexes 6: Hydrodynamic diameter (nm) of the nanocarrier/CPT conjugates measured 
with DLS according to two different mathematical data treatments (number average 
and intensity average). 
 
 
  
 Annexes 7: 1H-13C HSQC spectrum of low-water soluble rhodamine B (RHB(C17)2). 
 Annexes 8: 1H-1H NMR COSY of the 2nd generation bis-GMPA dendrimer, D[G2](NH3+Cl-)24, recorded in CD3OD at 500 MHz.
 Annexes 9: 1H-13C NMR HSQC of the 2nd generation bis-GMPA dendrimer, D[G2](NH3+Cl-)24, recorded in CD3OD at 500/100 MHz. 
 Annexes 10: 1H-1H COSY spectrum of DHP[bisMPA,G2+3](NHBoc)120 recorded in CDCl3 at 400 MHz.
 Annexes 11: Fluorescence spectra of the free antimalarial drugs (CQs, PQs and QNs) 
and of the bisGMPA-[Plu]-bisGMPA/hydrophilic antimalarial drug conjugates 
(HDLDBC/CQs, HDLDBC/PQs and HDLDBC/QNs). 
 Annexes 12: Heparin complexation by the DHP/hydrophilic drug conjugates studied 
according to the MB spectroscopic competition assay. The EC100 corresponded to the 
ratio A665/A565 ratio measured for free MB in water. 
  
 Annexes 13: Heparin complexation by the DHP[G3+3](NH3+Cl-)248 and 
DHP[G3+3](NH3+Cl-,RhB), bearing 192 terminal amino groups. As the rhodamine 
showed intense absorbance at 565 nm, the complexation was studied only measuring 
the absorbance at 665 nm. The EC100 corresponded at the absorbance intensity of free 
MB in water at 665 nm. 
 
  
 Annexes 14: Growing inhibition assays (GIAs) of free chloroquine (CQ) (up), 
primaquine (PQ) (middle) and quinacrine (QN) (down) and encapsulated within their 
hydrophilic salt form in DHP[G4+3](NH3+Cl-)424 and bisGMPA-[PLU]-bisGMPA.  
 
Annexes 15: Growing inhibition assays (GIAs) of free quinacrine without (QN) and with 
heparin (QN & Hep), DHP[G4+3]/Hep complexe, DHP[G4+3]/QNs conjugate and 
DHP[G4+3]/QNs/Hep conjugate. 
 
